in_alterations,diseases,title,nct_id,out_alterations,countries,recruiting_status
MYCN Amplification,Neuroblastoma,Surgery in Treating Patients With Neuroblastoma,NCT00003122,MYCN Amplification,Austria|Netherlands|Ireland|Wales|England|Italy|United Kingdom|Scotland|France|Northern Ireland|Switzerland|Spain,Unknown status
BCL2 Fusion|FLT3 ITD|MYC Fusion,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|Myelodysplastic Syndromes|Non-Hodgkin Lymphoma|Refractory Anemia with Excess Blasts|Small Lymphocytic Lymphoma,Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow,NCT00003838,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(8;21)(q22;q22),United States,Recruiting
MYCN Amplification,Neuroblastoma,"Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma",NCT00030719,MYCN Amplification,Wales|England|United Kingdom|Scotland|Northern Ireland|Portugal|Switzerland|Spain|Austria|Sweden|Belgium|Norway|Ireland|Denmark|Italy|Israel|France,Unknown status
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Diffuse Large B-Cell Lymphoma|Mediastinal Large B-Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma,Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma,NCT00073957,,United States,Unknown status
,Central Nervous System Cancer|Malignant Leptomeningeal Tumor|Medulloblastoma|Neuroblastoma|Primitive Neuroectodermal Tumor|Rhabdoid Tumor,"Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer",NCT00089245,,United States|U.S.A.,Recruiting
,Multicentric Angiofollicular Lymphoid Hyperplasia,Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,NCT00092222,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Malignant Solid Tumor,Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers,NCT00095862,,United States,Suspended
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A-MLLT3 Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,"Acute Myeloid Leukemia|Acute Promyelocytic Leukemia|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant,NCT00096161,BCR-ABL1 Fusion,United States|Italy,"Active, not recruiting"
del(17)(p10),Chronic Lymphocytic Leukemia,"Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",NCT00104858,,United States|Denmark|Italy,"Active, not recruiting"
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Overexpression,Non-Hodgkin Lymphoma,Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma,NCT00110149,,United States|U.S.A.,Unknown status
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|del(5)(q10),Acute Myeloid Leukemia,Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer,NCT00112593,,United States,Completed
,Juvenile Myelomonocytic Leukemia,Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML),NCT00167219,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]),NCT00179764,,United States,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,"Acute Myeloid Leukemia|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative","Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer",NCT00255684,BCR-ABL1 Fusion,United States,Terminated
MAGE-A3-DP4 antigen Expression Positive|MAGEA3 Expression|MAGEA3 Overexpression,Head and Neck Squamous Cell Carcinoma,MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck,NCT00257738,,United States,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|IKZF1 Frameshift|IKZF1 Fusion|IKZF1 Mutation|IKZF1 Nonsense|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|B-Cell Prolymphocytic Leukemia|Burkitt Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Chronic Myeloid Leukemia|Follicular Lymphoma|Hodgkin Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Mature T-Cell and NK-Cell Neoplasm|Multiple Myeloma|Myelodysplastic Syndromes|Myeloproliferative Neoplasm,Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,NCT00305682,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|IKZF1 Frameshift|IKZF1 Fusion|IKZF1 Mutation|IKZF1 Nonsense|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 13|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(13)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Chronic Myeloid Leukemia|Follicular Lymphoma|Lymphoblastic Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Myelofibrosis|Non-Hodgkin Lymphoma|Plasma Cell Leukemia|Prolymphocytic Leukemia,Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases,NCT00309842,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
IL2RA Overexpression,Hairy Cell Leukemia,LMB-2 to Treat Hairy Cell Leukemia,NCT00321555,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|Monosomy 5|Monosomy 7|TCF3-PBX1 Fusion|Trisomy 19|Very Complex karyotype|del(5)(q10)|del(7)(q10)|t(1;19)(q23;p13)|t(4;11)(q21;q23)|t(9;22)(q34;q11),Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndromes,Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia,NCT00357565,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI,NCT00363649,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|KMT2A Fusion|Monosomy 7|del(5)(q10)|t(4;11)(q21;q23)|t(9;22)(q34;q11),Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Refractory Anemia|Refractory Anemia with Excess Blasts,Laboratory-Treated Peripheral Blood Cell Infusion After Donor Stem Cell Transplant in Treating Patients With Hematologic Cancers or Other Diseases,NCT00376480,,United States,Unknown status
,Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Myelodysplastic Syndromes|Paroxysmal Nocturnal Hemoglobinuria|Polycythemia Vera,Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders,NCT00397813,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States|U.S.A.,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer,NCT00411788,,United States,Completed
,Astrocytoma|Cancer|Central Nervous System Primitive Neuroectodermal Tumor|Ependymoma|Glioma|Medulloblastoma|Melanoma|Neuroblastoma|Retinoblastoma|Rhabdoid Tumor|Sarcoma|Small Cell Lung Carcinoma,Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer,NCT00445965,,United States|U.S.A.,"Active, not recruiting"
B-cell receptor CD22 Expression Positive|B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression|CD22 Expression|CD22 Overexpression,Acute Lymphoblastic Leukemia,Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia,NCT00450944,,United States,Unknown status
,Breast Carcinoma,Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer,NCT00461773,,United States,Unknown status
,Breast Carcinoma,Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer,NCT00470249,,England|United Kingdom,Unknown status
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Hodgkin Lymphoma,Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma,NCT00484874,B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression,United States,Unknown status
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|Normal karyotype|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Double-Hit Lymphoma|Hodgkin Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Non-Hodgkin Lymphoma|Small Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Cord Blood Expansion on Mesenchymal Stem Cells,NCT00498316,CBFB-MYH11 Fusion|Complex karyotype|DEK-NUP214 Fusion|KMT2A-MLLT3 Fusion|Monosomy 5|Monosomy 7|Normal karyotype|PML-RARA Fusion|RPN1-MECOM Fusion|RUNX1-RUNX1T1 Fusion|Very Complex karyotype|del(5)(q10)|del(7)(q10)|inv(16)(p13q22)|inv(3)(q21q26)|t(16;16)(p13;q22)|t(3;3)(q21;q26)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States,Completed
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Gastric Adenocarcinoma,"Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma",NCT00515411,,United States|U.S.A.,"Active, not recruiting"
B-cell receptor CD22 Expression Positive|CD22 Expression|CD22 Overexpression,Non-Hodgkin Lymphoma,Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease,NCT00515892,,United States|Poland,Unknown status
,Breast Carcinoma,Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer,NCT00516425,,England|United Kingdom,Unknown status
,Breast Carcinoma,Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer,NCT00542191,,United States,Recruiting
KMT2A Fusion|KMT2A Germline Amplification|KMT2A Germline Mutation|KMT2A Germline Rearrangement,Acute Lymphoblastic Leukemia,Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,NCT00550992,BCR-ABL1 Fusion|IGH-MYC Fusion,Austria|Czech Republic|Netherlands|Belgium|United States|England|Italy|United Kingdom|U.S.A.|France|Germany,Unknown status
CAMPATH-1 antigen Expression Positive|CD52 Expression|CD52 Overexpression,Anaplastic Large Cell Lymphoma|Peripheral T-Cell Lymphoma,"Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma",NCT00562068,ALK Fusion,England|United Kingdom,Unknown status
,Breast Carcinoma,Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,NCT00570323,,United States|U.S.A.,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma|Lymphoma|Malignant Solid Tumor,Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery,NCT00576654,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States|U.S.A.,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|ROS1 Amplification|ROS1 Fusion|ROS1 Inversion|ROS1 Mutation,Cancer,"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",NCT00585195,,"United States|Korea, Republic of|U.S.A.|Australia",Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",NCT00618657,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Juvenile Myelomonocytic Leukemia|Lymphoma|Myelodysplastic Syndromes,Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies,NCT00619879,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(8;21)(q22;q22),Acute Myeloid Leukemia,Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia,NCT00630565,FLT3 ITD,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Follicular Lymphoma,"Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma",NCT00637832,,England|United Kingdom,Unknown status
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,"Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery",NCT00651976,,United States|U.S.A.,Recruiting
,Head and Neck Squamous Cell Carcinoma,"A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer",NCT00660218,,United States,Unknown status
CD247 Expression|CD247 Overexpression|CD3D Expression|CD3D Overexpression|CD3E Expression|CD3E Overexpression|CD3G Expression|CD3G Overexpression|CD7 Expression|CD7 Overexpression|T-cell Antigen CD7 Expression Positive|T-cell surface glycoprotein CD3 delta chain Expression Positive|T-cell surface glycoprotein CD3 epsilon chain Expression Positive|T-cell surface glycoprotein CD3 gamma chain Expression Positive|T-cell surface glycoprotein CD3 zeta chain Expression Positive|TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Enteropathy-Associated T-Cell Lymphoma,High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma,NCT00669812,CD4 Expression|CD4 Overexpression|CD5 Expression|CD5 Overexpression|CD8A Expression|CD8A Overexpression|T-cell surface glycoprotein CD4 Expression Positive|T-cell surface glycoprotein CD5 Expression Positive|T-cell surface glycoproteinCD8 alpha chain Expression Positive,England|United Kingdom,Unknown status
BCR-ABL1 Fusion|Complex karyotype|FLT3 ITD|KMT2A Fusion|Monosomal karyotype|Very Complex karyotype,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors,NCT00679536,,United States|U.S.A.,Unknown status
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,Total Marrow Irradiation for Refractory Acute Leukemia,NCT00686556,,United States,"Active, not recruiting"
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Diffuse Large B-Cell Lymphoma,Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma,NCT00689845,,England|United Kingdom|Scotland,Unknown status
AXL Amplification|AXL Fusion|AXL Mutation|AXL Overexpression|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|Tyrosine-protein kinase receptor UFO Expression Positive,Cancer|Malignant Solid Tumor,Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies,NCT00697632,,"Canada|United States|Korea, Republic of|U.S.A.",Recruiting
KIT Mutation,Melanoma,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",NCT00700882,,United States,Unknown status
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|DEK-NUP214 Fusion|FLT3 ITD|Monosomy 5|Monosomy 7|RUNX1-CBFA2T3 Fusion|RUNX1-RUNX1T1 Fusion|del(5)(q10)|inv(16)(p13q22)|t(16;16)(p13;q22)|t(8;21)(q22;q22),Acute Myeloid Leukemia,Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia,NCT00703820,,Republic of Singapore|Singapore|United States|U.S.A.,"Active, not recruiting"
MAGE-A3-DP4 antigen Expression Positive|MAGEA3 Expression|MAGEA3 Overexpression,Head and Neck Squamous Cell Carcinoma,Four Doses of MAGE Vaccine for Patients With Squamous Cell Carcinoma of the Head and Neck,NCT00704041,,United States,Unknown status
DNA nucleotidylexotransferase Expression Positive|DNTT Expression|DNTT Overexpression,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia,Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia,NCT00709215,,United States,Unknown status
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer,NCT00712140,,England|United Kingdom|Scotland,Unknown status
BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase),NCT00718263,ABL1 T315I,Argentina|Russian Federation|Singapore|United States|Japan|Egypt|Scotland|United Kingdom|Thailand|Spain|Czech Republic|Sweden|Turkey|Belgium|Finland|Brazil|Denmark|Poland|Italy|France|Germany,Recruiting
,Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Chronic Myeloid Leukemia|Follicular Lymphoma|Lymphoblastic Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Mixed Phenotype Acute Leukemia|Multiple Myeloma|Myelodysplastic Syndromes|Myelofibrosis|Non-Hodgkin Lymphoma|Prolymphocytic Leukemia,"Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease",NCT00719888,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer,NCT00723099,,United States|U.S.A.,Suspended
Protein S100-B Expression Positive|S100B Expression|S100B Overexpression,Melanoma,0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma,NCT00729807,TP53 Mutation,United States,Completed
,Breast Carcinoma,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer,NCT00733408,,United States,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|Normal karyotype|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Lymphoblastic Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasm|Myeloproliferative Neoplasm,Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.,NCT00739141,CBFB-MYH11 Fusion|Complex karyotype|DEK-NUP214 Fusion|KMT2A-MLLT3 Fusion|Monosomy 5|Monosomy 7|Normal karyotype|PML-RARA Fusion|RPN1-MECOM Fusion|RUNX1-RUNX1T1 Fusion|Very Complex karyotype|del(5)(q10)|del(7)(q10)|inv(16)(p13q22)|inv(3)(q21q26)|t(16;16)(p13;q22)|t(3;3)(q21;q26)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
,Breast Carcinoma|Lymphoma|Malignant Solid Tumor,A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer,NCT00748553,,United States,Completed
del(17)(p10),Chronic Lymphocytic Leukemia,A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy,NCT00774345,,Russian Federation|United States|England|Scotland|Portugal|Austria|Netherlands|Sweden|Ireland|Poland|France|Colombia|Romania|Hungary|United Kingdom|Spain|New Zealand|Canada|Czech Republic|Belgium|Denmark|Italy|Mexico|South Africa|Israel|Australia|Germany,"Active, not recruiting"
,High Grade Cervical Intraepithelial Neoplasia,Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia,NCT00788164,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|del(17)(p10),Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia,"Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer",NCT00789776,,United States,"Active, not recruiting"
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(8;21)(q22;q22),Acute Myeloid Leukemia|Myelodysplastic Syndromes|Refractory Anemia with Excess Blasts,"Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias",NCT00801489,FLT3 ITD,United States|U.S.A.,Recruiting
KIT Expression|KIT Mutation|Mast/stem cell growth factor receptor Kit Expression Positive|PDGFRA Mutation,Gastrointestinal Stromal Tumor,A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment,NCT00812240,KIT Expression|Mast/stem cell growth factor receptor Kit Expression Positive,Lebanon|United States|U.S.A.|France,Unknown status
,Breast Carcinoma,Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores,NCT00832338,,United States,Terminated
,Acute Myeloid Leukemia,"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia",NCT00840177,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States|U.S.A.,Recruiting
,Colorectal Carcinoma,Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer,NCT00842257,KRAS Codon 12 Missense|KRAS Codon 13 Missense,United States,Completed
del(5)(q10),Myelodysplastic Syndromes,Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia,NCT00843882,,United States,"Active, not recruiting"
NF2 Mutation,Schwannoma,Concentration and Activity of Lapatinib in Vestibular Schwannomas,NCT00863122,,United States,Unknown status
MYCN Amplification,Neuroblastoma,Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma,NCT00877110,MYCN Amplification,United States|U.S.A.,"Active, not recruiting"
Complex karyotype|FLT3 D835A|FLT3 D835E|FLT3 D835H|FLT3 D835N|FLT3 D835V|FLT3 D835Y|FLT3 I836D|FLT3 I836F|FLT3 I836H|FLT3 I836L|FLT3 I836M|FLT3 I836V|FLT3 ITD|KMT2A Fusion|Monosomy 5|Monosomy 7|Very Complex karyotype|del(5)(q10)|del(7)(q10),Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129),NCT00887068,,United States|U.S.A.,"Active, not recruiting"
del(1)(p10)|del(19)(q10),Glioma,Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma,NCT00887146,,Canada|Austria|Netherlands|Belgium|United States|U.S.A.|France,Recruiting
,Acute Myeloid Leukemia,QUILT-3.018: Neukoplast‰ã¢ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia,NCT00900809,PML-RARA Fusion,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Sarcoma,Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,NCT00902044,,United States|U.S.A.,Recruiting
EGFR Amplification,Head and Neck Carcinoma,Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma,NCT00903461,,United States|U.S.A.,Terminated
,Breast Carcinoma,A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer,NCT00907959,,United States,Unknown status
MLANA Expression|MLANA Overexpression|Melanoma antigen recognized by T-cells 1 Expression Positive,Melanoma,Study of Gene Modified Immune Cells in Patients With Advanced Melanoma,NCT00910650,,United States|U.S.A.,Recruiting
MYCN Amplification,Neuroblastoma,"Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ë_-glucan for High-Risk Neuroblastoma",NCT00911560,MYCN Amplification,United States|U.S.A.,Recruiting
,Breast Carcinoma,Phase II Trial of EVEROLIMUS å± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer,NCT00912340,,United States,"Active, not recruiting"
,Breast Carcinoma,Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,NCT00921115,,United States,"Active, not recruiting"
B-cell receptor CD22 Expression Positive|B-lymphocyte antigen CD19 Expression Positive|B-lymphocyte antigen CD20 Expression Positive|CD19 Expression|CD19 Overexpression|CD22 Expression|CD22 Overexpression|ITGAX Expression|ITGAX Overexpression|Integrin alpha-X Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Hairy Cell Leukemia,Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia,NCT00923013,,United States|U.S.A.,Recruiting
,Kaposi Sarcoma,Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma,NCT00923936,F2 Mutation|F5 Mutation|PROC Mutation|PROS1 Mutation|SERPINC1 Mutation,United States|U.S.A.,Recruiting
CD19 Overexpression,Mature B-Cell Lymphoma/Leukemia,CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma,NCT00924326,,United States,"Active, not recruiting"
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Anaplastic Large Cell Lymphoma|Malignant Solid Tumor|Neuroblastoma,Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,NCT00939770,,Canada|United States,"Active, not recruiting"
DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation,Colorectal Carcinoma,Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency,NCT00952016,MSH2 Expression,England|United Kingdom,Terminated
,Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS),NCT00956787,,United States,Unknown status
,Breast Carcinoma,Radiation Therapy or Standard Therapy in Treating Women With Stage II Breast Cancer Who Have Undergone Mastectomy,NCT00966888,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,Scotland|United Kingdom,Unknown status
,Breast Carcinoma,Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer,NCT00971737,,United States|U.S.A.,"Active, not recruiting"
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Diffuse Large B-Cell Lymphoma,Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma,NCT00974792,,England|United Kingdom,Unknown status
,High Grade Cervical Intraepithelial Neoplasia,Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3),NCT00988559,,United States|U.S.A.,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma|Malignant Solid Tumor,A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors,NCT00999401,,United States|U.S.A.,Recruiting
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation,Malignant Solid Tumor,A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies,NCT01004224,,"Singapore|United States|Thailand|Spain|Austria|Netherlands|Turkey|Taiwan|Korea, Republic of|Italy|U.S.A.|Israel|Australia|France|Germany","Active, not recruiting"
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Diffuse Large B-Cell Lymphoma,Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma,NCT01004991,,United States,Completed
Complex karyotype|Hypodiploidy|IGH-FGFR3 Fusion|IGH-MAF Fusion|del(17)(p10)|t(14;16)(q32;q23)|t(4;14)(p16;q32),Chronic Lymphocytic Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Leukemia|Small Lymphocytic Lymphoma|T-Cell Prolymphocytic Leukemia (T-PLL),"Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia",NCT01008462,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients,NCT01027416,TP53 Mutation,United States,Completed
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Burkitt Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes,Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies,NCT01028716,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
,Anaplastic Large Cell Lymphoma,Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy,NCT01035463,ALK Fusion,United States|U.S.A.,Unknown status
BRAF Mutation|CCND1 Amplification|CCND1 Mutation|CCND2 Amplification|CCND2 Mutation|CCND3 Amplification|CCND3 Mutation|CCNE1 Amplification|CCNE1 Mutation|CCNE2 Amplification|CCNE2 Mutation|CDK2 Amplification|CDK2 Mutation|CDK4 Mutation|CDK6 Mutation|CDKN1A Mutation|CDKN1B Mutation|CDKN2A Mutation|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|KRAS Mutation|RB1 Amplification|RB1 Expression|RB1 Mutation|RB1 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression|Retinoblastoma-associated protein Expression Positive,Breast Carcinoma|Colorectal Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Germ Cell Tumor|Malignant Solid Tumor,PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER,NCT01037790,,United States,Recruiting
,Acute Myeloid Leukemia,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,NCT01041703,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States|Israel|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,NCT01042379,,Canada|United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|FLT3 ITD,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit,NCT01050946,CBFB-MYH11 Inversion|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,,Closed
B-lymphocyte antigen CD19 Expression Positive|B-lymphocyte antigen CD20 Expression Positive|CD19 Expression|CD19 Overexpression|CD5 Expression|CD5 Overexpression|MS4A1 Expression|MS4A1 Overexpression|T-cell surface glycoprotein CD5 Expression Positive,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,NCT01066663,CCND1 Expression|CCND1 Overexpression|G1/S-specific cyclin-D1 Expression Positive|IGH-CCND1 Fusion|t(11;14)(q13;32),United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Follicular Lymphoma|Lymphoma|Lymphoplasmacytic Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma,Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen,NCT01077518,,Argentina|Puerto Rico|Russian Federation|Hong Kong|United States|Japan|Ukraine|England|United Kingdom|Greece|Canada|Austria|Belgium|Brazil|Poland|Italy|Slovakia|France|Germany,"Active, not recruiting"
,Colorectal Carcinoma,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,NCT01079780,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Hypodiploidy|KMT2A-AFF1 Fusion|Very Complex karyotype,Acute Lymphoblastic Leukemia,Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,NCT01085617,ETV6-RUNX1 Fusion|IGH-MYC Fusion|IGK-MYC Fusion|IGL-MYC Fusion|Very Complex karyotype,England|United Kingdom,Unknown status
,Acute Myeloid Leukemia,A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS,NCT01085656,PML-RARA Fusion,United States,Terminated
CD19 Expression|CD19 Overexpression,Mature B-Cell Lymphoma/Leukemia,Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation,NCT01087294,,United States,Suspended
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Oropharyngeal Squamous Cell Carcinoma,Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx,NCT01088802,,United States,"Active, not recruiting"
BRAF Fusion|BRAF Mutation|KIAA1549 Fusion,Medulloblastoma,Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma,NCT01089101,,United States,Recruiting
,Breast Carcinoma,"Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer",NCT01090128,,United States,Terminated
,Breast Carcinoma,Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer,NCT01093235,,England|United Kingdom,Unknown status
Complex karyotype|Monosomal karyotype|Very Complex karyotype,Acute Myeloid Leukemia,Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia,NCT01093573,,United States,"Active, not recruiting"
CD276 Expression|CD276 Overexpression|CD276 antigen Expression Positive,Desmoplastic Small Round Cell Tumor|Malignant Solid Tumor,Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum,NCT01099644,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer,NCT01104571,,England|United Kingdom,Unknown status
CCND1 Expression|CCND1 Overexpression|G1/S-specific cyclin-D1 Expression Positive|IGH-CCND1 Fusion|t(11;14)(q13;32),Mantle Cell Lymphoma,Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma,NCT01111188,,United States,"Active, not recruiting"
EGFR Amplification,Glioblastoma,PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma,NCT01112527,,United States,"Active, not recruiting"
,Glioma,A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas,NCT01130077,,United States|U.S.A.,Recruiting
FH Germline Mutation|FH Mutation,Renal Cell Carcinoma,A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer,NCT01130519,,United States|U.S.A.,Recruiting
PDGFRA Amplification,Glioma,Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas,NCT01140568,,United States|U.S.A.,Recruiting
,Breast Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",NCT01145430,,United States,"Active, not recruiting"
,Breast Carcinoma,Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery,NCT01147016,,United States,"Active, not recruiting"
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Follicular Lymphoma,Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma,NCT01147393,,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Carcinoma,Safety Study of MGAH22 in HER2-positive Carcinomas,NCT01148849,,"United States|Korea, Republic of","Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PGR Expression|PGR Overexpression|Progesterone receptor Expression Positive,Breast Carcinoma|Invasive Ductal Carcinoma,Excision Followed by Radiofrequency Ablation for Breast Cancer,NCT01153035,,United States,Recruiting
CA6 Expression|CA6 Overexpression|Carbonic anhydrase 6 Expression Positive,Malignant Solid Tumor,First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor,NCT01156870,,United States|France|Spain,Completed
BCR-ABL1 Fusion|del(5)(q10),Chronic Myeloid Leukemia|Myelodysplastic Syndromes,"Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS",NCT01159028,,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",NCT01160211,,"Puerto Rico|Russian Federation|Singapore|Hong Kong|United States|England|Portugal|Greece|China|Ireland|Brazil|Korea, Republic of|Poland|France|Bulgaria|Lithuania|Serbia|Croatia|Colombia|Argentina|Romania|Hungary|Japan|Philippines|Ukraine|United Kingdom|India|Spain|Canada|Turkey|Belgium|Norway|Taiwan|Italy|South Africa|Israel|Australia|Peru|Germany","Active, not recruiting"
,Neuroblastoma,131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma,NCT01163383,,,Closed
MYCN Amplification,Neuroblastoma,"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",NCT01175356,,United States,Completed
del(17)(p10),Chronic Lymphocytic Leukemia|Mature T-Cell and NK-Cell Lymphoma/Leukemia,"Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies",NCT01181258,,United States,Completed
EGFR Amplification|EGFR Overexpression|Epidermal Growth Factor Receptor Overexpression,Glioma,Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG),NCT01182350,EGFR Amplification|EGFR Overexpression|Epidermal Growth Factor Receptor Overexpression|MGMT Promoter Methylation Positive,United States,"Active, not recruiting"
ERBB2 Amplification,Gastric Carcinoma,"CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",NCT01191697,,United States,"Active, not recruiting"
BCL2 Fusion|BCL6 Fusion|MYC Fusion,Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,NCT01193842,,United States,"Active, not recruiting"
,Breast Carcinoma,Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer,NCT01194869,,United States,Terminated
BCR-ABL1 Fusion|CD19 Overexpression|KMT2A Fusion,Acute Lymphoblastic Leukemia,CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL),NCT01195480,,England|United Kingdom|Scotland|Germany,Terminated
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Carcinoma|Gastric Adenocarcinoma,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",NCT01196390,,United States,"Active, not recruiting"
,"Myelodysplastic Syndrome, Unclassifiable|Refractory Anemia|Refractory Cytopenia with Multilineage Dysplasia|Refractory anemia with ring sideroblasts (RARS)",Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes,NCT01196715,,England|United Kingdom,Unknown status
,Malignant Solid Tumor,Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance,NCT01197170,,United States,"Active, not recruiting"
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,Expanded Access Protocol (EAP) Using the CliniMACSå¨ Device for Pediatric Haplocompatible Donor Stem Cell Transplant,NCT01200017,,U.S.A.,Closed
,Ampulla of Vater Adenocarcinoma|Small Intestinal Carcinoma,CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,NCT01202409,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States,"Active, not recruiting"
MYC Amplification|MYC Fusion|MYC Overexpression|Myc proto-oncogene protein Expression Positive|Myc proto-oncogene protein Overexpression Positive,Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Hodgkin Lymphoma|Non-Hodgkin Lymphoma,Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation,NCT01203020,,United States,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Juvenile Myelomonocytic Leukemia|Lymphoblastic Lymphoma|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|Prolymphocytic Leukemia|Small Lymphocytic Lymphoma,"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",NCT01203722,BCR-ABL1 Fusion|KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
IGH-FGFR3 Fusion|TP53 Frameshift|TP53 Nonsense|TP53 c.1-c.137 Missense|TP53 c.142-c.212 Missense|TP53 c.217-c.1178 Missense|del(1)(p10)|del(17)(p10)|dup(1)(q10qter),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Multiple Myeloma|Myelodysplastic Syndromes,Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies,NCT01204164,,United States,Completed
CBL Mutation|FLT3 ITD|RPN1-MECOM Inversion|Trisomy 11|Trisomy 3,Acute Myeloid Leukemia,"Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)",NCT01211691,,United States|Australia,Suspended
,Breast Carcinoma,A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,NCT01216176,,United States,"Active, not recruiting"
"AKT1 Amplification|AKT1 Mutation|EGFR Amplification|EGFR Mutation|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|KIT Amplification|KIT Mutation|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|PDGFRA Amplification|PDGFRA Mutation|PIK3CA Amplification|PIK3CA Mutation|PTEN Deletion|PTEN Loss|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression",Malignant Solid Tumor,"Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules",NCT01226316,,Canada|Netherlands|Singapore|United States|Japan|Denmark|Italy|U.S.A.|France|Spain,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(17)(p10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia,Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant,NCT01231412,,United States|Denmark|U.S.A.|Germany,"Active, not recruiting"
CD38 Expression|ZAP70 Expression|del(11)(q22q23)|del(17)(p10),Chronic Lymphocytic Leukemia,Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL),NCT01243190,,United States,"Active, not recruiting"
del(17)(p10),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Hodgkin Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Multiple Myeloma|Myelodysplastic/Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma,"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",NCT01251575,,United States|Denmark|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia,Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant,NCT01252667,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
del(11)(q22q23),Chronic Lymphocytic Leukemia,"Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)",NCT01253460,,United States|U.S.A.,"Active, not recruiting"
JAK2 V617F,Essential Thrombocythemia|Polycythemia Vera,Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET),NCT01259817,JAK2 Exon 12 Mutation,Canada|Sweden|Netherlands|Belgium|United States|England|United Kingdom|Italy|U.S.A.|Northern Ireland|France,Completed
JAK2 V617F,Essential Thrombocythemia|Polycythemia Vera,Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET),NCT01259856,,United States|Ireland|England|United Kingdom|Italy|U.S.A.|Northern Ireland|France,"Active, not recruiting"
,Breast Carcinoma,TKI258 for Metastatic Inflammatory Breast Cancer Patients,NCT01262027,,United States,Completed
BCR-ABL1 Fusion|CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A-AFF1 Fusion|NPM1 Exon 12 Mutation|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL),NCT01266083,Complex karyotype|FLT3 ITD|Monosomal karyotype|Very Complex karyotype,United States,"Active, not recruiting"
,Breast Carcinoma,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",NCT01272037,,"Canada|Puerto Rico|United States|Ireland|Korea, Republic of|U.S.A.|France|Republic of Korea|Spain",Recruiting
,Acute Myeloid Leukemia,Nonmyeloablative Allogeneic Transplant,NCT01272817,CBFB-MYH11 Inversion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,United States,Unknown status
,Breast Carcinoma|Desmoid-Type Fibromatosis|Endometrial Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer|Uterine Sarcoma,Endoxifen in Adults With Hormone Receptor Positive Solid Tumors,NCT01273168,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer,NCT01273610,,United States,"Active, not recruiting"
KRAS Mutation,Colorectal Carcinoma,Study of REOLYSINå¨ in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,NCT01274624,,United States|U.S.A.,"Active, not recruiting"
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Hereditary Breast and Ovarian Cancer Syndrome,Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer,NCT01276704,,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer,NCT01283789,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Desmoplastic Small Round Cell Tumor|Ewing Sarcoma|Neuroblastoma|Rhabdomyosarcoma,A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias,NCT01287104,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|KMT2A-MLLT3 Fusion|Monosomy 5|Monosomy 7|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|del(5)(q10)|inv(16)(p13q22)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,"Active, not recruiting"
,Breast Carcinoma,Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer,NCT01289353,,United States,"Active, not recruiting"
MS4A1 Overexpression,Non-Hodgkin Lymphoma,Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL),NCT01294579,,United States|U.S.A.,Completed
,Breast Carcinoma|Malignant Solid Tumor|Non-Hodgkin Lymphoma,A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,NCT01296555,,Canada|United States|U.S.A.|Spain,Recruiting
PTEN Deletion|PTEN Mutation,Malignant Solid Tumor,BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors,NCT01297452,,United States,Completed
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,NCT01300962,,United States|U.S.A.,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",NCT01305941,,United States|U.S.A.,"Active, not recruiting"
AKT1 Mutation|AKT2 Mutation|AKT3 Mutation|BRAF Mutation|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ERBB2 Amplification|ERBB2 Mutation|HRAS Mutation|KIT Mutation|KRAS Mutation|NRAS Mutation|PDGFRA Amplification|PDGFRA Mutation|PIK3CA Amplification|PIK3CA Mutation|PTEN Mutation,Non-Small Cell Lung Carcinoma|Small Cell Lung Carcinoma|Thymic Carcinoma,"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",NCT01306045,EGFR Exon 20 Insertion|EGFR T790M,United States,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|RUNX1-RUNX1T1 Fusion|del(5)(q10),Acute Myeloid Leukemia,Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy,NCT01307579,,Canada|Puerto Rico|United States|U.S.A.,"Active, not recruiting"
,Colorectal Carcinoma,Study of Imprime PGGå¨ in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer,NCT01309126,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Puerto Rico|United States|France|Germany,Terminated
,Colorectal Carcinoma,"Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer",NCT01312857,KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Acute Leukemia|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Hodgkin Lymphoma|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma,A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies,NCT01315132,,United States|U.S.A.,Recruiting
Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors,NCT01324479,EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,"Singapore|Hong Kong|United States|Thailand|Spain|Canada|Netherlands|Norway|Taiwan|Korea, Republic of|Italy|Israel|Australia|France|Germany","Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Ependymoma|Glioma|Medulloblastoma,Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer,NCT01325207,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|Hypodiploidy|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|RPN1-MECOM Inversion|Very Complex karyotype|del(11)(q23)|del(5)(q10)|del(7)(q10),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen,NCT01328496,,United States,Completed
MS4A1 Overexpression,Mature B-Cell Lymphoma/Leukemia,Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas,NCT01329900,,United States,"Active, not recruiting"
BRAF V600E,Non-Small Cell Lung Carcinoma,Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.,NCT01336634,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,"Netherlands|United States|Norway|Japan|Taiwan|Korea, Republic of|England|Italy|United Kingdom|France|Germany|Spain","Active, not recruiting"
ALK Fusion,Anaplastic Large Cell Lymphoma,Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma,NCT01336920,,United States,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 D835A|FLT3 D835E|FLT3 D835H|FLT3 D835N|FLT3 D835V|FLT3 D835Y|FLT3 I836D|FLT3 I836F|FLT3 I836H|FLT3 I836L|FLT3 I836M|FLT3 I836V|FLT3 ITD|Hyperdiploidy|IGH-MYC Fusion|KIT Exon 11 Mutation|KIT Exon 13 Mutation|KIT Exon 14 Mutation|KIT Exon 17 Mutation|KIT Exon 9 Mutation|KIT K642E|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 17|Monosomy 18|Monosomy 20|Monosomy 5|Monosomy 7|NPM1-MLF1 Fusion|Normal karyotype|RPN1-MECOM Fusion|RPN1-MECOM Inversion|TCF3-PBX1 Fusion|Trisomy 13|Trisomy 8|Very Complex karyotype|del(17)(p10)|del(3)(q10)|del(5)(q10)|del(7)(q10),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndromes,Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,NCT01338987,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A-MLLT3 Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,United States|U.S.A.,"Active, not recruiting"
TP53 Mutation,Leukemia|Lymphoma|Malignant Solid Tumor,Phase I Study of Pazopanib and Vorinostat,NCT01339871,,United States,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(17)(p10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Burkitt Lymphoma|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Juvenile Myelomonocytic Leukemia|Mantle Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma|Plasma Cell Leukemia|Plasma Cell Neoplasm|Small Lymphocytic Lymphoma|T-Cell Prolymphocytic Leukemia (T-PLL),"Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide",NCT01342289,BCR-ABL1 Fusion|KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States,Recruiting
,Synovial Sarcoma,A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1‡¦Ïå_‰µ‰_T in HLA-A2+ Patients With Synovial Sarcoma,NCT01343043,,Canada|United States|England|United Kingdom|U.S.A.|France,Recruiting
NF2 Mutation,Schwannoma,Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma,NCT01345136,,United States|U.S.A.,Recruiting
APC Deletion|APC Loss|APC Mutation|AXIN1 Deletion|AXIN1 Loss|AXIN1 Mutation|BRAF Mutation|BTRC Mutation|CSNK1A1 Mutation|CTNNA1 Mutation|CTNNB1 Amplification|CTNNB1 Mutation|DVL1 Mutation|FZD1 Mutation|FZD10 Mutation|FZD2 Mutation|FZD3 Mutation|FZD4 Mutation|FZD5 Mutation|FZD6 Mutation|FZD7 Mutation|FZD8 Mutation|FZD9 Mutation|GSK3B Mutation|LRP5 Amplification|LRP5 Mutation|LRP6 Amplification|LRP6 Mutation|WISP3 Mutation|WNT1 Amplification|WNT1 Mutation|WT1 Mutation,Colorectal Carcinoma|Malignant Solid Tumor|Pancreatic Carcinoma,A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands,NCT01351103,,Netherlands|United States|U.S.A.|Spain,Recruiting
,Breast Carcinoma,Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer,NCT01351909,,United States,"Active, not recruiting"
,Acute Myeloid Leukemia,Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML),NCT01352650,CBFB-MYH11 Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13.1q22)|t(15;17)(q22;q12)|t(16;16)(p13.1;q22)|t(8;21)(q22;q22),United States,"Active, not recruiting"
IDH1 Mutation|del(1)(p10)|del(19)(q10),Glioma,Proton Radiation Therapy for Gliomas,NCT01358058,,United States|U.S.A.,Recruiting
,Breast Carcinoma|Malignant Solid Tumor|Prostate Carcinoma,"Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors",NCT01362374,,United States|England|United Kingdom|France|Spain,"Active, not recruiting"
,,SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma,NCT01362790,,United States|U.S.A.,"Active, not recruiting"
NF1 Mutation,Neurofibroma,AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors,NCT01362803,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Acute Lymphoblastic Leukemia|Burkitt Leukemia|Burkitt Lymphoma|Lymphoblastic Lymphoma,Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL),NCT01363128,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Endometrial Carcinoma,Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,NCT01367002,,United States|U.S.A.,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|inv(11)(p15;q23)|inv(16)(p13q22)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(16;16)(p13;q22)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(8;21)(q22;q22)|t(9;11)(p21;q23),Acute Myeloid Leukemia,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,NCT01371981,BCR-ABL1 Fusion|PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(9;22)(q34;q11),New Zealand|Canada|Puerto Rico|United States|U.S.A.|Australia,Recruiting
ESR1 Mutation|IGF1R Mutation|PGR Mutation,Breast Carcinoma,"Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor",NCT01372618,,United States,Completed
MUC1 Expression|MUC1 Overexpression|Mucin-1 Expression Positive,Non-Small Cell Lung Carcinoma,Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer,NCT01383148,EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Belgium|Hungary|United States|Wales|Poland|England|Italy|United Kingdom|Israel|France|Germany|Spain,Terminated
BRAF Fusion|BRAF Mutation|NF1 Mutation,Glioma,AZD6244 in Children With Low-Grade Gliomas,NCT01386450,BRAF Fusion|BRAF Mutation|NF1 Mutation,,Closed
CD276 Overexpression|CD276 antigen Overexpression,Bladder Carcinoma|Breast Carcinoma|Head and Neck Carcinoma|Melanoma|Non-Small Cell Lung Carcinoma|Prostate Carcinoma|Renal Cell Carcinoma,Safety Study of MGA271 in Refractory Cancer,NCT01391143,,United States|U.S.A.,Recruiting
Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Malignant Solid Tumor,Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors,NCT01391533,MET Amplification,United States|Italy|France|Spain,Completed
TNFRSF8 Overexpression,Hodgkin Lymphoma,Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma,NCT01393717,,United States,Completed
KIT Mutation,Acral Melanoma|Mucosal Melanoma,A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread,NCT01395121,,England|United Kingdom,Unknown status
,Gastrointestinal Stromal Tumor,A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor,NCT01396148,KIT A502_Y503insFA|KIT A829P|KIT Amplification|KIT D816H|KIT D816I|KIT D816V|KIT D816Y|KIT D820E|KIT D820V|KIT D820Y|KIT E490K|KIT E554_K558del|KIT E554_V559del|KIT Exon 11 Mutation|KIT Exon 13 Mutation|KIT Exon 14 Mutation|KIT Exon 17 Mutation|KIT Exon 18 Mutation|KIT Exon 8 Mutation|KIT Exon 9 Mutation|KIT F504L|KIT Fusion|KIT G565V|KIT H697Y|KIT I653T|KIT I841V|KIT K550N|KIT K558N|KIT K642E|KIT L576P|KIT N463S|KIT N566D|KIT N566_D572del|KIT N566_T574del|KIT N655K|KIT N655S|KIT N822I|KIT N822K|KIT N822Y|KIT P577_D579del|KIT P577_E583dup|KIT P838L|KIT Q556_W557insL|KIT Q575_L576ins PE|KIT R634W|KIT S864F|KIT V559A|KIT V559C|KIT V559D|KIT V559G|KIT V560A|KIT V560D|KIT V560G|KIT V560del|KIT V569G|KIT V654A|KIT V852I|KIT W557R|KIT Y553N|KIT Y570H|KIT Y823D,United States|U.S.A.|France,Recruiting
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML),NCT01397734,,United States|U.S.A.,"Active, not recruiting"
,Adenocarcinoma of the Gastroesophageal Junction|Breast Carcinoma|Colorectal Carcinoma|Gastric Carcinoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Pancreatic Carcinoma,An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors,NCT01397929,,England|United Kingdom,Completed
,Acute Myeloid Leukemia,Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients,NCT01398462,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|FLT3 ITD|KMT2A Fusion|RPN1-MECOM Fusion|RPN1-MECOM Inversion|RUNX1-RUNX1T1 Fusion,"United States|Korea, Republic of",Completed
PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),Acute Promyelocytic Leukemia,"Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin",NCT01409161,,United States|U.S.A.,Recruiting
BUB3 Expression|SOX4 Expression|Sex Determining Region Y Expression Positive|del(3)(p10)|del(9)(p10)|mitotic checkpoint protein BUB3 Expression Positive,Oral Cavity Squamous Cell Carcinoma,Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions,NCT01414426,,United States|U.S.A.,Recruiting
CCND1 Expression|CCND1 Overexpression|G1/S-specific cyclin-D1 Expression Positive|IGH-CCND1 Fusion|t(11;14)(q13;32),Mantle Cell Lymphoma,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",NCT01415752,,Canada|United States|U.S.A.,Recruiting
MYCN Amplification,Desmoplastic Small Round Cell Tumor|Malignant Solid Tumor|Melanoma|Neuroblastoma|Osteosarcoma|Soft Tissue Sarcoma,Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors,NCT01419834,MYCN Amplification,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia,Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),NCT01424982,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,Acute Lymphoblastic Leukemia|Non-Hodgkin Lymphoma,In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies,NCT01430390,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only",NCT01434303,,United States,"Active, not recruiting"
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Malignant Solid Tumor,Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors,NCT01434316,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|Mature B-Cell Lymphoma/Leukemia,High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma,NCT01434472,,United States|U.S.A.,Recruiting
ESR1 Amplification,Breast Carcinoma,Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ,NCT01439711,,United States,"Active, not recruiting"
,Breast Carcinoma,Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer,NCT01441947,,United States|U.S.A.,"Active, not recruiting"
,Cancer,Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases,NCT01447056,,United States|U.S.A.,"Active, not recruiting"
ERBB2 Amplification,Gastric Carcinoma,A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer,NCT01450696,,"Russian Federation|United States|England|Scotland|Portugal|China|Panama|Brazil|Korea, Republic of|Poland|Chile|Serbia|Bosnia and Herzegovina|Hungary|Philippines|Ukraine|United Kingdom|Spain|New Zealand|Czech Republic|Turkey|Italy|Mexico|South Africa|Australia|Peru|Germany",Terminated
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",NCT01454102,,Canada|United States,"Active, not recruiting"
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Lung Carcinoma|Non-Small Cell Lung Carcinoma,FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer,NCT01455389,EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States|U.S.A.,Recruiting
"PTEN Large Deletion|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Expression Negative",Breast Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Gastric Adenocarcinoma|Glioblastoma Multiforme|Head and Neck Squamous Cell Carcinoma|Melanoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Prostate Carcinoma,"A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency",NCT01458067,PTEN Expression|PTEN Overexpression,"United States|Korea, Republic of|England|United Kingdom",Completed
BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia,NCT01460693,,England|United Kingdom,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Non-Hodgkin Lymphoma,A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab,NCT01461928,,Russian Federation|Egypt|Wales|England|Greece|Austria|Sweden|Brazil|Slovakia|Slovenia|France|Bulgaria|Lithuania|Colombia|Ecuador|Argentina|Romania|Hungary|United Kingdom|Switzerland|Albania|Spain|Turkey|Norway|Italy|Germany,"Active, not recruiting"
del(17)(p10),Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia,Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL,NCT01465334,,United States,"Active, not recruiting"
,Breast Carcinoma,Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib,NCT01466972,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|Normal karyotype|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Double-Hit Lymphoma|Hodgkin Lymphoma|Myelodysplastic Syndromes|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma,Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies,NCT01471067,CBFB-MYH11 Fusion|Complex karyotype|DEK-NUP214 Fusion|KMT2A-MLLT3 Fusion|Monosomy 5|Monosomy 7|Normal karyotype|PML-RARA Fusion|RPN1-MECOM Fusion|RUNX1-RUNX1T1 Fusion|Very Complex karyotype|del(5)(q10)|del(7)(q10)|inv(16)(p13q22)|inv(3)(q21q26)|t(16;16)(p13;q22)|t(3;3)(q21;q26)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States|U.S.A.,Completed
,Breast Carcinoma,Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer,NCT01471106,,United States|U.S.A.,Recruiting
Complex karyotype|Monosomal karyotype|Very Complex karyotype,Acute Myeloid Leukemia,Fludarabine-IV Busulfan å± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS),NCT01471444,,United States,"Active, not recruiting"
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Lymphoma|Malignant Solid Tumor,A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II),NCT01482715,,Canada|United States|England|United Kingdom|Scotland|Israel|Spain,"Active, not recruiting"
APC Mutation,Familial Adenomatous Polyposis,Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP),NCT01483144,,Canada|Netherlands|Belgium|United States|England|Scotland|United Kingdom|Germany|Spain,"Active, not recruiting"
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|FANCA Mutation|FANCB Mutation|FANCC Mutation|FANCD2 Mutation|FANCE Mutation|FANCF Mutation|FANCG Mutation|FANCI Mutation|FANCL Mutation|FANCM Mutation|PALB2 Mutation,Pancreatic Carcinoma,ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,NCT01489865,,United States|U.S.A.,Recruiting
,Burkitt Lymphoma|Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma,Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT),NCT01490723,,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer,NCT01491737,,Turkey|United States|Brazil|England|Italy|United Kingdom|Scotland|France|India|Spain,"Active, not recruiting"
ALK Fusion,Anaplastic Large Cell Lymphoma,Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma,NCT01492088,,Netherlands|United States|Italy|Mexico|Scotland|United Kingdom|U.S.A.|France|Germany|Spain,"Active, not recruiting"
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,Non-Hodgkin Lymphoma,A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy,NCT01493453,,England|United Kingdom,Unknown status
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,NCT01494662,,United States|U.S.A.,"Active, not recruiting"
BRAF V600E|BRAF V600K,Melanoma,Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,NCT01495988,,United States,Terminated
,Cancer,Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies,NCT01498484,,United States|U.S.A.,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,NCT01501487,,United States,"Active, not recruiting"
Hypodiploidy|IGH-FGFR3 Fusion|IGH-MAF Fusion|Monosomy 13|Monosomy 17|t(14;16)(q32;q23)|t(4;14)(p16;q32),Multiple Myeloma,"90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma",NCT01503242,,United States|U.S.A.,Suspended
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,NCT01506609,,Argentina|Russian Federation|Romania|Hungary|United States|Czechia|Ukraine|Spain|Canada|Netherlands|Sweden|Belgium|Norway|Finland|Brazil|Denmark|Poland|Israel|Australia|France,"Active, not recruiting"
BRAF V600E|BRAF V600K,Melanoma,BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,NCT01512251,,United States,Unknown status
,Malignant Solid Tumor,A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors,NCT01517464,RB1 Expression|RB1 Overexpression,United States,Completed
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations,NCT01519323,,United States|Poland|England|Italy|United Kingdom|Israel|Slovakia|U.S.A.|Australia|France|Germany|Spain,Terminated
,Colorectal Carcinoma|Malignant Solid Tumor,Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment,NCT01520389,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States,Completed
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia,CNDO-109-AANK for AML in First Complete Remission (CR1),NCT01520558,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Unknown status
ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Carcinoma|Gastric Carcinoma,Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer,NCT01522768,,United States|U.S.A.,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,Acute Myeloid Leukemia,Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies,NCT01523223,,United States|U.S.A.,"Active, not recruiting"
,Acute Lymphoblastic Leukemia,Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,NCT01523977,BCR-ABL1 Fusion|IGH-MYC Fusion|IGK-MYC Fusion|IGL-MYC Fusion|t(2;8)(p12;q24)|t(8;14)(q21;q32)|t(8;22)(q24;q11)|t(9;22)(q34;q11),United States|U.S.A.,"Active, not recruiting"
DNA excision repair protein ERCC-1 Expression High|ERCC1 Overexpression,Pancreatic Carcinoma,Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1,NCT01524575,ERCC1 Overexpression,United States,Unknown status
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Colorectal Carcinoma|Malignant Solid Tumor|Multiple Myeloma,A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers,NCT01524978,,United States|China|England|Scotland|United Kingdom|France|Germany|Spain,"Active, not recruiting"
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer,NCT01525589,,United States|U.S.A.|Spain,Recruiting
,Breast Carcinoma,Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer,NCT01525966,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Breast Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Leukemia|Lymphoma|Malignant Solid Tumor,A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901,NCT01526473,,United States,"Active, not recruiting"
BRAF Mutation,Cancer,Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer,NCT01531361,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Colorectal Carcinoma|Malignant Solid Tumor,Erlotinib in Combination With Pralatrexate in Advanced Malignancies,NCT01532011,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States,Completed
EGFR Exon 19 Deletion|EGFR L858R,Non-Small Cell Lung Carcinoma,Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations,NCT01532089,,United States|U.S.A.,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer,NCT01532960,,United States,Terminated
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia,"Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",NCT01534260,KMT2A-MLLT3 Fusion|PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
RB1 Amplification,Ovarian Carcinoma|Pancreatic Carcinoma,A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression,NCT01536743,,United States,"Active, not recruiting"
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Central Nervous System Lymphoma|Intraocular Lymphoma,Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma,NCT01542918,,United States|U.S.A.,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Malignant Solid Tumor,A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors,NCT01543698,,Canada|Singapore|Belgium|United States|Italy|Australia|France|Switzerland|Spain,"Active, not recruiting"
,Acute Myeloid Leukemia|RAEB-2,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,NCT01546038,BCR-ABL1 Fusion|PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(9;22)(q34;q11),Canada|United States|Poland|Italy|U.S.A.|Germany|Spain,"Active, not recruiting"
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|ROS1 Fusion|ROS1 Inversion,Cancer,Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer,NCT01548144,,United States,"Active, not recruiting"
,Breast Carcinoma,Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer,NCT01548677,,Belgium|England|United Kingdom|France|Germany,"Active, not recruiting"
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia,NCT01550185,PML-RARA Fusion,United States,Terminated
KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Trisomy 11|del(11)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,Phase II Temozolomide + Vorinostat in Patients With Relapse/Refractory AML,NCT01550224,,United States,"Active, not recruiting"
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Afatinib With CT and RT for EGFR-Mutant NSCLC,NCT01553942,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Diffuse Large B-Cell Lymphoma|Mediastinal Large B-Cell Lymphoma,Study of Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,NCT01555541,,United States|U.S.A.,Recruiting
,Lymphoma|Mature T-Cell and NK-Cell Lymphoma/Leukemia,"Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE",NCT01555892,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Fulvestrant With or Without Ganetespib in HR+ Breast Cancer,NCT01560416,,United States|U.S.A.,"Active, not recruiting"
SMAD4 Amplification,Pancreatic Carcinoma,"Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas",NCT01560949,,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,NCT01566721,,"Wales|England|Malaysia|Portugal|Greece|El Salvador|Morocco|Panama|Brazil|Guatemala|Korea, Republic of|Algeria|Slovenia|Chile|Colombia|Ecuador|Argentina|Hungary|Ukraine|Northern Ireland|Albania|New Zealand|Canada|Turkey|Finland|Taiwan|Italy|South Africa|Peru|Germany|Russian Federation|Singapore|Hong Kong|Egypt|Scotland|Thailand|Saudi Arabia|Netherlands|Sweden|Vietnam|Pakistan|Ireland|Poland|Slovakia|Bulgaria|France|Lithuania|Serbia|Bosnia and Herzegovina|Croatia|Romania|Uruguay|Philippines|United Kingdom|United Arab Emirates|Switzerland|Spain|Venezuela|Czech Republic|Norway|Dominican Republic|Mexico|Australia|Indonesia","Active, not recruiting"
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,CT Antigen TCR-redirected T Cells for Ovarian Cancer.,NCT01567891,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery,NCT01570998,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer,NCT01572038,,Hong Kong|Egypt|Wales|England|Scotland|Portugal|Greece|Saudi Arabia|Austria|Netherlands|Sweden|Pakistan|Morocco|China|Brazil|Poland|Algeria|Slovenia|France|Lithuania|Serbia|Ecuador|Argentina|Hungary|Uruguay|Ukraine|United Kingdom|United Arab Emirates|Spain|Lebanon|Canada|Venezuela|Turkey|Belgium|Finland|Italy|Mexico|Israel|Australia|Peru|Germany|Estonia,"Active, not recruiting"
Complex karyotype|Monosomal karyotype|Very Complex karyotype,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Hodgkin Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma,Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning,NCT01572662,,United States,"Active, not recruiting"
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR),NCT01573702,,United States|U.S.A.,Recruiting
FLT3 ITD,Acute Myeloid Leukemia,Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia,NCT01578109,,United States|U.S.A.,"Active, not recruiting"
MSLN Expression|Mesothelin Expression Positive,Cancer,CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer,NCT01583686,,United States,Recruiting
,Cervical Carcinoma|Malignant Solid Tumor,Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers,NCT01585428,,United States,Completed
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|PALB2 Mutation,Pancreatic Carcinoma,Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,NCT01585805,,Canada|United States|Israel|U.S.A.,Recruiting
HLA-A*02 Positive|TYR Expression|Tyrosinase Expression Positive,Melanoma,Transfer of Genetically Engineered Lymphocytes in Melanoma Patients,NCT01586403,,United States|U.S.A.,Recruiting
MYCN Amplification|NUT family member 1 Expression Positive|NUTM1 Expression|NUTM1 Fusion|NUTM1 Overexpression,Malignant Solid Tumor|NUT Midline Carcinoma,"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",NCT01587703,,"Canada|Netherlands|United States|Korea, Republic of|England|United Kingdom|U.S.A.|Australia|France|Spain",Recruiting
EPHA2 Expression|EPHA2 Overexpression|Ephrin type-A receptor 2 Expression Positive,Malignant Solid Tumor,EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery,NCT01591356,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib,NCT01593254,ABL1 F317L|ABL1 T315A|ABL1 T315I|ABL1 V299L,"Argentina|Hungary|United States|Thailand|Spain|Canada|Austria|Czech Republic|Belgium|China|Brazil|Korea, Republic of|Poland|Italy|U.S.A.|France","Active, not recruiting"
CD19 Overexpression,Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia|Mature B-Cell Lymphoma/Leukemia,Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma,NCT01593696,,United States,"Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Ruxolitinib in Estrogen Receptor Positive Breast Cancer,NCT01594216,,United States|U.S.A.,"Active, not recruiting"
BRAF Mutation,Cancer,Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer,NCT01596140,,United States,"Active, not recruiting"
,Breast Carcinoma,Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer,NCT01596751,,United States|U.S.A.,Recruiting
ESR1 Mutation,Breast Carcinoma,AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer,NCT01597388,,United States,"Active, not recruiting"
BCR-ABL1 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|TCF3-PBX1 Fusion|t(1;19)(q23;p13)|t(4;11)(q21;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adult T-Cell Leukemia/Lymphoma|Burkitt Lymphoma|Lymphoma|Prolymphocytic Leukemia,Double Cord Versus Haploidentical (BMT CTN 1101),NCT01597778,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(8;21)(q22;q22),United States|U.S.A.,Recruiting
,Acute Myeloid Leukemia,Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor,NCT01598025,CBFB-MYH11 Inversion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,United States|U.S.A.,"Active, not recruiting"
ESR1 Mutation|PGR Mutation,Breast Carcinoma,S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy,NCT01598298,,United States|U.S.A.,"Active, not recruiting"
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Diffuse Large B-Cell Lymphoma|Mediastinal Large B-Cell Lymphoma,"Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma",NCT01599559,,"Argentina|United States|Ukraine|England|United Kingdom|Scotland|Northern Ireland|Portugal|Switzerland|Canada|Sweden|Norway|Korea, Republic of|Poland|Italy|U.S.A.|Germany",Recruiting
DHH Overexpression|Desert hedgehog protein overexpression positive|IHH Overexpression|PTCH1 Overexpression|Protein patched homolog 1 overexpression positive|SHH Overexpression|SMO Overexpression|Smoothened homolog Overexpression|Sonic hedgehog Overexpression|indian hedgehog overexpression positive,Medulloblastoma,Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway,NCT01601184,,Italy|Scotland|United Kingdom|France|Switzerland,Recruiting
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies,NCT01606579,,United States,Completed
,Breast Carcinoma,Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer,NCT01609127,,United States,Unknown status
FOLR1 Expression|FOLR1 Overexpression|Folate receptor alpha Expression Positive|Folate receptor alpha Overexpression Positive,Malignant Solid Tumor,"First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors",NCT01609556,,Canada|United States|U.S.A.,"Active, not recruiting"
,Breast Carcinoma,Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,NCT01610284,,"Russian Federation|Singapore|United States|Czechia|England|Thailand|Greece|Austria|Netherlands|China|Brazil|Korea, Republic of|Poland|Slovakia|France|Argentina|Hungary|Japan|United Kingdom|Switzerland|Spain|Canada|Belgium|Taiwan|Italy|South Africa|Israel|Australia|Peru|Germany","Active, not recruiting"
,Breast Carcinoma,Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy,NCT01612247,,United States,Unknown status
,Acute Lymphoblastic Leukemia,A Study for Older Adults With Acute Lymphoblastic Leukaemia,NCT01616238,IGH-MYC Fusion|IGK-MYC Fusion|TRA-MYC Fusion|t(2;8)(p12;q24)|t(8;14)(q21;q32)|t(8;14)(q24;q32)|t(8;22)(q24;q11),England|Scotland|United Kingdom,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|Normal karyotype|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(17)(p10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Double-Hit Lymphoma|Hodgkin Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma,Natural Killer (NK) Cells in Cord Blood Transplantation,NCT01619761,CBFB-MYH11 Fusion|Complex karyotype|DEK-NUP214 Fusion|KMT2A-MLLT3 Fusion|Monosomy 5|Monosomy 7|Normal karyotype|PML-RARA Fusion|RPN1-MECOM Fusion|RUNX1-RUNX1T1 Fusion|Very Complex karyotype|del(5)(q10)|del(7)(q10)|inv(16)(p13q22)|inv(3)(q21q26)|t(16;16)(p13;q22)|t(3;3)(q21;q26)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer,NCT01620190,,United States|U.S.A.,Recruiting
WT1 Overexpression,Acute Myeloid Leukemia,Clinical Study of WT2725 in Patients With Advanced Malignancies,NCT01621542,PML-RARA Fusion,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,NCT01622868,,"United States|Korea, Republic of|U.S.A.|Republic of Korea",Recruiting
,Breast Carcinoma|Ovarian Carcinoma,Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,NCT01623349,,United States|U.S.A.,"Active, not recruiting"
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,"Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer",NCT01625234,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PIK3CA Mutation,Breast Carcinoma,"Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",NCT01625286,PIK3CA Mutation,"Singapore|Czechia|Japan|England|Scotland|United Kingdom|Spain|Canada|Korea, Republic of|Mexico|Bulgaria|France|Peru","Active, not recruiting"
CD19 Expression,Chronic Lymphocytic Leukemia|Mature B-Cell Lymphoma/Leukemia,Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma,NCT01626495,,United States,"Active, not recruiting"
KMT2A-MLLT3 Fusion,Acute Myeloid Leukemia,"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia",NCT01627041,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,United States,"Active, not recruiting"
Complex karyotype|FLT3 D835A|FLT3 D835E|FLT3 D835H|FLT3 D835N|FLT3 D835V|FLT3 D835Y|FLT3 I836D|FLT3 I836F|FLT3 I836H|FLT3 I836L|FLT3 I836M|FLT3 I836V|FLT3 ITD|Monosomal karyotype|Very Complex karyotype,Acute Myeloid Leukemia,The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.,NCT01627314,,United States,Terminated
,Breast Carcinoma,"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",NCT01633060,,"United States|England|Scotland|Thailand|Greece|Austria|Netherlands|Sweden|Korea, Republic of|Poland|Bulgaria|France|Colombia|Argentina|Hungary|United Kingdom|Spain|Lebanon|Canada|Belgium|Norway|Finland|Italy|U.S.A.|Germany","Active, not recruiting"
,Adenocarcinoma of the Gastroesophageal Junction|Breast Carcinoma|Colorectal Carcinoma|Fallopian Tube Carcinoma|Gastric Adenocarcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer|Renal Cell Carcinoma,A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors,NCT01633970,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion|KMT2A Fusion|TCF3-PBX1 Fusion,Acute Lymphoblastic Leukemia,Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation,NCT01634217,,United States|U.S.A.,"Active, not recruiting"
,Hodgkin Lymphoma,Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma,NCT01636388,,United States,Recruiting
BRAF Mutation,Lymphoma|Malignant Solid Tumor,"Study of Vemurafenib, Carboplatin, and Paclitaxel",NCT01636622,,United States,"Active, not recruiting"
BRAF V600E,Melanoma,A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,NCT01638676,,United States,Recruiting
,Breast Carcinoma,Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC,NCT01639248,,United States|China,Recruiting
AXL Amplification|AXL Fusion|AXL Mutation|AXL Overexpression|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|NTRK1 Fusion|NTRK2 Fusion|NTRK3 Fusion|RET Fusion|ROS1 Fusion|Tyrosine-protein kinase receptor UFO Expression Positive,Non-Small Cell Lung Carcinoma,Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity,NCT01639508,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|RPN1-MECOM Inversion|Trisomy 21|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(17)(p10)|del(20)(q10)|del(3)(q10)|del(7)(q10)|del(9)(q10),Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndromes,"Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant",NCT01640301,BCR-ABL1 Fusion|CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,United States|U.S.A.,Suspended
ERBB2 Amplification,Gastric Carcinoma,A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer,NCT01641939,,"Russian Federation|Singapore|United States|Czechia|Wales|England|Scotland|Malaysia|China|Panama|Brazil|Guatemala|Korea, Republic of|Poland|France|Argentina|Romania|Hungary|Japan|Philippines|United Kingdom|Spain|Canada|Turkey|Belgium|Finland|Taiwan|Italy|Mexico|Peru|Germany",Terminated
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Colorectal Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,NCT01642342,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Study of Erlotinib and Metformin in Triple Negative Breast Cancer,NCT01650506,,United States,"Active, not recruiting"
"AKT1 Amplification|AKT1 Mutation|AKT2 Amplification|AKT2 Mutation|AKT3 Amplification|AKT3 Mutation|CRKL Mutation|EGFR Amplification|EGFR Mutation|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|IRS2 Mutation|KIT Amplification|KIT Mutation|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|MTOR Mutation|PDGFRA Amplification|PDGFRA Mutation|PIK3CA Amplification|PIK3CA Mutation|PIK3CG Mutation|PIK3R1 Mutation|PIK3R2 Mutation|PTEN Large Deletion|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|RICTOR Amplification|RICTOR Mutation|RNF43 Mutation|RPTOR Mutation|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression|TSC1 Mutation|TSC2 Mutation",Breast Carcinoma|Cancer|Squamous Cell Lung Carcinoma,A Study of LY3023414 in Participants With Advanced Cancer,NCT01655225,,United States|Italy,Recruiting
PAX8-PPARG Fusion,Thyroid Gland Carcinoma,Pioglitazone in Thyroid Cancers,NCT01655719,,United States|U.S.A.,Completed
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma,NCT01656642,,United States|U.S.A.,"Active, not recruiting"
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Anaplastic Large Cell Lymphoma|Hodgkin Lymphoma,Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL),NCT01657331,,Canada|United States|U.S.A.,"Active, not recruiting"
BRAF V600E|BRAF V600K,Melanoma,Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,NCT01657591,,United States,"Active, not recruiting"
FLT3 Codon 835 Missense|FLT3 Codon 836 Missense|FLT3 ITD,Acute Myeloid Leukemia,A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations,NCT01657682,,United States,Recruiting
ESR1 Amplification,Breast Carcinoma,Tamoxifen Citrate in Treating Premenopausal Women With Estrogen Receptor-Positive Breast Cancer,NCT01658566,TP53 Mutation,,Closed
BRAF V600D|BRAF V600E|BRAF V600K,Melanoma,Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma,NCT01659151,,United States|U.S.A.,"Active, not recruiting"
NF1 Mutation,Malignant Peripheral Nerve Sheath Tumor (MPNST),SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors,NCT01661283,,United States,"Active, not recruiting"
MYCN Amplification,Malignant Solid Tumor|Neuroblastoma,Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors,NCT01662804,MYCN Amplification,United States,"Active, not recruiting"
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Oropharyngeal Squamous Cell Carcinoma,Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients,NCT01663259,,United States|U.S.A.,"Active, not recruiting"
MTOR Mutation,Renal Cell Carcinoma,"Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",NCT01664182,,United States,"Active, not recruiting"
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Hodgkin Lymphoma|Mature B-Cell Non-Hodgkin Lymphoma,Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma,NCT01665768,,United States|U.S.A.,Recruiting
BRAF Mutation,Melanoma,BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma,NCT01667419,,Russian Federation|United States|Czechia|Wales|England|Scotland|Portugal|Austria|Netherlands|Sweden|Ireland|Brazil|Poland|France|Serbia|Croatia|Argentina|Ukraine|United Kingdom|Switzerland|Spain|New Zealand|Canada|Belgium|Norway|Italy|Mexico|South Africa|U.S.A.|Israel|Australia|Germany|Estonia,"Active, not recruiting"
IGH-MAF Fusion|IGH-MAFB Fusion|del(17)(p10)|t(14;16)(q32;q23)|t(14;20)(q32;q12),Multiple Myeloma,"S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",NCT01668719,,United States|U.S.A.,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa,NCT01670500,,United States|U.S.A.,Recruiting
ERBB2 Mutation|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,NCT01670877,,New Zealand|Canada|United States|U.S.A.,Recruiting
,Breast Carcinoma,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,NCT01674140,,Puerto Rico|United States|U.S.A.,Recruiting
,Breast Carcinoma,Cisplatin + RT for Triple Negative Breast Cancer,NCT01674842,,United States|U.S.A.,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Glioma|Langerhans Cell Histiocytosis|Malignant Solid Tumor|Melanoma|Thyroid Gland Papillary Carcinoma,"A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects",NCT01677741,,Canada|United States|Denmark|England|United Kingdom|U.S.A.|Australia|France|Germany|Spain,Recruiting
BRAF V600E|BRAF V600K,Melanoma,Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,NCT01682213,,United States,"Active, not recruiting"
KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Trisomy 11|del(11)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndromes|Myeloproliferative Neoplasm,"A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving",NCT01684150,,Netherlands|United States|Germany,Completed
MS4A1 Overexpression,Diffuse Large B-Cell Lymphoma|Mature B-Cell Lymphoma/Leukemia,Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL,NCT01686165,,United States,"Active, not recruiting"
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Oropharyngeal Squamous Cell Carcinoma,"Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer",NCT01687413,,United States,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Leukemia of Ambiguous Lineage|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndromes,"Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes",NCT01690520,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
,Adenoid Cystic Carcinoma|B-Cell Neoplasm|Breast Carcinoma|Cholangiocarcinoma|Chronic Lymphocytic Leukemia|Hepatocellular Carcinoma|Lymphoma|Malignant Solid Tumor|T-Cell and NK-Cell Neoplasm,A Study of LY3039478 in Participants With Advanced Cancer,NCT01695005,,United States|Denmark|England|United Kingdom|U.S.A.|France|Germany|Spain,Recruiting
,Breast Carcinoma,"Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",NCT01697293,,United States|U.S.A.,Recruiting
,Cancer,Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies,NCT01697527,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop),NCT01698905,,"Argentina|Russian Federation|Singapore|United States|Japan|England|United Kingdom|Spain|Greece|Canada|Belgium|Brazil|Korea, Republic of|Poland|Mexico|Israel|Australia|France|Tunisia|Germany","Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,"Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",NCT01698918,,United States|Portugal,Recruiting
,Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma,Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma,NCT01700946,ETV6-RUNX1 Fusion|Hyperdiploidy|t(12;21)(p13;q22),United States|U.S.A.,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,NCT01701037,,United States|U.S.A.,Unknown status
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|del(5)(q10),Acute Myeloid Leukemia,Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia,NCT01701323,,United States|U.S.A.,"Active, not recruiting"
BRAF Mutation,Melanoma,Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,NCT01701674,BRAF Mutation,United States,"Active, not recruiting"
,Acute Myeloid Leukemia,Phase I/II Study of DFP-10917 in Patients With Acute Leukemia,NCT01702155,PML-RARA Fusion,United States|U.S.A.,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment,NCT01702571,,China|Indonesia,Recruiting
MYCN Amplification,Neuroblastoma,High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN),NCT01704716,MYCN Amplification,Hungary|England|Scotland|United Kingdom|Northern Ireland|Portugal|Switzerland|Spain|Greece|Austria|Czech Republic|Sweden|Belgium|Norway|Ireland|Denmark|Poland|Italy|Israel|Slovakia|Slovenia|Australia|France,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Nasopharyngeal Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer,NCT01706939,,United States,"Active, not recruiting"
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|del(11)(q22q23)|del(5)(q10)|dup(11)(q22q23),Acute Myeloid Leukemia|Myelodysplastic Syndromes|Myeloproliferative Neoplasm,Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,NCT01707004,BCR-ABL1 Fusion,United States|U.S.A.,"Active, not recruiting"
BRAF V600E,Thyroid Gland Papillary Carcinoma,Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer,NCT01709292,,United States|U.S.A.,Recruiting
,Head and Neck Squamous Cell Carcinoma|Oropharyngeal carcinoma,Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,NCT01711541,,United States,Recruiting
MYCN Amplification,Neuroblastoma,Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma,NCT01711554,MYCN Amplification,Canada|United States|U.S.A.,Recruiting
,Head and Neck Squamous Cell Carcinoma,TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.,NCT01711658,CDKN2A Expression|CDKN2A Overexpression,Canada|United States|U.S.A.,Recruiting
BCR-ABL1 Fusion,Acute Myeloid Leukemia|Diffuse Large B-Cell Lymphoma,"A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Hematologic Malignancies (MK-8628-001)",NCT01713582,PML-RARA Fusion,,Closed
BRAF Mutation,Colorectal Carcinoma,"Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",NCT01719380,,"Canada|Netherlands|Belgium|United States|Norway|Japan|Korea, Republic of|Italy|Australia|France|Germany|Spain","Active, not recruiting"
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,"Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Peripheral T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified","CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study",NCT01719835,ALK Expression|ALK tyrosine kinase receptor Expression Positive,England|United Kingdom,Recruiting
Trisomy 19|Trisomy 8|del(7)(q10),Myelodysplastic Syndromes,Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk,NCT01720225,,United States,"Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|MDM2 Amplification,Breast Carcinoma|Malignant Solid Tumor|Multiple Myeloma,A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma,NCT01723020,,Netherlands|United States|U.S.A.|France,"Active, not recruiting"
BRAF Mutation,Thyroid Cancer,Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,NCT01723202,,United States|U.S.A.,"Active, not recruiting"
Antigen KI-67 Expression Positive|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|MKI67 Expression|MKI67 Overexpression|PIK3CA Mutation,Breast Carcinoma,PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,NCT01723774,PIK3CA Mutation,United States|U.S.A.,Recruiting
BRAF V600E,Melanoma,LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,NCT01726738,,United States|U.S.A.,"Active, not recruiting"
MS4A1 Overexpression,Mature B-Cell Lymphoma/Leukemia,Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma,NCT01729806,,United States,"Active, not recruiting"
Complex karyotype|Monosomy 7|RPN1-MECOM Fusion|RPN1-MECOM Inversion|Very Complex karyotype|del(7)(q10),Acute Myeloid Leukemia|Myelodysplastic Syndromes,"Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",NCT01729845,PML-RARA Fusion,United States|U.S.A.,"Active, not recruiting"
KRAS Mutation,Colorectal Carcinoma,A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer,NCT01729923,KRAS Mutation,United States,Terminated
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Malignant Solid Tumor,Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,NCT01730118,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer",NCT01730833,,United States|U.S.A.,Recruiting
HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Non-Small Cell Lung Carcinoma|Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma,Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer,NCT01737502,,United States|U.S.A.,Recruiting
KIT Mutation,Gastrointestinal Stromal Tumor|Malignant Solid Tumor|Melanoma,Ipilimumab and Imatinib Mesylate in Advanced Cancer,NCT01738139,KIT D816H|KIT D816I|KIT D816V|KIT D816Y|KIT Exon 18 Mutation|KIT T670I|KIT V654A|KIT V654E|KIT V654L,United States|U.S.A.,Recruiting
BRAF V600E|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Rectal Cancer,"Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",NCT01740648,,United States|U.S.A.,Recruiting
EGFR Amplification,Malignant Solid Tumor|Squamous Cell Lung Carcinoma,A Study of ABT-414 in Subjects With Solid Tumors,NCT01741727,,Canada|United States,Completed
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Cancer,"Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)",NCT01742286,,Canada|Netherlands|United States|England|Italy|United Kingdom|U.S.A.|Australia|France|Germany|Spain,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.,NCT01743989,,Romania|Belgium|Denmark,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|BRAF Mutation|CDKN2A Mutation|CTGF Expression|Connective tissue growth factor Expression Positive|DDR2 Mutation|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|TRIM16 Expression|Tripartite motif-containing protein 16 Expression Positive,Lymphoma|Malignant Solid Tumor,Dasatinib and Crizotinib in Advanced Cancer,NCT01744652,,United States,"Active, not recruiting"
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation,NCT01746251,,United States|U.S.A.,"Active, not recruiting"
del(17)(p10),Chronic Lymphocytic Leukemia,CD19 Redirected Autologous T Cells,NCT01747486,,United States|U.S.A.,"Active, not recruiting"
BRAF V600E,Glioma,Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas,NCT01748149,,United States|U.S.A.,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Lymphoma|Malignant Solid Tumor,AZD1775 for Advanced Solid Tumors,NCT01748825,,United States|U.S.A.,Recruiting
,Non-Small Cell Lung Carcinoma,Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.,NCT01750281,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Netherlands|Hungary|United States|Brazil|Poland|Bulgaria|France|Germany,"Active, not recruiting"
del(11)(q10),Chronic Lymphocytic Leukemia,A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL,NCT01750567,,United States,Recruiting
BRAF V600E,Colorectal Carcinoma,BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),NCT01750918,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Netherlands|Belgium|United States|Japan|England|Italy|United Kingdom|U.S.A.|France|Spain,"Active, not recruiting"
BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD),NCT01751425,,United States|U.S.A.,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Non-Small Cell Lung Carcinoma,AUY922 for Advanced ALK-positive NSCLC,NCT01752400,,United States|U.S.A.,"Active, not recruiting"
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FGFR4 Amplification|FGFR4 Fusion|FGFR4 Mutation,Malignant Solid Tumor,Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations,NCT01752920,,United States|Italy|U.S.A.,"Active, not recruiting"
,Breast Carcinoma,Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery,NCT01754519,BRCA2 Mutation,United States,Terminated
Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Hepatocellular Carcinoma,Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy,NCT01755767,,Argentina|United States|Switzerland|Portugal|Spain|New Zealand|Canada|Sweden|Austria|Netherlands|Belgium|Brazil|Italy|Australia|France|Germany,"Active, not recruiting"
FLT3 ITD,Acute Myeloid Leukemia,Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission,NCT01757535,BCR-ABL1 Fusion|CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(8;21)(q22;q22)|t(9;22)(q34;q11),"Russian Federation|United States|Czechia|England|Portugal|Austria|Ireland|Brazil|Korea, Republic of|Poland|France|Lithuania|United Kingdom|Spain|Canada|Turkey|Belgium|Finland|Taiwan|Italy|Mexico|Israel|U.S.A.|Australia|Germany",Recruiting
MYCN Amplification,Neuroblastoma,Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma,NCT01757626,MYCN Amplification,United States|U.S.A.,Recruiting
,Malignant Solid Tumor,A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors,NCT01760525,TP53 Mutation,Singapore|United States|France|Switzerland|Germany,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 17|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|RPN1-MECOM Inversion|TP53 Mutation|Trisomy 11|Trisomy 21|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(12)(p10)|del(17)(p10)|del(5)(q10)|del(7)(q10)|del(9)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Hematologic and Lymphocytic Disorder|Hodgkin Lymphoma|Myelodysplastic Syndromes|Myeloma|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma,Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,NCT01760655,KMT2A-MLLT3 Fusion|del(5)(q10)|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Melanoma,Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,NCT01763164,,"Russian Federation|United States|Wales|England|Scotland|Portugal|Greece|Austria|Netherlands|Sweden|Brazil|Korea, Republic of|Poland|Slovakia|France|Argentina|Hungary|Japan|United Kingdom|Switzerland|Spain|Canada|Czech Republic|Turkey|Belgium|Italy|South Africa|Israel|Australia|Germany","Active, not recruiting"
BRAF Mutation,Melanoma,A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf),NCT01765543,,United States|Egypt|Brazil|South Africa|Croatia,Completed
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer,NCT01766297,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States,Recruiting
BRAF V600E|BRAF V600K,Melanoma,Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,NCT01767454,,United States,Completed
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Malignant Solid Tumor,A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients,NCT01767623,,Turkey|Israel|Australia,Recruiting
NF2 Mutation,Schwannoma,Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas,NCT01767792,,United States,"Active, not recruiting"
,Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor),NCT01772004,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States|U.S.A.,Recruiting
ERBB2 Amplification,Breast Carcinoma,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),NCT01772472,,Hong Kong|United States|England|Scotland|Greece|Austria|Sweden|China|Ireland|Panama|Brazil|Guatemala|France|Serbia|Colombia|Argentina|United Kingdom|Switzerland|Spain|Canada|Czech Republic|Turkey|Belgium|Taiwan|Italy|Mexico|South Africa|Israel|Peru|Germany,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Gastric Carcinoma,A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,NCT01774786,,"Russian Federation|United States|Malaysia|Kazakhstan|Thailand|Austria|Netherlands|El Salvador|China|Macedonia, The Former Yugoslav Republic of|Panama|Brazil|Guatemala|Korea, Republic of|Poland|Bulgaria|Croatia|Romania|Hungary|Japan|Switzerland|Spain|Canada|Turkey|Belgium|Finland|Taiwan|Italy|Mexico|Australia|Peru|Germany","Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PIK3CA Mutation,Breast Carcinoma,Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer,NCT01776008,,United States,"Active, not recruiting"
,Colorectal Carcinoma,A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer,NCT01776307,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States|U.S.A.,Recruiting
,Breast Carcinoma,Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,NCT01779050,,United States|U.S.A.,"Active, not recruiting"
BRAF Mutation|MAP2K1 Mutation|NRAS Mutation,Cancer|Melanoma,"Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies",NCT01781429,,United States|U.S.A.,"Active, not recruiting"
NRAS Mutation,Melanoma,A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,NCT01781572,,Netherlands|United States|Italy|U.S.A.|Australia|Germany,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",NCT01783756,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients,NCT01784068,,Hungary,Recruiting
ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer,NCT01784640,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States,"Active, not recruiting"
,Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|B-Cell Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Diffuse Large B-Cell Lymphoma|Mature T-Cell and NK-Cell Lymphoma/Leukemia|Mediastinal Large B-Cell Lymphoma|Peripheral T-Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma,Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency,NCT01787409,IGH-CCND1 Fusion|t(11;14)(q13;32),United States|U.S.A.,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Malignant Solid Tumor,"Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers",NCT01787500,KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V,United States|U.S.A.,"Active, not recruiting"
Complex karyotype|KMT2A Fusion|Monosomy 5|Monosomy 7|RPN1-MECOM Inversion|Trisomy 8|Very Complex karyotype|del(12)(p10)|del(5)(q10)|del(7)(q10)|i(17)(q10)|inv(3)(q21q26),Primary Myelofibrosis|Secondary Myelofibrosis,Ruxolitinib Prior to Transplant in Patients With Myelofibrosis,NCT01790295,,Canada|Sweden|Netherlands|Belgium|United States|England|United Kingdom|Italy|U.S.A.|Israel|Germany,"Active, not recruiting"
PIK3CA Mutation,Breast Carcinoma,BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer,NCT01791478,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL),NCT01791985,,England|United Kingdom|Scotland,"Active, not recruiting"
,Breast Carcinoma,Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer,NCT01792050,,United States|Poland,"Active, not recruiting"
,Breast Carcinoma,A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.,NCT01792726,,Saudi Arabia|United States|England|Italy|United Kingdom|Scotland|France|Switzerland|Spain,Recruiting
,Ependymoma,Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod,NCT01795313,,United States|U.S.A.,Recruiting
FGFR1 Amplification|FGFR2 Amplification,Adenocarcinoma of the Gastroesophageal Junction|Breast Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Non-Small Cell Lung Carcinoma,Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours,NCT01795768,,England|United Kingdom,Unknown status
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome,NCT01795924,,United States,Unknown status
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa,NCT01796197,,United States|U.S.A.,Recruiting
,Breast Carcinoma,"Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",NCT01797120,,United States,"Active, not recruiting"
EGFR Amplification,Glioblastoma,Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme,NCT01800695,,Netherlands|United States|Australia,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia,Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia,NCT01801046,KMT2A-MLLT3 Fusion|PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
,Colorectal Carcinoma,Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,NCT01802320,BRAF D594E|BRAF D594G|BRAF D594H|BRAF D594N|BRAF D594V|BRAF G466V|BRAF G469A|BRAF G469E|BRAF G469L|BRAF G469V|BRAF G596R|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF R444W|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|BRAF Y472C|HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|RPN1-MECOM Inversion|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(17)(p10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia,NCT01802333,KMT2A-MLLT3 Fusion,Canada|United States,"Active, not recruiting"
,Acute Lymphoblastic Leukemia,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,NCT01802814,BCR-ABL1 Fusion|t(9;22)(q34;q11),Czechia|Japan|England|United Kingdom|Portugal|Switzerland|Austria|Netherlands|Sweden|Belgium|Norway|Ireland|Finland|Denmark|Poland|Italy|Israel|Australia|France|Germany,Recruiting
,Breast Carcinoma,Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients,NCT01802970,,United States,Recruiting
,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Carcinoma|Gastric Adenocarcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma|Pancreatic Carcinoma,Safety and Tolerability Study in Solid Tumors,NCT01803282,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,United States,Recruiting
Complex karyotype|Monosomal karyotype|Monosomy 5|Monosomy 7|Very Complex karyotype,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia,NCT01804101,PML-RARA Fusion,United States|U.S.A.,"Active, not recruiting"
NTRK1 Fusion|NTRK1 Mutation|NTRK2 Fusion|NTRK2 Mutation|NTRK3 Fusion|NTRK3 Mutation,Malignant Solid Tumor,Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors,NCT01804530,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,"De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia",NCT01804985,,England|United Kingdom,"Active, not recruiting"
B-lymphocyte antigen CD20 Expression Positive|EBV Positive|Epstein-Barr virus (EBV) encoded small nuclear RNAs Expression Positive|MS4A1 Expression|MS4A1 Overexpression|TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Lymphoma,Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas,NCT01805037,,United States|U.S.A.,Unknown status
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer,NCT01805076,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States|U.S.A.,Recruiting
CD19 Overexpression,Chronic Lymphocytic Leukemia|Mature B-Cell Lymphoma/Leukemia,A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies,NCT01805375,,England|United Kingdom|Scotland,"Active, not recruiting"
KIT Expression|KIT Overexpression|Mast/stem cell growth factor receptor Kit Expression Positive|Mast/stem cell growth factor receptor Kit Overexpression,Acute Myeloid Leukemia,"Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",NCT01806571,,United States|U.S.A.,Recruiting
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,NCT01807091,Complex karyotype|Monosomal karyotype|PML-RARA Fusion|Very Complex karyotype,United States|U.S.A.,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Aggressive Systemic Mastocytosis|Mast Cell Leukemia,Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia,NCT01807598,FIP1L1-PDGFRA Fusion|del(4)(q12q12),United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,NCT01808573,,"Republic of Singapore|Russian Federation|Singapore|Hong Kong|United States|Wales|England|Portugal|Austria|Netherlands|Sweden|Ireland|Brazil|Korea, Republic of|France|Argentina|Japan|United Kingdom|Switzerland|Spain|Canada|Czech Republic|Turkey|Belgium|Finland|Taiwan|Denmark|Italy|Israel|U.S.A.|Australia|Germany",Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Hodgkin Lymphoma|Non-Hodgkin Lymphoma,Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma,NCT01811368,,United States|U.S.A.,Recruiting
,Chronic Myeloid Leukemia|Myelodysplastic Syndromes,Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant,NCT01812252,PML-RARA Fusion,United States|U.S.A.,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma,NCT01813214,,United States|U.S.A.,Terminated
RET Fusion|RET Inversion,Non-Small Cell Lung Carcinoma,Ponatinib in Advanced NSCLC w/ RET Translocations,NCT01813734,,United States|U.S.A.,Recruiting
,Colorectal Carcinoma,Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,NCT01814501,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery,NCT01816035,,United States|U.S.A.,Completed
BCR-ABL1 Fusion|Complex karyotype|FLT3 ITD|Hypodiploidy|KMT2A-AFF1 Fusion|Monosomy 5|Monosomy 7|Very Complex karyotype|del(5)(q10)|del(7)(q10),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,Phase I/II Study of Treg/Tcon Addback to CD34 Selected Partially Matched Related Donor Stem Cells With Myeloablative Conditioning for High Risk Hematologic Malignancies,NCT01818479,,United States|U.S.A.,Suspended
,Breast Carcinoma,Ixabepilone and SBRT For Metastatic Breast Cancer,NCT01818999,,United States,Terminated
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|RUNX1-RUNX1T1 Fusion|del(5)(q10),Acute Myeloid Leukemia,Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,NCT01820624,,United States,Completed
,Acute Myeloid Leukemia,"Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",NCT01822015,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States|U.S.A.,"Active, not recruiting"
ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer,NCT01822496,EGFR T790M,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|DNMT3A Mutation|FLT3 ITD|HRAS Mutation|KIT Mutation|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|KRAS Mutation|Monosomal karyotype|Monosomy 5|Monosomy 7|NRAS Mutation|RPN1-MECOM Fusion|RPN1-MECOM Inversion|RUNX1-RUNX1T1 Fusion|TET2 Mutation|TP53 Mutation|Trisomy 11|Trisomy 21|Very Complex karyotype|del(11)(q10)|del(17)(p10)|del(20)(q10)|del(5)(q10)|del(7)(q10)|del(9)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndromes,Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,NCT01823198,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Mutation|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,NCT01823835,,"Netherlands|United States|Korea, Republic of|U.S.A.|Spain","Active, not recruiting"
,Juvenile Myelomonocytic Leukemia,"Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia",NCT01824693,NF1 Mutation|PTPN11 Exon 13 Mutation|PTPN11 Exon 3 Mutation|PTPN11 Germline Mutation,New Zealand|Canada|United States|Australia,"Active, not recruiting"
,Breast Carcinoma,A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS),NCT01824836,,United States|U.S.A.,Recruiting
WT1 Expression|WT1 Overexpression|Wilms tumor protein Expression Positive,Multiple Myeloma,WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation,NCT01827137,,United States|U.S.A.,"Active, not recruiting"
ATM Deletion|ATM Mutation|ATR Deletion|ATR Mutation|BRAF Mutation|ERCC1 Deletion|ERCC1 Mutation|HRAS Mutation|KRAS Mutation|MLH1 Deletion|MLH1 Mutation|MSH2 Deletion|MSH2 Mutation|NBN Deletion|NBN Mutation|NF1 Deletion|NF1 Mutation|NRAS Mutation|PARP1 Deletion|PARP1 Mutation|PARP2 Deletion|PARP2 Mutation|RAD51 Deletion|RAD51 Mutation|TP53 Deletion|TP53 Loss|TP53 Mutation,Malignant Solid Tumor,Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,NCT01827384,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Eribulin in HER2 Negative Metastatic BrCa,NCT01827787,,United States|U.S.A.,"Active, not recruiting"
ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer,NCT01828021,ERBB2 Amplification,United States|U.S.A.,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Non-Small Cell Lung Carcinoma,LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer,NCT01828099,,"Russian Federation|Singapore|England|Thailand|Portugal|Greece|Austria|Netherlands|Sweden|China|Ireland|Brazil|Korea, Republic of|Poland|France|Colombia|Argentina|Hungary|Japan|United Kingdom|India|Spain|Lebanon|Turkey|Norway|Taiwan|Denmark|Italy|Mexico|Australia|Germany","Active, not recruiting"
ALK Fusion,Non-Small Cell Lung Carcinoma,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,NCT01828112,,"Russian Federation|Singapore|Hong Kong|United States|Japan|England|United Kingdom|Scotland|Portugal|Switzerland|Spain|Lebanon|Canada|Netherlands|Turkey|Belgium|Ireland|Korea, Republic of|Italy|Israel|France|Germany","Active, not recruiting"
RET Fusion,Non-Small Cell Lung Carcinoma,Sunitinib in Never-Smokers With Lung Adenocarcinoma,NCT01829217,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|RET Fusion,United States|U.S.A.,"Active, not recruiting"
NPM1 Mutation,Acute Myeloid Leukemia,Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,NCT01835288,,United States,Not yet recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer,NCT01837095,,United States|U.S.A.|Spain,"Active, not recruiting"
MET Amplification,Breast Carcinoma,cMet CAR RNA T Cells Targeting Breast Cancer,NCT01837602,,United States|U.S.A.,"Active, not recruiting"
RET Germline Mutation|RET Mutation,Thyroid Gland Medullary Carcinoma,Ponatinib for Advanced Medullary Thyroid Cancer,NCT01838642,RET Germline Mutation|RET Mutation,United States,Terminated
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,"Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia",NCT01839240,,United States,"Active, not recruiting"
,Breast Carcinoma,APBI Proton Feasibility and Phase II Study,NCT01839838,,United States|U.S.A.,Recruiting
,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndromes,PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant,NCT01841333,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,"Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.",NCT01844765,,Canada,Recruiting
BRCA1 Mutation|BRCA2 Mutation,Ovarian Carcinoma,Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.,NCT01844986,,"Russian Federation|United States|Japan|England|Scotland|United Kingdom|Spain|Canada|Netherlands|China|Brazil|Korea, Republic of|Poland|Italy|Israel|Australia|France","Active, not recruiting"
CBFB Fusion|CBFB-MYH11 Inversion|FLT3 D835A|FLT3 D835E|FLT3 D835H|FLT3 D835N|FLT3 D835V|FLT3 D835Y|FLT3 I836D|FLT3 I836F|FLT3 I836H|FLT3 I836L|FLT3 I836M|FLT3 I836V|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,NCT01846624,PML-RARA Fusion,United States,"Active, not recruiting"
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|RUNX1-RUNX1T1 Fusion|del(5)(q10),Acute Myeloid Leukemia,Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,NCT01849276,PML-RARA Fusion,United States,"Active, not recruiting"
,Chronic Myeloid Leukemia,Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response,NCT01850004,BCR-ABL1 Fusion,Canada|United States|Italy|U.S.A.|France|Germany|Spain,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),NCT01853748,,United States|U.S.A.,Recruiting
EGFR Exon 20 Insertion,Non-Small Cell Lung Carcinoma,Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR,NCT01854034,,United States|U.S.A.,Completed
CD79A Mutation|CD79B Mutation,Anaplastic Large Cell Lymphoma,Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma,NCT01854606,,"Netherlands|Hong Kong|United States|Taiwan|Korea, Republic of|Italy|France|Germany",Completed
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer,NCT01855828,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Diffuse Large B-Cell Lymphoma,Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma,NCT01856192,,United States|U.S.A.,"Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer,NCT01857193,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer,NCT01857271,,United States|U.S.A.,Recruiting
MYCN Amplification,Neuroblastoma,Therapy for Children With Advanced Stage Neuroblastoma,NCT01857934,MYCN Amplification,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma,A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation,NCT01859026,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|Mature B-Cell Lymphoma/Leukemia,Treatment for Advanced B-Cell Lymphoma,NCT01859819,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Hypodiploidy|IKZF1 Frameshift|IKZF1 Mutation|IKZF1 Nonsense|KMT2A Fusion|TCF3-HLF Fusion|t(17;19)(q22; p13)|t(9;22)(q34;q11),B Acute Lymphoblastic Leukemia,T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,NCT01860937,,United States|U.S.A.,"Active, not recruiting"
,Colorectal Carcinoma,Phase I/II Trial of Antagonism of HER in GI Cancer,NCT01862003,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,England|Scotland|United Kingdom,Recruiting
,Breast Carcinoma,"A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer",NCT01862081,,Canada|Belgium|United States|U.S.A.|Spain,"Active, not recruiting"
,Breast Carcinoma,A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery,NCT01864746,,"United States|Japan|England|United Kingdom|Spain|Canada|Austria|Ireland|Brazil|Korea, Republic of|Italy|U.S.A.|Australia|France|Germany",Recruiting
FGFR1 Amplification,Non-Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma,"Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",NCT01868022,,Netherlands|Russian Federation|Belgium|United States|Denmark|England|United Kingdom|U.S.A.|France|Spain,"Active, not recruiting"
,Myelodysplastic Syndromes,Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.,NCT01868477,,"Canada|Argentina|Sweden|China|Korea, Republic of|Algeria|U.S.A.",Recruiting
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy,NCT01869114,,United States|U.S.A.,Recruiting
CD33 Expression|CD33 Overexpression|Myeloid cell surface antigen CD33 Expression Positive,Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|Acute Promyelocytic Leukemia,Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia,NCT01869803,,United States|U.S.A.,Suspended
,Breast Carcinoma,BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer,NCT01870505,,United States|U.S.A.,"Active, not recruiting"
"MET Amplification|MET Mutation|PTEN Large Deletion|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Expression Negative",Glioblastoma,Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma,NCT01870726,PTEN Expression|PTEN Overexpression,Netherlands|United States|U.S.A.|Switzerland|Germany|Spain,Completed
,Colorectal Carcinoma|Head and Neck Squamous Cell Carcinoma,A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors,NCT01871311,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States,Recruiting
MS4A1 Overexpression,Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma,Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies,NCT01871675,,United States,Completed
IL2RA Expression|IL2RA Overexpression|Interleukin-2 receptor subunit alpha Expression Positive,Cutaneous T Cell Lymphoma,A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma,NCT01871727,,United States|U.S.A.|Australia,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",NCT01872260,,"United States|Korea, Republic of|England|Italy|Scotland|United Kingdom|U.S.A.|Australia|France|Switzerland|Spain",Recruiting
PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),Acute Myeloid Leukemia,Omacetaxine for Consolidation and Maintenance,NCT01873495,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer",NCT01873833,,United States|U.S.A.,Recruiting
,Oropharyngeal Squamous Cell Carcinoma,Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC,NCT01874171,,Netherlands|Ireland|Wales|England|Scotland|United Kingdom,"Active, not recruiting"
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Endometrial Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,NCT01874353,,"Russian Federation|United States|Japan|England|Scotland|United Kingdom|Spain|Canada|Netherlands|Belgium|China|Brazil|Korea, Republic of|Poland|Italy|Israel|Australia|France|Germany","Active, not recruiting"
Complex karyotype|FLT3 D835A|FLT3 D835E|FLT3 D835H|FLT3 D835N|FLT3 D835V|FLT3 D835Y|FLT3 I836D|FLT3 I836F|FLT3 I836H|FLT3 I836L|FLT3 I836M|FLT3 I836V|FLT3 ITD|Monosomal karyotype|Very Complex karyotype,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene,NCT01875237,,United States|U.S.A.,Terminated
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",NCT01875666,,United States|U.S.A.,"Active, not recruiting"
,Melanoma,Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma,NCT01876212,KIT A502_Y503insFA|KIT A829P|KIT Amplification|KIT D816H|KIT D816I|KIT D816V|KIT D816Y|KIT D820E|KIT D820V|KIT D820Y|KIT E490K|KIT E554_K558del|KIT E554_V559del|KIT Exon 11 Mutation|KIT Exon 13 Mutation|KIT Exon 14 Mutation|KIT Exon 17 Mutation|KIT Exon 18 Mutation|KIT Exon 8 Mutation|KIT Exon 9 Mutation|KIT F504L|KIT Fusion|KIT G565V|KIT H697Y|KIT I653T|KIT I841V|KIT K550N|KIT K558N|KIT K642E|KIT L576P|KIT N463S|KIT N566D|KIT N566_D572del|KIT N566_T574del|KIT N655K|KIT N655S|KIT N822I|KIT N822K|KIT N822Y|KIT P577_D579del|KIT P577_E583dup|KIT P838L|KIT Q556_W557insL|KIT Q575_L576ins PE|KIT R634W|KIT S864F|KIT V559A|KIT V559C|KIT V559D|KIT V559G|KIT V560A|KIT V560D|KIT V560G|KIT V560del|KIT V569G|KIT V654A|KIT V852I|KIT W557R|KIT Y553N|KIT Y570H|KIT Y823D,United States|U.S.A.,Recruiting
BRAF V600E,Melanoma,Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib,NCT01876641,,United States|U.S.A.,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|Complex karyotype|KMT2A Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|Very Complex karyotype|del(5)(q10)|del(7)(q10),Acute Myeloid Leukemia,"Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia",NCT01876953,,United States,"Active, not recruiting"
RET Fusion,Non-Small Cell Lung Carcinoma,Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung,NCT01877083,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,"Singapore|Hong Kong|United States|Japan|Taiwan|Korea, Republic of|Thailand","Active, not recruiting"
,Lymphoma|Malignant Solid Tumor,"A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",NCT01877382,TP53 Deletion|TP53 Frameshift|TP53 Missense|TP53 Nonsense,United States|U.S.A.,Recruiting
BRAF V600E|BRAF V600K,Colorectal Carcinoma|Malignant Solid Tumor|Melanoma,"Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors",NCT01877811,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|CCND1 Expression|CCND1 Overexpression|CCND2 Expression|CCND2 Overexpression|CCND3 Expression|CCND3 Overexpression|G1/S-specific cyclin-D1 Expression Positive|G1/S-specific cyclin-D2 Expression Positive|G1/S-specific cyclin-D3 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Mantle Cell Lymphoma,Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL),NCT01880567,,United States|U.S.A.,Recruiting
FLT3 ITD,Acute Myeloid Leukemia,Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML,NCT01883362,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),Canada|United States|U.S.A.,Recruiting
"PIK3CB Amplification|PIK3CB Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency",Breast Carcinoma|Malignant Solid Tumor|Prostate Carcinoma|Squamous Cell Lung Carcinoma,AZD8186 First Time In Patient Ascending Dose Study,NCT01884285,,Canada|United States|England|United Kingdom|U.S.A.|Spain,Recruiting
,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,"Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia",NCT01885689,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes,IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,NCT01885897,,United States|U.S.A.,Recruiting
,Chronic Lymphocytic Leukemia,"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia",NCT01886872,IGH-CCND1 Fusion,Canada|United States,"Active, not recruiting"
,,"Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia",NCT01887587,,United States,Terminated
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Non-Small Cell Lung Carcinoma,A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation,NCT01887886,,"United States|Japan|Taiwan|Korea, Republic of|Malaysia|France|Germany|Spain",Completed
FGFR2 Mutation,Malignant Endometrial Neoplasm,Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma,NCT01888562,,,Closed
,Glioma|Medulloblastoma,A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma,NCT01891747,IDH1 Mutation,United States,"Active, not recruiting"
CD22 Overexpression,Acute Lymphoblastic Leukemia,Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL),NCT01891981,,United States,Completed
CTAG1B Expression|CTAG1B Overexpression|CTAG2 Expression|CTAG2 Overexpression|Cancer/testis antigen 1 Expression Positive|Cancer/testis antigen 2 Expression Positive,Multiple Myeloma,CT Antigen TCR-Engineered T Cells for Myeloma,NCT01892293,,United States,"Active, not recruiting"
FLT3 ITD,Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,AC220 With 5-Aza or Low Dose Cytarabine,NCT01892371,,United States|U.S.A.,Recruiting
JAK2 R683G|JAK2 R683S|JAK2 R683T|JAK2 V617F,Myelodysplastic Syndromes,Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),NCT01895842,,United States|U.S.A.,"Active, not recruiting"
Apoptosis regulator Bcl-2 Expression Positive|Apoptosis regulator Bcl-2 Overexpression Positive|BCL2 Amplification|BCL2 Expression|BCL2 Fusion|BCL2 Mutation|BCL2 Overexpression|MYC Amplification|MYC Expression|MYC Fusion|MYC Mutation|MYC Overexpression|Myc proto-oncogene protein Expression Positive|Myc proto-oncogene protein Overexpression Positive,Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|Double-Hit Lymphoma|Follicular Lymphoma|Hodgkin Lymphoma|Mantle Cell Lymphoma|Mature B-Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma,Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,NCT01897012,,United States|U.S.A.,Recruiting
BRAF V600E,Melanoma,A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,NCT01897116,,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,NCT01897441,,United States|U.S.A.,Recruiting
EZH2 Mutation,B-Cell Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Malignant Solid Tumor,"Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL",NCT01897571,EZH2 Mutation,Canada|United States|Poland|England|Italy|Scotland|United Kingdom|Australia|France|Germany,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Oropharyngeal carcinoma,Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer,NCT01898494,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia|Myelodysplastic Syndromes,Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),NCT01898793,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
MUC1 Expression|MUC1 Overexpression|TA-MUC1 Expression Positive,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,PankoMab-GEX‰ã¢ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer,NCT01899599,,Russian Federation|Romania|Hungary|Poland|England|Italy|United Kingdom|Germany|Spain,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy,NCT01901094,,Canada|United States|U.S.A.,Recruiting
JAK2 V617F,Essential Thrombocythemia|Polycythemia Vera|Primary Myelofibrosis,A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera,NCT01901432,,Poland|England|Italy|United Kingdom|France|Northern Ireland|Germany,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Malignant Solid Tumor,"Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",NCT01902173,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Suspended
,,A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma,NCT01904123,,United States,Not yet recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|RPN1-MECOM Inversion|RUNX1-RUNX1T1 Fusion|TP53 Mutation|Trisomy 11|Trisomy 21|Very Complex karyotype|del(11)(q10)|del(17)(p10)|del(20)(q10)|del(5)(q10)|del(7)(q10)|del(9)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndromes,NK Cells to Prevent Disease Relapse for Patients High Risk Myeloid Malignancies,NCT01904136,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,NCT01904643,PML-RARA Fusion,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Cardiac Safety Study in Patients With HER2 + Breast Cancer,NCT01904903,,United States,Recruiting
BRCA1 Deletion|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Deletion|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma|Hereditary Breast and Ovarian Cancer Syndrome,Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer,NCT01905046,,United States|U.S.A.,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,"A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients",NCT01905592,,Hungary|United States|Scotland|United Kingdom|Portugal|Iceland|Spain|Greece|Canada|Netherlands|Belgium|Poland|Italy|Israel|U.S.A.|France,"Active, not recruiting"
,,Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide,NCT01907165,,United States|U.S.A.,"Active, not recruiting"
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Malignant Solid Tumor,Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction,NCT01907802,,Canada|United States,"Active, not recruiting"
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Acute Myeloid Leukemia,Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia,NCT01907815,,United States,"Active, not recruiting"
BRAF V600E|BRAF V600K,Melanoma,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,NCT01909453,,"Russian Federation|Singapore|United States|England|Scotland|Portugal|Greece|Netherlands|Sweden|Brazil|Korea, Republic of|Poland|Slovakia|France|Colombia|Argentina|Hungary|Japan|United Kingdom|Switzerland|Spain|Canada|Czech Republic|Turkey|Norway|Italy|Mexico|South Africa|Israel|Australia|Germany","Active, not recruiting"
Complex karyotype|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomy 5|Monosomy 7|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,PH 2 ADI-PEG 20 Acute Myeloid Leukemia,NCT01910012,BCR-ABL1 Fusion|DEK-NUP214 Fusion|KMT2A-MLLT3 Fusion|RPN1-MECOM Fusion|RPN1-MECOM Inversion,United States|Taiwan,"Active, not recruiting"
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Non-Small Cell Lung Carcinoma,INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer,NCT01911507,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States|U.S.A.,Recruiting
KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma,"Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",NCT01912625,,United States|U.S.A.,Recruiting
ERBB2 Amplification,Breast Carcinoma,"Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",NCT01912963,,United States|U.S.A.,"Active, not recruiting"
,Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes,NCT01913951,,United States|U.S.A.,"Active, not recruiting"
IDH2 R140G|IDH2 R140L|IDH2 R140Q|IDH2 R140W|IDH2 R172K|IDH2 R172M|IDH2 R172S,Acute Myeloid Leukemia,Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation,NCT01915498,,United States|France,"Active, not recruiting"
AKT1 E17K,Breast Carcinoma|Malignant Solid Tumor,Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients,NCT01915576,AKT1 E17K,United States|France|Switzerland|Germany,Completed
,Breast Carcinoma,GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer,NCT01918306,,United States,Terminated
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Bladder Carcinoma|Breast Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Head and Neck Squamous Cell Carcinoma|Non-Small Cell Lung Carcinoma|Urothelial Carcinoma,A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,NCT01920061,,Canada|United States|England|Italy|United Kingdom|U.S.A.|Spain,Recruiting
,B Acute Lymphoblastic Leukemia|T Acute Lymphoblastic Leukemia,"A Novel ""Pediatric-Inspired"" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia",NCT01920737,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Hodgkin Lymphoma,"Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma",NCT01920932,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,ARRY-380 + Trastuzuamab for Breast w/ Brain Mets,NCT01921335,,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy,NCT01922921,,United States,Recruiting
,Breast Carcinoma,"Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",NCT01923168,,Colombia|Hong Kong|United States|Japan|Spain|Lebanon|Canada|Austria|Czech Republic|Netherlands|Belgium|Brazil|Italy|U.S.A.|Israel|Australia|Bulgaria|Germany,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,HER2-positive Breast Cancer With Brain Metastasis (GCC 1345),NCT01924351,,United States|U.S.A.,Withdrawn
B-cell receptor CD22 Expression Positive|CD22 Expression|CD22 Overexpression,Acute Biphenotypic Leukemia|Acute Leukemia|B Acute Lymphoblastic Leukemia|Burkitt Leukemia,"S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",NCT01925131,,United States|U.S.A.,Recruiting
ESR1 Amplification,Breast Carcinoma,"FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer",NCT01928186,,United States,Completed
,Bladder Carcinoma|Breast Carcinoma|Gastric Carcinoma|Pancreatic Carcinoma|Small Cell Lung Carcinoma,A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors,NCT01928394,,Canada|United States|Finland|Denmark|England|Italy|United Kingdom|Scotland|U.S.A.|Germany|Spain,Recruiting
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|PIK3CA Mutation,Breast Carcinoma|Malignant Solid Tumor,Phase 1b Trial of BGJ398/BYL719 in Solid Tumors,NCT01928459,,"Canada|Netherlands|Singapore|Belgium|United States|Korea, Republic of|Italy|Australia|France|Switzerland|Germany|Spain",Completed
,Breast Carcinoma,Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer,NCT01928589,,United States|U.S.A.,Recruiting
,Breast Carcinoma,NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer,NCT01931163,,United States,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Oropharyngeal Squamous Cell Carcinoma,Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer,NCT01932697,,United States|U.S.A.,Suspended
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma,Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC,NCT01933932,,Russian Federation|United States|England|Scotland|Portugal|Austria|Netherlands|Sweden|Brazil|Poland|Bulgaria|Chile|France|Argentina|Romania|Hungary|Ukraine|United Kingdom|Spain|Canada|Turkey|Belgium|Italy|Mexico|Israel|Australia|Peru|Germany,"Active, not recruiting"
ERBB2 Amplification|ESR1 Amplification,Breast Carcinoma,Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases,NCT01934894,,United States,"Active, not recruiting"
RET Amplification|RET Fusion,Lung Adenocarcinoma|Lung Carcinoma,Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers,NCT01935336,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States|U.S.A.,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Head and Neck Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer",NCT01935921,CDKN2A Expression|CDKN2A Overexpression,United States|U.S.A.,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer,NCT01937117,,United States|U.S.A.,Recruiting
,Breast Carcinoma|Diffuse Large B-Cell Lymphoma|Gastric Carcinoma,Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer,NCT01938638,,"Singapore|United States|Taiwan|Korea, Republic of|U.S.A.",Completed
,Breast Carcinoma,Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer,NCT01938833,,United States,Terminated
,Breast Carcinoma,IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins,NCT01939847,,United States|U.S.A.,"Active, not recruiting"
BRAF V600E|BRAF V600K,Melanoma,"Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",NCT01940809,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma,NCT01942993,,United States,Terminated
BRAF V600E|BRAF V600K,Melanoma,Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma,NCT01943422,,United States|U.S.A.,"Active, not recruiting"
,Acute Myeloid Leukemia,Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma,NCT01943682,PML-RARA Fusion|Trisomy 21,United States,Recruiting
BCL2 Fusion|BCL2 Overexpression|BCL6 Fusion|BCL6 Overexpression|MYC Fusion|MYC Overexpression,Acute Myeloid Leukemia|Hematopoietic and Lymphoid Malignancy|Multiple Myeloma|Non-Hodgkin Lymphoma,"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies",NCT01943851,,United States|England|United Kingdom|U.S.A.|Australia,Recruiting
BRCA1 Deletion|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Deletion|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,"A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",NCT01945775,,"Russian Federation|United States|Ukraine|England|United Kingdom|Spain|Ireland|Taiwan|Brazil|Korea, Republic of|Poland|Italy|U.S.A.|Israel|France|Australia|Germany","Active, not recruiting"
BRAF V600E|BRAF V600K,Thyroid Cancer,Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery,NCT01947023,,United States|U.S.A.,Recruiting
ALK Fusion,Non-Small Cell Lung Carcinoma,Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC,NCT01947608,,,Closed
FGFR1 Amplification,Squamous Cell Lung Carcinoma,Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens,NCT01948141,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|FGFR1 Amplification,United States,"Active, not recruiting"
,Mature T-Cell and NK-Cell Lymphoma/Leukemia,Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma,NCT01948180,,"United States|Korea, Republic of|England|United Kingdom|U.S.A.|France",Recruiting
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation,Malignant Solid Tumor,Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations,NCT01948297,,United States|U.S.A.|Spain,Recruiting
,Breast Carcinoma|Malignant Solid Tumor,Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer,NCT01948843,ASS1 Overexpression,United States,Completed
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Denosumab for Breast Cancer With Bone Mets,NCT01952054,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,NCT01953588,,Puerto Rico|United States|U.S.A.,Recruiting
CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Hodgkin Lymphoma|Mediastinal Large B-Cell Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Non-Hodgkin Lymphoma,A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013),NCT01953692,,Canada|United States|Italy|U.S.A.|Australia|France,Recruiting
,Sarcoma,iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma/VEGAS,NCT01953900,,United States,Recruiting
EGFR Amplification|EGFR Mutation|ERBB2 Mutation|ERBB3 Mutation,Malignant Solid Tumor,"An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification",NCT01953926,,"United States|Finland|Denmark|Korea, Republic of|England|Italy|United Kingdom|Israel|U.S.A.|Australia|Spain",Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Cancer,A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors,NCT01954043,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|England|United Kingdom|Australia,Completed
,Leiomyosarcoma|Lymphoma|Mature T-Cell and NK-Cell Lymphoma/Leukemia|Nasopharyngeal Carcinoma,Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma,NCT01956084,,United States,Recruiting
,Breast Carcinoma,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2),NCT01958021,,"Russian Federation|Singapore|United States|England|Thailand|Austria|Netherlands|Sweden|Ireland|Brazil|Korea, Republic of|France|Argentina|Hungary|United Kingdom|Spain|Lebanon|Canada|Czech Republic|Turkey|Belgium|Norway|Finland|Taiwan|Denmark|Italy|South Africa|Israel|Australia|Germany","Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,NCT01959490,,United States|U.S.A.,"Active, not recruiting"
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Diffuse Large B-Cell Lymphoma,"Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma",NCT01959698,,United States|U.S.A.,Recruiting
,Colorectal Carcinoma,Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer,NCT01960023,BRAF D594E|BRAF D594G|BRAF D594H|BRAF D594N|BRAF D594V|BRAF G466V|BRAF G469A|BRAF G469E|BRAF G469L|BRAF G469V|BRAF G596R|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF R444W|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|BRAF Y472C|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R|PIK3CA D549N|PIK3CA E542K|PIK3CA E545A|PIK3CA E545G|PIK3CA E545K|PIK3CA E545Q|PIK3CA E545V|PIK3CA H1047L|PIK3CA H1047R|PIK3CA Q546E|PIK3CA Q546K|PIK3CA Q546L|PIK3CA Q546P|PIK3CA Q546R,United States,"Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT),NCT01960803,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States,Recruiting
,Breast Carcinoma,BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB),NCT01961531,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Chronic Myeloid Leukemia|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|Plasma Cell Leukemia|Prolymphocytic Leukemia,Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases,NCT01962636,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Not yet recruiting
,Lymphoma|Post-Transplant Lymphoproliferative Disorder,Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma,NCT01964755,,United States,Recruiting
,Breast Carcinoma,Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer,NCT01964924,,United States|U.S.A.,"Active, not recruiting"
ERBB3 Expression|ERBB3 Overexpression|Receptor tyrosine-protein kinase erbB-3 Expression Positive,Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colorectal Carcinoma|Gastric Carcinoma|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|Melanoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma,"Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",NCT01966445,,Netherlands|United States|U.S.A.|Australia,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer,NCT01966471,,"Russian Federation|Singapore|Hong Kong|United States|Czechia|Wales|England|Scotland|Thailand|Sweden|El Salvador|Panama|Brazil|Guatemala|Korea, Republic of|Poland|Chile|France|Bosnia and Herzegovina|Colombia|Argentina|Romania|Hungary|Uruguay|Japan|Philippines|Ukraine|United Kingdom|Switzerland|Spain|Canada|Belgium|Norway|Taiwan|Italy|Mexico|Georgia|Israel|Australia|Peru|Germany","Active, not recruiting"
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer,NCT01967095,,United States|U.S.A.,"Active, not recruiting"
SDHB Germline Loss|SDHB Germline Mutation|SDHB Loss|SDHB Mutation|SDHC Germline Loss|SDHC Germline Mutation|SDHC Loss|SDHC Mutation|VHL Germline Loss|VHL Germline Mutation|VHL Loss|VHL Mutation,Paraganglioma|Pheochromocytoma,"Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma",NCT01967576,,United States,"Active, not recruiting"
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Malignant Solid Tumor|Meningioma,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer,NCT01967823,,United States,Recruiting
SLC39A6 Expression|SLC39A6 Overexpression|Zinc transporter ZIP6 Expression Positive,Breast Carcinoma,A Safety Study of SGN-LIV1A in Breast Cancer Patients,NCT01969643,,United States|U.S.A.,Recruiting
ALK Fusion|ROS1 Fusion,Non-Small Cell Lung Carcinoma,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,NCT01970865,,"Singapore|United States|Korea, Republic of|Italy|U.S.A.|Australia|Spain",Recruiting
AKT1 Mutation|AKT2 Mutation|AKT3 Mutation|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR Amplification|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ERBB2 Amplification|ERBB2 Mutation|MTOR Mutation|PIK3CA Amplification|PIK3CA Mutation|PTEN Loss|PTEN Mutation|STK11 Mutation|TSC1 Mutation|TSC2 Mutation,Malignant Solid Tumor,First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies,NCT01971515,,United States|U.S.A.,Recruiting
,Breast Carcinoma,A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer,NCT01973309,,United States|U.S.A.,"Active, not recruiting"
,Colorectal Carcinoma|Malignant Solid Tumor,Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination,NCT01973868,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States|U.S.A.,"Active, not recruiting"
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",NCT01974765,,United States|U.S.A.,Recruiting
FGFR1 Amplification|FGFR1 Mutation|FGFR1-TACC1 Fusion|FGFR2 Amplification|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Mutation|FGFR3-TACC3 Fusion,Glioma,A Phase 2 Study of BGJ398 in Patients With Recurrent GBM,NCT01975701,,Netherlands|Belgium|United States|Australia|Switzerland|Spain,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PGR Expression|PGR Overexpression|Progesterone receptor Expression Positive|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Cervical Carcinoma|Colorectal Carcinoma|Ovarian Carcinoma|Renal Cell Carcinoma,A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab,NCT01975831,,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|RB1 Expression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression|Retinoblastoma-associated protein Expression Positive,Breast Carcinoma,Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1),NCT01976169,,United States|U.S.A.,Recruiting
RAD23B Expression|UV excision repair protein RAD23 homolog B Expression Positive,Cancer,Phase 1 Trial of CXD101 in Patients With Advanced Cancer,NCT01977638,,England|United Kingdom,Recruiting
BRAF V600E|BRAF V600K,Melanoma,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",NCT01978236,,United States|U.S.A.|Australia,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Anaplastic Large Cell Lymphoma,Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma,NCT01979536,,United States|U.S.A.,Suspended
,Myelofibrosis,A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis,NCT01981850,,Canada|Netherlands|United States|Italy|Scotland|United Kingdom|Israel|U.S.A.|France|Germany,"Active, not recruiting"
,Breast Carcinoma,Cisplatin vs Paclitaxel for Triple Neg,NCT01982448,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer,NCT01983501,,Canada|United States,"Active, not recruiting"
KRAS Mutation,Malignant Solid Tumor,A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS,NCT01986166,,United States|Spain,Completed
NUT family member 1 Expression Positive|NUTM1 Expression|NUTM1 Fusion|NUTM1 Overexpression,Malignant Solid Tumor|NUT Midline Carcinoma,A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies,NCT01987362,,United States|U.S.A.,"Active, not recruiting"
KRAS Mutation,Colorectal Carcinoma|Malignant Solid Tumor,Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors,NCT01988896,,"Canada|Singapore|United States|Korea, Republic of|U.S.A.|Australia|Germany","Active, not recruiting"
BRCA1 Mutation|BRCA2 Mutation|ERBB2 Amplification,Breast Carcinoma|Ovarian Carcinoma,"Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations",NCT01989546,,United States|U.S.A.,"Active, not recruiting"
BRAF V600E|BRAF V600K,Malignant Solid Tumor|Melanoma,"Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",NCT01989585,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Canada|United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptinå¨ [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02),NCT01989676,,"Argentina|Russian Federation|Romania|Hungary|United States|Czechia|Japan|Philippines|Ukraine|Thailand|Portugal|India|Greece|Latvia|Turkey|Brazil|Korea, Republic of|Poland|Mexico|South Africa|Slovakia|Chile|Serbia|Peru","Active, not recruiting"
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Breast Carcinoma,Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR),NCT01990209,,United States,Recruiting
,Breast Carcinoma,Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy,NCT01990352,,United States|U.S.A.,Suspended
,Breast Carcinoma,Cryoablation of Small Breast Tumors in Early Stage Breast Cancer,NCT01992250,,United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PIK3CA Mutation,Breast Carcinoma,Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer,NCT01992952,PIK3CA Mutation,England|United Kingdom|Scotland,Unknown status
Complex karyotype|KMT2A Fusion|Monosomy 5|Monosomy 7|Very Complex karyotype|del(5)(q10)|del(7)(q10),Acute Myeloid Leukemia|Myelodysplastic Syndromes,Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse,NCT01995578,,United States|U.S.A.,Recruiting
MAGEA3 Expression|MAGEA3 Overexpression|MAGEC1 Expression|MAGEC1 Overexpression|Melanoma-associated antigen 3 Expression Positive|Melanoma-associated antigen C1 Expression Positive|WT1 Expression|WT1 Overexpression|Wilms tumor protein Expression Positive,Multiple Myeloma,"CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation",NCT01995708,,United States|U.S.A.,Recruiting
GPNMB Expression|GPNMB Overexpression|Transmembrane glycoprotein NMB Expression Positive,Breast Carcinoma,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",NCT01997333,,Canada|Belgium|United States|England|Italy|United Kingdom|Scotland|U.S.A.|Australia|France|Germany|Spain,Recruiting
ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer,NCT01998126,,United States,"Active, not recruiting"
FOLR1 Expression|FOLR1 Overexpression|FOLR2 Expression|FOLR2 Overexpression|FOLR3 Expression|FOLR3 Overexpression|Folate receptor alpha Expression Positive|Folate receptor alpha Overexpression Positive|Folate receptor beta Expression Positive|Folate receptor beta Overexpression Positive|Folate receptor gamma Expression Positive|Folate receptor gamma Overexpression Positive,Breast Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma,Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors,NCT01999738,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC),NCT01999985,EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,United States|U.S.A.,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.,NCT02000596,,United States,Terminated
BRCA1 Mutation|BRCA2 Mutation|ESR1 Amplification|PARP1 Mutation,Breast Carcinoma,Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,NCT02000622,,"Russian Federation|Romania|Hungary|United States|Czechia|Japan|England|Scotland|United Kingdom|Switzerland|Spain|Turkey|China|Taiwan|Korea, Republic of|Poland|Italy|Mexico|Bulgaria|France|Peru","Active, not recruiting"
,Breast Carcinoma,STAR Cape+BKM120 MBC With Brain Met,NCT02000882,,United States,Recruiting
,Oropharyngeal Squamous Cell Carcinoma,"ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer",NCT02002182,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",NCT02003209,,Puerto Rico|United States,"Active, not recruiting"
,Acute Lymphoblastic Leukemia,Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia,NCT02003222,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States|Israel|U.S.A.,Recruiting
TP53 Frameshift|TP53 Mutation|TP53 Nonsense|del(17)(p10),Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Prolymphocytic Leukemia,Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL),NCT02007044,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer,NCT02007512,,Canada|Belgium|United States|Ireland|England|Italy|United Kingdom|Scotland|Spain,"Active, not recruiting"
MET Amplification,Colorectal Carcinoma,Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer,NCT02008383,KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V,United States|U.S.A.,Recruiting
NF1 Mutation,Malignant Peripheral Nerve Sheath Tumor (MPNST),SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors),NCT02008877,,United States,"Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.,NCT02010021,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia,NCT02011945,ABL1 T315A|ABL1 T315I,Canada|United States|Italy|U.S.A.|Australia|France|Germany|Spain,"Active, not recruiting"
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer,NCT02013219,EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,"Hong Kong|Korea, Republic of|England|United Kingdom|U.S.A.|France|Spain",Recruiting
Glucocorticoid receptor Expression Positive|NR3C1 Expression|NR3C1 Overexpression,Bladder Carcinoma|Breast Carcinoma|Fallopian Tube Carcinoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer|Prostate Carcinoma|Sarcoma|Urothelial Carcinoma,Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,NCT02014337,,United States|U.S.A.,"Active, not recruiting"
,Chronic Myeloid Leukemia,"Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia",NCT02014558,,United States|Italy|Germany,"Active, not recruiting"
BRAF V600E|ERBB2 Amplification|ERBB2 Expression|ERBB2 Mutation|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Colorectal Carcinoma|Gastric Carcinoma|Malignant Solid Tumor|Melanoma,A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,NCT02014909,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States|U.S.A.,"Active, not recruiting"
,Gastrointestinal Stromal Tumor,Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors,NCT02015065,KIT A502_Y503insFA|KIT A829P|KIT Amplification|KIT D816H|KIT D816I|KIT D816V|KIT D816Y|KIT D820E|KIT D820V|KIT D820Y|KIT E490K|KIT E554_K558del|KIT E554_V559del|KIT Exon 11 Mutation|KIT Exon 13 Mutation|KIT Exon 14 Mutation|KIT Exon 17 Mutation|KIT Exon 18 Mutation|KIT Exon 8 Mutation|KIT Exon 9 Mutation|KIT F504L|KIT Fusion|KIT G565V|KIT H697Y|KIT I653T|KIT I841V|KIT K550N|KIT K558N|KIT K642E|KIT L576P|KIT N463S|KIT N566D|KIT N566_D572del|KIT N566_T574del|KIT N655K|KIT N655S|KIT N822I|KIT N822K|KIT N822Y|KIT P577_D579del|KIT P577_E583dup|KIT P838L|KIT Q556_W557insL|KIT Q575_L576ins PE|KIT R634W|KIT S864F|KIT V559A|KIT V559C|KIT V559D|KIT V559G|KIT V560A|KIT V560D|KIT V560G|KIT V560del|KIT V569G|KIT V654A|KIT V852I|KIT W557R|KIT Y553N|KIT Y570H|KIT Y823D|PDGFRA Amplification|PDGFRA Codon 842 Missense|PDGFRA D842I|PDGFRA D842V|PDGFRA D842Y|PDGFRA Exon 12 Mutation|PDGFRA Exon 14 Mutation|PDGFRA Exon 18 Mutation,United States,"Active, not recruiting"
BRAF V600E|BRAF V600K|HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Cancer,Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases,NCT02015117,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus,NCT02015559,,United States|U.S.A.,Recruiting
del(5)(q10),"Myelodysplastic Syndrome with Isolated del(5q)|Myelodysplastic Syndrome, Unclassifiable|Refractory Anemia|Refractory Anemia with Excess Blasts|Refractory Cytopenia with Multilineage Dysplasia|Refractory Cytopenia with Unilineage Dysplasia|Refractory anemia with ring sideroblasts (RARS)",Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102),NCT02016781,,United States|U.S.A.,Recruiting
,Glioblastoma,A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients,NCT02017717,,United States|England|United Kingdom|Scotland|Switzerland|Spain|Netherlands|Belgium|Denmark|Poland|Italy|U.S.A.|Australia|France|Germany,"Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer,NCT02018458,,United States,Recruiting
,Non-Small Cell Lung Carcinoma,Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer,NCT02018523,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States,"Active, not recruiting"
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,NCT02019069,,United States,"Active, not recruiting"
HRAS Mutation|KRAS Mutation|NRAS Mutation,Malignant Solid Tumor,PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors,NCT02022982,,United States|U.S.A.,Recruiting
del(1)(p10)|del(19)(q10),Glioma,Everolimus With and Without Temozolomide in Adult Low Grade Glioma,NCT02023905,Phospho-PRAS40 Positive|del(1)(p10)|del(19)(q10),United States|U.S.A.,Recruiting
ERBB2 Amplification,Breast Carcinoma,A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer,NCT02025192,,United States,"Active, not recruiting"
,Melanoma,Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4,NCT02027935,,United States|U.S.A.,Recruiting
BRAF V600E|BRAF V600K,Melanoma,Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,NCT02027961,BRAF V600E|BRAF V600K,Canada|United States|Italy|France,"Active, not recruiting"
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,Acute Leukemia|Non-Hodgkin Lymphoma,A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia,NCT02028455,,United States,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,"Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",NCT02029417,PML-RARA Fusion,United States,Terminated
del(17)(p10),Chronic Lymphocytic Leukemia,"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia",NCT02029443,,United States|England|Italy|United Kingdom|Scotland,"Active, not recruiting"
,Non-Small Cell Lung Carcinoma|Peritoneal Mesothelioma|Pleural Mesothelioma,Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin,NCT02029690,ASS1 Overexpression,England|United Kingdom,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|Normal karyotype|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome,NCT02029950,CBFB-MYH11 Fusion|Complex karyotype|DEK-NUP214 Fusion|KMT2A-MLLT3 Fusion|Monosomy 5|Monosomy 7|Normal karyotype|PML-RARA Fusion|RPN1-MECOM Fusion|RUNX1-RUNX1T1 Fusion|Very Complex karyotype|del(5)(q10)|del(7)(q10)|inv(16)(p13q22)|inv(3)(q21q26)|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(16;16)(p13;q22)|t(3;3)(q21;q26)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|NPM1 Mutation|RUNX1-RUNX1T1 Fusion|del(5)(q10),Acute Myeloid Leukemia,Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,NCT02030405,,United States,Terminated
RB1 Expression,Multiple Myeloma,Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma,NCT02030483,,United States,Terminated
MYCN Amplification,Neuroblastoma,N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan,NCT02030964,MYCN Amplification,Canada|United States|U.S.A.|Australia,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Head and Neck Squamous Cell Carcinoma|Nasopharyngeal Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer,NCT02031250,CDKN2A Expression|CDKN2A Overexpression,United States|U.S.A.,Recruiting
CD274 Expression|CD274 High Expression|CD274 Low Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Non-Small Cell Lung Carcinoma,A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer,NCT02031458,,Singapore|Hong Kong|United States|Japan|England|United Kingdom|Switzerland|Spain|Canada|Netherlands|Turkey|Belgium|Italy|Georgia|Slovenia|Australia|Bulgaria|France|Bosnia and Herzegovina|Germany,"Active, not recruiting"
,Breast Carcinoma,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,NCT02032277,,"Russian Federation|Hungary|United States|Czechia|England|United Kingdom|Scotland|Spain|Canada|Netherlands|Belgium|Taiwan|Korea, Republic of|Italy|Australia|France|Germany","Active, not recruiting"
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,NCT02032823,,"Puerto Rico|United States|Wales|England|Scotland|Portugal|Iceland|Austria|Netherlands|Sweden|China|Korea, Republic of|Poland|France|Argentina|Hungary|Japan|United Kingdom|Northern Ireland|Switzerland|Spain|Canada|Belgium|Taiwan|Italy|Israel|U.S.A.|Australia|Germany",Recruiting
BRAF V600E,Cholangiocarcinoma|Gastrointestinal Stromal Tumor|Germ Cell Tumor|Glioma|Hairy Cell Leukemia|Multiple Myeloma|Small Intestinal Adenocarcinoma|Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,NCT02034110,,"United States|Spain|Canada|Austria|Netherlands|Sweden|Belgium|Norway|Denmark|Korea, Republic of|Italy|U.S.A.|France|Germany",Recruiting
PML-RARA Fusion,Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia,"Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia",NCT02034227,,United States,Terminated
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,"A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)",NCT02034916,,United States|England|United Kingdom|France|Germany|Spain,"Active, not recruiting"
,Breast Carcinoma,A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer,NCT02037529,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx,NCT02038010,,United States,"Active, not recruiting"
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A-MLLT3 Fusion|RUNX1-RUNX1T1 Fusion,Acute Myeloid Leukemia,Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant,NCT02038153,,United States|U.S.A.,Unknown status
,Breast Carcinoma|Colorectal Carcinoma|Glioblastoma|Non-Small Cell Lung Carcinoma,A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer,NCT02038699,,United States,Withdrawn
SSTR1 Expression|SSTR1 Overexpression|SSTR2 Expression|SSTR2 Overexpression|SSTR3 Expression|SSTR3 Overexpression|SSTR4 Expression|SSTR4 Overexpression|SSTR5 Expression|SSTR5 Overexpression|Somatostatin receptor type 1 Expression Positive|Somatostatin receptor type 1 Overexpression|Somatostatin receptor type 2 Expression Positive|Somatostatin receptor type 2 Overexpression|Somatostatin receptor type 3 Expression Positive|Somatostatin receptor type 3 Overexpression|Somatostatin receptor type 4 Expression Positive|Somatostatin receptor type 4 Overexpression|Somatostatin receptor type 5 Expression Positive|Somatostatin receptor type 5 Overexpression,Neuroendocrine Tumor,68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors,NCT02038738,,United States,Not yet recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma|Ovarian Carcinoma,Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma,NCT02039388,,Austria|Czech Republic|Belgium|Ireland|Denmark|England|United Kingdom|Germany,Recruiting
FLT3 ITD,Acute Myeloid Leukemia,(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive,NCT02039726,,"Singapore|Hungary|United States|Wales|England|United Kingdom|Scotland|Spain|Canada|Czech Republic|Netherlands|Belgium|China|Taiwan|Korea, Republic of|Poland|Italy|U.S.A.|Australia|France|Serbia|Germany|Croatia",Recruiting
BRAF V600D|BRAF V600E|BRAF V600K|BRAF V600R,Melanoma,Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,NCT02039947,,Canada|United States|Italy|U.S.A.|Australia|France|Germany|Spain,"Active, not recruiting"
CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Non-Small Cell Lung Carcinoma,"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",NCT02041533,ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,"United States|England|Greece|Austria|Netherlands|Sweden|Brazil|Korea, Republic of|Poland|France|Argentina|Romania|Hungary|Japan|United Kingdom|Switzerland|Spain|Canada|Czech Republic|Turkey|Belgium|Finland|Taiwan|Italy|Mexico|Australia|Germany","Active, not recruiting"
Cellular tumor antigen p53 Cytoplasmic Expression Positive|TP53 Mutation,Lymphoma|Malignant Solid Tumor,MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies,NCT02042989,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia,Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma,NCT02043587,,United States|U.S.A.,Recruiting
Complex karyotype|Hyperdiploidy|Hypodiploidy|IGH Fusion|MYC Fusion|Monosomy 13|Monosomy 14|StrucGain(1)(q10qter)|Trisomy 14|Very Complex karyotype|del(1)(p10)|del(13)(q10)|del(17)(p10),Multiple Myeloma,Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma,NCT02043860,,United States,Terminated
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,"Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",NCT02044796,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States|U.S.A.,Recruiting
del(17)(p10),Chronic Lymphocytic Leukemia,Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion,NCT02044822,,Romania|Hungary|United States|England|United Kingdom|Scotland|Portugal|Spain|Austria|Czech Republic|Belgium|Denmark|Poland|Italy|Australia|France,Terminated
IGF1R Expression|IGF1R Overexpression|Insulin-like growth factor 1 receptor Expression Positive,Cancer,Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R,NCT02045368,,United States,Completed
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia|Myelodysplastic Syndromes,Adoptive Transfer of Haplo-identical DLI for AML and MDS,NCT02046122,KMT2A-MLLT3 Fusion|PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
,Breast Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",NCT02046421,,United States|U.S.A.,"Active, not recruiting"
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma,"Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC",NCT02047344,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States|Taiwan|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Gastric Carcinoma|Lung Carcinoma|Melanoma,A Phase II Study of Dacomitinib in Progressive Brain Metastases,NCT02047747,,United States|U.S.A.,Terminated
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Head and Neck Squamous Cell Carcinoma,"Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer",NCT02048020,,United States|U.S.A.,"Active, not recruiting"
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|NTRK1 Amplification|NTRK1 Fusion|NTRK1 Mutation|NTRK2 Amplification|NTRK2 Fusion|NTRK2 Mutation|NTRK3 Amplification|NTRK3 Fusion|NTRK3 Mutation,Lymphoma|Malignant Solid Tumor,"A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas",NCT02048488,,United States|Taiwan|Poland|Scotland|United Kingdom|Spain,"Active, not recruiting"
IGH Mutation,Chronic Lymphocytic Leukemia,"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",NCT02048813,IGH-CCND1 Fusion|del(17)(p13),United States,"Active, not recruiting"
PGR Expression|PGR Overexpression|Progesterone receptor Expression Positive,Prostate Carcinoma,Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer,NCT02049190,,Scotland|United Kingdom,Recruiting
,Glioblastoma,A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma,NCT02049489,,United States|U.S.A.,"Active, not recruiting"
CCND1 Expression|CCND1 Overexpression|G1/S-specific cyclin-D1 Expression Positive|IGH-CCND1 Fusion|t(11;14)(q13;32),B-Cell Non-Hodgkin Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma,Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma,NCT02049541,,United States|U.S.A.,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,"MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",NCT02049801,,United States,"Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer,NCT02049957,,Belgium|United States|U.S.A.|France,Recruiting
BRAF Exon 15 Mutation,Melanoma,A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,NCT02050321,,United States,Terminated
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,B Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma,"Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)",NCT02050347,,United States,Recruiting
,Breast Carcinoma|Head and Neck Squamous Cell Carcinoma|Malignant Solid Tumor,A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,NCT02051751,,United States|Italy|France|Spain,Completed
FGF1 Amplification|FGF1 Mutation|FGF10 Amplification|FGF10 Mutation|FGF11 Amplification|FGF11 Mutation|FGF12 Amplification|FGF12 Mutation|FGF13 Amplification|FGF13 Mutation|FGF14 Amplification|FGF14 Mutation|FGF16 Amplification|FGF16 Mutation|FGF17 Amplification|FGF17 Mutation|FGF18 Amplification|FGF18 Mutation|FGF19 Amplification|FGF19 Mutation|FGF2 Amplification|FGF2 Mutation|FGF20 Amplification|FGF20 Mutation|FGF21 Amplification|FGF21 Mutation|FGF22 Amplification|FGF22 Mutation|FGF23 Amplification|FGF23 Mutation|FGF3 Amplification|FGF3 Mutation|FGF4 Amplification|FGF4 Mutation|FGF5 Amplification|FGF5 Mutation|FGF6 Amplification|FGF6 Mutation|FGF7 Amplification|FGF7 Mutation|FGF8 Amplification|FGF8 Mutation|FGF9 Amplification|FGF9 Mutation|FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FGFR4 Amplification|FGFR4 Fusion|FGFR4 Mutation,Malignant Solid Tumor|Multiple Myeloma,A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities,NCT02052778,,United States|Scotland|United Kingdom|U.S.A.|Australia|France|Spain,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread,NCT02057133,,United States,Recruiting
,Lymphoma,3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma,NCT02057445,,United States|U.S.A.,Recruiting
RB1 Expression|Retinoblastoma-associated protein Expression Positive,Prostate Carcinoma,A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer,NCT02059213,,United States|U.S.A.,"Active, not recruiting"
,Endometrial Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",NCT02059265,WT1 Expression|WT1 Overexpression,United States,"Active, not recruiting"
DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation,Colorectal Carcinoma,"An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread",NCT02060188,DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation,Canada|Belgium|United States|Ireland|Italy|U.S.A.|Australia|France|Spain,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer",NCT02060253,,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,DC Vaccine for Patients With Ductal Carcinoma In Situ,NCT02061332,,United States,Completed
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy,NCT02061423,,United States|U.S.A.,Enrolling by invitation
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer,NCT02063724,,United States|U.S.A.,Enrolling by invitation
,Endometrial Carcinoma,Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA,NCT02064725,,Czech Republic|United States|Ukraine|Slovakia|U.S.A.|Belarus,"Active, not recruiting"
NRAS Mutation,Malignant Solid Tumor|Melanoma,"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",NCT02065063,BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|NRAS Mutation,United States,Terminated
,Nasopharyngeal Carcinoma,TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC,NCT02065362,,United States,"Active, not recruiting"
CTNNA1 Expression|CTNNA1 Mutation|CTNNA1 Overexpression|CTNNA2 Expression|CTNNA2 Mutation|CTNNA2 Overexpression|CTNNA3 Expression|CTNNA3 Mutation|CTNNA3 Overexpression|CTNNB1 Expression|CTNNB1 Mutation|CTNNB1 Overexpression|Monosomy 6,Medulloblastoma,International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma,NCT02066220,MYC Amplification|MYCN Amplification,Czechia|England|United Kingdom|Portugal|Switzerland|Spain|Austria|Netherlands|Sweden|Belgium|Norway|Ireland|Denmark|Poland|Italy|France|Germany,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer,NCT02066532,,United States|U.S.A.,Recruiting
,Breast Carcinoma,PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer,NCT02067416,,United States,Terminated
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|PTEN Germline Loss|PTEN Germline Mutation|PTEN Loss|PTEN Mutation|TP53 Germline Loss|TP53 Germline Mutation|TP53 Loss|TP53 Mutation,Hereditary Breast and Ovarian Cancer Syndrome,Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer,NCT02068092,,United States,Recruiting
Monosomy 3|StrucGain(8)(q10qter),Uveal Melanoma,Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma,NCT02068586,,United States|U.S.A.,Recruiting
,Breast Carcinoma,"Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer",NCT02069093,,United States,Completed
CTAG1B Expression|Cancer/testis antigen 1 Expression Positive,Cancer,"Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies",NCT02070406,,United States|U.S.A.,Recruiting
"FH Deletion|FH Loss|FH Mutation|Fumarate hydratase, mitochondrial Deficiency|Fumarate hydratase, mitochondrial Expression Negative|IDH1 Mutation|IDH2 Mutation|SDHA Deletion|SDHA Loss|SDHA Mutation|SDHB Deletion|SDHB Loss|SDHB Mutation|SDHC Deletion|SDHC Loss|SDHC Mutation|SDHD Deletion|SDHD Loss|SDHD Mutation|Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Deficiency|Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Expression Negative|Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Deficiency|Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Expression Negative|Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Deficiency|Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Expression Negative|Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Deficiency|Succinate dehydrogenase cytochrome b560 subunit, mitochondrial Expression Negative",Breast Carcinoma|Gastrointestinal Stromal Tumor|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma|Peritoneal Mesothelioma|Pleural Mesothelioma|Renal Cell Carcinoma,Study of the Glutaminase Inhibitor CB-839 in Solid Tumors,NCT02071862,FH Overexpression|SDHA Overexpression|SDHB Overexpression|SDHC Overexpression|SDHD Overexpression,United States|U.S.A.,Recruiting
KIT Fusion|KIT Mutation,Melanoma,PLX3397 KIT in Acral aNd mucOsal Melanoma,NCT02071940,,England|United Kingdom,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel,NCT02073487,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer,NCT02073916,,United States,Recruiting
IDH1 Mutation,Cholangiocarcinoma|Chondrosarcoma|Glioma|Malignant Solid Tumor,"Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation",NCT02073994,,United States|U.S.A.|France,"Active, not recruiting"
IDH1 Codon 132 Missense,Hematopoietic and Lymphoid Malignancy,Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation,NCT02074839,,United States|U.S.A.|France,Recruiting
,Breast Carcinoma,CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer,NCT02074878,,United States,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Non-Small Cell Lung Carcinoma,A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants,NCT02075840,,"Russian Federation|Singapore|Hong Kong|United States|Egypt|England|Scotland|Thailand|Portugal|Costa Rica|Greece|China|Brazil|Guatemala|Korea, Republic of|Poland|Chile|France|Serbia|Bosnia and Herzegovina|Ukraine|United Kingdom|Switzerland|Spain|New Zealand|Canada|Turkey|Taiwan|Italy|Mexico|Israel|Australia|Germany","Active, not recruiting"
,Breast Carcinoma,Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer,NCT02076074,,United States|U.S.A.,Recruiting
,Cancer,Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate,NCT02076997,Trisomy 21,United States|U.S.A.,Recruiting
EFNA4 Expression|EFNA4 Overexpression|Ephrin-A4 Expression Positive,Breast Carcinoma|Fallopian Tube Carcinoma|Malignant Solid Tumor|Ovarian Carcinoma|Primary Peritoneal Cancer,A Study Of PF-06647263 In Patients With Advanced Solid Tumors,NCT02078752,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,"A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)",NCT02078960,,"United States|Korea, Republic of|U.S.A.",Recruiting
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Malignant Solid Tumor,Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors,NCT02079740,,United States,Recruiting
,Cancer,Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors,NCT02080416,,United States,Terminated
BCR-ABL1 Fusion|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia,A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL,NCT02081378,,"Netherlands|Singapore|United States|Japan|Korea, Republic of|Italy|U.S.A.|Australia|France|Germany|Spain",Recruiting
EZH2 A677G|EZH2 A687V|EZH2 Y641C|EZH2 Y641F|EZH2 Y641H|EZH2 Y641N|EZH2 Y641S,Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Multiple Myeloma,"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma",NCT02082977,EZH2 A677G|EZH2 A687V|EZH2 Y641C|EZH2 Y641F|EZH2 Y641H|EZH2 Y641N|EZH2 Y641S,United States|England|United Kingdom|U.S.A.|France,Recruiting
FLT3 ITD,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndromes,Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,NCT02083250,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(8;21)(q22;q22),United States|U.S.A.,Recruiting
,Colorectal Carcinoma,Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,NCT02083653,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Austria|Russian Federation|Belgium|Hungary|United States|Poland|Italy|France|Germany|Spain,"Active, not recruiting"
CD274 Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Melanoma|Non-Small Cell Lung Carcinoma,MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,NCT02085070,,United States|U.S.A.,Recruiting
,Acute Myeloid Leukemia,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,NCT02085408,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States|Israel|India,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Lung Carcinoma|Non-Small Cell Lung Carcinoma,MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC),NCT02088112,EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,"United States|Japan|Korea, Republic of","Active, not recruiting"
,Breast Carcinoma,Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,NCT02088684,,"Singapore|United States|Taiwan|Korea, Republic of|England|Italy|United Kingdom|U.S.A.|France|Spain","Active, not recruiting"
KRAS Mutation|NRAS Mutation,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|RAEB-2,"MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy",NCT02089230,,United States|U.S.A.,Recruiting
BRAF Mutation|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ERBB2 Amplification|ERBB2 Expression|ERBB2 Mutation|ERBB2 Overexpression|PTCH1 Mutation|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression|SMO Mutation,Adenocarcinoma of the Gastroesophageal Junction|Breast Carcinoma|Gastric Carcinoma|Malignant Solid Tumor,"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",NCT02091141,EGFR Exon 20 Insertion|EGFR Exon 20 Mutation|HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer",NCT02091960,,Canada|Belgium|United States|England|Italy|Scotland|United Kingdom|U.S.A.|Spain,"Active, not recruiting"
Nectin-4 Expression Positive|PVRL4 Expression,Bladder Carcinoma|Fallopian Tube Carcinoma|Malignant Ovarian Epithelial Tumor|Malignant Solid Tumor|Primary Peritoneal Carcinoma|Urothelial Carcinoma,A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4,NCT02091999,,Canada|United States|U.S.A.,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,NCT02093403,,United States,"Active, not recruiting"
ALK Fusion,Non-Small Cell Lung Carcinoma,"A Phase 2, Multicenter, Randomized Study of AP26113",NCT02094573,,"Singapore|Hong Kong|United States|England|United Kingdom|Switzerland|Spain|Canada|Austria|Netherlands|Sweden|Belgium|Norway|Denmark|Korea, Republic of|Italy|Australia|France|Germany","Active, not recruiting"
,Melanoma,Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,NCT02094872,BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,United States|U.S.A.,"Active, not recruiting"
,Colorectal Carcinoma|Malignant Solid Tumor,Regorafenib and Cetuximab in Patients With Advanced Malignancy,NCT02095054,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States|U.S.A.,Recruiting
,Breast Carcinoma,GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients,NCT02095184,,United States,Recruiting
NF1 Mutation,Neurofibroma,MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1,NCT02096471,,United States|U.S.A.,"Active, not recruiting"
BRAF V600E|BRAF V600K,Malignant Solid Tumor|Melanoma,"Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",NCT02097225,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|NTRK1 Amplification|NTRK1 Fusion|NTRK1 Mutation|NTRK2 Amplification|NTRK2 Fusion|NTRK2 Mutation|NTRK3 Amplification|NTRK3 Fusion|NTRK3 Mutation|ROS1 Amplification|ROS1 Fusion|ROS1 Inversion|ROS1 Mutation,Malignant Solid Tumor,"Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.",NCT02097810,,"United States|Korea, Republic of|U.S.A.",Recruiting
Cellular tumor antigen p53 Expression Positive|TP53 Mutation,Ovarian Carcinoma,"p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",NCT02098343,,Netherlands|Sweden|Belgium|United States|England|United Kingdom|Scotland|France|Spain,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Hodgkin Lymphoma,Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients,NCT02098512,,United States|U.S.A.,Recruiting
MYCN Amplification,Neuroblastoma,Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma,NCT02100930,MYCN Amplification,United States|U.S.A.,Recruiting
,Head and Neck Squamous Cell Carcinoma,PD 0332991 and Cetuximab in Patients With Incurable SCCHN,NCT02101034,CDKN2A Expression|CDKN2A Overexpression,United States|U.S.A.,Recruiting
"BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR Amplification|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|Equilibrative nucleoside transporter 1 Overexpression|Hepatocyte growth factor receptor Expression Positive|MET Amplification|MET Exon 14 Skipping|MGMT Large Deletion|MGMT Loss|MGMT Mutation|MYC Amplification|MYC Fusion|Methylated-DNA--protein-cysteine methyltransferase Expression Negative|PARP1 Mutation|PIK3CA Mutation|PTEN Deletion|PTEN Large Deletion|PTEN Loss|PTEN Mutation|PTGS2 Amplification|PTGS2 Overexpression|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|Prostaglandin G/H synthase 2 Overexpression|SLC29A1 Amplification|SLC29A1 Overexpression|TOP2A Amplification|Thymidine phosphorylase Overexpression|VEGFA Amplification",Breast Carcinoma,Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer,NCT02101385,,United States|U.S.A.,Recruiting
NF1 Mutation,Neurofibroma,Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +),NCT02101736,,United States|U.S.A.,"Active, not recruiting"
,Acute Lymphoblastic Leukemia,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,NCT02101853,BCR-ABL1 Fusion,New Zealand|Canada|Puerto Rico|United States|U.S.A.|Australia,Recruiting
EGFR Amplification,Glioblastoma|Glioma|Gliosarcoma,Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma,NCT02101905,,United States|U.S.A.,Recruiting
,Myelodysplastic Syndromes,Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS,NCT02103478,,United States,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,AML Therapy With Irradiated Allogeneic Cells,NCT02105116,,United States|U.S.A.,Terminated
,Squamous Cell Lung Carcinoma,"Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",NCT02106546,ALK Fusion|EGFR Exon 19 Deletion|EGFR L858R,Puerto Rico|Russian Federation|United States|Egypt|Wales|England|Scotland|Portugal|Greece|Austria|Latvia|Netherlands|Sweden|Ireland|Brazil|Poland|Slovakia|France|Lithuania|Serbia|Croatia|Hungary|Ukraine|United Kingdom|Belarus|Switzerland|Spain|New Zealand|Canada|Czech Republic|Turkey|Norway|Finland|Denmark|Italy|Mexico|South Africa|Israel|Australia|Germany|Estonia,"Active, not recruiting"
ESR1 Amplification|PGR Amplification,Breast Carcinoma,A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,NCT02107703,,"Puerto Rico|Russian Federation|Romania|United States|Japan|Switzerland|Spain|Greece|Canada|Belgium|Finland|Taiwan|Denmark|Korea, Republic of|Poland|Italy|Mexico|Australia|France|Germany","Active, not recruiting"
,Melanoma|Neuroblastoma|Osteosarcoma,A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors,NCT02107963,,United States|U.S.A.,Completed
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR Codon 790 Missense|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR Mutation|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,"A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies",NCT02108964,EGFR T790M,"Canada|Netherlands|Singapore|United States|Japan|Taiwan|Korea, Republic of|Italy|U.S.A.|Germany|Spain",Recruiting
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|PDGFRA Amplification|PDGFRB Amplification|VEGFA Amplification|VEGFB Amplification,Non-Small Cell Lung Carcinoma|Small Cell Lung Carcinoma,"A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations",NCT02109016,,United States|Italy|France|Germany|Spain,Completed
BRD4 Mutation|MIB1 Mutation|MKI67 Mutation,Breast Carcinoma,"Lifestyle, Exercise and Nutrition Study 2 (LEAN 2)",NCT02110641,,United States,"Active, not recruiting"
MAGEA3 Overexpression|Melanoma-associated antigen 3 Expression Positive,Cancer,T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive,NCT02111850,,United States,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations,NCT02113813,,United States|U.S.A.,"Active, not recruiting"
,Cervical Squamous Cell Carcinoma|Head and Neck Squamous Cell Carcinoma|Hypopharyngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma|Nasopharyngeal Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck,NCT02113878,,United States|U.S.A.,Recruiting
,Acute Myeloid Leukemia,SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia,NCT02113982,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|PML-RARA Fusion,United States|U.S.A.,Recruiting
SMARCB1 Large Deletion|SMARCB1 Loss|SMARCB1 Mutation|SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Expression Negative,Rhabdoid Tumor,Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,NCT02114229,SMARCB1 Expression,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone,NCT02115048,,Romania|United States|Bosnia and Herzegovina|Spain,"Active, not recruiting"
,Breast Carcinoma,Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,NCT02115282,,United States|South Africa|U.S.A.|Republic of South Africa,Recruiting
FLT3 ITD,Acute Biphenotypic Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Promyelocytic Leukemia|Adult T-Cell Leukemia/Lymphoma|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Chronic Myeloid Leukemia|Follicular Lymphoma|Hodgkin Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Mature T-Cell and NK-Cell Lymphoma/Leukemia|Multiple Myeloma|Myelodysplastic Syndromes|Prolymphocytic Leukemia,Treg Cells for AGVHD in Non-myeloablative UCB Transplant,NCT02118311,BCR-ABL1 Fusion|CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|KMT2A Fusion|KMT2A-AFF1 Fusion|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|TCF3-PBX1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(1;19)(q23;p13)|t(4;11)(q21;q23)|t(8;21)(q22;q22)|t(9;22)(q34;q11),United States,Withdrawn
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Juvenile Myelomonocytic Leukemia|Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndromes,Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies,NCT02120157,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),Canada|United States|U.S.A.,Recruiting
,Breast Carcinoma,A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer,NCT02120417,,United States|England|Italy|Scotland|United Kingdom|France|Portugal|Spain,"Active, not recruiting"
,Breast Carcinoma,Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer,NCT02120469,,United States|U.S.A.,Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,"Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm",NCT02121418,,United States|U.S.A.,"Active, not recruiting"
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Breast Carcinoma|Fallopian Tube Carcinoma|Melanoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Sarcoma,"Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",NCT02122861,,United States|U.S.A.,Recruiting
NTRK1 Amplification|NTRK1 Fusion|NTRK1 Mutation|NTRK2 Amplification|NTRK2 Fusion|NTRK2 Mutation|NTRK3 Amplification|NTRK3 Fusion|NTRK3 Mutation,Malignant Solid Tumor,Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors,NCT02122913,,United States|U.S.A.,Recruiting
,Breast Carcinoma,BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer,NCT02123823,,"Austria|Netherlands|Sweden|Belgium|Taiwan|Korea, Republic of|Scotland|United Kingdom|France|Spain","Active, not recruiting"
,Cancer|Colorectal Carcinoma,A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer,NCT02124148,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States|U.S.A.,Recruiting
CBFB-MYH11 Inversion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,Acute Myeloid Leukemia,Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS,NCT02124174,,United States,Recruiting
,Head and Neck Squamous Cell Carcinoma|Nasopharyngeal Squamous Cell Carcinoma,"Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",NCT02124707,,United States|U.S.A.,Recruiting
BRAF Fusion|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|NF1 Mutation,Glioma|Neurofibroma|Solid Neoplasm,"Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",NCT02124772,,Canada|United States|England|United Kingdom|U.S.A.|Australia|France,Recruiting
,Breast Carcinoma,Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity,NCT02124902,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia,Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission,NCT02126553,BCR-ABL1 Fusion|CBFB-MYH11 Inversion|KMT2A-MLLT3 Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(16;16)(p13;q22)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
,Melanoma,Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists,NCT02126579,,United States,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive,Head and Neck Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design,NCT02128906,CDKN2A Expression|CDKN2A Overexpression,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia,NCT02129062,,United States,Terminated
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A-MLLT3 Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,Acute Myeloid Leukemia|Acute Promyelocytic Leukemia,Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies,NCT02129101,,United States|U.S.A.,"Active, not recruiting"
NOTCH3 Expression|NOTCH3 Overexpression|Neurogenic locus notch homolog protein 3 Expression Positive,Malignant Solid Tumor,A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors,NCT02129205,,United States|U.S.A.,"Active, not recruiting"
NF2 Mutation,Schwannoma,Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas,NCT02129647,,United States|U.S.A.,Recruiting
,Non-Small Cell Lung Carcinoma,Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy,NCT02129699,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,England|Scotland|United Kingdom|Switzerland|Spain|Austria|Belgium|Ireland|Poland|Italy|Israel|Slovenia|France|Germany,Recruiting
BRAF V600E|BRAF V600K,Melanoma,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022),NCT02130466,BRAF V600E|BRAF V600K,Canada|United States|Italy|Australia,Recruiting
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,"A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",NCT02130557,,"Singapore|United States|Wales|England|Thailand|Netherlands|Sweden|Korea, Republic of|Poland|Slovakia|France|Hungary|Ukraine|United Kingdom|Spain|Canada|Czech Republic|Belgium|Norway|Finland|Taiwan|Denmark|Italy|Mexico|South Africa|Israel|Australia|Germany","Active, not recruiting"
MET Amplification,Brain metastasis|Non-Small Cell Lung Carcinoma,Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases,NCT02132598,,United States|U.S.A.,Recruiting
,Non-Small Cell Lung Carcinoma,Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,NCT02132884,ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ROS1 Fusion|ROS1 Inversion,United States|U.S.A.,Terminated
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer",NCT02132949,,United States|England|United Kingdom|Scotland|Portugal|Costa Rica|Spain|Canada|Norway|Denmark|Poland|Italy|Mexico|France|Germany,"Active, not recruiting"
,Non-Small Cell Lung Carcinoma,Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung),NCT02134015,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Hungary|United States|England|United Kingdom|Scotland|Spain|Canada|Czech Republic|Belgium|Poland|Italy|U.S.A.|Germany,"Active, not recruiting"
,Non-Small Cell Lung Carcinoma,Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection,NCT02134886,ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|EGFR T790M|KRAS Mutation,United States,Terminated
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Non-Small Cell Lung Carcinoma,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,NCT02134912,,United States|U.S.A.,Recruiting
,Nasopharyngeal Carcinoma,Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA,NCT02135042,,Republic of Singapore|Canada|Singapore|United States|China|Taiwan|U.S.A.,Recruiting
,Chronic Lymphocytic Leukemia,"A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL",NCT02135133,CCND1 Overexpression|IGH-CCND1 Fusion,United States,Suspended
,Melanoma,A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,NCT02138292,BRAF D594E|BRAF D594G|BRAF D594H|BRAF D594N|BRAF D594V|BRAF G466V|BRAF G469A|BRAF G469E|BRAF G469L|BRAF G469V|BRAF G596R|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF R444W|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|BRAF Y472C,United States|U.S.A.,"Active, not recruiting"
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Pancreatic Carcinoma,Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer,NCT02138383,,United States|U.S.A.,"Active, not recruiting"
,Breast Carcinoma|Malignant Solid Tumor,Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel,NCT02138812,,Canada|United States|U.S.A.,"Active, not recruiting"
GLI1 Expression|GLI1 Overexpression|Zinc finger protein GLI1 Expression Positive,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Adenocarcinoma|Gastric Adenocarcinoma,LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma,NCT02138929,,United States|U.S.A.,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,NCT02139358,,United States|U.S.A.,"Active, not recruiting"
BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Multiple Myeloma,"UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib",NCT02140840,,United States,Withdrawn
KMT2A Fusion|dup(11)(q22q23),Acute Myeloid Leukemia,A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene,NCT02141828,,Canada|United States,Completed
BRAF V600E,Melanoma,"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",NCT02143050,,United States,Recruiting
ABL1 Fusion|ABL2 Fusion|BCR-ABL1 Fusion|CRLF2 Fusion|CSF1R Fusion|EPOR Fusion|FGFR1 Fusion|FGFR2 Fusion|FLT3 Mutation|IL7R Mutation|JAK1 Fusion|JAK1 Mutation|JAK2 Fusion|JAK2 Mutation|NTRK3 Fusion|PDGFRA Fusion|PDGFRB Fusion|PTK2B Fusion|SH2B3 Deletion|SH2B3 Loss|SH2B3 Mutation|TSLP Fusion|TYK2 Fusion|t(9;22)(q34;q11),B Acute Lymphoblastic Leukemia,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia",NCT02143414,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,AZD9291 in Combination With Ascending Doses of Novel Therapeutics,NCT02143466,EGFR T790M,"Canada|Russian Federation|United States|Japan|Taiwan|Korea, Republic of|U.S.A.",Recruiting
,Leukemia|Lymphoma|Malignant Solid Tumor|Multiple Myeloma|Myelodysplastic Syndromes,Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt,NCT02143635,TP53 Mutation|del(17)(p13),Netherlands|Singapore|United States|Japan|Taiwan|U.S.A.|France|Germany|Spain,Recruiting
CBFB-MYH11 Fusion|Complex karyotype|DEK-NUP214 Fusion|KMT2A-MLLT3 Fusion|Monosomy 5|Monosomy 7|Normal karyotype|PML-RARA Fusion|RPN1-MECOM Fusion|RUNX1-RUNX1T1 Fusion|Very Complex karyotype|del(5)(q10)|del(7)(q10)|inv(16)(p13q22)|inv(3)(q21q26)|t(16;16)(p13;q22)|t(3;3)(q21;q26)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Promyelocytic Leukemia|Adult T-Cell Leukemia/Lymphoma|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Chronic Myeloid Leukemia|Follicular Lymphoma|Hodgkin Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Mature T-Cell and NK-Cell Lymphoma/Leukemia|Multiple Myeloma|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Prolymphocytic Leukemia,Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases,NCT02145039,BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|Normal karyotype|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Thyroid Gland Adenocarcinoma,"Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study",NCT02145143,,United States,"Active, not recruiting"
MUC16 Expression|MUC16 Overexpression|Mucin-16 Expression Positive,Fallopian Tube Carcinoma|Malignant Ovarian Epithelial Tumor|Pancreatic Ductal Adenocarcinoma|Primary Peritoneal Cancer,A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer,NCT02146313,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,"TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)",NCT02147990,EGFR Exon 20 Insertion|EGFR T790M,"Hong Kong|United States|England|United Kingdom|Switzerland|Spain|Canada|Netherlands|Taiwan|Korea, Republic of|Australia|France|Germany","Active, not recruiting"
,Colorectal Carcinoma,Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1),NCT02149108,HRAS Missense|HRAS Mutation|KRAS Mutation|NRAS Mutation,"Russian Federation|Hong Kong|United States|England|Scotland|Portugal|Austria|Netherlands|Sweden|Korea, Republic of|Poland|France|Argentina|Japan|United Kingdom|Spain|Canada|Czech Republic|Turkey|Belgium|Taiwan|Denmark|Italy|Mexico|Israel|Australia|Germany",Completed
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FGFR4 Amplification|FGFR4 Fusion|FGFR4 Mutation,Cholangiocarcinoma,"A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma",NCT02150967,,Singapore|Belgium|United States|Taiwan|Thailand|Germany,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,NCT02151981,,"Russian Federation|Hong Kong|Hungary|United States|Japan|England|Scotland|United Kingdom|Spain|Canada|Netherlands|Sweden|China|Taiwan|Korea, Republic of|Italy|Mexico|Australia|France|Germany","Active, not recruiting"
KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V,Non-Small Cell Lung Carcinoma,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,NCT02152631,,"Argentina|Puerto Rico|Russian Federation|Romania|United States|Japan|Ukraine|Spain|Greece|Canada|Austria|Turkey|China|Taiwan|Brazil|Korea, Republic of|Poland|Italy|Israel|U.S.A.|France|Germany","Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Mutation|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Malignant Solid Tumor,"Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients",NCT02152943,,United States|U.S.A.,Recruiting
,Glioblastoma|Gliosarcoma,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,NCT02152982,del(1)(p10)|del(19)(q10),Puerto Rico|United States|U.S.A.,Suspended
HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Thyroid Gland Adenocarcinoma,Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,NCT02152995,BRAF V600E|HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
MAGEA3 Amplification|MAGEA3 Expression|MAGEA3 Overexpression|Melanoma-associated antigen 3 Expression Positive,Cancer,T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive,NCT02153905,,United States,Recruiting
CCND1 Amplification|CCND1 Expression|CCND1 Mutation|CCND1 Overexpression|CCND2 Amplification|CCND2 Expression|CCND2 Mutation|CCND2 Overexpression|CCND3 Amplification|CCND3 Expression|CCND3 Mutation|CCND3 Overexpression|CDK4 Amplification|CDK4 Expression|CDK4 Mutation|CDK4 Overexpression|CDK6 Amplification|CDK6 Expression|CDK6 Mutation|CDK6 Overexpression|Cyclin-dependent kinase 4 Expression Positive|Cyclin-dependent kinase 6 Expression Positive|FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|G1/S-specific cyclin-D1 Expression Positive|G1/S-specific cyclin-D2 Expression Positive|G1/S-specific cyclin-D3 Expression Positive|HGF Amplification|HGF Expression|HGF Overexpression|Hepatocyte growth factor Expression Positive|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|PIK3CA Amplification|PIK3CA Mutation,Squamous Cell Lung Carcinoma,S1400 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer,NCT02154490,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,United States|U.S.A.,Recruiting
ERBB2 Amplification|ESR1 Amplification,Breast Carcinoma,Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,NCT02154529,,United States,"Active, not recruiting"
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib,NCT02155465,,United States,"Active, not recruiting"
,Breast Carcinoma,Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer,NCT02157051,,United States|U.S.A.,Recruiting
del(17)(p10),Chronic Lymphocytic Leukemia,"Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia",NCT02157324,,United States,"Active, not recruiting"
TP53 Deletion|TP53 Mutation,Breast Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma|Small Cell Lung Carcinoma,"An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",NCT02157792,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense|TP53 Deletion|TP53 Mutation,United States|England|United Kingdom|Scotland|U.S.A.,Recruiting
,Breast Carcinoma,"Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer",NCT02158507,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States|U.S.A.,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",NCT02159066,,Canada|Netherlands|United States|England|Italy|United Kingdom|Australia|Switzerland|Germany|Spain,"Active, not recruiting"
FLT3 ITD|IL3RA Expression|IL3RA Overexpression|Interleukin-3 receptor subunit alpha Expression Positive,Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm,Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm,NCT02159495,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States|U.S.A.,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Oropharyngeal carcinoma,"A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer",NCT02159703,,United States|U.S.A.,Recruiting
CCND1 Expression|CCND1 Overexpression|G1/S-specific cyclin-D1 Expression Positive|G1/S-specific cyclin-D1 Overexpression|IGH-CCND1 Fusion|t(11;14)(q13;32),Mantle Cell Lymphoma,Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma,NCT02159755,,United States|U.S.A.,"Active, not recruiting"
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FGFR4 Amplification|FGFR4 Fusion|FGFR4 Mutation,Cancer,BGJ398 for Patients With Tumors With FGFR Genetic Alterations,NCT02160041,,United States|U.S.A.,Recruiting
,Breast Carcinoma,"A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors",NCT02162719,,"Singapore|Belgium|United States|Taiwan|Korea, Republic of|Italy|U.S.A.|France|Spain","Active, not recruiting"
MYCN Amplification,Central Nervous System Neoplasm|Choroid Plexus Neoplasm|Craniopharyngioma|Dysembryoplastic Neuroepithelial Tumor|Ependymoma|Ewing Sarcoma|Germ Cell Tumor|Glioma|Kidney Wilms Tumor|Medulloblastoma|Meningioma|Neuroblastoma|Neuroectodermal Tumor of Soft Tissue|Soft Tissue Sarcoma,Molecular-Guided Therapy for Childhood Cancer,NCT02162732,,Lebanon|United States|U.S.A.,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Head and Neck Squamous Cell Carcinoma,Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma,NCT02163057,,United States,"Active, not recruiting"
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",NCT02163694,,"Republic of Singapore|Puerto Rico|Russian Federation|Singapore|United States|England|Portugal|Austria|Latvia|Netherlands|Sweden|Korea, Republic of|Poland|Chile|France|Lithuania|Colombia|Argentina|Romania|Hungary|Ukraine|United Kingdom|Belarus|Spain|Canada|Czech Republic|Turkey|Belgium|Norway|Finland|Taiwan|Denmark|Italy|Mexico|South Africa|Israel|U.S.A.|Australia|Germany|Estonia",Recruiting
,Cervical Carcinoma,ADXS11-001 High Dose HPV+ Cervical Cancer,NCT02164461,,United States,"Active, not recruiting"
TFE3 Fusion|TFE3 Inversion|TFEB Fusion|TFEB Inversion,Malignant Solid Tumor|Renal Cell Carcinoma,VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors,NCT02164838,,Canada|United States|U.S.A.,Completed
BRAF V600E,Colorectal Carcinoma,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,NCT02164916,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States,"Active, not recruiting"
CTAG1B Expression|CTAG1B Overexpression|CTAG2 Expression|CTAG2 Overexpression|Cancer/testis antigen 1 Expression Positive|Cancer/testis antigen 2 Expression Positive,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",NCT02166905,,United States|U.S.A.,Recruiting
,B Acute Lymphoblastic Leukemia,Study of Efficacy and Safety of CTL019 in Adult ALL Patients,NCT02167360,MYC Fusion,United States,Not yet recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|PIK3CA Mutation|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",NCT02167854,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Follicular Lymphoma|Hodgkin Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Myelodysplastic Syndromes|Myelofibrosis|T Lymphoblastic Leukemia/Lymphoma,"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source",NCT02167958,CBFB-MYH11 Inversion|KMT2A-MLLT3 Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(16;16)(p13;q22)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
Hypodiploidy|IGH-FGFR3 Fusion|IGH-WHSC1 Fusion|Nullisomy 13|Nullisomy 17|StrucGain(1)(q10qter)|del(1)(p10)|del(13)(q10)|del(17p)|t(14;16)(q32;q23)|t(14;20)(q32;q12)|t(4;14)(p16;q32),Multiple Myeloma|Plasma Cell Leukemia,Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma,NCT02168101,,United States,Recruiting
,Breast Carcinoma|Colorectal Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,"Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",NCT02168777,,United States,Terminated
ATM Frameshift|ATM Large Deletion (Exon -1)|ATM Loss|ATM Mutation|BCR-ABL1 Fusion|BIRC3 Mutation|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|IGH-FGFR3 Fusion|IGH-WHSC1 Fusion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|Nullisomy 13|Nullisomy 17|RPN1-MECOM Fusion|SF3B1 Mutation|StrucGain(1)(q10qter)|TCF3-PBX1 Fusion|TP53 Frameshift|TP53 Large Deletion|TP53 Mutation|TP53 Nonsense|Trisomy 11|Very Complex karyotype|del(1)(p10)|del(11)(q10)|del(13)(q10)|del(17)(p10)|del(17)(p13)|del(17p)|del(5)(q10)|del(6)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(14;16)(q32;q23)|t(14;20)(q32;q12)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(4;14)(p16;q32)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Prolymphocytic Leukemia,Nonmyeloablative Haploidentical Transplant Followed by MLN9708,NCT02169791,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Recruiting
,Cervical Carcinoma,A Study of INO-3112 DNA Vaccine With Electroporation in Patients With Cervical Cancer,NCT02172911,,United States|U.S.A.,"Active, not recruiting"
BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma|Non-Small Cell Lung Carcinoma|Renal Cell Carcinoma,A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors,NCT02174172,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Netherlands|United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification,NCT02177175,,United States,"Active, not recruiting"
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Negative|HPV Positive,Head and Neck Squamous Cell Carcinoma,"Window Trial 5-aza in HNSCC, T-tare",NCT02178072,CDKN2A Expression|CDKN2A Overexpression,United States|U.S.A.,Recruiting
,Breast Carcinoma|Endometrial Carcinoma|Head and Neck Squamous Cell Carcinoma|Non-Small Cell Lung Carcinoma|Renal Cell Carcinoma|Urothelial Carcinoma,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)",NCT02178722,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|RPN1-MECOM Inversion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|i(17)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia|Hodgkin Lymphoma|Myelodysplastic Syndromes|Myelofibrosis|Non-Hodgkin Lymphoma,Intra-Osseous Co-Transplant of UCB and hMSC,NCT02181478,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ERBB2 Exon 20 Insertion|ERBB2 Mutation,Non-Small Cell Lung Carcinoma,Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity,NCT02183883,,England|United Kingdom,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Pancreatic Adenocarcinoma,Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy,NCT02184195,,"United States|England|Scotland|United Kingdom|Spain|Canada|Netherlands|Belgium|Korea, Republic of|Italy|Israel|U.S.A.|Australia|France|Germany",Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy,NCT02186301,EGFR Exon 20 Insertion,"Hong Kong|United States|Taiwan|Korea, Republic of|Italy|Germany|Spain","Active, not recruiting"
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|ROS1 Amplification|ROS1 Fusion|ROS1 Inversion|ROS1 Mutation,Cancer|Non-Small Cell Lung Carcinoma,Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE),NCT02186821,,United States|U.S.A.,Completed
,Non-Small Cell Lung Carcinoma,"Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients",NCT02187367,EGFR Mutation,Czech Republic|Philippines|Scotland|United Kingdom|Malaysia|Thailand|Germany,Recruiting
ERBB2 Amplification,Breast Carcinoma,A Study Of PF-05280014 Or Trastuzumab Plus Taxotereå¨ And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),NCT02187744,,Czech Republic|Russian Federation|Hungary|United States|Ukraine|Poland|Italy|Slovakia|Belarus|Serbia,Completed
CCND1 Amplification|CCND3 Amplification|CDK4 Amplification|CDK4 Mutation|CDK6 Amplification|CDK6 Mutation|CDKN2A Mutation,Breast Carcinoma|Cancer,LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE),NCT02187783,,United States|U.S.A.,"Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer,NCT02187991,,United States,Recruiting
HRAS Mutation|KRAS Mutation|NRAS Mutation,Colorectal Carcinoma|Malignant Solid Tumor,Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer,NCT02188264,BRAF D594E|BRAF D594G|BRAF D594H|BRAF D594N|BRAF D594V|BRAF G466V|BRAF G469A|BRAF G469E|BRAF G469L|BRAF G469V|BRAF G596R|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF R444W|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|BRAF Y472C,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,ER Reactivation Therapy for Breast Cancer,NCT02188745,,United States,Recruiting
EGFR Mutation|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|PIK3CA Amplification|PIK3CA Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Endometrial Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies,NCT02189174,PIK3CA Amplification|PIK3CA Mutation,Canada|Singapore|United States|Japan|Spain,Terminated
,Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,Leukemia SPORE Phase II 3-arm DAC Randomized Study for R/R and Elderly Acute AML and MDS,NCT02190695,,United States,Recruiting
EGFR Expression|EGFR Overexpression|Epidermal Growth Factor Receptor Overexpression|Epidermal growth factor receptor Expression Positive,Adenocarcinoma of the Gastroesophageal Junction|Anal Carcinoma|Cholangiocarcinoma|Colorectal Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Hepatocellular Carcinoma|Non-Small Cell Lung Carcinoma|Pancreatic Carcinoma|Sarcoma|Small Intestinal Carcinoma|Urothelial Carcinoma,"Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas",NCT02192541,,United States,Completed
Hypodiploidy|IGH-FGFR3 Fusion|IGH-WHSC1 Fusion|Nullisomy 13|Nullisomy 17|StrucGain(1)(q10qter)|del(1)(p10)|del(13)(q10)|del(17p)|t(14;16)(q32;q23)|t(14;20)(q32;q12)|t(4;14)(p16;q32),Multiple Myeloma,UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus,NCT02192775,,United States,Recruiting
FLT1 Amplification|FLT1 Mutation|FLT4 Amplification|FLT4 Mutation|KDR Amplification|KDR Frameshift|PDGFRA Amplification|PDGFRA Mutation|PDGFRB Amplification|PDGFRB Mutation|TP53 Mutation,Non-Small Cell Lung Carcinoma,Pazopanib in Molecularly Selected Patients With Advanced NSCLC,NCT02193152,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),NCT02193282,EGFR T790M,United States|U.S.A.,Recruiting
IDH1 R132H,Glioma,IDH1 Peptide Vaccine for Recurrent Grade II Glioma,NCT02193347,,United States|U.S.A.,Recruiting
,Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies,NCT02193958,,United States|U.S.A.,Recruiting
BRAF V600E|BRAF V600K,Melanoma,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,NCT02196181,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
FLT3 ITD,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,NCT02196857,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Hodgkin Lymphoma|Juvenile Myelomonocytic Leukemia|Mature T-Cell and NK-Cell Lymphoma/Leukemia|Myelodysplastic Syndromes|Non-Hodgkin Lymphoma,Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen,NCT02199041,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Terminated
,Colorectal Carcinoma,Regorafenib + Panitumumab for Colorectal Cancers,NCT02199223,KRAS A146P|KRAS A146T|KRAS A146V|KRAS Codon 59 Missense|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS Codon 59 Missense|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States,Terminated
,Multiple Myeloma,"Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",NCT02199665,,United States|U.S.A.,"Active, not recruiting"
BRAF V600E|BRAF V600K|BRAF V600R,Melanoma,Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,NCT02200562,,United States,Terminated
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PGR Expression|PGR Overexpression|Progesterone receptor Expression Positive,Breast Carcinoma,Cryoablation of Low Risk Small Breast Cancer- Ice3 Trial,NCT02200705,,United States|U.S.A.,Recruiting
MTOR Mutation|TSC1 Mutation|TSC2 Mutation,Cancer,Everolimus for Cancer With TSC1 or TSC2 Mutation,NCT02201212,,United States|U.S.A.,Recruiting
ALK Fusion,Non-Small Cell Lung Carcinoma,Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial),NCT02201992,,United States|U.S.A.,Recruiting
FOLH1 Expression|FOLH1 Overexpression|Glutamate Carboxypeptidase 2 Expression Positive,Prostate Carcinoma,Phase 1 of EC1169 In Patients With Recurrent MCRPC,NCT02202447,,United States,Recruiting
ERBB2 Amplification|ESR1 Amplification|FGFR1 Amplification,Breast Carcinoma,"A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer",NCT02202746,,United States,"Active, not recruiting"
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer|Prostate Carcinoma,"A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer",NCT02203513,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States|U.S.A.,Recruiting
,Acute Myeloid Leukemia,Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo),NCT02203773,CBFB-MYH11 Inversion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,United States|U.S.A.|Australia|France|Germany,Recruiting
Complex karyotype|DEK-NUP214 Fusion|FLT3 D835A|FLT3 D835E|FLT3 D835H|FLT3 D835N|FLT3 D835V|FLT3 D835Y|FLT3 I836D|FLT3 I836F|FLT3 I836H|FLT3 I836L|FLT3 I836M|FLT3 I836V|FLT3 ITD|KMT2A Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|RPN1-MECOM Inversion|Trisomy 8|Very Complex karyotype|del(20)(q10)|del(3)(q10)|del(7)(q10),Acute Myeloid Leukemia|Myelodysplastic Syndromes,Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS,NCT02204020,,United States|U.S.A.,Withdrawn
,Acute Myeloid Leukemia,"A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia",NCT02204085,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|Mammaglobin-A Expression Positive|SCGB2A2 Expression|SCGB2A2 Overexpression,Breast Carcinoma,Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,NCT02204098,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Gastric Adenocarcinoma,Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma,NCT02205047,,"England|United Kingdom|Scotland|Northern Ireland|Portugal|Switzerland|Spain|Netherlands|Belgium|Norway|Korea, Republic of|Italy|Israel|France|Germany|Estonia",Recruiting
Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Colorectal Carcinoma|Head and Neck Squamous Cell Carcinoma,"Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",NCT02205398,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Canada|Belgium|United States|Italy|U.S.A.|France|Germany|Spain,Suspended
EGFR Exon 19 Deletion|EGFR L858R,Non-Small Cell Lung Carcinoma,Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC),NCT02206763,,United States,Terminated
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Endocrine Response in Women With Invasive Lobular Breast Cancer,NCT02206984,,United States,Recruiting
,Head and Neck Squamous Cell Carcinoma,"A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma Larynx",NCT02207439,CDKN2A Expression|CDKN2A Overexpression,United States,Recruiting
CD274 Expression|CD274 High Expression|CD274 Low Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Head and Neck Squamous Cell Carcinoma,Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,NCT02207530,,"Hungary|United States|Czechia|England|Scotland|United Kingdom|Malaysia|Spain|Canada|Belgium|Taiwan|Korea, Republic of|Georgia|Israel|France|Germany","Active, not recruiting"
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma|Endometrial Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",NCT02208375,,United States|U.S.A.,Recruiting
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Liposarcoma|Melanoma|Synovial Sarcoma,Adoptive Therapy Using Antigen-Specific CD4 T-Cells,NCT02210104,,United States,Not yet recruiting
NF1 Germline Mutation|NF1 Mutation,Malignant Peripheral Nerve Sheath Tumor (MPNST)|Neurofibroma,Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1,NCT02211768,,United States|U.S.A.,Recruiting
CTNNB1 Expression|CTNNB1 Overexpression|Monosomy 6,Medulloblastoma,Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma,NCT02212574,MYC Amplification|MYCN Amplification,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer,NCT02213042,,Argentina|Russian Federation|Hong Kong|United States|Philippines|Thailand|Spain|Austria|Brazil|Italy|Mexico|U.S.A.|Peru,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Follicular Lymphoma,"A Study Of PF-05280586 (Rituximab-Pfizer) Or MabTheraå¨ (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)",NCT02213263,,"Puerto Rico|Russian Federation|United States|England|Portugal|Greece|Austria|Brazil|Korea, Republic of|Poland|France|Croatia|Romania|Japan|Ukraine|United Kingdom|Belarus|Switzerland|India|Spain|Lebanon|Turkey|Belgium|Italy|Mexico|South Africa|Georgia|U.S.A.|Peru|Germany",Recruiting
EGFR Amplification|ERBB2 Amplification|FGFR2 Amplification|MET Amplification,Adenocarcinoma of the Gastroesophageal Junction|Gastric Carcinoma,PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,NCT02213289,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,NCT02213744,,Canada|Austria|Czech Republic|Belgium|United States|Italy|U.S.A.|France|Germany|Spain,Terminated
MYC Amplification|MYC Expression|MYC Fusion|MYC Mutation|MYC Overexpression|Myc proto-oncogene protein Expression Positive|Myc proto-oncogene protein Overexpression Positive,B-Cell Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Hairy Cell Leukemia|Hodgkin Lymphoma|Intraocular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Mature B-Cell Lymphoma/Leukemia|Small Intestinal Lymphoma|Small Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas,NCT02213913,,United States|U.S.A.,Recruiting
CCND1 Mutation|IGH Fusion,Anaplastic Large Cell Lymphoma,"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma",NCT02213926,,United States|Scotland|United Kingdom,"Active, not recruiting"
"PTEN Deletion|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Expression Negative",Prostate Carcinoma,Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer,NCT02215096,PTEN Overexpression,United States|England|United Kingdom|U.S.A.,Recruiting
TNFRSF17 Expression|TNFRSF17 Overexpression|Tumor necrosis factor receptor superfamily member 17 Expression Positive,Multiple Myeloma,Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma,NCT02215967,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer,NCT02216786,,Scotland|United Kingdom,Unknown status
CD70 Expression|CD70 Overexpression|CD70 antigen Expression Positive|CD70 antigen Overexpression,Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma|Renal Cell Carcinoma,Safety Study of SGN-CD70A in Cancer Patients,NCT02216890,,United States|U.S.A.,Completed
AXL Amplification|AXL Fusion|AXL Mutation|DDR2 Amplification|DDR2 Mutation|KDR Amplification|KDR Mutation|KIT Amplification|KIT Mutation|MET Amplification|MET Fusion|MET Mutation|NTRK1 Amplification|NTRK1 Fusion|NTRK1 Mutation|NTRK2 Amplification|NTRK2 Fusion|NTRK2 Mutation|NTRK3 Amplification|NTRK3 Fusion|NTRK3 Mutation|PDGFRA Amplification|PDGFRA Mutation|RET Amplification|RET Fusion|RET Mutation,Head and Neck Squamous Cell Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer,NCT02219711,,United States|U.S.A.,Recruiting
del(17)(p10),Chronic Lymphocytic Leukemia,UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia,NCT02222688,,United States|U.S.A.,Recruiting
,Breast Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma,A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors,NCT02222922,,United States|U.S.A.|Spain,"Active, not recruiting"
BRAF V600E|BRAF V600K,Melanoma,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,NCT02224781,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
,Oropharyngeal Squamous Cell Carcinoma,Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma,NCT02225496,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,"An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)",NCT02225574,,United States|U.S.A.,Completed
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer,NCT02226276,,United States|U.S.A.,"Active, not recruiting"
FLT3 ITD,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adult T-Cell Leukemia/Lymphoma|Aggressive Systemic Mastocytosis|Angioimmunoblastic T-Cell Lymphoma|Blastic Plasmacytoid Dendritic Cell Neoplasm|Chronic Eosinophilic Leukemia, NOS|Chronic Myeloid Leukemia|Hodgkin Lymphoma|Langerhans Cell Histiocytosis|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Mast Cell Leukemia|Mature T-Cell and NK-Cell Lymphoma/Leukemia|Multiple Myeloma|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|T-Cell Prolymphocytic Leukemia (T-PLL)",Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation,NCT02226861,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|KIT Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(8;21)(q22;q22),United States,Recruiting
,Acute Lymphoblastic Leukemia,Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma,NCT02227108,KMT2A Fusion,Canada|Netherlands|United States|England|Italy|United Kingdom|Australia|France|Spain,Terminated
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Malignant Solid Tumor|Pancreatic Adenocarcinoma,Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,NCT02227940,,United States|U.S.A.,Recruiting
,B Acute Lymphoblastic Leukemia,Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients,NCT02228096,MYC Fusion,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,"Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer",NCT02228369,,"United States|Taiwan|Korea, Republic of|Australia","Active, not recruiting"
BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors,NCT02228382,,Austria|Netherlands|Sweden|Belgium|United States|Norway|Finland|Italy|U.S.A.|France|Germany|Spain,Recruiting
,Acute Lymphoblastic Leukemia,Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults,NCT02228772,IGH-MYC Fusion|IGK-MYC Fusion|IGL-MYC Fusion,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Vaccination of High Risk Breast Cancer Patients,NCT02229084,,United States,Enrolling by invitation
,Breast Carcinoma,Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus,NCT02229136,,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",NCT02229149,,United States,"Active, not recruiting"
BRAF Mutation,Melanoma,Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,NCT02230306,,United States,Terminated
,Non-Small Cell Lung Carcinoma,LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research,NCT02231164,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States|Georgia|Thailand,Terminated
BRAF V600E|BRAF V600K,Melanoma,Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo),NCT02231775,,United States,Recruiting
CXCR4 Mutation,"Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome (WHIMS)",Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome,NCT02231879,,United States,Recruiting
,"Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Mycosis Fungoides|Peripheral T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified",Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma,NCT02232516,ALK Expression|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,United States|U.S.A.,Recruiting
Complex karyotype|Monosomal karyotype|Very Complex karyotype,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox),NCT02233504,,United States,Recruiting
,Acute Myeloid Leukemia,Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ‰ä´ 60,NCT02234037,PML-RARA Fusion,United States,Terminated
,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Carcinoma|Gastric Adenocarcinoma|Gastric Carcinoma,Nintedanib in Patients With Advanced Esophagogastric Cancer,NCT02234596,,United States|U.S.A.,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,NCT02236000,,United States|U.S.A.,Recruiting
FLT3 ITD,Acute Myeloid Leukemia,A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,NCT02236013,BCR-ABL1 Fusion|CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(8;21)(q22;q22)|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
CREBBP Mutation|EP300 Mutation,Urothelial Carcinoma,Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes,NCT02236195,,United States,Completed
,Breast Carcinoma,"Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score",NCT02236572,,United States|U.S.A.,"Active, not recruiting"
BIRC5 Expression|BIRC5 Overexpression|Baculoviral IAP repeat-containing protein 5 Expression Positive|CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive|MAGEA4 Expression|MAGEA4 Overexpression|Melanoma antigen preferentially expressed in tumors Expression Positive|Melanoma-associated antigen 4 Expression Positive|PRAME Expression|PRAME Overexpression|Protein SSX2 Expression Positive|SSX2 Expression|SSX2 Overexpression,Malignant Solid Tumor,TAA-Specific CTLS for Solid Tumors (TACTASOM),NCT02239861,,United States,Recruiting
,Ampulla of Vater Carcinoma|Bladder Transitional Cell Carcinoma|Cholangiocarcinoma|Distal Bile Duct Carcinoma|Gallbladder Carcinoma|Intrahepatic Cholangiocarcinoma|Malignant Solid Tumor|Renal Pelvis Transitional Cell Carcinoma|Squamous Cell Lung Carcinoma|Ureter Transitional Cell Carcinoma|Urethral Carcinoma|Urothelial Carcinoma,"Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",NCT02240238,CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Romania|United States|Poland|Italy|U.S.A.|Bulgaria,Recruiting
,Myelodysplastic Syndromes,Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes,NCT02240706,del(5)(q10),United States|U.S.A.,Recruiting
,Head and Neck Squamous Cell Carcinoma|Lung Carcinoma,Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies,NCT02241369,,United States,Recruiting
KRAS Mutation,Malignant Solid Tumor,A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors,NCT02243917,,United States|U.S.A.,Recruiting
MYCN Amplification,Neuroblastoma,Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma,NCT02245997,MYCN Amplification,United States|U.S.A.,Recruiting
,Breast Carcinoma,A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,NCT02246621,,"Puerto Rico|Russian Federation|United States|England|Scotland|Greece|Austria|Netherlands|Sweden|Korea, Republic of|Slovakia|France|Japan|United Kingdom|Spain|New Zealand|Canada|Turkey|Belgium|Taiwan|Italy|Mexico|Israel|Australia|Germany","Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,AZD9496 First Time in Patients Ascending Dose Study,NCT02248090,,"United States|Korea, Republic of|England|United Kingdom","Active, not recruiting"
KRAS Mutation,Colorectal Adenocarcinoma,Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma,NCT02248805,KRAS Mutation,United States|U.S.A.,Recruiting
DDIT3 Fusion,Liposarcoma,Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery,NCT02249949,,United States|U.S.A.,Recruiting
,Non-Small Cell Lung Carcinoma,"Safety and Efficacy Study of Nabå¨-Paclitaxel With CC-486 or Nabå¨-Paclitaxel With Durvalumab, and Nabå¨-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer",NCT02250326,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Canada|United States|England|Italy|United Kingdom|U.S.A.|France|Germany|Spain,"Active, not recruiting"
MYD88 L265P,Diffuse Large B-Cell Lymphoma,Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation,NCT02252146,,United States|U.S.A.,Completed
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy",NCT02252887,,United States|U.S.A.,"Active, not recruiting"
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive,Oropharyngeal Squamous Cell Carcinoma,Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer,NCT02254278,,Saudi Arabia|Canada|United States|U.S.A.,"Active, not recruiting"
Complex karyotype|Monosomal karyotype|Very Complex karyotype,Acute Myeloid Leukemia,Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML,NCT02255162,,United States|U.S.A.,"Active, not recruiting"
RB1 Expression|RB1 Overexpression|Retinoblastoma-associated protein Expression Positive,Central Nervous System Neoplasm,"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors",NCT02255461,,United States|U.S.A.,Recruiting
BRAF V600E,Melanoma,"The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",NCT02257424,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,NCT02258451,,"Singapore|Hong Kong|United States|Czechia|Japan|England|United Kingdom|Northern Ireland|Switzerland|Spain|Canada|Austria|Netherlands|Belgium|Norway|China|Taiwan|Korea, Republic of|Poland|Italy|Israel|U.S.A.|France|Germany",Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,NCT02258464,,"Singapore|Hong Kong|United States|Czechia|England|Austria|Netherlands|Sweden|Ireland|China|Korea, Republic of|Poland|France|United Kingdom|Northern Ireland|Switzerland|Spain|Canada|Norway|Finland|Taiwan|Denmark|Israel|U.S.A.|Germany",Recruiting
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma,Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase,NCT02258607,,United States,Terminated
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Oropharyngeal Squamous Cell Carcinoma,Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer,NCT02258659,,United States|U.S.A.,"Active, not recruiting"
,Non-Small Cell Lung Carcinoma,"A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",NCT02259582,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Belgium|United States|Italy|U.S.A.|Australia|Spain,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases,NCT02260531,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PIK3CA Mutation,Breast Carcinoma|Malignant Solid Tumor,"Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",NCT02260661,,United States|England|Scotland|United Kingdom,Completed
CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Head and Neck Squamous Cell Carcinoma,"A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer",NCT02262741,,Canada|United States|U.S.A.,"Active, not recruiting"
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations,NCT02263898,,United States|U.S.A.,Withdrawn
,Lymphoma|Malignant Solid Tumor,ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas,NCT02264613,TP53 Mutation,United States|U.S.A.,Recruiting
ATM Mutation|Serine-protein kinase ATM Deficiency,Gastric Adenocarcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,NCT02264678,ATM Overexpression,"United States|Korea, Republic of|England|United Kingdom|U.S.A.|France",Recruiting
,Non-Small Cell Lung Carcinoma,Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,NCT02264990,ALK Fusion,"Russian Federation|Argentina|Hungary|United States|Czechia|Japan|England|United Kingdom|Scotland|Northern Ireland|Spain|New Zealand|Canada|Netherlands|Turkey|Taiwan|Finland|Korea, Republic of|Denmark|South Africa|Israel|U.S.A.|Australia|Germany","Active, not recruiting"
FGFR2 Fusion,Cholangiocarcinoma,Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions,NCT02265341,,United States|U.S.A.,Recruiting
,Chronic Myeloid Leukemia,The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study),NCT02269267,BCR-ABL1 Fusion,United States|U.S.A.,"Active, not recruiting"
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment,NCT02269579,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,United States|U.S.A.,Recruiting
,Breast Carcinoma,Phase II Study of Everolimus Beyond Progression,NCT02269670,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia,SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission,NCT02270463,KMT2A-MLLT3 Fusion|PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
FLT3 D835A|FLT3 D835E|FLT3 D835H|FLT3 D835N|FLT3 D835V|FLT3 D835Y|FLT3 I836D|FLT3 I836F|FLT3 I836H|FLT3 I836L|FLT3 I836M|FLT3 I836V|FLT3 ITD,Acute Myeloid Leukemia,Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies,NCT02270788,,United States|U.S.A.,"Active, not recruiting"
ALK Fusion,Non-Small Cell Lung Carcinoma,Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy,NCT02271139,,United States,Completed
BCL2 Amplification|BCL2 Fusion|BCL6 Amplification|BCL6 Fusion|MYC Amplification|MYC Fusion,Mature B-Cell Lymphoma/Leukemia,Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma,NCT02272686,,United States,"Active, not recruiting"
TP53 Mutation,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",NCT02272790,,Canada|United States|U.S.A.,Recruiting
ABL1 Amplification|ABL1 Fusion|ABL1 Mutation|FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FGFR4 Amplification|FGFR4 Fusion|FGFR4 Mutation|FLT3 Amplification|FLT3 Fusion|FLT3 Mutation|IGH-FGFR3 Fusion|KIT Amplification|KIT Fusion|KIT Mutation|PDGFRA Amplification|PDGFRA Fusion|PDGFRA Mutation|PDGFRB Amplification|PDGFRB Fusion|PDGFRB Mutation|RET Amplification|RET Fusion|RET Mutation,Cancer|Multiple Myeloma,"Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.",NCT02272998,IGH-FGFR3 Fusion,United States|U.S.A.,Recruiting
IDH2 Mutation,Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Glioma|Malignant Solid Tumor|Medulloblastoma,"Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",NCT02273739,,United States|France,Completed
,Breast Carcinoma|Pancreatic Neuroendocrine Neoplasm|Renal Cell Carcinoma,"Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer",NCT02273752,,United States,Terminated
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI),NCT02273973,,"United States|Czechia|England|Scotland|Portugal|Austria|El Salvador|Panama|Brazil|Guatemala|Korea, Republic of|Poland|Chile|France|Hungary|United Kingdom|Switzerland|Spain|Belgium|Italy|Mexico|U.S.A.|Australia|Peru|Germany",Completed
Cellular tumor antigen p53 Overexpression Positive|TP53 Mutation|TP53 Overexpression,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer,NCT02275039,,United States|U.S.A.,"Active, not recruiting"
,Breast Carcinoma,Molecular Triaging and Diagnostic Imaging to Guide Neoadjuvant Therapy,NCT02276443,,United States|U.S.A.,Recruiting
ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,"Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",NCT02277457,,United States,Withdrawn
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Gastric Carcinoma|Malignant Solid Tumor,First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients,NCT02277717,,Netherlands|Belgium|England|Scotland|United Kingdom|Spain,Recruiting
,Breast Carcinoma,"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",NCT02278120,,"Russian Federation|Singapore|Hong Kong|United States|Malaysia|Thailand|Portugal|Greece|Saudi Arabia|Brazil|Korea, Republic of|Poland|Bulgaria|France|Colombia|Argentina|Hungary|United Arab Emirates|Switzerland|India|Spain|Lebanon|Canada|Turkey|Belgium|Taiwan|Italy|Mexico|U.S.A.|Australia|Germany","Active, not recruiting"
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|RNF43 Mutation|RSPO1 Fusion,Colorectal Carcinoma,Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations,NCT02278133,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Canada|Netherlands|Singapore|Belgium|United States|Italy|Israel|Australia|France|Spain,"Active, not recruiting"
IGH-FGFR3 Fusion|IGH-WHSC1 Fusion|StrucGain(1)(q10qter)|del(17)(p10),Multiple Myeloma,Trial of Combination of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma,NCT02279394,,United States|U.S.A.,"Active, not recruiting"
NTRK1 Fusion|NTRK2 Fusion|NTRK3 Fusion|ROS1 Fusion|ROS1 Inversion,Colorectal Carcinoma|Malignant Solid Tumor,"A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",NCT02279433,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,United States|U.S.A.,Recruiting
,Anal Carcinoma|Cervical Carcinoma|Oropharyngeal carcinoma|Penile Carcinoma|Vaginal Carcinoma|Vulvar Carcinoma,T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers,NCT02280811,,United States,Completed
,Breast Carcinoma|Gastric Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,"Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors",NCT02281409,ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States|U.S.A.,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Oropharyngeal Squamous Cell Carcinoma,De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study,NCT02281955,,United States|U.S.A.,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Endometrial Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.,NCT02282020,,"Argentina|Hungary|United States|Scotland|United Kingdom|Spain|Canada|Czech Republic|Belgium|Brazil|Korea, Republic of|Poland|Italy|Mexico|Israel|U.S.A.",Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation,NCT02282345,,United States|U.S.A.,Recruiting
CREBBP Mutation|EP300 Mutation,Diffuse Large B-Cell Lymphoma|Follicular Lymphoma,Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma,NCT02282358,,United States|U.S.A.,"Active, not recruiting"
NF2 Mutation,Meningioma|Schwannoma,Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma,NCT02282917,,United States,Recruiting
FLT3 Mutation,Acute Myeloid Leukemia,A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations,NCT02283177,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States|U.S.A.,Recruiting
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Non-Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma,A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer,NCT02283320,,Russian Federation|United States,Completed
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",NCT02283658,,United States,"Active, not recruiting"
,Breast Carcinoma,Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen,NCT02285179,,Netherlands|Scotland|United Kingdom|France|Spain,Recruiting
BRAF Fusion|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NF1 Mutation|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Glioma|Malignant Solid Tumor,Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors,NCT02285439,BRAF Fusion|NF1 Mutation,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Malignant Solid Tumor,"Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)",NCT02286219,,Canada|United States|U.S.A.,"Active, not recruiting"
ATM Deletion|ATM Loss|ATM Mutation|ATR Deletion|ATR Loss|ATR Mutation|BRCA1 Deletion|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Deletion|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|C11orf30 Deletion|C11orf30 Loss|C11orf30 Mutation|FANCA Amplification|FANCB Amplification|FANCC Amplification|FANCD2 Amplification|FANCE Amplification|FANCF Amplification|FANCG Amplification|FANCI Amplification|FANCL Amplification|FANCM Amplification|MRE11A Deletion|MRE11A Loss|MRE11A Mutation|NBN Loss|NBN Mutation|PALB2 Deletion|PALB2 Loss|PALB2 Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|RAD50 Deletion|RAD50 Loss|RAD50 Mutation|myChoice HRD Positive,Cancer,Phase II Study of BMN 673,NCT02286687,,United States,"Active, not recruiting"
,Glioblastoma,"Ph I Personalized NeoAntigen Cancer Vaccine With Radiotherapy for Patients With MGMT Unmethylated, Newly Diagnosed Glioblastoma",NCT02287428,,United States|U.S.A.,"Active, not recruiting"
,Melanoma,PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma,NCT02288897,BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,United States|Italy|U.S.A.|Australia,Recruiting
ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ERBB2 Amplification|ERBB2 Overexpression,Non-Small Cell Lung Carcinoma,"A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",NCT02289833,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,"United States|Korea, Republic of|Poland|Italy|U.S.A.|Switzerland|Germany|Spain","Active, not recruiting"
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma,A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies,NCT02290951,,United States|U.S.A.|Germany,Recruiting
,Cervical Carcinoma|Head and Neck Squamous Cell Carcinoma,Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer,NCT02291055,,United States,Recruiting
,Breast Carcinoma,Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,NCT02291913,,United States,"Active, not recruiting"
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Non-Small Cell Lung Carcinoma,Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.,NCT02292550,,"Korea, Republic of|Italy|U.S.A.|France|Spain",Recruiting
,Colorectal Carcinoma,Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery,NCT02292758,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States,Recruiting
,Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma,Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma,NCT02293109,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer,NCT02294786,,Greece|Russian Federation|Hong Kong|Czechia|Poland|England|Italy|United Kingdom|Israel|France,"Active, not recruiting"
,Breast Carcinoma,Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention,NCT02295059,,United States|U.S.A.,Recruiting
BRAF Fusion|BRAF Mutation,Melanoma,Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,NCT02296112,BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
EGFR Exon 19 Deletion|EGFR L858R,Non-Small Cell Lung Carcinoma,AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,NCT02296125,,"Russian Federation|United States|England|Scotland|Malaysia|Thailand|Portugal|Saudi Arabia|Sweden|Vietnam|China|Brazil|Korea, Republic of|Poland|Bulgaria|France|Romania|Hungary|Japan|Philippines|Ukraine|United Kingdom|Switzerland|Spain|Canada|Czech Republic|Turkey|Belgium|Taiwan|Italy|Israel|Australia|Germany","Active, not recruiting"
HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes,NCT02296242,,United States|U.S.A.,Recruiting
,Head and Neck Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,NCT02296684,CDKN2A Expression|CDKN2A Overexpression,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer,NCT02296801,,Canada|United States|Wales|England|United Kingdom|U.S.A.|Northern Ireland,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,NCT02297698,,United States|U.S.A.,Recruiting
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FLT1 Amplification|FLT1 Mutation|FLT4 Amplification|FLT4 Mutation|KDR Amplification|KDR Mutation|PDGFRA Amplification|PDGFRA Mutation|PDGFRB Amplification|PDGFRB Mutation|TP53 Mutation,Non-Small Cell Lung Carcinoma,Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer,NCT02299141,,United States|U.S.A.,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Non-Small Cell Lung Carcinoma,Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC),NCT02299505,,"Russian Federation|United States|England|Scotland|Malaysia|Thailand|Greece|Austria|Netherlands|Brazil|Korea, Republic of|Poland|Bulgaria|Colombia|Hungary|United Kingdom|India|Spain|Lebanon|Canada|Czech Republic|Belgium|Taiwan|Italy|U.S.A.|Australia|Germany",Recruiting
CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|Trisomy 11|del(11)(q10)|del(5)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),Acute Myeloid Leukemia,Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,NCT02299518,,United States|U.S.A.,Recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Bladder Carcinoma|Renal Pelvis and Ureter Carcinoma|Urethral Carcinoma|Urothelial Carcinoma,Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,NCT02300610,,United States|U.S.A.,Recruiting
BRAF Mutation,Melanoma,Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,NCT02300935,BRAF Mutation,United States,Withdrawn
TP53 Frameshift|TP53 Nonsense|TP53 c.1-c.137 Missense|TP53 c.142-c.212 Missense|TP53 c.217-c.1178 Missense|del(11)(q10)|del(17)(p10),Chronic Lymphocytic Leukemia,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),NCT02301156,,United States|U.S.A.,"Active, not recruiting"
,Breast Carcinoma,A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer,NCT02301988,,United States|U.S.A.|Portugal|Spain,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PGR Expression|PGR Overexpression|Progesterone receptor Expression Positive|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects,NCT02302196,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense|CHEK2 Mutation,United States,Recruiting
NUTM1 Fusion,Breast Carcinoma|Malignant Solid Tumor,"Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors",NCT02307240,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",NCT02308020,,New Zealand|Canada|Austria|Belgium|United States|Italy|Israel|U.S.A.|Australia|France|Spain,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Anal Carcinoma|Cervical Carcinoma|Cervical Squamous Cell Carcinoma|Oropharyngeal carcinoma|Penile Carcinoma|Vaginal Carcinoma|Vulvar Carcinoma,Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies,NCT02308241,,United States|U.S.A.,"Active, not recruiting"
,Breast Carcinoma|Non-Small Cell Lung Carcinoma|Pancreatic Carcinoma,"Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",NCT02309177,,United States|U.S.A.,Recruiting
,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,"Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis",NCT02309515,CCND1 Expression|CCND1 Overexpression|G1/S-specific cyclin-D1 Expression Positive|IGH-CCND1 Fusion|t(11;14)(q13;32),United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",NCT02311933,,United States|U.S.A.,"Active, not recruiting"
BCR-ABL1 Fusion|t(9;22)(q34;q11),B Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia,Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML),NCT02311998,,United States|U.S.A.,Recruiting
IGH-CCND1 Fusion|IGH-CCND3 Fusion|t(11;14)(q13;32)|t(6;14)(p21;q32),Multiple Myeloma,A Study of Oral Ixazomib Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation,NCT02312258,,"Russian Federation|Singapore|United States|England|Scotland|Thailand|Portugal|Greece|Austria|Sweden|Brazil|Korea, Republic of|Poland|Chile|Serbia|Argentina|Hungary|Japan|United Kingdom|Spain|Canada|Czech Republic|Turkey|Taiwan|Denmark|Italy|Mexico|South Africa|U.S.A.|Israel|Australia|Germany",Recruiting
BRAF Mutation|HRAS Mutation|KRAS Mutation|NRAS Mutation,Malignant Solid Tumor,Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors,NCT02313012,,United States|Australia,Terminated
,Adenocarcinoma of the Gastroesophageal Junction|Gastric Carcinoma,A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,NCT02314117,,Argentina|Puerto Rico|Russian Federation|Hungary|United States|Japan|England|Scotland|United Kingdom|Spain|Canada|Czech Republic|Netherlands|Belgium|Finland|Denmark|Poland|Italy|Mexico|Israel|U.S.A.|France|Germany,"Active, not recruiting"
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma|Hereditary Breast and Ovarian Cancer Syndrome,Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy,NCT02314156,,United States|U.S.A.,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ROS1 Fusion,Non-Small Cell Lung Carcinoma,A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC,NCT02314364,,United States|U.S.A.,Recruiting
ALK Expression|ALK Fusion|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|BRAF Codon 600 Missense|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|RET Amplification|RET Fusion|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Non-Small Cell Lung Carcinoma,Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity,NCT02314481,,Scotland|United Kingdom,Recruiting
,Breast Carcinoma,Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer,NCT02315196,,United States|U.S.A.,Recruiting
B-cell receptor CD22 Expression Positive|CD22 Expression|CD22 Overexpression,B Acute Lymphoblastic Leukemia|Lymphoma,Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies,NCT02315612,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,NCT02316509,,United States|U.S.A.|Spain,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,"Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer",NCT02317016,,United States|England|Scotland|United Kingdom|France|Spain,"Active, not recruiting"
MSLN Expression|Mesothelin Expression Positive,Malignant Solid Tumor|Pancreatic Ductal Adenocarcinoma|Pleural Mesothelioma,"A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors",NCT02317419,,Canada|United States|Denmark|France,Terminated
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Malignant Solid Tumor,"Talazoparib, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",NCT02317874,,United States|U.S.A.,Recruiting
EGFR Exon 19 Deletion|EGFR L858R,Non-Small Cell Lung Carcinoma,"A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label",NCT02318368,,"Republic of Singapore|Singapore|Hong Kong|United States|Taiwan|Korea, Republic of|Italy|U.S.A.|Australia","Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Breast Carcinoma|Colorectal Carcinoma|Gastric Carcinoma|Head and Neck Squamous Cell Carcinoma|Malignant Solid Tumor,Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,NCT02318901,BRAF D594E|BRAF D594G|BRAF D594H|BRAF D594N|BRAF D594V|BRAF G466V|BRAF G469A|BRAF G469E|BRAF G469L|BRAF G469V|BRAF G596R|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF R444W|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|BRAF Y472C|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States,Recruiting
CD274 Low Expression|CD274 No Expression|Programmed cell death 1 ligand 1 Expression Negative,Head and Neck Squamous Cell Carcinoma,"Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",NCT02319044,CD274 Expression|CD274 Overexpression,"Hungary|United States|Czechia|England|Scotland|United Kingdom|Malaysia|Spain|Canada|Belgium|Taiwan|Korea, Republic of|Georgia|Israel|Australia|France|Germany","Active, not recruiting"
,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndromes,"Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies",NCT02319369,TP53 Frameshift|TP53 Missense|TP53 Nonsense,United States|U.S.A.,Recruiting
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Sarcoma,NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy,NCT02319824,,United States|U.S.A.,Completed
MLANA Expression|MLANA Overexpression|Melanoma antigen recognized by T-cells 1 Expression Positive,Melanoma,MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,NCT02320305,,United States,"Active, not recruiting"
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression,NCT02321501,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer,NCT02321540,,United States|U.S.A.,"Active, not recruiting"
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,"TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",NCT02322281,EGFR Exon 20 Insertion,"Netherlands|United States|Taiwan|Korea, Republic of|England|Italy|United Kingdom|Australia|France|Germany|Spain","Active, not recruiting"
,Breast Carcinoma,"A Study of Cobimetinib in Combination With Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, and Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-line Treatment for Participants With Metastatic Triple-Negative Breast Cancer",NCT02322814,,"Romania|United States|England|United Kingdom|Spain|Latvia|Belgium|Taiwan|Korea, Republic of|Italy|South Africa|U.S.A.|Israel|Australia|Lithuania",Recruiting
FLT3 ITD,Acute Myeloid Leukemia,"Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)",NCT02323113,FLT3 Mutation,Canada|United States,Recruiting
EGFR T790M|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Non-Small Cell Lung Carcinoma,Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,NCT02323126,EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Netherlands|Singapore|United States|Italy|U.S.A.|Australia|France|Switzerland|Germany|Spain,Recruiting
,Bladder Carcinoma|Breast Carcinoma|Gastric Carcinoma|Ovarian Carcinoma|Soft Tissue Sarcoma,A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors,NCT02323191,,Belgium|United States|U.S.A.|France|Spain,Recruiting
FLT3 Mutation,Acute Myeloid Leukemia,Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations,NCT02323607,CBFB-MYH11 Inversion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(16;16)(p13;q22)|t(8;21)(q22;q22),United States|U.S.A.,Recruiting
Beta-klotho Expression Positive|FGFR4 Expression|FGFR4 Overexpression|Fibroblast growth factor receptor 4 Expression Positive|KLB Expression|KLB Overexpression,Malignant Solid Tumor,FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression,NCT02325739,,"Singapore|Hong Kong|United States|Japan|Taiwan|Korea, Republic of|Italy|U.S.A.|France|Germany|Spain",Recruiting
BRCA1 Mutation|BRCA2 Mutation,Ovarian Carcinoma,"BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment",NCT02326844,,United States,Terminated
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA,NCT02326974,,United States|U.S.A.,Recruiting
BRAF V600E,Colorectal Carcinoma|Head and Neck Squamous Cell Carcinoma|Hodgkin Lymphoma|Melanoma|Non-Hodgkin Lymphoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma,"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)",NCT02327078,,United States|U.S.A.,Recruiting
BRAF D594E|BRAF D594G|BRAF D594H|BRAF D594N|BRAF D594V|BRAF G466V|BRAF G469A|BRAF G469E|BRAF G469L|BRAF G469V|BRAF G596R|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF R444W|BRAF Y472C|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V,Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,"A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic Malignancies",NCT02327169,,United States|England|United Kingdom|U.S.A.|France|Spain,Recruiting
,Breast Carcinoma|Non-Small Cell Lung Carcinoma|Pancreatic Ductal Adenocarcinoma,"Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers",NCT02327468,,United States|U.S.A.,Recruiting
del(11)(q10)|del(17)(p10),Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Richter Syndrome,"A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies",NCT02329847,,United States|Poland|Israel|Australia|Spain,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma|Malignant Solid Tumor|Ovarian Carcinoma|Pancreatic Adenocarcinoma|Sarcoma|Small Cell Lung Carcinoma,Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),NCT02331251,,United States,Recruiting
CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Lymphoma|Malignant Solid Tumor|Melanoma,"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)",NCT02332668,,"United States|England|United Kingdom|New Zealand|Canada|Sweden|Brazil|Korea, Republic of|Italy|Israel|U.S.A.|Australia|France|Germany",Recruiting
CCND1 Expression|CCND1 Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Negative|G1/S-specific cyclin-D1 Overexpression|RB1 Expression|RB1 Overexpression|Retinoblastoma-associated protein Expression Positive,Bladder Carcinoma|Urothelial Carcinoma,Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy,NCT02334527,CDKN2A Expression|CDKN2A Overexpression,United States|U.S.A.,Recruiting
,Multiple Myeloma,SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy,NCT02334865,,United States|U.S.A.,Recruiting
CD274 Expression|CD274 High Expression|CD274 Low Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Bladder Carcinoma|Urothelial Carcinoma,Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52),NCT02335424,,,"Active, not recruiting"
FLT3 Codon 835 Missense|FLT3 Codon 836 Missense|FLT3 ITD,Acute Myeloid Leukemia,First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia,NCT02335814,FLT3 Codon 835 Missense|FLT3 Codon 836 Missense|FLT3 ITD,United States|U.S.A.,"Active, not recruiting"
EGFR Exon 19 Deletion|EGFR L858R|EGFR T790M,Non-Small Cell Lung Carcinoma,Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.,NCT02335944,,"Canada|Singapore|United States|Norway|Taiwan|Korea, Republic of|Italy|U.S.A.|Australia|France|Germany|Spain",Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Chronic Lymphocytic Leukemia,A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities,NCT02336048,,Latvia|Hungary|England|Italy|United Kingdom|Israel|Spain,Recruiting
,Glioblastoma,Phase 2 Study of MEDI4736 in Patients With Glioblastoma,NCT02336165,,United States|U.S.A.|Australia,"Active, not recruiting"
ALK Fusion,Non-Small Cell Lung Carcinoma,A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges,NCT02336451,,"Russian Federation|Singapore|Hong Kong|United States|England|United Kingdom|Spain|Canada|Netherlands|Turkey|Belgium|Taiwan|Brazil|Korea, Republic of|Italy|U.S.A.|Australia|France|Germany",Recruiting
Monosomy 3,Uveal Melanoma,Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases,NCT02336763,,United States,Terminated
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS,NCT02336984,,United States,"Active, not recruiting"
MYCN Amplification|PIK3CA Mutation|PTEN Mutation,Neuroblastoma,SF1126 for Patients With Relapsed or Refractory Neuroblastoma,NCT02337309,,Canada|United States,"Active, not recruiting"
del(17)(p10),Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Acalabrutinib in Patients With Relapsed/Refractory and Treatment naÌøve Deletion 17p CLL/SLL,NCT02337829,,United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,"A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer",NCT02338349,,United States|U.S.A.,"Active, not recruiting"
"AKT1 Amplification|AKT1 Mutation|AKT2 Amplification|AKT2 Mutation|AKT3 Amplification|AKT3 Mutation|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|CRKL Mutation|EGFR Amplification|EGFR Mutation|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|IRS2 Mutation|KIT Amplification|KIT Mutation|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|MTOR Mutation|PDGFRA Amplification|PDGFRA Mutation|PIK3CA Amplification|PIK3CA Mutation|PIK3CG Mutation|PIK3R1 Mutation|PIK3R2 Mutation|PTEN Large Deletion|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|RICTOR Amplification|RICTOR Mutation|RNF43 Mutation|RPTOR Mutation|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression|TSC1 Mutation|TSC2 Mutation",Malignant Solid Tumor,Trial of Olaparib in Combination With AZD5363 (ComPAKT),NCT02338622,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,England|United Kingdom,Unknown status
BRAF Mutation,Melanoma,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,NCT02339571,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
PML-RARA Fusion,Acute Promyelocytic Leukemia,Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,NCT02339740,,New Zealand|Canada|United States|U.S.A.|Australia,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PIK3CA Mutation,Breast Carcinoma,A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy,NCT02340221,,"Russian Federation|United States|Czechia|Thailand|Portugal|Greece|Austria|Netherlands|Sweden|China|Korea, Republic of|Poland|Bulgaria|France|Serbia|Bosnia and Herzegovina|Colombia|Romania|Spain|Canada|Turkey|Finland|Taiwan|Italy|Mexico|U.S.A.|Australia|Peru|Germany",Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI),NCT02342353,,United States|U.S.A.,Recruiting
,Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma,Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,NCT02342782,Complex karyotype|Loss of Y|Monosomy 7|Normal karyotype|Very Complex karyotype|del(20)(q10)|del(5)(q10)|del(7)(q10)|del(7)(q12),United States|U.S.A.,Recruiting
,Liposarcoma,Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma,NCT02343172,TP53 Mutation,,Closed
EGFR Amplification,Glioblastoma,Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas,NCT02343406,,Singapore|Hungary|United States|Czechia|England|Scotland|United Kingdom|Spain|Finland|Taiwan|Poland|Italy|Mexico|Australia|France|Germany,Recruiting
BCL2 Amplification|BCL2 Fusion|BCL2 Overexpression|MYC Amplification|MYC Fusion|MYC Overexpression,Diffuse Large B-Cell Lymphoma|Double-Hit Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Transformed Lymphoma,"A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma",NCT02343536,,United States|U.S.A.,Recruiting
ALK Fusion,Mature B-Cell Lymphoma/Leukemia|Mature T-Cell and NK-Cell Lymphoma/Leukemia,Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies,NCT02343679,,United States|U.S.A.,Withdrawn
Hepatocyte growth factor receptor Expression Positive|MET Expression|MET Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Colorectal Adenocarcinoma|Esophageal Carcinoma|Gastric Adenocarcinoma|Small Intestinal Adenocarcinoma,"C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",NCT02344810,,United States,Unknown status
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",NCT02345772,,United States,Unknown status
RB1 Expression|RB1 Overexpression|Retinoblastoma-associated protein Expression Positive,Glioma,Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma,NCT02345824,,United States,Recruiting
,Breast Carcinoma,Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy,NCT02348320,,United States|U.S.A.,Recruiting
,Acute Myeloid Leukemia,"SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",NCT02348489,CBFB-MYH11 Inversion|RUNX1-RUNX1T1 Fusion,"Russian Federation|United States|Scotland|Austria|Netherlands|Sweden|Korea, Republic of|Poland|Bulgaria|France|Serbia|Romania|Hungary|Japan|United Kingdom|Spain|Canada|Czech Republic|Belgium|Finland|Taiwan|Denmark|Italy|U.S.A.|Australia|Germany","Active, not recruiting"
EGFR Exon 19 Deletion|EGFR L858R|EGFR T790M,Non-Small Cell Lung Carcinoma,Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M),NCT02349633,,"United States|Korea, Republic of|U.S.A.",Recruiting
KRAS A146P|KRAS A146T|KRAS A146V|KRAS A59E|KRAS A59G|KRAS A59P|KRAS A59S|KRAS A59T|KRAS A59V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS A59D|NRAS A59G|NRAS A59P|NRAS A59S|NRAS A59T|NRAS A59V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Colorectal Adenocarcinoma,FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type,NCT02350530,,China,Recruiting
,Breast Carcinoma,S-equol in Women With Triple Negative Breast Cancer,NCT02352025,,United States,Suspended
TSC1 Mutation|TSC2 Mutation,Malignant Solid Tumor,"Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations",NCT02352844,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy,NCT02353728,,United States,Not yet recruiting
Complex karyotype|Monosomal karyotype|Very Complex karyotype,Acute Myeloid Leukemia,A Phase 1 Trial of a Single ProHemaå¨ CB Product for Pediatric Patients With Hematologic Malignancies,NCT02354417,,United States,Terminated
,High Grade Cervical Intraepithelial Neoplasia,Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3),NCT02354534,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations,NCT02355431,EGFR T790M,United States,Withdrawn
,Glioma,A Vaccine Trial for Low Grade Gliomas,NCT02358187,,United States|U.S.A.,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma|Malignant Solid Tumor,Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer,NCT02358200,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States|U.S.A.,"Active, not recruiting"
,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Carcinoma|Gastric Adenocarcinoma,Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach,NCT02358863,,United States|U.S.A.,Recruiting
,Myelodysplastic Syndromes,A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome,NCT02363491,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib,NCT02364609,,United States|U.S.A.,Recruiting
,Non-Small Cell Lung Carcinoma,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,NCT02364999,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Russian Federation|United States|Czechia|Malaysia|Thailand|Greece|Netherlands|Brazil|Poland|Bulgaria|Chile|France|Croatia|Romania|Hungary|Japan|Philippines|Ukraine|India|Spain|Turkey|Italy|South Africa|Australia|Germany,Recruiting
ANO1 Expression|ANO1 Overexpression|Anoctamin-1 Expression Positive|Anoctamin-1 Overexpression|KIT Expression|KIT Mutation|KIT Overexpression|Mast/stem cell growth factor receptor Kit Expression Positive|Mast/stem cell growth factor receptor Kit Overexpression|PDGFRA Mutation,Gastrointestinal Stromal Tumor,A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST),NCT02365441,,Netherlands|Sweden|Singapore|Norway|Finland|Scotland|United Kingdom|Slovakia|Australia|France|Spain,Recruiting
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FGFR4 Amplification|FGFR4 Fusion|FGFR4 Mutation,Urothelial Carcinoma,An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer,NCT02365597,,"Russian Federation|Romania|United States|England|United Kingdom|Scotland|Spain|Austria|Belgium|Moldova, Republic of|Taiwan|Korea, Republic of|Israel|U.S.A.|France|Germany",Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PGR Expression|PGR Overexpression|Progesterone receptor Expression Positive,Breast Carcinoma,CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI),NCT02365714,BRCA1 Deletion|BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Deletion|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense|CDH1 Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|STK11 Mutation|TP53 Deletion|TP53 Loss|TP53 Mutation,United States,Terminated
,Breast Carcinoma,Phase II Trial of Ra-223 Dichloride and Hormonal Treatment,NCT02366130,,United States|U.S.A.,Recruiting
,Breast Carcinoma|Malignant Solid Tumor,Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,NCT02366949,,Canada|Netherlands|United States|U.S.A.,Recruiting
BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Ameloblastoma,Dabrafenib in Treating Patients With BRAF Mutated Ameloblastoma,NCT02367859,,United States,Not yet recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Breast Carcinoma,Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC),NCT02368691,,United States|U.S.A.,Recruiting
FGFR2 Amplification|FGFR2 Expression|Fibroblast growth factor receptor 2 Expression Positive,Malignant Solid Tumor,"Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)",NCT02368951,,"Singapore|United States|Korea, Republic of",Terminated
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive,Head and Neck Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,"Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Platin, 5-FU, Cetuximab, and Taxane",NCT02369458,CDKN2A Expression|CDKN2A Overexpression,United States|U.S.A.,Recruiting
CD274 Expression|CD274 High Expression|CD274 Low Expression|CD274 No Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Negative|Programmed cell death 1 ligand 1 Expression Positive,Head and Neck Squamous Cell Carcinoma,Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,NCT02369874,CD274 Expression|CD274 Overexpression,"Argentina|Russian Federation|Romania|Hungary|Czechia|Japan|Ukraine|Spain|Belgium|Taiwan|Brazil|Korea, Republic of|Poland|Italy|Georgia|Israel|U.S.A.|Australia|Bulgaria|France|Serbia|Peru|Germany|Croatia",Recruiting
B-cell receptor CD22 Expression Positive|B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression|CD22 Expression|CD22 Overexpression,B-Cell Non-Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|Hairy Cell Leukemia,HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma,NCT02370160,,United States|U.S.A.,Recruiting
,Breast Carcinoma,A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer,NCT02370238,,Belgium|United States|Czechia|Poland|Italy|U.S.A.|France|Spain,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,"Node Negative, Invasive Breast Cancer Single Fraction IOERT",NCT02370797,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States,Recruiting
BCR-ABL1 Fusion|CD34 Expression|CD34 Overexpression|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hematopoietic progenitor cell antigen CD34 Overexpression Positive|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|NPM1-MLF1 Fusion|RPN1-MECOM Fusion|RPN1-MECOM Inversion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(3)(q10)|del(5)(q10)|del(7)(q10)|del(7)(q12)|inv(11)(p15;q23)|inv(3)(q21q26)|inv(3)(q21q26.2)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(3;5)(q25.1;q34)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia|Myelodysplastic Syndromes,Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease,NCT02370888,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant,NCT02374099,,Belgium|United States|Italy|France|Germany|Spain,"Active, not recruiting"
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,Acute Lymphoblastic Leukemia|Non-Hodgkin Lymphoma,Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy,NCT02374333,,United States,Recruiting
CDH3 Expression|CDH3 Overexpression|Cadherin-3 Expression Positive,Breast Carcinoma|Esophageal Carcinoma|Head and Neck Carcinoma,PCA062 in pCAD-positive Tumors.,NCT02375958,,Singapore|United States|Japan|Italy|U.S.A.|France|Spain,Recruiting
,Breast Carcinoma,BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer,NCT02379247,,United States|U.S.A.,Recruiting
,Malignant Solid Tumor,"HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA",NCT02379520,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,NCT02379585,,United States,Terminated
CD276 Expression|CD276 Overexpression|CD276 antigen Expression Positive,Breast Carcinoma|Colorectal Carcinoma|Head and Neck Squamous Cell Carcinoma|Melanoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Pancreatic Carcinoma|Peritoneal Mesothelioma|Pleural Mesothelioma|Prostate Carcinoma|Renal Cell Carcinoma|Soft Tissue Sarcoma|Thyroid Cancer|Urothelial Carcinoma,Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer,NCT02381314,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|FLT3 ITD,Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndromes,Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia,NCT02381548,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(16;16)(p13;q22)|t(8;21)(q22;q22),United States|U.S.A.,Recruiting
IDH1 R132C|IDH1 R132G|IDH1 R132H|IDH1 R132L|IDH1 R132P|IDH1 R132S,Cancer,A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations,NCT02381886,,Canada|Netherlands|Singapore|Belgium|United States|U.S.A.|Australia|Germany|Spain,Suspended
,Non-Small Cell Lung Carcinoma,Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC,NCT02382406,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States|U.S.A.,Recruiting
BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib,NCT02382549,,United States,Recruiting
HRAS Missense,Malignant Solid Tumor|Thyroid Cancer,Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations,NCT02383927,,"Netherlands|Belgium|United States|Korea, Republic of|Italy|Scotland|United Kingdom|U.S.A.|France|Spain",Recruiting
,Breast Carcinoma,A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,NCT02384239,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Phase I Study of the Combination of MLN9708 and Fulvestrant,NCT02384746,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Malignant Solid Tumor,Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors,NCT02386501,,United States|U.S.A.,Recruiting
Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Colorectal Carcinoma|Glioblastoma|Gliosarcoma|Renal Cell Carcinoma,INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme,NCT02386826,,United States,Recruiting
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Fallopian Tube Carcinoma|Melanoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Sarcoma,"A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",NCT02387125,,United States|U.S.A.,Recruiting
"NRG1 Expression|NRG4 Expression|Pro-neuregulin-1, membrane-bound isoform Expression Positive|Pro-neuregulin-4, membrane-bound isoform Expression Positive",Non-Small Cell Lung Carcinoma,A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC,NCT02387216,ALK Fusion|EGFR Exon 19 Deletion|EGFR L858R,Canada|Hungary|United States|U.S.A.|Germany|Spain,Recruiting
,Head and Neck Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer,NCT02388932,,United States|U.S.A.,Terminated
,Breast Carcinoma,Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC),NCT02389764,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PIK3CA Mutation,Breast Carcinoma|Malignant Solid Tumor,PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib,NCT02389842,,England|United Kingdom,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,NCT02390427,,United States|U.S.A.,Recruiting
TG Expression|Thyroglobulin Expression Positive,Thyroid Cancer,Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer,NCT02390739,,United States|U.S.A.,Recruiting
,Acute Myeloid Leukemia,FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia,NCT02392429,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States|U.S.A.,Recruiting
,Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndromes,ONC201 in Relapsed/Refractory Acute Leukemias and High-Risk Myelodysplastic Syndromes (HR-MDS),NCT02392572,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma|Diffuse Large B-Cell Lymphoma|Lymphoma|Malignant Solid Tumor|Peripheral T-Cell Lymphoma,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas",NCT02392611,,United States,Recruiting
ATM Deletion|ATM Mutation|ATR Deletion|ATR Mutation|BARD1 Mutation|BRCA1 Deletion|BRCA1 Mutation|BRCA2 Deletion|BRCA2 Mutation|BRIP1 Mutation|CHEK1 Mutation|CHEK2 Mutation|FANCA Mutation|FANCB Mutation|FANCC Mutation|FANCD2 Mutation|FANCE Mutation|FANCF Mutation|FANCG Mutation|FANCI Mutation|FANCL Mutation|FANCM Mutation|MCPH1 Mutation|MRE11A Deletion|MRE11A Mutation|NBN Deletion|NBN Mutation|PALB2 Deletion|PALB2 Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|RAD50 Deletion|RAD50 Mutation|RAD51 Mutation|RAD51B Mutation|RAD51C Mutation|RAD51D Mutation|SLX4 Mutation,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations,NCT02392676,,"United States|Philippines|Korea, Republic of|England|Scotland|United Kingdom|Peru",Withdrawn
FGF1 Mutation|FGF10 Mutation|FGF11 Mutation|FGF12 Mutation|FGF13 Mutation|FGF14 Mutation|FGF16 Mutation|FGF17 Mutation|FGF18 Mutation|FGF19 Mutation|FGF2 Mutation|FGF20 Mutation|FGF21 Mutation|FGF22 Mutation|FGF23 Mutation|FGF3 Mutation|FGF4 Mutation|FGF5 Mutation|FGF6 Mutation|FGF7 Mutation|FGF8 Mutation|FGF9 Mutation|FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FGFR4 Amplification|FGFR4 Fusion|FGFR4 Mutation,Endometrial Carcinoma|Gastric Carcinoma|Malignant Solid Tumor|Multiple Myeloma|Myeloproliferative Neoplasm|Squamous Cell Lung Carcinoma|Urothelial Carcinoma,"Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",NCT02393248,,United States|U.S.A.,Recruiting
ALK Fusion,Non-Small Cell Lung Carcinoma,Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer,NCT02393625,,Canada|Netherlands|Singapore|Belgium|Hong Kong|United States|Italy|U.S.A.|Australia|Spain,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC),NCT02393794,,United States|U.S.A.,Recruiting
,Non-Small Cell Lung Carcinoma,Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200),NCT02395172,ALK Fusion,"Russian Federation|United States|England|Scotland|Brazil|Korea, Republic of|Poland|Slovakia|France|Bulgaria|Chile|Croatia|Colombia|Argentina|Romania|Hungary|Japan|United Kingdom|Switzerland|Spain|Czech Republic|Turkey|Belgium|Taiwan|Denmark|Italy|Mexico|South Africa|Israel|Australia|Peru","Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Reversing Therapy Resistance With Epigenetic-Immune Modification,NCT02395627,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy,NCT02398773,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PGR Expression|PGR Overexpression|Progesterone receptor Expression Positive,Breast Carcinoma,The IDEA Study (Individualized Decisions for Endocrine Therapy Alone),NCT02400190,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States,Recruiting
FLT3 Codon 835 Missense|FLT3 Codon 836 Missense|FLT3 ITD,Acute Myeloid Leukemia,Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients,NCT02400255,,United States|U.S.A.,Recruiting
FLT3 Mutation,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,NCT02400281,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States|U.S.A.,Recruiting
KIT Fusion|KIT Mutation,Melanoma,A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,NCT02400385,,United States,Withdrawn
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,NCT02400476,,Canada|United States|U.S.A.|Australia,Recruiting
ATM Deletion|ATM Mutation|ATR Deletion|ATR Mutation|BARD1 Mutation|BRCA1 Deletion|BRCA1 Mutation|BRCA2 Deletion|BRCA2 Mutation|BRIP1 Mutation|CHEK1 Mutation|CHEK2 Mutation|FANCA Mutation|FANCB Mutation|FANCC Mutation|FANCD2 Mutation|FANCE Mutation|FANCF Mutation|FANCG Mutation|FANCI Mutation|FANCL Mutation|FANCM Mutation|MCPH1 Mutation|MRE11A Deletion|MRE11A Mutation|NBN Deletion|NBN Mutation|PALB2 Deletion|PALB2 Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|RAD50 Deletion|RAD50 Mutation|RAD51 Mutation|RAD51B Mutation|RAD51C Mutation|RAD51D Mutation|SLX4 Mutation,Breast Carcinoma,Talazoparib Beyond BRCA (TBB) Trial,NCT02401347,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States|U.S.A.,Recruiting
FGFR3 Expression|FGFR3 Fusion|FGFR3 Mutation|Fibroblast growth factor receptor 3 Expression Positive,Urothelial Carcinoma,A Phase 1b/2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,NCT02401542,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer,NCT02402712,,Hungary|Wales|England|United Kingdom|Portugal|Spain|Canada|Belgium|Poland|Italy|Mexico|Bulgaria|France|Germany,"Active, not recruiting"
,Breast Carcinoma,Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC),NCT02402764,,United States,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Non-Small Cell Lung Carcinoma|Pancreatic Carcinoma,A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,NCT02403271,,United States|U.S.A.,"Active, not recruiting"
Complex karyotype|FLT3 ITD|Monosomal karyotype|RPN1-MECOM Fusion|RPN1-MECOM Inversion|Very Complex karyotype,Acute Myeloid Leukemia,A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML,NCT02403310,CBFB-MYH11 Inversion|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion,United States,"Active, not recruiting"
,Breast Carcinoma|Malignant Solid Tumor|Melanoma|Non-Small Cell Lung Carcinoma,Phase I/II Study of PDR001 in Patients With Advanced Malignancies,NCT02404441,,Hungary|United States|Thailand|Spain|Lebanon|Canada|Netherlands|Turkey|Norway|Taiwan|Poland|Italy|U.S.A.|France|Germany,Recruiting
,Cervical Carcinoma,Clinical Trial Safety and Feasibility of TA-CIN Vaccine in Combination With GPI-0100 Adjuvant in Patients With a History of HPV16 Associated Cervical Cancer,NCT02405221,,United States,Not yet recruiting
Complex karyotype|TP53 Frameshift|TP53 Nonsense|Very Complex karyotype|del(17)(p10)|del(5)(q10),Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,"A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",NCT02406742,,Austria|United States|Italy|U.S.A.|Germany|Spain,Recruiting
NF1 Germline Mutation|NF1 Mutation,Neurofibroma,Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery,NCT02407405,,United States,Recruiting
BRAF Mutation|KRAS Mutation|NRAS Mutation,Malignant Solid Tumor|Multiple Myeloma,Phase I Trial of RO5126766,NCT02407509,,England|United Kingdom,Unknown status
WT1 Expression|WT1 Overexpression|Wilms tumor protein Expression Positive,Mesothelioma|Non-Small Cell Lung Carcinoma,Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma,NCT02408016,,United States|U.S.A.,Recruiting
BRAF V600E|RET Fusion,Thyroid Gland Papillary Carcinoma,Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer,NCT02408887,,United States|U.S.A.,Recruiting
CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Non-Small Cell Lung Carcinoma,A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110],NCT02409342,,"Russian Federation|Romania|Hungary|United States|Japan|Ukraine|England|United Kingdom|Thailand|Northern Ireland|Spain|Greece|Turkey|China|Brazil|Korea, Republic of|Poland|Italy|U.S.A.|France|Serbia|Germany",Recruiting
CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Non-Small Cell Lung Carcinoma,A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111),NCT02409355,,"Russian Federation|Romania|Hungary|United States|England|United Kingdom|Spain|Greece|Czech Republic|Korea, Republic of|Poland|Italy|France|Serbia|Germany","Active, not recruiting"
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC,NCT02411448,EGFR T790M,"Romania|Hong Kong|United States|Japan|England|United Kingdom|Spain|Greece|Canada|Turkey|Taiwan|Korea, Republic of|Italy|U.S.A.|France|Germany",Recruiting
,Breast Carcinoma,MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC),NCT02411656,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer,NCT02413320,,United States|U.S.A.,Recruiting
MET Amplification,Non-Small Cell Lung Carcinoma,Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer,NCT02414139,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|MET Amplification,"Russian Federation|Singapore|United States|England|Austria|Netherlands|Sweden|Brazil|Korea, Republic of|Poland|France|Argentina|Japan|United Kingdom|Switzerland|Spain|Lebanon|Canada|Turkey|Belgium|Norway|Taiwan|Italy|Mexico|U.S.A.|Israel|Germany",Recruiting
,Glioma,P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA,NCT02414165,del(1)(p10)|del(19)(q10),"Canada|United States|Korea, Republic of|U.S.A.|Israel","Active, not recruiting"
MSLN Expression|Mesothelin Expression Positive,Breast Carcinoma|Non-Small Cell Lung Carcinoma|Pleural Mesothelioma,Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin,NCT02414269,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer,NCT02414646,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy,NCT02414776,,United States,Unknown status
NF1 Mutation,Brain Cancer,"Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors",NCT02415153,,United States|U.S.A.,"Active, not recruiting"
,Adenocarcinoma,CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases,NCT02416466,,United States,"Active, not recruiting"
,Acute Myeloid Leukemia,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,NCT02416908,PML-RARA Fusion,United States|U.S.A.,Recruiting
KEAP1 Mutation|NFE2L2 Mutation,Squamous Cell Lung Carcinoma,TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer,NCT02417701,,United States,Recruiting
FLT3 Mutation|HRAS Mutation|KRAS Mutation|NRAS Mutation,Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation,NCT02418000,FLT3 Mutation,United States|U.S.A.,Recruiting
,Breast Carcinoma|Malignant Solid Tumor,Study of BMS-986158 in Subjects With Select Advanced Solid Tumors,NCT02419417,,Canada|Netherlands|Belgium|United States|England|United Kingdom|Australia|France|Spain,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,B Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma,Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,NCT02419469,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States|U.S.A.,"Active, not recruiting"
KMT2A Fusion,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,NCT02419755,,United States|U.S.A.,Terminated
ABL1 Fusion|ABL2 Fusion|CRLF2 Fusion|CRLF2 Mutation|CRLF2 Overexpression|CSF1R Fusion|EPOR Fusion|FLT3 Mutation|IL7R Mutation|JAK1 Fusion|JAK1 Mutation|JAK2 Fusion|JAK2 Mutation|NTRK3 Fusion|PDGFRB Fusion|PTK2B Fusion|SH2B3 Deletion|SH2B3 Loss|SH2B3 Mutation|TSLP Fusion|TYK2 Fusion,B Acute Lymphoblastic Leukemia,Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),NCT02420717,,United States|U.S.A.,Recruiting
del(17)(p10),Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,"Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",NCT02420912,,United States|U.S.A.,Recruiting
FLT3 Mutation,Acute Myeloid Leukemia,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,NCT02421939,BCR-ABL1 Fusion,"United States|Japan|England|United Kingdom|Spain|Canada|Turkey|Belgium|Ireland|Taiwan|Korea, Republic of|Poland|Italy|Israel|U.S.A.|France|Germany",Recruiting
,Breast Carcinoma,Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy,NCT02422498,,United States|U.S.A.,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Malignant Solid Tumor,"A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",NCT02422589,,United States|Denmark|Italy|U.S.A.|Germany|Spain,Recruiting
,Breast Carcinoma,Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.,NCT02422615,,"Russian Federation|Singapore|United States|England|Malaysia|Thailand|Portugal|Austria|Netherlands|Sweden|Korea, Republic of|Poland|Bulgaria|France|Jordan|Colombia|Argentina|Hungary|United Kingdom|Switzerland|Spain|Lebanon|Canada|Czech Republic|Turkey|Belgium|Norway|Denmark|Italy|Mexico|U.S.A.|Australia|Germany","Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis,NCT02422641,,United States|U.S.A.,Recruiting
,Breast Carcinoma,PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer,NCT02423603,,Wales|England|United Kingdom|Scotland|Northern Ireland,Unknown status
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,NCT02424617,EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States|U.S.A.,Recruiting
,Breast Carcinoma,A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130),NCT02425891,,"Russian Federation|Singapore|Hong Kong|United States|Wales|England|Thailand|Costa Rica|Greece|Austria|Sweden|Brazil|Guatemala|Korea, Republic of|Poland|France|Serbia|Colombia|Hungary|Japan|Ukraine|United Kingdom|Switzerland|Spain|Canada|Turkey|Belgium|Norway|Taiwan|Italy|Mexico|U.S.A.|Australia|Germany",Recruiting
,Malignant Solid Tumor,Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,NCT02426892,,United States|U.S.A.,"Active, not recruiting"
,Chronic Lymphocytic Leukemia,"Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia",NCT02427451,BTK Codon 481 Missense,United States|U.S.A.,Recruiting
,Breast Carcinoma,Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy,NCT02427581,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Mantle Cell Lymphoma,A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,NCT02427620,,United States|U.S.A.,Recruiting
BRAF V600E|BRAF V600K,Melanoma,Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,NCT02427893,,United States|U.S.A.,Withdrawn
BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Histiocytosis|Malignant Solid Tumor,A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors,NCT02428712,,United States|U.S.A.,Recruiting
IDH1 Mutation|IDH2 Mutation,Cholangiocarcinoma|Gallbladder Carcinoma,Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma,NCT02428855,,United States|U.S.A.,"Active, not recruiting"
,Breast Carcinoma,Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC),NCT02435680,,"Austria|Czech Republic|Turkey|Belgium|Hong Kong|United States|Taiwan|Korea, Republic of|Australia|France|Germany|Spain",Recruiting
BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL,NCT02435849,MYC Fusion,Canada|Austria|Belgium|United States|Norway|Japan|Italy|U.S.A.|Australia|France|Germany|Spain,"Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab,NCT02436993,,United States|U.S.A.,Recruiting
BRAF Mutation|HRAS Mutation|KRAS Mutation|NRAS Mutation,Malignant Solid Tumor|Melanoma,"A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours",NCT02437227,,England|United Kingdom,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,NCT02437318,,"Russian Federation|Hong Kong|United States|Czechia|Wales|England|Thailand|Portugal|Greece|Austria|Netherlands|Sweden|Brazil|Korea, Republic of|Bulgaria|Chile|France|Argentina|Romania|Hungary|Japan|United Kingdom|United Arab Emirates|India|Spain|Lebanon|Canada|Belgium|Taiwan|Denmark|Italy|Mexico|Israel|U.S.A.|Australia|Peru|Germany",Recruiting
,Prostate Carcinoma,A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC,NCT02438007,,Canada|Belgium|United States|Wales|England|Italy|United Kingdom|Scotland|U.S.A.|Australia|France|Spain,Terminated
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,"S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",NCT02438722,,United States|U.S.A.,Recruiting
Hypodiploidy|IGH-CCND1 Fusion|IGH-CCND3 Fusion|IGH-FGFR3 Fusion|IGH-WHSC1 Fusion|Nullisomy 13|Nullisomy 17|StrucGain(1)(q10qter)|del(1)(p10)|del(13)(q10)|del(17p)|t(11;14)(q13;32)|t(14;16)(q32;q23)|t(14;20)(q32;q12)|t(4;14)(p16;q32)|t(6;14)(p21;q32),Multiple Myeloma|Plasma Cell Leukemia,Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),NCT02440464,,United States|U.S.A.,Recruiting
SSTR2 Expression|SSTR2 Overexpression|Somatostatin receptor type 2 Expression Positive,Malignant Solid Tumor|Neuroendocrine Tumor,Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors,NCT02441062,,United States|U.S.A.,Recruiting
,Breast Carcinoma,"A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",NCT02441946,,"Canada|Austria|Netherlands|Belgium|United States|Taiwan|Korea, Republic of|Italy|U.S.A.|Germany|Spain",Completed
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Glioblastoma,T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma,NCT02442297,,United States,Recruiting
CD274 Expression|CD274 High Expression|CD274 Low Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Adenocarcinoma of the Gastroesophageal Junction|Bladder Transitional Cell Carcinoma|Gastric Adenocarcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Non-Small Cell Lung Carcinoma|Urethral Carcinoma,"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer",NCT02443324,,United States|Japan|England|United Kingdom|U.S.A.|France|Germany|Spain,Recruiting
KMT2A Fusion,Acute Lymphoblastic Leukemia,CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies,NCT02443831,,England|Scotland|United Kingdom,Recruiting
,Breast Carcinoma,Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy,NCT02445391,,United States|U.S.A.|Republic of South Africa,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 17|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(13)(q10)|del(17)(p10)|del(5)(q10)|del(7)(q10)|i(17)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Adult Acute Lymphocytic Leukemia|Myelodysplastic Syndromes,Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia,NCT02446964,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
CD274 Expression|CD274 High Expression|CD274 Low Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Breast Carcinoma,Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086),NCT02447003,,New Zealand|Puerto Rico|Belgium|United States|England|Italy|United Kingdom|U.S.A.|Australia|France|Germany,"Active, not recruiting"
FLT3 ITD|KRAS Mutation|NRAS Mutation|PTPN11 Mutation,Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndromes|Refractory Anemia with Excess Blasts,Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML),NCT02447666,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(8;21)(q22;q22),England|United Kingdom|Switzerland|Spain|Austria|Czech Republic|Netherlands|Sweden|Belgium|Ireland|Denmark|Italy|France|Germany,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,"Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer",NCT02448251,,United States|U.S.A.,Recruiting
,Breast Carcinoma,A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,NCT02448771,,United States|U.S.A.,Recruiting
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Colorectal Carcinoma,Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer,NCT02448810,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,"Active, not recruiting"
CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Bladder Carcinoma,A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection [IMvigor010],NCT02450331,,"Russian Federation|United States|Czechia|England|Greece|Netherlands|China|Korea, Republic of|Poland|France|Serbia|Japan|Ukraine|United Kingdom|Switzerland|Spain|Canada|Turkey|Belgium|Finland|Taiwan|Italy|Israel|U.S.A.|Australia|Germany",Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations,NCT02450591,EGFR Exon 20 Insertion|EGFR T790M,United States|U.S.A.,Recruiting
EGFR T790M,Non-Small Cell Lung Carcinoma,AZD9291 US Expanded Access Program,NCT02451852,,,Closed
NCAM1 Expression|NCAM1 Overexpression|Neural cell adhesion molecule 1 Expression Positive,Malignant Peripheral Nerve Sheath Tumor (MPNST)|Neuroblastoma|Pleuropulmonary Blastoma|Rhabdomyosarcoma|Synovial Sarcoma|Wilms Tumor,"Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma",NCT02452554,,United States|U.S.A.,"Active, not recruiting"
,Non-Small Cell Lung Carcinoma,Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,NCT02453282,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,"Russian Federation|Hungary|United States|Japan|Thailand|Switzerland|Spain|Canada|Netherlands|Vietnam|Belgium|Taiwan|Korea, Republic of|Italy|Australia|France|Germany","Active, not recruiting"
,Breast Carcinoma|Malignant Solid Tumor,"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",NCT02453620,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,"Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC",NCT02454842,EGFR T790M,United States|Australia,Terminated
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours,NCT02454933,,,Closed
BIRC5 Expression|BIRC5 Overexpression|Baculoviral IAP repeat-containing protein 5 Expression Positive,Glioblastoma,SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma,NCT02455557,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery,NCT02455791,,United States|U.S.A.,"Active, not recruiting"
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Thyroid Gland Adenocarcinoma,Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379,NCT02456701,,United States,Completed
,Breast Carcinoma,"Women's Triple-Negative First-Line Study: Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",NCT02456857,,United States|U.S.A.,Recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Breast Carcinoma,Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer,NCT02457910,,United States|U.S.A.,Suspended
,Acute Lymphoblastic Leukemia,Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease,NCT02458014,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer,NCT02463032,,United States|U.S.A.,Recruiting
,Lung Adenocarcinoma|Non-Small Cell Lung Carcinoma,A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC,NCT02463994,ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ROS1 Fusion|ROS1 Inversion,United States,"Active, not recruiting"
ALK Expression|ALK Fusion|ALK tyrosine kinase receptor Expression Positive,Anaplastic Large Cell Lymphoma,Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma,NCT02464228,ALK Expression|ALK Fusion|ALK tyrosine kinase receptor Expression Positive,United States|U.S.A.|Spain,Recruiting
"A2M-ALK Fusion|ACTG2-ALK Fusion|AFAP1-NTRK2 Fusion|AGBL4-NTRK2 Fusion|AGTRAP-BRAF Fusion|AKAP9-BRAF Fusion|AKT1 E17K|ALK-PTPN3 Fusion|ATIC-ALK Fusion|BAG4-FGFR1 Fusion|BCAN-NTRK1 Fusion|BRAF A598V|BRAF D594A|BRAF D594G|BRAF D594N|BRAF D594V|BRAF E586K|BRAF F595L|BRAF G464E|BRAF G464R|BRAF G464V|BRAF G466A|BRAF G466E|BRAF G466R|BRAF G466V|BRAF G469A|BRAF G469E|BRAF G469V|BRAF G596R|BRAF I463S|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF N581S|BRAF R462I|BRAF T599I|BRAF V600D|BRAF V600E|BRAF V600K|BRAF V600R|BRAF Y472C|BRCA1 A1708E|BRCA1 A1823T|BRCA1 C39R|BRCA1 C44S|BRCA1 D1692H|BRCA1 D1692N|BRCA1 D1692Y|BRCA1 E1559K|BRCA1 E1559Q|BRCA1 E787S|BRCA1 Frameshift|BRCA1 G1706E|BRCA1 G1738R|BRCA1 G1788V|BRCA1 H41R|BRCA1 I1685A|BRCA1 I1766S|BRCA1 L1764P|BRCA1 L22S|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 M1775K|BRCA1 M1775R|BRCA1 M1I|BRCA1 M1R|BRCA1 M1T|BRCA1 M1V|BRCA1 Nonsense|BRCA1 Q1395Q|BRCA1 R1495M|BRCA1 R1699W|BRCA1 R71G|BRCA1 R71K|BRCA1 S1715R|BRCA1 Splice Site|BRCA1 T1685A|BRCA1 T1685I|BRCA1 T37K|BRCA1 V1838E|BRCA2 D2723G|BRCA2 D2723H|BRCA2 E2663V|BRCA2 Frameshift|BRCA2 G2748D|BRCA2 I2627F|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 M1I|BRCA2 M1R|BRCA2 Nonsense|BRCA2 R2336L|BRCA2 R2336P|BRCA2 R2659T|BRCA2 R3052W|BRCA2 S2670L|BRCA2 Splice Site|BRCA2 T2722R|BRCA2 V159M|BRCA2 V211I|BRCA2 V211L|BRCA2 W2626C|BTBD1-NTRK3 Fusion|C2orf44-ALK Fusion|CARS-ALK Fusion|CCDC6-ROS1 Fusion|CCND1 Amplification|CCND2 Amplification|CCND3 Amplification|CD74-NTRK1 Fusion|CD74-ROS1 Fusion|CDC27-BRAF Fusion|CDK4 Amplification|CDK6 Amplification|CEL-NTRK1 Fusion|CEP85L-ROS1 Fusion|CLIP1-ROS1 Fusion|CLIP4-ALK Fusion|CLTC-ALK Fusion|CLTC-ROS1 Fusion|COX5A-NTRK3 Fusion|DCTN1-ALK Fusion|DDR2 I638F|DDR2 L239R|DDR2 S768R|DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|EGFR A750_E758delinsG|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M|EML4-ALK Fusion|ERBB2 A771_Y772insYVMA|ERBB2 A775_G776insYVMA|ERBB2 Amplification|ERBB2 D769H|ERBB2 D769Y|ERBB2 E321G|ERBB2 E770_A771insAYVM|ERBB2 Exon 20 Insertion|ERBB2 G309A|ERBB2 G309E|ERBB2 G660D|ERBB2 G660R|ERBB2 G776delinsVC|ERBB2 G778_S779insG|ERBB2 I767M|ERBB2 L755S|ERBB2 S310F|ERBB2 S310Y|ERBB2 S779_P780insVGS|ERBB2 V659E|ERBB2 V777L|ERBB2 V777_G778insCG|ERBB2 V777_G778insGSP|ERBB2 V842I|ERC1-ROS1 Fusion|ERLIN2-FGFR1 Fusion|ETV6-NTRK3 Fusion|EZR-ROS1 Fusion|FAM131B-BRAF Fusion|FCHSD1-BRAF Fusion|FGFR1 K656E|FGFR1 K656M|FGFR1 T141R|FGFR1-TACC1 Fusion|FGFR2 A648T|FGFR2 C383R|FGFR2 G305R|FGFR2 I547V|FGFR2 K659N|FGFR2 K660E|FGFR2 N549D|FGFR2 N549S|FGFR2 N550H|FGFR2 N550K|FGFR2 P253R|FGFR2 S252L|FGFR2 S252W|FGFR2 V395D|FGFR2 Y376C|FGFR2-AFF3 Fusion|FGFR2-BICC1 Fusion|FGFR2-CASP7 Fusion|FGFR2-CIT Fusion|FGFR2-KIAA1967 Fusion|FGFR2-MGEA5 Fusion|FGFR2-OFD1 Fusion|FGFR2-TACC3 Fusion|FGFR3 A393E|FGFR3 D641N|FGFR3 G372C|FGFR3 G382R|FGFR3 G699C|FGFR3 K652E|FGFR3 K652M|FGFR3 K652Q|FGFR3 K652T|FGFR3 K715M|FGFR3 R248C|FGFR3 R399C|FGFR3 S249C|FGFR3 S373C|FGFR3 Y375C|FGFR3-AES Fusion|FGFR3-BAIAP2L1 Fusion|FGFR3-ELAVL3 Fusion|FGFR3-TACC3 Fusion|GNA11 Q209L|GNA11 Q209P|GNAQ Q209L|GNAQ Q209P|GNAQ Q209R|GNAQ R183Q|GOPC-ROS1 Fusion|GTF2IRD1-ALK Fusion|HIP1-ALK Fusion|HLA-A-ROS1 Fusion|IRF2BP2-NTRK1 Fusion|KDELR2-ROS1 Fusion|KIAA1549-BRAF Fusion|KIAA1598-ROS1 Fusion|KIF5B-ALK Fusion|KIT D572_P573insPTQLPYD|KIT D572_P573insPTQLPYDH|KIT D572_P573insPTQLPYDHKWEF|KIT D572_P573insPTQLPYDHKWEFP|KIT D587del|KIT E554_D572del|KIT E554_E561del|KIT E554_E562del|KIT E554_I563delinsG|KIT E554_I571del|KIT E554_I571delinsG|KIT E554_K558del|KIT E554_N564del|KIT E554_P573delinsG|KIT E562_N572del|KIT Exon 11 Deletion|KIT Exon 11 Insertion|KIT Exon 9 Deletion|KIT Exon 9 Insertion|KIT F584_P585insIDPTQLPYDHKWEFR|KIT H588del|KIT I563_D572del|KIT I563_L576del|KIT I563_T574delinsK|KIT I571_D572insDPTQLPYD|KIT I571_D572insDPTQLPYDHKWEF|KIT I571_D572insDPTQLPYDHKWEFP|KIT I571_L576del|KIT I579_N595del|KIT K550_V555delinsI|KIT K558_D572del|KIT K558_G565del|KIT K558_G565delinsR|KIT K558_N564del|KIT K558_Q575del|KIT K558_V559del|KIT K558_V559delinsN|KIT K558_V560del|KIT K558_V560delinsI|KIT K558_V560delinsN|KIT K558_Y570delinsN|KIT K558delinsNP|KIT K642E|KIT L576P|KIT L576_D579delinsP|KIT L576_P577insPYDH|KIT L576_P577insPYDHKWEF|KIT L576_Y578delinsP|KIT L576del|KIT M552_E554del|KIT M552_E554delinsK|KIT M552_E561delinsK|KIT M552_K558del|KIT M552_Q556del|KIT M552_Q556delinsK|KIT M552_V555del|KIT M552_V555delinsI|KIT M552_W557del|KIT M552_W557delinsK|KIT M552_W557delinsR|KIT M552_Y553del|KIT M552_Y553delinsN|KIT M560_D580del|KIT M560_W565del|KIT M560_Y561del|KIT N564_L576del|KIT N564_P573delinsT|KIT N564_P577del|KIT N564_Y578del|KIT P551_M552delinsL|KIT P551_Q556del|KIT P551_V555delinsL|KIT P551_V560delinsL|KIT P551del|KIT P559_E562del|KIT P559_V563del|KIT P577_Y578insYDH|KIT P577_Y578insYDS|KIT Q556_D572delinsH|KIT Q556_E561del|KIT Q556_I571delinsP|KIT Q556_K558del|KIT Q556_L576del|KIT Q556_V559del|KIT Q556_V559delinsHT|KIT Q556_V559delinsP|KIT Q556_V560del|KIT Q556_V560delinsP|KIT Q556_W557del|KIT Q556_W557delinsP|KIT Q556_W557delinsR|KIT Q575_L576insLPYDHKWEF|KIT Q575_L576insLPYDHKWEFP|KIT S501_A502insAF|KIT S501_A502insAY|KIT T500_S501insSA|KIT T670I|KIT V555_K558del|KIT V555_N566delinsD|KIT V555_P573delinsG|KIT V555_Q556del|KIT V555_T574delinsG|KIT V555_V559del|KIT V555_V560del|KIT V555_Y570del|KIT V559D|KIT V559_G565del|KIT V559_I571del|KIT V559_L576del|KIT V559_P573delinsA|KIT V559_V560del|KIT V559del|KIT V560D|KIT V560G|KIT V560_E561delinsG|KIT V560_I571del|KIT V567_E569del|KIT V568_I571del|KIT V568_L584del|KIT V569_D572del|KIT V569_Q575del|KIT V654A|KIT W557G|KIT W557_E562delinsL|KIT W557_K558delinsE|KIT W557_P573delinsS|KIT W557_Q575del|KIT W557_V559del|KIT W557_V559delinsF|KIT W557_V560del|KIT W557_V560delinsF|KIT W565_E569del|KIT W565_E570del|KIT W565_K566del|KIT Y553_T574delinsS|KIT Y553_V559del|KIT Y568_L576delinsF|KIT Y570_I571insIDPTQLPYD|KIT Y570_I571insIDPTQLPYDH|KIT Y570_I571insIDPTQLPYDHKWEFPSD|KIT Y578_L584del|KLC1-ALK Fusion|LMNA-NTRK1 Fusion|LRIG3-ROS1 Fusion|MEMO1-ALK Fusion|MET Amplification|MET Exon 14 Skipping|MLH1 Frameshift|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Nonsense|MPRIP-NTRK1 Fusion|MSH2 Frameshift|MSH2 Large Deletion|MSH2 Loss|MSH2 Nonsense|MSN-ROS1 Fusion|MTOR A1459P|MTOR A2210P|MTOR C1483F|MTOR C1483R|MTOR C1483W|MTOR C1483Y|MTOR E1799K|MTOR F1888I|MTOR F1888L|MTOR L1460P|MTOR L2209V|MTOR L2216P|MTOR L2220F|MTOR N2206S|MTOR R2217W|MTOR S2215F|MTOR S2215P|MTOR S2215Y|MYO5A-ROS1 Fusion|NACC2-NTRK2 Fusion|NCOA1-ALK Fusion|NF1 Frameshift|NF1 Nonsense|NF2 Frameshift|NF2 Nonsense|NFASC-NTRK1 Fusion|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R|NTRK1-DYNC2H1 Fusion|PAPSS1-BRAF Fusion|PIK3CA C420R|PIK3CA E453K|PIK3CA E542K|PIK3CA E542V|PIK3CA E545A|PIK3CA E545D|PIK3CA E545G|PIK3CA E545K|PIK3CA E545Q|PIK3CA G1049R|PIK3CA G106V|PIK3CA G118D|PIK3CA H1047L|PIK3CA H1047R|PIK3CA H1047Y|PIK3CA K111E|PIK3CA K111N|PIK3CA M1043I|PIK3CA M1043V|PIK3CA N1044K|PIK3CA N345I|PIK3CA N345K|PIK3CA P539R|PIK3CA Q546E|PIK3CA Q546K|PIK3CA Q546P|PIK3CA Q546R|PIK3CA R88Q|PIK3CA R93W|PIK3CA T1025S|PPFIBP1-ROS1 Fusion|PRKAR1A-ALK Fusion|PTCH1 W844C|PTEN A121E|PTEN A121P|PTEN A126V|PTEN A34D|PTEN C105F|PTEN C124R|PTEN C124S|PTEN C136Y|PTEN C71Y|PTEN D107Y|PTEN D92A|PTEN D92E|PTEN D92G|PTEN D92H|PTEN D92V|PTEN F341V|PTEN G127E|PTEN G129E|PTEN G129R|PTEN G129V|PTEN G165E|PTEN G165R|PTEN G165V|PTEN G251C|PTEN G36R|PTEN H123D|PTEN H61D|PTEN H61R|PTEN H93D|PTEN H93Y|PTEN I122S|PTEN K125E|PTEN L112P|PTEN L112R|PTEN L181P|PTEN L345Q|PTEN Large Deletion|PTEN Loss|PTEN M35R|PTEN N48K|PTEN P96Q|PTEN R130G|PTEN R130L|PTEN R130Q|PTEN R173C|PTEN R173H|PTEN R173P|PTEN S170N|PTEN S170R|PTEN T131I|PTEN V133I|PTEN V343E|PTEN Y155C|PTEN Y16C|PTEN Y174N|PTEN Y27S|PTEN Y68D|PTEN Y68H|PWWP2A-ROS1 Fusion|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Expression Negative|QKI-NTRK2 Fusion|RANBP2-ALK Fusion|RB1 Expression|RB1 Overexpression|RNF213-NTRK1 Fusion|Retinoblastoma-associated protein Expression Positive|SDC4-ROS1 Fusion|SEC31A-ALK Fusion|SLC34A2-ROS1 Fusion|SLC45A3-BRAF Fusion|SLC45A3-FGFR2 Fusion|SMEK2-ALK Fusion|SMO L412F|SMO P641A|SMO S533N|SMO W535L|SND1-BRAF Fusion|SQSTM1-NTRK1 Fusion|SQSTM1-NTRK2 Fusion|SSBP2-NTRK1 Fusion|STRN-ALK Fusion|TAX1BP1-BRAF Fusion|TFG-ALK Fusion|TFG-NTRK1 Fusion|TFG-ROS1 Fusion|TPM1-ALK Fusion|TPM3-ALK Fusion|TPM3-NTRK1 Fusion|TPM3-ROS1 Fusion|TPM4-ALK Fusion|TPR-ALK Fusion|TPR-NTRK1 Fusion|TRAF1-ALK Fusion|TRIM24-BRAF Fusion|TRIM24-NTRK2 Fusion|TSC1 E636fs|TSC1 Q527*|TSC1 Q781*|TSC2 Q1178*|VCL-ALK Fusion|VCL-NTRK2 Fusion|ZCCHC8-ROS1 Fusion",Leukemia|Lymphoma|Malignant Solid Tumor|Multiple Myeloma,"NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma",NCT02465060,"AGTRAP-BRAF Fusion|AKAP9-BRAF Fusion|AKT1 E17K|BRAF A598V|BRAF Codon 600 Missense|BRAF D594A|BRAF D594G|BRAF D594N|BRAF D594V|BRAF E586K|BRAF F595L|BRAF G464E|BRAF G464R|BRAF G464V|BRAF G466A|BRAF G466E|BRAF G466R|BRAF G466V|BRAF G469A|BRAF G469E|BRAF G469V|BRAF G596R|BRAF I463S|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF N581S|BRAF R462I|BRAF T599I|BRAF V600D|BRAF V600E|BRAF V600K|BRAF V600R|BRAF Y472C|CDC27-BRAF Fusion|EGFR T790M|FAM131B-BRAF Fusion|FCHSD1-BRAF Fusion|HRAS G12A|HRAS G12C|HRAS G12D|HRAS G12R|HRAS G12S|HRAS G12V|HRAS G13C|HRAS G13D|HRAS G13R|HRAS G13S|HRAS G13V|HRAS Q61E|HRAS Q61H|HRAS Q61K|HRAS Q61L|HRAS Q61P|HRAS Q61R|KIAA1549-BRAF Fusion|KIT A829P|KIT D816A|KIT D816E|KIT D816G|KIT D816H|KIT D816V|KIT D816Y|KIT D820A|KIT D820E|KIT D820G|KIT D820Y|KIT N822H|KIT N822K|KIT Y823D|KRAS A146T|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12F|KRAS G12L|KRAS G12N|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13E|KRAS G13R|KRAS G13S|KRAS G13V|KRAS G15D|KRAS G15S|KRAS Q61E|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|MLH1 Expression|MLH1 Overexpression|MSH2 Expression|MSH2 Overexpression|MTOR A1459P|MTOR A2210P|MTOR C1483F|MTOR C1483R|MTOR C1483W|MTOR C1483Y|MTOR E1799K|MTOR F1888I|MTOR F1888L|MTOR L1460P|MTOR L2209V|MTOR L2216P|MTOR N2206S|MTOR R2217W|MTOR S2215F|MTOR S2215P|MTOR S2215Y|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R|PAPSS1-BRAF Fusion|PIK3CA C420R|PIK3CA E453K|PIK3CA E542K|PIK3CA E542V|PIK3CA E545A|PIK3CA E545D|PIK3CA E545G|PIK3CA E545K|PIK3CA E545Q|PIK3CA G1049R|PIK3CA G106V|PIK3CA G118D|PIK3CA H1047L|PIK3CA H1047R|PIK3CA H1047Y|PIK3CA K111E|PIK3CA K111N|PIK3CA M1043I|PIK3CA M1043V|PIK3CA N1044K|PIK3CA N345I|PIK3CA N345K|PIK3CA P539R|PIK3CA Q546E|PIK3CA Q546K|PIK3CA Q546P|PIK3CA Q546R|PIK3CA R88Q|PIK3CA R93W|PIK3CA T1025S|PIK3R1 R348*|PTEN A121E|PTEN A121P|PTEN A126V|PTEN A34D|PTEN C105F|PTEN C124R|PTEN C124S|PTEN C136Y|PTEN C71Y|PTEN D107Y|PTEN D92A|PTEN D92E|PTEN D92G|PTEN D92H|PTEN D92V|PTEN F341V|PTEN G127E|PTEN G129E|PTEN G129R|PTEN G129V|PTEN G165E|PTEN G165R|PTEN G165V|PTEN G251C|PTEN G36R|PTEN H123D|PTEN H61D|PTEN H61R|PTEN H93D|PTEN H93Y|PTEN I122S|PTEN K125E|PTEN L112P|PTEN L112R|PTEN L181P|PTEN L345Q|PTEN M35R|PTEN N48K|PTEN P96Q|PTEN R130G|PTEN R130L|PTEN R130Q|PTEN R173C|PTEN R173H|PTEN R173P|PTEN S170N|PTEN S170R|PTEN T131I|PTEN V133I|PTEN V343E|PTEN Y155C|PTEN Y16C|PTEN Y174N|PTEN Y27S|PTEN Y68D|PTEN Y68H|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Expression Negative|SLC45A3-BRAF Fusion|SMO E518A|SMO E518K|SMO I408V|SMO L221R|SMO M525L|SMO N219D|SMO V321M|SND1-BRAF Fusion|TAX1BP1-BRAF Fusion|TRIM24-BRAF Fusion",Puerto Rico|United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|MET Amplification,Non-Small Cell Lung Carcinoma,"A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",NCT02468661,,"Netherlands|Singapore|Belgium|United States|Japan|Korea, Republic of|Italy|U.S.A.|France|Germany|Spain",Recruiting
,Breast Carcinoma|Gastric Carcinoma|Head and Neck Squamous Cell Carcinoma|Malignant Solid Tumor|Melanoma|Non-Small Cell Lung Carcinoma|Renal Cell Carcinoma|Urothelial Carcinoma,A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,NCT02471846,,"United States|Korea, Republic of|U.S.A.|France|Spain",Recruiting
,Acute Myeloid Leukemia,An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,NCT02472145,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),"Russian Federation|United States|Wales|England|United Kingdom|Scotland|Spain|Sweden|Turkey|Belgium|Taiwan|Korea, Republic of|Poland|Israel|U.S.A.|Australia|France|Germany",Recruiting
,Acute Myeloid Leukemia,"6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",NCT02472626,PML-RARA Fusion,United States,Withdrawn
,Head and Neck Squamous Cell Carcinoma,A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients,NCT02473731,,United States,Completed
,Breast Carcinoma,Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer,NCT02474173,,United States|U.S.A.,Recruiting
EGFR T790M,Non-Small Cell Lung Carcinoma,Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC,NCT02474355,,Saudi Arabia|Argentina|China|Brazil|United Arab Emirates,Recruiting
CD276 Expression|CD276 Overexpression|CD276 antigen Expression Positive,Head and Neck Squamous Cell Carcinoma|Melanoma|Squamous Cell Lung Carcinoma,Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer,NCT02475213,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Chronic Lymphocytic Leukemia,"Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL",NCT02475681,,Colombia|Hungary|United States|England|United Kingdom|Spain|New Zealand|Canada|Sweden|Belgium|Brazil|Poland|Italy|Israel|U.S.A.|Australia|Chile|France|Lithuania|Germany,"Active, not recruiting"
B-lymphocyte antigen CD19 Expression Positive|BCR-ABL1 Fusion|CD19 Expression|CD19 Overexpression|CD247 Expression|CD247 Overexpression|CD3D Expression|CD3D Overexpression|CD3E Expression|CD3E Overexpression|CD3G Expression|CD3G Overexpression|CD4 Expression|CD4 Overexpression|CD8A Expression|CD8A Overexpression|ETV6-RUNX1 Fusion|ITGAE Overexpression|KMT2A-AFF1 Fusion|MME Expression|MME Overexpression|Neprilysin Expression Positive|T-cell surface glycoprotein CD3 delta chain Expression Positive|T-cell surface glycoprotein CD3 epsilon chain Expression Positive|T-cell surface glycoprotein CD3 gamma chain Expression Positive|T-cell surface glycoprotein CD3 zeta chain Expression Positive|T-cell surface glycoprotein CD4 Expression Positive|T-cell surface glycoproteinCD8 alpha chain Expression Positive|t(12;21)(p13;q22)|t(4;11)(q21;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia,Administration of Donor MultiTAA-Specific T Cells for ALL,NCT02475707,,United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,NCT02476786,,United States,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer,NCT02476968,,Canada|Hungary|Czechia|Wales|Poland|England|Italy|United Kingdom|Scotland|Bulgaria|Northern Ireland|Spain,Recruiting
del(11)(q10)|del(17)(p10),Chronic Lymphocytic Leukemia,Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia,NCT02477696,,Hungary|United States|Wales|England|United Kingdom|Spain|New Zealand|Netherlands|Turkey|Belgium|Denmark|Poland|Italy|Israel|U.S.A.|Australia|France|Germany,Recruiting
CDKN2A Deletion|CDKN2A Large Deletion|CDKN2A Loss|CDKN2A Mutation|Cyclin-dependent kinase inhibitor 2A Deficiency|Cyclin-dependent kinase inhibitor 2A Expression Negative,Malignant Solid Tumor,Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors,NCT02478320,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Pilot Trial of Type I-Polarized Autologous Dendritic Cell Vaccine Incorporating Tumor Blood Vessel Antigen-Derived Peptides in Patients With Metastatic Breast Cancer,NCT02479230,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer,NCT02481050,,United States,"Active, not recruiting"
IDH1 Mutation|IDH2 Mutation,Malignant Solid Tumor,"Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation",NCT02481154,,United States|U.S.A.,Recruiting
TP53 Frameshift|TP53 Large Deletion|TP53 Loss|TP53 Nonsense|del(11)(q10)|del(17)(p10),Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,"Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients",NCT02481297,IGH Mutation,United States|U.S.A.,Recruiting
MYC Fusion,"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma","Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma",NCT02481310,,United States|U.S.A.,Not yet recruiting
,Breast Carcinoma|Fallopian Tube Carcinoma|Malignant Solid Tumor|Ovarian Carcinoma|Primary Peritoneal Cancer|Squamous Cell Lung Carcinoma,"Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours",NCT02482311,,Canada|United States|U.S.A.,"Active, not recruiting"
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer,NCT02482376,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Lymphoma,Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies,NCT02483000,,United States,Recruiting
"AKT1 Amplification|AKT1 Mutation|AKT2 Amplification|AKT2 Mutation|AKT3 Amplification|AKT3 Mutation|CRKL Mutation|EGFR Amplification|EGFR Mutation|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|IRS2 Mutation|KIT Amplification|KIT Mutation|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|MTOR Mutation|PDGFRA Amplification|PDGFRA Mutation|PIK3CA Amplification|PIK3CA Mutation|PIK3CG Mutation|PIK3R1 Mutation|PIK3R2 Mutation|PTEN Large Deletion|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|RICTOR Amplification|RICTOR Mutation|RNF43 Mutation|RPTOR Mutation|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression|TSC1 Mutation|TSC2 Mutation",Malignant Solid Tumor,Study of Oral PQR309 in Patients With Advanced Solid Tumors,NCT02483858,,United States|England|Scotland|United Kingdom|Switzerland|Spain,Recruiting
,Breast Carcinoma,Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy,NCT02483871,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,Phase II Trial of HM61713 for the Treatment of ‰ä´2nd Line T790M Mutation Positive Adenocarcinoma of the Lung,NCT02485652,,"Canada|United States|Philippines|Taiwan|Korea, Republic of|Italy|Malaysia|U.S.A.|Australia|Germany|Spain","Active, not recruiting"
CD274 Expression|CD274 High Expression|CD274 Low Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Non-Small Cell Lung Carcinoma,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010],NCT02486718,,"Russian Federation|Hong Kong|United States|England|Portugal|Netherlands|China|Korea, Republic of|Poland|France|Romania|Hungary|Japan|Ukraine|United Kingdom|Northern Ireland|Spain|Canada|Belgium|Taiwan|Italy|Israel|U.S.A.|Australia|Germany",Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 17|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Trisomy 21|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(17)(p10)|del(20)(q10)|del(5)(q10)|del(7)(q10)|del(9)(q10)|i(17)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Lymphoma|Myelodysplastic Syndromes,Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,NCT02487459,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Not yet recruiting
,Adenocarcinoma of the Gastroesophageal Junction|Cervical Carcinoma|Gastric Carcinoma|Head and Neck Squamous Cell Carcinoma|Merkel Cell Carcinoma|Nasopharyngeal Carcinoma|Vaginal Carcinoma|Vulvar Carcinoma,"An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors",NCT02488759,,Argentina|United States|Japan|England|United Kingdom|Scotland|Spain|Netherlands|Belgium|Taiwan|U.S.A.|France|Germany,Recruiting
,Breast Carcinoma,Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer,NCT02488967,,Canada|United States|U.S.A.,Recruiting
,Breast Carcinoma,Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,NCT02489448,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Endometrial Carcinoma,A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma,NCT02491099,,United States,Recruiting
,Breast Carcinoma,"Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer",NCT02491983,,Saudi Arabia|Czech Republic|Russian Federation|Wales|England|Italy|United Kingdom|United Arab Emirates|France|Germany|Spain,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,NCT02492711,,"United States|England|United Kingdom|Scotland|Portugal|Spain|Canada|Austria|Czech Republic|Netherlands|Belgium|Finland|Denmark|Korea, Republic of|Italy|U.S.A.|Israel|France|Germany",Recruiting
IDH1 Mutation|IDH2 Mutation,Leukemia|Lymphoma,Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation,NCT02492737,,United States|U.S.A.|France,"Active, not recruiting"
,"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Chronic Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myelofibrosis|Polycythemia Vera",TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea,NCT02493530,,United States|U.S.A.,Recruiting
"ANPEP Expression|ANPEP Overexpression|Aminopeptidase N Expression Positive|BCR-ABL1 Fusion|CBFB-MYH11 Inversion|CD33 Expression|CD33 Overexpression|HLA class II histocompatibility antigen, DR alpha chain Expression Positive|HLA-DRA Expression|HLA-DRA Overexpression|HLA-DRB1 Expression|HLA-DRB1 Overexpression|KIT Expression|KIT Overexpression|KMT2A-AFF1 Fusion|Major histocompatibility complex, class II, DR beta 1 Expression Positive|Mast/stem cell growth factor receptor Kit Expression Positive|Myeloid cell surface antigen CD33 Expression Positive|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|WT1 Expression|WT1 Overexpression|Wilms tumor protein Expression Positive|inv(16)(p13q22)|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(4;11)(q21;q23)|t(8;21)(q22;q22)|t(9;22)(q34;q11)",Acute Myeloid Leukemia|Myelodysplastic Syndromes,Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM),NCT02494167,,United States,Recruiting
CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Adenocarcinoma of the Gastroesophageal Junction|Gastric Adenocarcinoma,Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),NCT02494583,,"Puerto Rico|Russian Federation|Hong Kong|United States|Czechia|England|Austria|Latvia|Netherlands|Brazil|Guatemala|Korea, Republic of|Poland|Chile|Lithuania|Colombia|Argentina|Hungary|Japan|United Kingdom|Switzerland|Spain|New Zealand|Belgium|Taiwan|Italy|Mexico|South Africa|U.S.A.|Australia|Germany","Active, not recruiting"
ABL1 Fusion|ABL2 Fusion|BCR-ABL1 Fusion|CRLF2 Fusion|CSF1R Fusion|EPOR Fusion|FLT3 Mutation|IL7R Mutation|JAK1 Fusion|JAK1 Mutation|JAK2 Fusion|JAK2 Mutation|NTRK3 Fusion|PDGFRB Fusion|PTK2B Fusion|SH2B3 Deletion|SH2B3 Loss|SH2B3 Mutation|TSLP Fusion|TYK2 Fusion|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia,Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older,NCT02494882,,United States|U.S.A.,Recruiting
FH Mutation|SDHB Mutation|SDHC Mutation|SDHD Mutation,Renal Cell Carcinoma,Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma,NCT02495103,,United States|U.S.A.,Recruiting
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Non-Small Cell Lung Carcinoma,"Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer",NCT02495636,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor,NCT02496663,EGFR T790M,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|FLT3 Mutation|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 17|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Trisomy 21|Very Complex karyotype|del(11)(q10)|del(17)(p10)|del(20)(q10)|del(5)(q10)|del(7)(q10)|del(9)(q10)|i(17)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR,NCT02497404,KMT2A-MLLT3 Fusion|PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Recruiting
,Breast Carcinoma|Non-Small Cell Lung Carcinoma|Pancreatic Carcinoma|Small Cell Lung Carcinoma,A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors,NCT02498613,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,Canada|United States|U.S.A.,Recruiting
MUC16 Expression|MUC16 Overexpression|Mucin-16 Expression Positive|Mucin-16 Overexpression Positive,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors,NCT02498912,,United States|U.S.A.,Recruiting
,Head and Neck Squamous Cell Carcinoma,Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,NCT02499120,CDKN2A Expression|CDKN2A Overexpression,"Russian Federation|Romania|Hungary|United States|Czechia|Japan|Ukraine|Spain|Taiwan|Korea, Republic of|Poland|Italy|Mexico|U.S.A.|Slovakia|Serbia",Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Hypopharyngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma|Malignant Solid Tumor|Oral Cavity Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma|Prostate Cancer,Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck,NCT02499328,,Belgium|United States|England|Italy|Scotland|United Kingdom|U.S.A.|Germany|Spain,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Mutation|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Malignant Solid Tumor,Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors,NCT02500199,,United States,Recruiting
,Non-Small Cell Lung Carcinoma,Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,NCT02503358,ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ROS1 Fusion|ROS1 Inversion,United States,Recruiting
EGFR Exon 19 Deletion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR L858R|EGFR L861Q,Non-Small Cell Lung Carcinoma,TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor,NCT02503722,EGFR T790M,Canada|United States,Recruiting
Hypodiploidy|IGH-FGFR3 Fusion|IGH-WHSC1 Fusion|Nullisomy 13|Nullisomy 17|StrucGain(1)(q10qter)|del(1)(p10)|del(13)(q10)|del(17p)|t(14;16)(q32;q23)|t(14;20)(q32;q12)|t(4;14)(p16;q32),Multiple Myeloma|Plasma Cell Leukemia,Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma,NCT02504359,,United States|U.S.A.,Recruiting
FLCN Germline Mutation|FLCN Mutation,Renal Cell Carcinoma,Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer,NCT02504892,,United States|U.S.A.,Recruiting
Hypodiploidy|IGH-FGFR3 Fusion|IGH-WHSC1 Fusion|Nullisomy 13|Nullisomy 17|StrucGain(1)(q10qter)|del(1)(p10)|del(13)(q10)|del(17p)|t(14;16)(q32;q23)|t(14;20)(q32;q12)|t(4;14)(p16;q32),Multiple Myeloma|Plasma Cell Leukemia|Plasmacytoma,Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,NCT02506959,,United States|U.S.A.,Recruiting
Hypodiploidy,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Ewing Sarcoma|Extracranial Neuroblastoma|Hodgkin Lymphoma|Myelodysplastic/Myeloproliferative Neoplasm|Neuroblastoma|Non-Hodgkin Lymphoma|Osteosarcoma|Primitive Neuroectodermal Tumor|Rhabdomyosarcoma,TCRë±ë_+/CD19+ Depleted Haploidentical HSCT + Zoledronate,NCT02508038,,United States|U.S.A.,Recruiting
,Colorectal Carcinoma,FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer,NCT02508077,BRAF D594E|BRAF D594G|BRAF D594H|BRAF D594N|BRAF D594V|BRAF G466V|BRAF G469A|BRAF G469E|BRAF G469L|BRAF G469V|BRAF G596R|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF R444W|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|BRAF Y472C|HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,"Active, not recruiting"
TP53 Mutation,Head and Neck Squamous Cell Carcinoma,"WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",NCT02508246,,United States|U.S.A.,Recruiting
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia,NCT02508324,PML-RARA Fusion,United States,Recruiting
PDGFRA D842I|PDGFRA D842V|PDGFRA D842Y,Gastrointestinal Stromal Tumor|Malignant Solid Tumor,Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors,NCT02508532,PDGFRA D842I|PDGFRA D842V|PDGFRA D842Y,Netherlands|Belgium|United States|Scotland|United Kingdom|U.S.A.|France|Germany,Recruiting
HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Colorectal Carcinoma,MErCuRIC1: MEK and MET Inhibition in Colorectal Cancer,NCT02510001,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,England|United Kingdom,Recruiting
EGFR Exon 19 Deletion|EGFR L858R,Non-Small Cell Lung Carcinoma,"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.",NCT02511106,,"Russian Federation|Hong Kong|United States|Thailand|Netherlands|Sweden|Vietnam|China|Brazil|Korea, Republic of|Poland|France|Romania|Hungary|Japan|Ukraine|Spain|Turkey|Belgium|Norway|Taiwan|Italy|Israel|U.S.A.|Australia|Germany",Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Non-Small Cell Lung Carcinoma,Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients,NCT02511184,,United States|U.S.A.,Recruiting
,Breast Carcinoma,PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer,NCT02513394,,"Canada|United States|Taiwan|Korea, Republic of|Mexico|Israel|U.S.A.|Australia|Switzerland",Recruiting
,Breast Carcinoma,Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC),NCT02513472,,United States|U.S.A.,"Active, not recruiting"
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Non-Small Cell Lung Carcinoma,Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma,NCT02513667,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD19 Expression Positive|B-lymphocyte antigen CD20 Expression Positive|CD19 Expression|CD19 Overexpression|CD5 Expression|CD5 Overexpression|FCER2 Expression|FCER2 Overexpression|Low affinity immunoglobulin epsilon Fc receptor Expression Positive|MS4A1 Expression|MS4A1 Overexpression|T-cell surface glycoprotein CD5 Expression Positive,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),NCT02514083,FCER2 Expression|FCER2 Overexpression|IGH-CCND1 Fusion|Low affinity immunoglobulin epsilon Fc receptor Expression Positive|t(11;14)(q13;32),United States,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older,NCT02514174,,United States|U.S.A.,Recruiting
Complex karyotype|Very Complex karyotype|del(11)(q22)|del(17)(p13),Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",NCT02518555,IGH Mutation,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Non-Hodgkin Lymphoma,"Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects",NCT02519270,,United States|U.S.A.,Recruiting
,Breast Carcinoma,"Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",NCT02520063,,United States|U.S.A.,Recruiting
Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Malignant Solid Tumor,A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors,NCT02520752,,United States|Denmark|England|Italy|United Kingdom|U.S.A.|Bulgaria|France|Spain,"Active, not recruiting"
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer,NCT02520778,,United States|U.S.A.,Recruiting
ALK Fusion,Non-Small Cell Lung Carcinoma,"Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer",NCT02521051,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer",NCT02521363,,United States|U.S.A.,Recruiting
Trisomy 21,Acute Myeloid Leukemia|Myelodysplastic Syndromes|Myeloproliferative Neoplasm,Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,NCT02521493,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),Canada|United States|U.S.A.,Recruiting
NF2 Mutation|SMO Mutation,Meningioma,Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas,NCT02523014,,United States|U.S.A.,Recruiting
RB1 Expression|Retinoblastoma-associated protein Expression Positive,Hepatocellular Carcinoma,LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma,NCT02524119,RB1 Deletion|RB1 Loss|RB1 Mutation,United States,Recruiting
,Glioblastoma,Oral ONC201 in Adult Recurrent Glioblastoma,NCT02525692,IDH1 Mutation|IDH2 Mutation,United States,Recruiting
DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation,Bladder Carcinoma|Breast Carcinoma|Colorectal Carcinoma|Head and Neck Squamous Cell Carcinoma|Melanoma|Non-Small Cell Lung Carcinoma|Renal Cell Carcinoma|Soft Tissue Sarcoma,GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors (ENGAGE-1),NCT02528357,,Netherlands|United States|U.S.A.|France,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|PGR Expression|PGR Overexpression|Progesterone receptor Expression Positive,Breast Carcinoma,Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors,NCT02528383,,United States,Recruiting
,Myeloproliferative Neoplasm|Primary Myelofibrosis,"Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",NCT02528877,,United States|U.S.A.,Withdrawn
FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation,Cancer,A Study of LY3076226 in Participants With Advanced or Metastatic Cancer,NCT02529553,,Canada|United States|U.S.A.,Recruiting
,Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes|Primary Myelofibrosis,Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies,NCT02530034,,United States,Not yet recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer,NCT02530411,,Wales|England|United Kingdom,Recruiting
FLT3 ITD,Acute Myeloid Leukemia|Myelodysplastic Syndromes,"Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",NCT02530476,PML-RARA Fusion,United States|U.S.A.,Recruiting
,Breast Carcinoma,"Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer",NCT02530489,,United States|U.S.A.,Recruiting
MS4A1 Overexpression,Diffuse Large B-Cell Lymphoma,Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),NCT02531308,,United States,Terminated
,Breast Carcinoma,Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC,NCT02531425,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer,NCT02531932,,United States,Recruiting
,Acute Myeloid Leukemia,Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML,NCT02532010,PML-RARA Fusion,United States,"Active, not recruiting"
AR Expression|AR-V Expression Positive,Prostate Carcinoma,"Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer",NCT02532114,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia,Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse,NCT02532231,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Follicular Lymphoma|Marginal Zone Lymphoma,Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma,NCT02532257,,United States|U.S.A.,Recruiting
,Melanoma,Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma,NCT02535078,,United States|England|United Kingdom|Scotland|U.S.A.|Germany,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer,NCT02535338,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion,Acute Lymphoblastic Leukemia,Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL),NCT02535364,,United States|U.S.A.,Suspended
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy,NCT02536339,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer,NCT02536742,,Belgium|England|Italy|United Kingdom|Scotland,Recruiting
,Breast Carcinoma,MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer,NCT02536794,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer,NCT02538471,,United States,Recruiting
B-lymphocyte antigen CD20 Expression Positive|BCR-ABL1 Fusion|MS4A1 Expression|MS4A1 Overexpression|t(9;22)(q34;q11),B Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia,"Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",NCT02538926,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States,Not yet recruiting
EGFR Amplification,Glioblastoma,Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma,NCT02540161,,United States|U.S.A.,Recruiting
,Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colorectal Carcinoma|Head and Neck Squamous Cell Carcinoma|Hepatocellular Carcinoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Pancreatic Carcinoma|Renal Cell Carcinoma|Urothelial Carcinoma,Study of E7046 in Subjects With Selected Advanced Malignancies,NCT02540291,,United States|U.S.A.|France,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant,NCT02540330,,United States|U.S.A.,Recruiting
CDKN2A Deletion|CDKN2A Large Deletion|CDKN2A Loss|CDKN2A Mutation|Cyclin-dependent kinase inhibitor 2A Deficiency|Cyclin-dependent kinase inhibitor 2A Expression Negative,Malignant Solid Tumor,Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery,NCT02540876,,United States|U.S.A.,Recruiting
,Head and Neck Squamous Cell Carcinoma,AMG 319 in HPV Positive and Negative HNSCC,NCT02540928,,England|United Kingdom,Recruiting
PROM1 Expression|PROM1 Overexpression|Prominin-1 Expression Positive,Acute Leukemia|Brain Cancer|Breast Carcinoma|Colorectal Carcinoma|Hepatocellular Carcinoma|Ovarian Carcinoma|Pancreatic Carcinoma,Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133,NCT02541370,,China,Recruiting
,Non-Small Cell Lung Carcinoma,Study of 1st Line Therapy Study of Durvalumab With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,NCT02542293,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Argentina|Romania|China|Japan|Brazil|United Arab Emirates|Bulgaria|Portugal|India,Recruiting
,Bladder Carcinoma|Breast Carcinoma|Head and Neck Squamous Cell Carcinoma|Melanoma|Non-Small Cell Lung Carcinoma|Renal Cell Carcinoma,A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,NCT02543645,,United States|U.S.A.,Terminated
MET Amplification|MET Mutation,Non-Small Cell Lung Carcinoma,Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET,NCT02544633,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,"Canada|Hungary|United States|Taiwan|Korea, Republic of|Poland|England|Italy|United Kingdom|U.S.A.|Australia",Recruiting
,Acute Myeloid Leukemia,A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML),NCT02545283,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),"Russian Federation|Wales|England|United Kingdom|Switzerland|Spain|New Zealand|Canada|Austria|Netherlands|Belgium|Norway|Finland|Korea, Republic of|Italy|Israel|Australia|France|Germany",Recruiting
,Adenocarcinoma of the Gastroesophageal Junction|Gastric Adenocarcinoma,Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,NCT02545504,,Colombia|Romania|Hungary|United States|England|Scotland|United Kingdom|Spain|Czech Republic|Turkey|Belgium|Poland|Italy|U.S.A.|Australia|Chile|France|Peru|Germany,Recruiting
,Glioblastoma,"Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma",NCT02546102,IDH1 Mutation|IDH2 Mutation,Canada|Austria|United States|U.S.A.,Recruiting
FGFR1 Fusion|FGFR2 Fusion|FGFR3 Fusion|FGFR3 G370C|FGFR3 G370R|FGFR3 G380R|FGFR3 R248C|FGFR3 S249C|FGFR3 S371C|FGFR3 Y373C,Bladder Carcinoma|Urothelial Carcinoma,"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer",NCT02546661,,Canada|United States|England|Scotland|United Kingdom|U.S.A.|France|Spain,Recruiting
FOLR1 Expression|FOLR1 Overexpression|Folate receptor alpha Expression Positive|Folate receptor alpha Overexpression Positive,Malignant Solid Tumor,"Phase I Study of MOv18 IgE, a First in Class Chimeric IgE Antibody in Patients With Advanced Solid Tumours",NCT02546921,,England|United Kingdom|Scotland,Recruiting
,Non-Small Cell Lung Carcinoma,Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,NCT02546986,ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Greece|United States|Italy|U.S.A.|France|Germany|Spain,"Active, not recruiting"
,Breast Carcinoma,Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer,NCT02547987,,United States,Recruiting
AKT1 Mutation|MTOR Mutation|PIK3CA Mutation|PIK3R1 Mutation|PIK3R2 Mutation|PTEN Deletion|PTEN Frameshift|PTEN Nonsense,Endometrial Carcinoma,Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer,NCT02549989,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NF1 Mutation|NF2 Mutation|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
,Breast Carcinoma|Head and Neck Squamous Cell Carcinoma|Malignant Solid Tumor|Melanoma|Non-Small Cell Lung Carcinoma,A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),NCT02554812,,Canada|Netherlands|United States|Japan|England|United Kingdom|U.S.A.|Australia|France,Recruiting
RB1 Expression|Retinoblastoma-associated protein Expression Positive,Prostate Carcinoma,"Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression",NCT02555189,,United States,Recruiting
,Breast Carcinoma,Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),NCT02555657,,"Russian Federation|Singapore|Hong Kong|United States|England|Malaysia|Thailand|Netherlands|Sweden|Ireland|Brazil|Guatemala|Korea, Republic of|Poland|France|Colombia|Argentina|Japan|Philippines|United Kingdom|Switzerland|Spain|New Zealand|Turkey|Belgium|Taiwan|Italy|Mexico|South Africa|U.S.A.|Australia|Peru|Germany","Active, not recruiting"
,Breast Carcinoma|Colorectal Carcinoma|Endometrial Adenocarcinoma|Gastric Carcinoma|Head and Neck Squamous Cell Carcinoma|Malignant Solid Tumor|Melanoma|Non-Small Cell Lung Carcinoma|Pancreatic Ductal Adenocarcinoma|Renal Cell Carcinoma|Urothelial Carcinoma,INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,NCT02559492,,United States|U.S.A.,Recruiting
MYCN Amplification,Neuroblastoma,Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,NCT02559778,MYCN Amplification,United States,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,NCT02560025,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States|U.S.A.,Recruiting
ALK Expression|ALK Fusion|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,"Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified",Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma,NCT02561273,ALK Expression|ALK Fusion|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,United States|U.S.A.,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,"A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer",NCT02561832,,United States|Spain,Completed
"AKT1 Amplification|AKT1 Mutation|AKT2 Amplification|AKT2 Mutation|AKT3 Amplification|AKT3 Mutation|CRKL Mutation|EGFR Amplification|EGFR Mutation|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|IRS2 Mutation|KIT Amplification|KIT Mutation|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|MTOR Mutation|PDGFRA Amplification|PDGFRA Mutation|PIK3CA Amplification|PIK3CA Mutation|PIK3CG Mutation|PIK3R1 Mutation|PIK3R2 Mutation|PTEN Large Deletion|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|RICTOR Amplification|RICTOR Mutation|RNF43 Mutation|RPTOR Mutation|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression|TSC1 Mutation|TSC2 Mutation",Aggressive Systemic Mastocytosis|Hematologic and Lymphocytic Disorder|Hematopoietic and Lymphoid System Neoplasm|Mast Cell Leukemia|Myelodysplastic Syndromes|Myeloid Neoplasm|Systemic Mastocytosis with Associated Clonal Hematological non-Mast-Cell Lineage Disease,Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies,NCT02561988,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States|Scotland|United Kingdom|U.S.A.,Recruiting
DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation,Colorectal Carcinoma,Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),NCT02563002,,"Singapore|United States|Japan|England|United Kingdom|Switzerland|Spain|Canada|Netherlands|Sweden|Norway|Ireland|Finland|Taiwan|Denmark|Korea, Republic of|Italy|South Africa|Israel|U.S.A.|Australia|France|Germany",Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65,NCT02564848,,United States,Recruiting
del(5)(q10),Acute Myeloid Leukemia|Aplastic Anemia|Chronic Myelomonocytic Leukemia|Hematopoietic and Lymphoid Malignancy|Hodgkin Lymphoma|Myelodysplastic Syndrome with Isolated del(5q)|Myelodysplastic Syndromes|Myeloma|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|RAEB-1|RAEB-2|Refractory Anemia|Refractory Cytopenia with Multilineage Dysplasia|Refractory Cytopenia with Multilineage Dysplasia and Ring Sideroblasts|Refractory anemia with ring sideroblasts (RARS),Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies,NCT02566304,,United States|U.S.A.,Recruiting
Antigen KI-67 Expression Positive|MKI67 Expression|MKI67 Overexpression,Small Cell Carcinoma|Small Cell Lung Carcinoma,"Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer",NCT02566993,,Romania|Hungary|United States|Czechia|England|United Kingdom|Portugal|Spain|Greece|Lebanon|Canada|Austria|Belgium|Brazil|Italy|Bulgaria|France|Germany,Recruiting
,Head and Neck Squamous Cell Carcinoma|Paranasal Sinus and Nasal Cavity Cancer,"VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma",NCT02567422,CDKN2A Expression|CDKN2A Overexpression,United States,Recruiting
FOXO1 Fusion,Rhabdomyosarcoma,Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,NCT02567435,FOXO1 Fusion,United States|U.S.A.,Suspended
,Colorectal Carcinoma,Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients,NCT02568046,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.|Spain,"Active, not recruiting"
ALK Fusion|NTRK1 Fusion|NTRK2 Fusion|NTRK3 Fusion|ROS1 Fusion,Malignant Solid Tumor,"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",NCT02568267,,"Singapore|Hong Kong|United States|Japan|England|United Kingdom|Spain|Netherlands|Belgium|Taiwan|Korea, Republic of|Poland|Italy|U.S.A.|Australia|France|Germany",Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy (HydranGea),NCT02569801,,"United States|Korea, Republic of|England|United Kingdom|Scotland|U.S.A.|Australia|Germany|Spain","Active, not recruiting"
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer,NCT02571530,,United States,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer,NCT02571725,,United States|U.S.A.,Recruiting
ALK Expression|ALK Fusion|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|B-cell Lymphoma 6 protein Expression Positive|BCL6 Expression|BCL6 Overexpression|NPM1-ALK Fusion|t(2;5)(p23;q35),Anaplastic Large Cell Lymphoma|Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma,"AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma",NCT02572453,,United States|U.S.A.,Recruiting
,Colorectal Carcinoma,Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,NCT02573220,HRAS G12R|HRAS G12V|HRAS G13C|HRAS G13R|HRAS Q61R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|Italy|U.S.A.,Recruiting
EGFR Amplification,Glioblastoma,A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification,NCT02573324,,"Russian Federation|Singapore|Hong Kong|United States|Czechia|Wales|England|Scotland|Portugal|Austria|Netherlands|Ireland|Brazil|Korea, Republic of|France|Colombia|Argentina|Japan|United Kingdom|Switzerland|Spain|New Zealand|Canada|Belgium|Taiwan|Italy|Mexico|South Africa|U.S.A.|Israel|Australia|Germany",Recruiting
MYCN Amplification,Neuroblastoma,Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells,NCT02573896,MYCN Amplification,United States,Not yet recruiting
NTRK1 Fusion|NTRK2 Fusion|NTRK3 Fusion,Malignant Solid Tumor,Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE),NCT02576431,,"Singapore|United States|Ireland|Denmark|Korea, Republic of|Scotland|United Kingdom|U.S.A.|Spain",Recruiting
"AKT1 Amplification|ARID1A Deletion|ARID1A Loss|ARID1A Mutation|ATM Loss|ATM Mutation|ATR Loss|ATR Mutation|ATRX Loss|ATRX Mutation|BARD1 Germline Mutation|BARD1 Mutation|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|BRIP1 Mutation|C11orf30 Loss|C11orf30 Mutation|CDK12 Mutation|CHEK1 Mutation|CHEK2 Mutation|CRTC1 Mutation|CRTC2 Mutation|EGFR Amplification|EGFR Mutation|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|FANCA Amplification|FANCA Mutation|FANCB Amplification|FANCB Mutation|FANCC Amplification|FANCC Mutation|FANCD2 Amplification|FANCD2 Mutation|FANCE Amplification|FANCE Mutation|FANCF Amplification|FANCF Mutation|FANCG Amplification|FANCG Mutation|FANCI Amplification|FANCI Mutation|FANCL Amplification|FANCL Mutation|FANCM Amplification|FANCM Mutation|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|KIT Amplification|KIT Mutation|KRAS Mutation|MDM2 Amplification|MDM2 Mutation|MDM4 Mutation|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|MLH1 Mutation|MRE11A Loss|MRE11A Mutation|MUTYH Mutation|NBN Loss|NBN Mutation|NPM1 Mutation|NPM1-MLF1 Fusion|PALB2 Loss|PALB2 Mutation|PARP1 Mutation|PARP2 Mutation|PDGFRA Amplification|PDGFRA Mutation|PIK3CA Amplification|PIK3CA Mutation|PPP2R1A Mutation|PPP2R2A Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|RAD50 Loss|RAD50 Mutation|RAD51 Mutation|RAD51B Mutation|RAD51C Mutation|RAD51D Mutation|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression|SLX4 Mutation|STAG2 Mutation|STK11 Mutation|TP53 Mutation|TSC1 Mutation|TSC2 Mutation|XRCC1 Mutation",Malignant Solid Tumor,OLAParib COmbinations,NCT02576444,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Gastric Carcinoma,A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.,NCT02576548,,United States|U.S.A.,Recruiting
,High Grade Cervical Intraepithelial Neoplasia,Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL,NCT02576561,,United States,Recruiting
CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Non-Small Cell Lung Carcinoma,Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),NCT02576574,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States|France,Recruiting
IDH2 Mutation,Acute Myeloid Leukemia,An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation,NCT02577406,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),"Russian Federation|United States|Czechia|Wales|England|United Kingdom|Northern Ireland|Spain|Canada|Austria|Turkey|Belgium|China|Taiwan|Brazil|Denmark|Korea, Republic of|Italy|U.S.A.|Australia|France|Germany",Recruiting
,Nasopharyngeal Carcinoma,"Multicentre, Randomized, Open-Label, Phase III Clinical Trial for Advanced Nasopharyngeal Carcinoma Patients",NCT02578641,,Singapore|United States|Taiwan|Malaysia|Thailand,Recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448),NCT02580448,,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),NCT02580708,EGFR Exon 20 Insertion|MET Amplification,United States,Completed
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Non-Hodgkin Lymphoma,An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas,NCT02581631,,Canada|United States|England|Italy|United Kingdom|U.S.A.|France|Spain,Recruiting
B-cell receptor CD22 Expression Positive|CD22 Expression|CD22 Overexpression,Non-Hodgkin Lymphoma,Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma,NCT02581878,,Sweden|England|United Kingdom,Recruiting
,Acute Myeloid Leukemia,MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age,NCT02582359,PML-RARA Fusion,United States|U.S.A.,Recruiting
"AKT1 Amplification|AKT1 Mutation|AKT2 Amplification|AKT2 Mutation|AKT3 Amplification|AKT3 Mutation|ARAF Mutation|BRAF Mutation|CRKL Mutation|EGFR Amplification|EGFR Mutation|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|HRAS Mutation|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|IRS2 Mutation|KIT Amplification|KIT Mutation|KRAS Mutation|MAP2K1 Mutation|MAP2K2 Mutation|MAP2K4 Mutation|MAP3K1 Mutation|MAPK1 Mutation|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|MTOR Mutation|NF1 Large Deletion|NF1 Loss|NF1 Mutation|NRAS Mutation|PDGFRA Amplification|PDGFRA Mutation|PIK3CA Amplification|PIK3CA Mutation|PIK3CG Mutation|PIK3R1 Mutation|PIK3R2 Mutation|PTEN Large Deletion|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|RAF1 Mutation|RET Amplification|RET Mutation|RICTOR Amplification|RICTOR Mutation|RNF43 Mutation|RPTOR Mutation|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression|SRC Mutation|STK11 Mutation|TSC1 Mutation|TSC2 Mutation",Breast Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Malignant Solid Tumor|Melanoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Pancreatic Carcinoma|Renal Cell Carcinoma|Squamous Cell Lung Carcinoma|Thyroid Gland Carcinoma,A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers,NCT02583542,KRAS Mutation,England|United Kingdom,Recruiting
FLT3 ITD,Acute Myeloid Leukemia,Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia,NCT02583893,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(16;16)(p13;q22)|t(8;21)(q22;q22),United States|U.S.A.,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Non-Small Cell Lung Carcinoma,"Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",NCT02584634,ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,"United States|Japan|Korea, Republic of|U.S.A.|Australia|France|Spain",Recruiting
,Merkel Cell Carcinoma,Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma,NCT02584829,,United States|U.S.A.,Recruiting
,Breast Carcinoma,TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,NCT02586675,,United States|U.S.A.,"Active, not recruiting"
FLT3 ITD|KMT2A-MLLT3 Fusion|Normal karyotype|Trisomy 8|t(9;11)(p21;q23)|t(9;11)(p22;q23),Acute Myeloid Leukemia,Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission,NCT02587871,BCR-ABL1 Fusion|CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RPN1-MECOM Fusion|RUNX1-RUNX1T1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(16)(p13q22)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(15;17)(q22;q12)|t(16;16)(p13;q22)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;22)(q34;q11),United States,Not yet recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations,NCT02588261,,"Republic of Singapore|Russian Federation|Singapore|United States|England|Malaysia|Thailand|Portugal|Netherlands|Korea, Republic of|Chile|France|Romania|Hungary|Japan|Ukraine|United Kingdom|Spain|Canada|Belgium|Taiwan|Italy|Australia|Peru|Germany",Recruiting
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Non-Small Cell Lung Carcinoma,NY-ESO-1‡¦Ïå_‰µ‰_T for Advanced NSCLC,NCT02588612,,United States|U.S.A.,Recruiting
TNFRSF8 Expression|Tumor Necrosis Factor receptor superfamily member 8 Deficiency|Tumor necrosis factor receptor superfamily member 8 Expression Positive,"Adult T-Cell Leukemia/Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Mycosis Fungoides|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Primary Cutaneous Gamma-Delta T-Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma",A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL),NCT02588651,,United States|U.S.A.,Recruiting
,Non-Small Cell Lung Carcinoma,Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer,NCT02590003,ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States|U.S.A.,Recruiting
ALK Fusion|EGFR Mutation|MAGEA10 Expression|MAGEA10 Overexpression|Melanoma-associated antigen 10 Expression Positive,Non-Small Cell Lung Carcinoma,MAGE A10‡¦Ï‰á‰_‰¦T for Advanced NSCLC,NCT02592577,,United States|U.S.A.,Recruiting
,Non-Small Cell Lung Carcinoma,"Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer",NCT02592967,,United States|U.S.A.,Recruiting
,Breast Carcinoma,"Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",NCT02593175,,United States,Recruiting
,Breast Carcinoma,Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer,NCT02593227,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Malignant Solid Tumor,"Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+",NCT02593708,,United States,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Diffuse Large B-Cell Lymphoma|Follicular Lymphoma,Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma,NCT02594163,,Czech Republic|United States|Poland|England|Italy|United Kingdom|Scotland|U.S.A.|France|Spain,Recruiting
,Breast Carcinoma,Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy,NCT02595372,,United States,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer,NCT02595905,,Puerto Rico|United States|U.S.A.,Recruiting
,Non-Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma,Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer,NCT02595944,ALK C1156Y|ALK D1091N|ALK D1225N|ALK Exon Deletion|ALK F1174C|ALK F1174I|ALK F1174L|ALK F1174V|ALK F1245C|ALK F1245L|ALK F1245V|ALK Fusion|ALK G1202R|ALK G1269A|ALK I1171N|ALK L1152R|ALK L1196M|ALK R1275Q|ALK S1206Y|ALK T1151M|ALK T1151dup|ALK Y1278S|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer,NCT02598427,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer,NCT02598557,,United States|Italy,Recruiting
ATM Mutation|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|BRIP1 Mutation|PALB2 Mutation,Prostate Carcinoma,"Docetaxel and Carboplatin in Treating Patients With Metastatic, Hormone Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway",NCT02598895,,United States|U.S.A.,Recruiting
EGFR Expression|EGFR Overexpression|Epidermal growth factor receptor Expression Positive,Adenocarcinoma of the Gastroesophageal Junction|Colorectal Carcinoma|Gastric Adenocarcinoma|Renal Cell Carcinoma|Urothelial Carcinoma,A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,NCT02599324,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,"United States|Korea, Republic of|England|United Kingdom|Scotland|U.S.A.|Spain",Recruiting
RB1 Expression|RB1 Overexpression|Retinoblastoma-associated protein Expression Positive,Breast Carcinoma,A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer,NCT02599363,,United States|U.S.A.,Recruiting
,Myelodysplastic Syndromes,Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS),NCT02599649,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer,NCT02599714,,United States|Scotland|United Kingdom,Recruiting
AR Expression|AR-V Expression Positive,Prostate Carcinoma,Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7,NCT02601014,,United States|U.S.A.,"Active, not recruiting"
SMARCB1 Deletion|SMARCB1 Loss|SMARCB1 Mutation|SS18-SSX1 Fusion|SS18-SSX2 Fusion|SS18-SSX4 Fusion|SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Expression Negative,Malignant Solid Tumor|Synovial Sarcoma,A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,NCT02601937,SMARCB1 Expression,Canada|Netherlands|United States|Denmark|England|Italy|United Kingdom|U.S.A.|Australia|France|Germany,Recruiting
SMARCA4 Deletion|SMARCA4 Loss|SMARCA4 Mutation|SMARCB1 Deletion|SMARCB1 Loss|SMARCB1 Mutation|SS18-SSX1 Fusion|SS18-SSX2 Fusion|SS18-SSX4 Fusion|SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Expression Negative|Transcription activator BRG1 Expression Negative,Malignant Solid Tumor|Rhabdoid Tumor|Synovial Sarcoma,"A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma",NCT02601950,SMARCA4 Expression|SMARCB1 Expression,Canada|Belgium|United States|Taiwan|England|Italy|United Kingdom|U.S.A.|Australia|France|Germany,Recruiting
Inactive tyrosine-protein kinase transmembrane receptor ROR1 Expression Positive|ROR1 Expression|ROR1 Overexpression,Acute Lymphoblastic Leukemia|Breast Carcinoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Non-Small Cell Lung Carcinoma,Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies,NCT02602821,,,Closed
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Breast Carcinoma,Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC),NCT02605486,,United States|U.S.A.,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Central Nervous System Neoplasm|Glioblastoma,Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis,NCT02605746,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer,NCT02605915,,United States|U.S.A.,Recruiting
RB1 Expression|RB1 Overexpression|Retinoblastoma-associated protein Expression Positive,Glioma,"A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy",NCT02607124,,United States,Recruiting
FOLH1 Expression|FOLH1 Overexpression|Glutamate Carboxypeptidase 2 Expression Positive,Renal Cell Carcinoma,Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA,NCT02607553,,United States,Completed
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Malignant Solid Tumor,A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State,NCT02608034,,"Russian Federation|United States|Korea, Republic of|Israel|U.S.A.",Recruiting
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FGFR4 Amplification|FGFR4 Fusion|FGFR4 Mutation,Malignant Solid Tumor,A Dose Escalation and Dose Expansion Study of PRN1371 in Adult Patients With Advanced Solid Tumors,NCT02608125,,United States|U.S.A.|Spain,Recruiting
RB1 Expression|RB1 Overexpression|Retinoblastoma-associated protein Expression Positive,Breast Carcinoma,[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer,NCT02608216,,United States,Recruiting
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Liposarcoma|Synovial Sarcoma,Trial of CMB305 and Atezolizumab in Patients With Sarcoma,NCT02609984,,United States|U.S.A.,Recruiting
,Pleural Mesothelioma,Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM),NCT02610140,,"Russian Federation|United States|England|United Kingdom|Scotland|Spain|Canada|Netherlands|Turkey|Belgium|Finland|Korea, Republic of|Poland|Italy|U.S.A.|Australia|France|Germany","Active, not recruiting"
PML-RARA Fusion,Acute Myeloid Leukemia,"An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",NCT02610777,,United States|Spain|Canada|Czech Republic|Netherlands|Belgium|Ireland|Italy|Israel|U.S.A.|Bulgaria|France|Germany,Recruiting
Hepatocyte growth factor receptor Expression Positive|MET Expression|MET Overexpression|MST1R Expression|MST1R Overexpression|Macrophage-stimulating protein receptor Expression Positive,Urothelial Carcinoma,LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer,NCT02612194,,United States,Recruiting
TP53 Large Deletion|TP53 Loss|TP53 Mutation,Cancer,Study of SNX-5422 in TP53 Null Cancers,NCT02612285,,United States|U.S.A.,Terminated
KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,Colorectal Carcinoma,A Trial of mFOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers,NCT02613650,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer,NCT02614794,,Canada|United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Brain metastasis|Non-Small Cell Lung Carcinoma,"Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases",NCT02616393,,United States|U.S.A.,Recruiting
,Glioblastoma,"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",NCT02617589,,Russian Federation|United States|Japan|England|United Kingdom|Scotland|Switzerland|Spain|Canada|Austria|Netherlands|Sweden|Belgium|Norway|Denmark|Poland|Italy|Israel|U.S.A.|Australia|France|Germany,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer,NCT02619669,,United States,Recruiting
,Malignant Solid Tumor,Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies,NCT02620839,,United States,Recruiting
,Breast Carcinoma,Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173),NCT02622074,,"Sweden|Singapore|Finland|Denmark|Korea, Republic of|England|United Kingdom|Germany|Spain",Recruiting
,Breast Carcinoma,A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer,NCT02623972,,United States|U.S.A.,Recruiting
,Breast Carcinoma,2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer,NCT02624700,,United States|U.S.A.,Recruiting
Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Malignant Solid Tumor,A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors,NCT02626234,,Greece|Austria|Belgium|United States|Czechia|England|Italy|United Kingdom|U.S.A.|Spain,Completed
PDGFRA Amplification,Glioblastoma,Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification,NCT02626364,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,NCT02626507,,United States,Recruiting
,Breast Carcinoma|Fallopian Tube Carcinoma|Malignant Solid Tumor|Ovarian Carcinoma|Primary Peritoneal Cancer,"Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer",NCT02627430,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States,Not yet recruiting
CD276 Expression|CD276 Overexpression|CD276 antigen Expression Positive,Malignant Solid Tumor,Safety Study of MGD009 in B7-H3-expressing Tumors,NCT02628535,,United States,Recruiting
IGH Mutation,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,"First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)",NCT02629809,TP53 Frameshift|TP53 Large Deletion|TP53 Loss|TP53 Nonsense|del(17)(p10),United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC,NCT02630186,EGFR Exon 20 Insertion,United States,"Active, not recruiting"
,Myelodysplastic Syndromes,"A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes",NCT02631070,,Russian Federation|United States|England|Scotland|United Kingdom|Spain|Canada|Netherlands|Sweden|Turkey|Belgium|Italy|U.S.A.|France|Germany,Recruiting
,Acute Myeloid Leukemia,"Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia",NCT02631252,PML-RARA Fusion,United States|U.S.A.,Not yet recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,Sequential Combo Immuno and Target Therapy (SECOMBIT) Study,NCT02631447,,Greece|Austria|Sweden|England|Italy|Scotland|United Kingdom|France|Switzerland|Germany|Spain,Recruiting
,Breast Carcinoma|Cervical Carcinoma|Gastric Carcinoma|Neuroendocrine Carcinoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Small Cell Lung Carcinoma,Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors,NCT02631733,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer,NCT02632045,,United States|U.S.A.,Recruiting
,Lung Papilloma,"Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement",NCT02632344,,United States|U.S.A.,Recruiting
CCND1 Expression|CCND1 Overexpression|G1/S-specific cyclin-D1 Overexpression|IGH-CCND1 Fusion|t(11;14)(q13;32),Mantle Cell Lymphoma,Ixazomib After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission,NCT02632396,,United States|U.S.A.,Recruiting
IDH1 Mutation|IDH2 Mutation,Acute Myeloid Leukemia,Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,NCT02632708,,Netherlands|United States|U.S.A.|Germany,Recruiting
Monosomy 17|Nullisomy 17|TP53 Frameshift|TP53 Nonsense|del(17)(p10),Multiple Myeloma,"Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",NCT02633059,,United States|U.S.A.,Recruiting
FLT3 Codon 835 Missense|FLT3 Codon 836 Missense|FLT3 ITD,Acute Myeloid Leukemia,Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation,NCT02634827,,United States|U.S.A.,Recruiting
,Ductal Carcinoma In Situ,Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer,NCT02636582,,United States|U.S.A.,Recruiting
,Breast Carcinoma,A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,NCT02637375,,,Closed
NTRK1 Fusion|NTRK2 Fusion|NTRK3 Fusion,Fibrosarcoma|Malignant Solid Tumor,Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors,NCT02637687,,United States|U.S.A.|Spain,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Adenocarcinoma of the Gastroesophageal Junction|Cholangiocarcinoma|Colorectal Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Hepatocellular Carcinoma|Pancreatic Carcinoma|Small Intestinal Carcinoma,Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies,NCT02638909,,United States|U.S.A.,Recruiting
MSLN Expression|MSLN Overexpression|Mesothelin Expression Positive,Mesothelioma|Non-Small Cell Lung Carcinoma,Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors,NCT02639091,,United States|Italy|U.S.A.,Recruiting
ENPP3 Expression|ENPP3 Overexpression|Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 Expression Positive,Clear Cell Renal Cell Carcinoma|Renal Cell Carcinoma,A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma,NCT02639182,,Canada|United States|U.S.A.,Recruiting
ARAF Mutation|BRAF Mutation|CRKL Mutation|HRAS Mutation|KRAS Mutation|MAP2K1 Mutation|MAP2K2 Mutation|MAP2K4 Mutation|MAP3K1 Mutation|MAPK1 Mutation|NF1 Mutation|NRAS Mutation|RAF1 Mutation|SRC Mutation,Glioma|Malignant Peripheral Nerve Sheath Tumor (MPNST)|Neuroblastoma|Rhabdoid Tumor|Rhabdomyosarcoma|Schwannoma|Soft Tissue Sarcoma,iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,NCT02639546,,Canada|United States|England|Italy|United Kingdom|Scotland|U.S.A.|Israel|France|Germany|Spain,Recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL),NCT02640209,,United States|U.S.A.,Recruiting
,Head and Neck Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma,NCT02641093,,United States,Recruiting
KIT Expression|Mast/stem cell growth factor receptor Kit Expression Positive,Malignant Solid Tumor,A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors,NCT02642016,,United States|U.S.A.,Recruiting
KRAS Mutation,Non-Small Cell Lung Carcinoma,Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer,NCT02642042,,United States|U.S.A.,Recruiting
NF1 Germline Mutation|NF1 Mutation,Neurofibroma,MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas,NCT02644512,,,Closed
"AKT1 Amplification|AKT1 Mutation|EGFR Amplification|EGFR Mutation|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|KIT Amplification|KIT Mutation|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|MTOR Mutation|NF1 Mutation|NF2 Mutation|PDGFRA Amplification|PDGFRA Mutation|PIK3CA Amplification|PIK3CA Mutation|PTEN Large Deletion|PTEN Loss|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|RHEB Mutation|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression|STK11 Mutation|TSC1 Mutation|TSC2 Mutation",Cancer,Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,NCT02646319,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|Monosomy 5|Monosomy 7|del(5)(q10),Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes,KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children,NCT02646839,,United States|U.S.A.,Enrolling by invitation
,Acute Lymphoblastic Leukemia,Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older,NCT02647190,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
,Breast Carcinoma,Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,NCT02648477,,United States|U.S.A.,Recruiting
MET Amplification,Malignant Solid Tumor,Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies,NCT02648724,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R,"United States|Denmark|Korea, Republic of|U.S.A.",Recruiting
BRAF V600E,Histiocytosis,Single-agent Cobimetinib for Adults With Histiocytic Disorders,NCT02649972,BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,United States|U.S.A.,Recruiting
ALK Fusion|NTRK1 Fusion|NTRK2 Fusion|NTRK3 Fusion|ROS1 Fusion,Malignant Solid Tumor,"Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions",NCT02650401,,United States|U.S.A.,Recruiting
MYCN Amplification,Neuroblastoma,Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma,NCT02650648,MYCN Amplification,United States|U.S.A.,Recruiting
,Malignant Solid Tumor,"A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors",NCT02650713,,Netherlands|United States|France|Spain,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,NCT02650752,,United States|U.S.A.,Recruiting
CTAG1B Expression|Cancer/testis antigen 1 Expression Positive,Malignant Solid Tumor,Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ES0-1,NCT02650986,,United States,Not yet recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Lymphoma|Mantle Cell Lymphoma,Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas,NCT02650999,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer,NCT02651610,,United States,Suspended
MS4A1 Expression,Diffuse Large B-Cell Lymphoma,Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL),NCT02653989,,United States,Withdrawn
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery",NCT02654119,,United States|U.S.A.,Recruiting
,Non-Small Cell Lung Carcinoma,Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC,NCT02654587,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Hungary|United States|Czechia|Poland|England|Italy|United Kingdom|France|Germany|Spain,Recruiting
,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy,NCT02655016,,United States|England|Scotland|United Kingdom|Switzerland|Spain|Canada|Belgium|Norway|Ireland|Finland|Denmark|Italy|U.S.A.|France|Germany,Recruiting
,Bladder Carcinoma|Breast Carcinoma|Colorectal Carcinoma|Head and Neck Carcinoma|Melanoma|Non-Small Cell Lung Carcinoma|Prostate Carcinoma|Renal Cell Carcinoma,Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,NCT02655822,,Canada|United States|U.S.A.|Australia,Recruiting
Protein Wnt-5a Deficiency|Protein Wnt-5a Expression Negative|WNT5A Deletion|WNT5A Loss,Breast Carcinoma|Colon Carcinoma|Prostate Carcinoma,"Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients",NCT02655952,,Denmark|England|United Kingdom,Recruiting
CCNE1 Amplification|MCL1 Amplification|MYC Amplification,Malignant Solid Tumor,"BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors",NCT02656849,,United States,Withdrawn
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",NCT02657343,,United States|U.S.A.,Recruiting
,Non-Small Cell Lung Carcinoma,A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132),NCT02657434,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,"Russian Federation|Hong Kong|United States|Wales|England|Scotland|Malaysia|Portugal|Austria|Netherlands|China|Ireland|Korea, Republic of|Poland|Bulgaria|Chile|France|Lithuania|Croatia|Argentina|Romania|Ukraine|United Kingdom|Spain|Taiwan|Italy|South Africa|Israel|U.S.A.|Australia|Peru",Recruiting
FGFR3 Fusion|FGFR3 Mutation,Bladder Carcinoma|Urothelial Carcinoma,BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder,NCT02657486,,United States|U.S.A.,Recruiting
,Breast Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer,NCT02657889,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|RB1 Expression|RB1 Overexpression|Retinoblastoma-associated protein Expression Positive,Endometrial Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer",NCT02657928,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer,NCT02658084,,United States,Recruiting
,Adenocarcinoma of the Gastroesophageal Junction|Breast Carcinoma|Fallopian Tube Carcinoma|Gastric Carcinoma|Head and Neck Squamous Cell Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer|Small Cell Lung Carcinoma,Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,NCT02658214,,"Korea, Republic of",Recruiting
,Glioma,Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype,NCT02658279,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|Normal karyotype|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Trisomy 13|Trisomy 21|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)|t(9;22)(q34;q11),Acute Myeloid Leukemia,Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia,NCT02658487,CBFB-MYH11 Fusion|Complex karyotype|DEK-NUP214 Fusion|KMT2A-MLLT3 Fusion|Monosomy 5|Monosomy 7|Normal karyotype|PML-RARA Fusion|RPN1-MECOM Fusion|RUNX1-RUNX1T1 Fusion|Very Complex karyotype|del(5)(q10)|del(7)(q10)|inv(16)(p13q22)|inv(3)(q21q26)|t(16;16)(p13;q22)|t(3;3)(q21;q26)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States|U.S.A.,Recruiting
TNFRSF17 Expression|TNFRSF17 Overexpression|Tumor necrosis factor receptor superfamily member 17 Expression Positive,Multiple Myeloma,Study of bb2121 in Multiple Myeloma,NCT02658929,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer,NCT02659514,,United States|U.S.A.,Recruiting
CDH3 Expression|CDH3 Overexpression|Cadherin-3 Expression Positive,Breast Carcinoma|Colorectal Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,PF-06671008 Dose Escalation Study in Advanced Solid Tumors,NCT02659631,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Burkitt Leukemia|Burkitt Lymphoma|Chronic Myeloid Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Hodgkin Lymphoma|Malignant Solid Tumor|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Myelofibrosis|T Lymphoblastic Leukemia/Lymphoma,URMC Related Haplo-identical Donor BMT,NCT02660281,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Chronic Myeloid Leukemia|Follicular Lymphoma|Lymphoblastic Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Mature T-Cell and NK-Cell Neoplasm|Multiple Myeloma|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|Plasma Cell Leukemia|Prolymphocytic Leukemia,Allo HSCT Using RIC for Hematological Diseases,NCT02661035,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Recruiting
,Malignant Pleural Mesothelioma,A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy,NCT02661659,,United States|U.S.A.,Withdrawn
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Anaplastic Large Cell Lymphoma|Cutaneous T Cell Lymphoma|Diffuse Large B-Cell Lymphoma|Hodgkin Lymphoma|Mycosis Fungoides|Non-Hodgkin Lymphoma,Administration of T Lymphocytes for Prevention of Relapse of Lymphomas,NCT02663297,ALK Expression|ALK Fusion|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|NPM1-ALK Fusion,United States|U.S.A.,Recruiting
"AKT1 Amplification|CCND1 Amplification|CDK4 Amplification|CDKN2A Deletion|EGFR Amplification|EGFR Mutation|EGFR T790M|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|KIT Amplification|KIT Mutation|KRAS Mutation|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|NF1 Deletion|NF1 Loss|NF1 Mutation|NRAS Mutation|PDGFRA Amplification|PDGFRA Mutation|PIK3CA Amplification|PIK3CA Mutation|PTEN Deletion|PTEN Loss|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|ROS1 Fusion|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression|STK11 Mutation|TSC1 Mutation|TSC2 Mutation",Non-Small Cell Lung Carcinoma,National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer,NCT02664935,AKT1 Amplification|AKT1 E17K|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|PIK3CA Amplification|PIK3CA D549N|PIK3CA E542K|PIK3CA E545A|PIK3CA E545G|PIK3CA E545K|PIK3CA E545Q|PIK3CA E545V|PIK3CA H1047L|PIK3CA H1047R|PIK3CA Q546E|PIK3CA Q546K|PIK3CA Q546L|PIK3CA Q546P|PIK3CA Q546R|PTEN Deletion|PTEN Loss|RB1 Deletion|RB1 Loss,Wales|England|United Kingdom|Scotland|Northern Ireland,Recruiting
PTPRC Expression|PTPRC Overexpression|Receptor-type tyrosine-protein Phosphatase C Expression Positive,Acute Myeloid Leukemia,"Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML",NCT02665065,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Recruiting
,Acute Myeloid Leukemia,A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia,NCT02665143,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|Normal karyotype|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasm,WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,NCT02666950,CBFB-MYH11 Fusion|Complex karyotype|DEK-NUP214 Fusion|KMT2A-MLLT3 Fusion|Monosomy 5|Monosomy 7|Normal karyotype|PML-RARA Fusion|RPN1-MECOM Fusion|RUNX1-RUNX1T1 Fusion|Very Complex karyotype|del(5)(q10)|del(7)(q10)|inv(16)(p13q22)|inv(3)(q21q26)|t(16;16)(p13;q22)|t(3;3)(q21;q26)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States,Not yet recruiting
,Glioblastoma,"An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",NCT02667587,,Russian Federation|United States|Japan|England|United Kingdom|Scotland|Switzerland|Spain|Canada|Austria|Netherlands|Sweden|Belgium|Norway|Denmark|Poland|Italy|Israel|U.S.A.|Australia|France|Germany,Recruiting
FLT3 ITD,Acute Myeloid Leukemia,Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML,NCT02668653,BCR-ABL1 Fusion|PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(9;22)(q34;q11),Canada|Hungary|United States,Recruiting
,Breast Carcinoma,Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,NCT02668666,,United States,Recruiting
,Breast Carcinoma,Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer,NCT02672475,,United States|U.S.A.,Recruiting
ERBB2 A775_G776insYVMA|ERBB2 Amplification|ERBB2 D769H|ERBB2 E757A|ERBB2 Expression|ERBB2 G776V|ERBB2 G778_P780dup|ERBB2 L755S|ERBB2 L755_E757del|ERBB2 L841V|ERBB2 L869R|ERBB2 Overexpression|ERBB2 V777L|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Neratinib in Treating Older Patients With Metastatic HER2-Positive Breast Cancer,NCT02673398,,United States,Recruiting
EGFR Mutation,Malignant Solid Tumor,"A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors",NCT02674555,,United States,Recruiting
DLL3 Expression|DLL3 Overexpression|Delta-like protein 3 Expression Positive,Small Cell Lung Carcinoma,Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY),NCT02674568,,Hungary|United States|Poland|U.S.A.|France|Germany|Spain,Recruiting
MYC Amplification|MYC Expression|MYC Fusion|MYC Overexpression|Myc proto-oncogene protein Expression Positive,Diffuse Large B-Cell Lymphoma,"Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations",NCT02674750,,United States|U.S.A.|Spain,Recruiting
CD33 Expression|CD33 Overexpression|Myeloid cell surface antigen CD33 Expression Positive,Acute Myeloid Leukemia,Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia,NCT02674763,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",NCT02675231,,"Argentina|United States|England|United Kingdom|Spain|Greece|Canada|Belgium|Brazil|Korea, Republic of|Italy|Mexico|U.S.A.|Australia|France|Germany",Recruiting
ERBB2 Amplification|ERBB2 Mutation,Malignant Solid Tumor,Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers,NCT02675829,,United States|U.S.A.,Recruiting
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome,NCT02676323,PML-RARA Fusion|Trisomy 21,United States|U.S.A.,Recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer,NCT02676986,,England|United Kingdom|Scotland,Recruiting
,Pancreatic Carcinoma,Olaparib for BRCAness Phenotype in Pancreatic Cancer,NCT02677038,,United States,Recruiting
IDH1 Mutation|IDH2 Mutation,Acute Myeloid Leukemia,A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML),NCT02677922,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),"United States|England|United Kingdom|Portugal|Switzerland|Spain|Canada|Netherlands|Korea, Republic of|Italy|U.S.A.|Australia|France|Germany",Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Carcinoma|Gastric Adenocarcinoma,Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial,NCT02678182,,England|United Kingdom,Recruiting
CBFB-MYH11 Inversion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(8;21)(q22;q22),Acute Myeloid Leukemia,Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia,NCT02680951,,United States|U.S.A.,Recruiting
Hypodiploidy|IGH-MAF Fusion|IGH-MAFB Fusion|IGH-WHSC1 Fusion|StrucGain(1)(q10qter)|TP53 Deletion|TP53 Loss|del(1)(p10)|del(13)(q10)|del(17)(p13)|t(14;16)(q32;q23)|t(14;20)(q32;q12)|t(4;14)(p16;q32),Diffuse Large B-Cell Lymphoma|Multiple Myeloma|Myeloma|T-Cell Non-Hodgkin Lymphoma,Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence,NCT02681302,,United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.,NCT02681523,,England|United Kingdom,Recruiting
CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Melanoma|Non-Small Cell Lung Carcinoma,Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer,NCT02681549,,United States|U.S.A.,Recruiting
SSTR1 Expression|SSTR1 Overexpression|SSTR2 Expression|SSTR2 Overexpression|SSTR3 Expression|SSTR3 Overexpression|SSTR4 Expression|SSTR4 Overexpression|SSTR5 Expression|SSTR5 Overexpression|Somatostatin receptor type 1 Expression Positive|Somatostatin receptor type 1 Overexpression|Somatostatin receptor type 2 Expression Positive|Somatostatin receptor type 2 Overexpression|Somatostatin receptor type 3 Expression Positive|Somatostatin receptor type 3 Overexpression|Somatostatin receptor type 4 Expression Positive|Somatostatin receptor type 4 Overexpression|Somatostatin receptor type 5 Expression Positive|Somatostatin receptor type 5 Overexpression,Lung Neuroendocrine Neoplasm,Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors,NCT02683941,,United States|England|Scotland|United Kingdom|Spain|Canada|Austria|Netherlands|Denmark|Poland|Italy|U.S.A.|France|Germany,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,NCT02684032,,United States|U.S.A.,Recruiting
IGH-FGFR3 Fusion|IGH-MAF Fusion|del(17)(p10)|dup(1)(q10qter)|t(14;16)(q32;q23)|t(4;14)(p16;q32),Multiple Myeloma,A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma,NCT02685826,,Canada|Netherlands|United States|Finland|Denmark|Italy|Germany|Spain,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Gastric Adenocarcinoma,"Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer",NCT02689284,,"Canada|Singapore|United States|Taiwan|Korea, Republic of|U.S.A.",Recruiting
EGFR Mutation|ERBB2 Mutation|JAK2 V617F,Malignant Solid Tumor,Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors,NCT02689336,,United States|U.S.A.,Recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Breast Carcinoma,Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC),NCT02689427,,United States,Recruiting
BCR-ABL1 Fusion,Chronic Myeloid Leukemia,Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib,NCT02689440,,United States|U.S.A.,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer,NCT02689921,,United States,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Hodgkin Lymphoma|Non-Hodgkin Lymphoma,Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL,NCT02690545,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer,NCT02692755,,United States,Recruiting
ABL1 Mutation|ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|ATM Deletion|ATM Germline Mutation|ATM Large Deletion (Exon -1)|ATM Loss|ATM Mutation|BCR-ABL1 Fusion|BRAF Amplification|BRAF Mutation|BRAF V600E|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|CDK4 Amplification|CDK6 Amplification|CDKN2A Deletion|CDKN2A Large Deletion|CDKN2A Loss|CSF1R Mutation|Cyclin-dependent kinase inhibitor 2A Deficiency|Cyclin-dependent kinase inhibitor 2A Expression Negative|EGFR Mutation|EPHA2 Mutation|ERBB2 Amplification|FLT1 Amplification|FLT1 Mutation|FLT1 Overexpression|FLT4 Amplification|FLT4 Mutation|FLT4 Overexpression|FYN Mutation|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|KDR Amplification|KDR Mutation|KDR Overexpression|KIT Amplification|KIT Mutation|LCK Mutation|LYN Mutation|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|MTOR Mutation|PDGFRA Mutation|PDGFRB Amplification|PDGFRB Mutation|POLD1 Mutation|POLE Mutation|PTCH1 Large Deletion (Exon -1)|PTCH1 Loss|PTCH1 Mutation|RAF1 Amplification|RAF1 Mutation|RET Amplification|RET Mutation|ROS1 Amplification|ROS1 Fusion|ROS1 Inversion|ROS1 Mutation|SRC Mutation|TSC1 Mutation|TSC2 Mutation|Vascular endothelial growth factor receptor 1 Overexpression|Vascular endothelial growth factor receptor 2 Overexpression|Vascular endothelial growth factor receptor 3 Overexpression|YES1 Mutation,Malignant Solid Tumor|Multiple Myeloma|Non-Hodgkin Lymphoma,TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,NCT02693535,BRAF D594E|BRAF D594G|BRAF D594H|BRAF D594N|BRAF D594V|BRAF G466V|BRAF G469A|BRAF G469E|BRAF G469L|BRAF G469V|BRAF G596R|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF R444W|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|BRAF Y472C|CDKN2A Expression|CDKN2A Overexpression|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States,Recruiting
EGFR Exon 19 Deletion|EGFR L858R,Non-Small Cell Lung Carcinoma,Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3),NCT02695290,,United States,Withdrawn
,Melanoma,Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma,NCT02696356,,United States|U.S.A.,Recruiting
NUT family member 1 Expression Positive|NUTM1 Expression|NUTM1 Fusion|NUTM1 Overexpression,Breast Carcinoma|NUT Midline Carcinoma|Non-Small Cell Lung Carcinoma|Prostate Carcinoma,A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006),NCT02698176,,Canada|Belgium|United States|France|Switzerland|Spain,Terminated
Apoptosis regulator Bcl-2 Overexpression Positive|B-lymphocyte antigen CD20 Expression Positive|BCL2 Fusion|BCL2 Overexpression|BCL6 Fusion|MS4A1 Expression|MYC Fusion|MYC Overexpression|Myc proto-oncogene protein Overexpression Positive,Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma,A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,NCT02700022,,United States|U.S.A.,Suspended
Complex karyotype|Hypodiploidy|IGH-FGFR3 Fusion|IGH-MAF Fusion|del(1)(p10)|del(17)(p10)|t(14;16)(q32;q23)|t(4;14)(p16;q32),Multiple Myeloma|Plasma Cell Leukemia,Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation,NCT02700841,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers,NCT02701348,,Scotland|United Kingdom,Recruiting
,Oropharyngeal Squamous Cell Carcinoma,Image-Guided Stereotactic Radiosurgery (SRS) Boost for HPV-Oropharyngeal Cancer,NCT02703493,CDKN2A Expression|CDKN2A Overexpression,United States,Recruiting
KRAS Mutation,Colorectal Carcinoma|Malignant Solid Tumor|Pancreatic Carcinoma,Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,NCT02703571,,Canada|Netherlands|Belgium|United States|Australia,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC),NCT02705339,,,Closed
ALK Fusion,Non-Small Cell Lung Carcinoma,Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors,NCT02706626,,United States,Recruiting
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation,Head and Neck Squamous Cell Carcinoma,"Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer",NCT02706691,,United States,Not yet recruiting
,Breast Carcinoma,Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In,NCT02708680,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,"Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",NCT02709083,,United States,Recruiting
DLL3 Expression|DLL3 Overexpression|Delta-like protein 3 Expression Positive,Malignant Solid Tumor,Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors,NCT02709889,,United States,Recruiting
KRAS Mutation,Bladder Carcinoma|Esophageal Carcinoma|Head and Neck Squamous Cell Carcinoma|Lung Adenocarcinoma|Non-Small Cell Lung Carcinoma|Urothelial Carcinoma,Genetic Predictors of Benefit to Pembrolizumab,NCT02710396,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States|U.S.A.,Recruiting
ARAF Mutation|BRAF Mutation|CRKL Mutation|HRAS Mutation|KRAS Mutation|MAP2K1 Mutation|MAP2K2 Mutation|MAP2K4 Mutation|MAP3K1 Mutation|MAPK1 Mutation|NF1 Mutation|NRAS Mutation|RAF1 Mutation|SRC Mutation,Malignant Solid Tumor,A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers,NCT02711345,,Singapore|United States|Japan|U.S.A.|Switzerland|Germany|Spain,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,"Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer",NCT02712723,,United States|U.S.A.,Recruiting
,Colorectal Carcinoma,Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery,NCT02713373,KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States|U.S.A.,Recruiting
GPNMB Expression|GPNMB Overexpression|Transmembrane glycoprotein NMB Expression Positive,Non-Small Cell Lung Carcinoma,"Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung",NCT02713828,,United States|U.S.A.,Recruiting
,Adenocarcinoma of the Gastroesophageal Junction|Gastric Adenocarcinoma|Hepatocellular Carcinoma|Pancreatic Carcinoma,A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,NCT02715531,,"United States|Taiwan|Korea, Republic of|U.S.A.",Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR Codon 719 Missense|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ERBB2 Exon 20 Insertion|ERBB2 Mutation,Non-Small Cell Lung Carcinoma,A Trial of AP32788 in Non-Small Cell Lung Cancer,NCT02716116,EGFR Exon 20 Insertion,United States|U.S.A.,Recruiting
,Glioblastoma,"Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma",NCT02717962,,United States,Recruiting
,Breast Carcinoma|Malignant Solid Tumor,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,NCT02719691,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR,NCT02720185,,United States,Recruiting
BRAF V600E|BRAF V600K,Melanoma,XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma,NCT02721459,,United States|U.S.A.,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Chronic Myeloid Leukemia|Follicular Lymphoma|Hodgkin Lymphoma|Lymphoblastic Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Mature T-Cell and NK-Cell Lymphoma/Leukemia|Multiple Myeloma|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Prolymphocytic Leukemia,UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep,NCT02722668,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|NRAS Mutation,Melanoma,"Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",NCT02723006,,United States|U.S.A.,Recruiting
FLT3 D835A|FLT3 D835E|FLT3 D835H|FLT3 D835N|FLT3 D835V|FLT3 D835Y|FLT3 I836D|FLT3 I836F|FLT3 I836H|FLT3 I836L|FLT3 I836M|FLT3 I836V|FLT3 ITD,Acute Myeloid Leukemia,Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant,NCT02723435,,United States,Not yet recruiting
,Breast Carcinoma,PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO),NCT02723877,,England|Scotland|United Kingdom|Spain,Recruiting
ABL1 Fusion|ABL2 Fusion|CRLF2 Fusion|CSF1R Fusion|EPOR Fusion|FLT3 Mutation|IL7R Mutation|JAK1 Fusion|JAK1 Mutation|JAK2 Fusion|JAK2 Mutation|NTRK3 Fusion|PDGFRB Fusion|PTK2B Fusion|SH2B3 Deletion|SH2B3 Loss|SH2B3 Mutation|TSLP Fusion|TYK2 Fusion,Acute Lymphoblastic Leukemia,A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,NCT02723994,BCR-ABL1 Fusion|Trisomy 21|t(9;22)(q34;q11),New Zealand|Canada|Puerto Rico|United States|Australia,Recruiting
CTNNB1 Mutation,Medulloblastoma,Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma,NCT02724579,,United States,Not yet recruiting
CD274 No Expression|Programmed cell death 1 ligand 1 Expression Negative,Breast Carcinoma,Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers,NCT02725489,,United States,Recruiting
,Breast Carcinoma,Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer,NCT02725541,,United States,Withdrawn
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Gastric Adenocarcinoma,Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer,NCT02726399,,United States|U.S.A.,Recruiting
,Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndromes|Myeloproliferative Neoplasm,"Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",NCT02728050,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,MRI-Based Preoperative Accelerated Partial Breast Irradiation,NCT02728076,,United States,Recruiting
,Multiple Myeloma,Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401),NCT02728102,Hypodiploidy|IGH-FGFR3 Fusion|IGH-MAFB Fusion|IGH-WHSC1 Fusion|Monosomy 13|StrucGain(1)(q10qter)|del(1)(p10)|del(17)(p10),United States|U.S.A.,Recruiting
PIK3CA Mutation,Endometrial Carcinoma,Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer,NCT02728258,,United States,Recruiting
NF1 Mutation,Neurofibroma,Photodynamic Therapy for Benign Dermal Neurofibromas,NCT02728388,,United States,Recruiting
B-lymphocyte antigen CD19 Expression Positive|B-lymphocyte antigen CD20 Expression Positive|CCND1 Expression|CCND1 Overexpression|CD19 Expression|CD19 Overexpression|G1/S-specific cyclin-D1 Expression Positive|G1/S-specific cyclin-D1 Overexpression|IGH-CCND1 Fusion|MS4A1 Expression|MS4A1 Overexpression|t(11;14)(q13;32),Mantle Cell Lymphoma,Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma,NCT02728531,,United States|U.S.A.,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Diffuse Large B-Cell Lymphoma|Follicular Lymphoma,"A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",NCT02729896,,United States|Poland|Germany,Recruiting
ALK Expression|ALK Fusion|ALK tyrosine kinase receptor Expression Positive|TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Anaplastic Large Cell Lymphoma,Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma,NCT02729961,,United States,Not yet recruiting
,Breast Carcinoma,Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients,NCT02730130,,United States,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia,Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia,NCT02730195,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.,NCT02732119,,United States,Recruiting
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,"A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS",NCT02732184,BCR-ABL1 Fusion|PML-RARA Fusion|t(15;17)(q24;q21),Canada|United States,Recruiting
del(11)(q10)|del(17)(p10),B-Cell Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Hodgkin Lymphoma,"A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia",NCT02733042,,Netherlands|United States|Japan|England|Italy|United Kingdom|Scotland|U.S.A.|France|Germany,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma|Gastric Carcinoma|Ovarian Carcinoma|Small Cell Lung Carcinoma,A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.,NCT02734004,ATM Frameshift|ATM Nonsense,"Netherlands|United States|England|Korea, Republic of|United Kingdom|Scotland|Israel|U.S.A.|France|Switzerland",Recruiting
,Breast Carcinoma,Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer,NCT02734290,,United States,Recruiting
TP53 Mutation,Head and Neck Squamous Cell Carcinoma,Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery,NCT02734537,CDKN2A Expression|CDKN2A Overexpression|TP53 Mutation,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Mutation|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,NCT02734615,ESR1 Mutation,Singapore|Belgium|United States|Japan|Italy|U.S.A.|France,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma","A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",NCT02734771,TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,United States,Recruiting
EWSR1 Fusion,Ewing Sarcoma,Pbi-shRNA‰ã¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma,NCT02736565,,United States,Recruiting
B-lymphocyte antigen CD19 Expression Positive|B-lymphocyte antigen CD20 Expression Positive|CCND1 Expression|CCND1 Overexpression|CD19 Expression|CD19 Overexpression|CD5 Expression|CD5 Overexpression|G1/S-specific cyclin-D1 Expression Positive|G1/S-specific cyclin-D1 Overexpression|MS4A1 Expression|MS4A1 Overexpression|T-cell surface glycoprotein CD5 Expression Positive|t(11;14)(q13;32),Mantle Cell Lymphoma,Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma,NCT02736617,,United States,Recruiting
ALK Fusion,Non-Small Cell Lung Carcinoma,ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients,NCT02737501,,"Singapore|Hong Kong|United States|England|United Kingdom|Scotland|Switzerland|Spain|Canada|Austria|Netherlands|Sweden|Norway|Luxembourg|Finland|Taiwan|Denmark|Korea, Republic of|Italy|U.S.A.|Australia|France|Germany",Recruiting
WT1 Expression|WT1 Overexpression|Wilms tumor protein Expression Positive,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer,NCT02737787,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor,NCT02738866,,United States,Recruiting
Melanoma antigen preferentially expressed in tumors Expression Positive|PRAME Expression|PRAME Overexpression,Acute Myeloid Leukemia|RAEB-1|RAEB-2,Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms,NCT02743611,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Comparison of Healthy Diets on Breast Cancer Markers,NCT02744079,,United States,Not yet recruiting
PSCA Expression|PSCA Overexpression|Prostate stem cell antigen Expression Positive,Pancreatic Carcinoma,Prostate Stem Cell Antigen (PSCA)-Specific CAR T Cells In Subjects With Non-Resectable Pancreatic Cancer,NCT02744287,,United States,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Hodgkin Lymphoma,Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,NCT02744612,,United States|U.S.A.,Recruiting
IDH1 R132C|IDH1 R132G|IDH1 R132H|IDH1 R132L|IDH1 R132P|IDH1 R132S,Malignant Solid Tumor,Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors,NCT02746081,,United States|Japan|Denmark|Germany,Recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,B Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia,Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia,NCT02746952,,United States|England|United Kingdom|France,Recruiting
,Breast Carcinoma,A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer,NCT02747004,,Argentina|Russian Federation|United States|Czechia|Spain|Austria|Turkey|Belgium|Taiwan|Brazil|Italy|Mexico|France|Germany,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,B-Cell Non-Hodgkin Lymphoma,Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab,NCT02747043,,"Romania|United States|Czechia|Japan|Spain|Greece|Canada|Korea, Republic of|Poland|Italy|Bulgaria|Australia|France|Germany",Recruiting
ARAF Mutation|BRAF Mutation|FLT1 Mutation|FLT3 Mutation|FLT4 Mutation|JAK1 Mutation|JAK2 Mutation|JAK3 Mutation|KDR Mutation|KIT Mutation|MAP2K1 Mutation|MAPK1 Mutation|PDGFRA Mutation|PDGFRB Mutation|RAF1 Mutation|STAT1 Mutation|STAT2 Mutation|STAT3 Mutation|STAT4 Mutation|STAT5A Mutation|STAT5B Mutation|STAT6 Mutation,Malignant Solid Tumor,Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan,NCT02747537,,United States|U.S.A.,Recruiting
FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FLT1 Amplification|FLT1 Mutation|FLT4 Amplification|FLT4 Mutation|KDR Amplification|KDR Mutation|PDGFRA Amplification|PDGFRA Fusion|PDGFRA Mutation|PDGFRB Amplification|PDGFRB Fusion|PDGFRB Mutation,Cancer,"Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations",NCT02747797,,United States,Withdrawn
GPC3 Expression|GPC3 Overexpression|Glypican-3 Expression Positive,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Carcinoma|Gastric Carcinoma|Malignant Solid Tumor,A Study of ERY974 in Patient With Advanced Solid Tumors,NCT02748837,,United States,Recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Salivary Gland Cancer,Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers,NCT02749903,,United States|U.S.A.,Recruiting
MET Exon 14 Skipping,Non-Small Cell Lung Carcinoma,A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor,NCT02750215,,United States|U.S.A.,Recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Breast Carcinoma,Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer,NCT02750358,,United States|U.S.A.,Recruiting
,Breast Carcinoma,"QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer",NCT02751528,ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,United States,Recruiting
MSLN Expression|MSLN Overexpression|Mesothelin Expression Positive|Mesothelin Overexpression,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer,NCT02751918,,"United States|Moldova, Republic of",Recruiting
FLT3 Codon 835 Missense|FLT3 Codon 836 Missense|FLT3 ITD,Acute Myeloid Leukemia,"A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy",NCT02752035,BCR-ABL1 Fusion,"United States|Japan|England|United Kingdom|Spain|Canada|Belgium|Taiwan|Korea, Republic of|Poland|Australia|France|Germany",Recruiting
,Breast Carcinoma,Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer,NCT02752685,,United States|U.S.A.,Recruiting
,Breast Adenocarcinoma,"Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)",NCT02753595,,United States,Recruiting
,Breast Carcinoma,A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer,NCT02755272,,United States|U.S.A.,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy,NCT02756364,,United States|Spain,Recruiting
TP53 Frameshift|TP53 Large Deletion|TP53 Loss|TP53 Nonsense|del(11)(q10)|del(17)(p10),Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL),NCT02756897,IGH Mutation,United States|U.S.A.,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR Germline T790M|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,"Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib",NCT02759835,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery,NCT02760030,,United States|U.S.A.,Recruiting
,Breast Carcinoma|Colorectal Carcinoma|Gastric Carcinoma|Melanoma|Mesothelioma|Ovarian Carcinoma|Pancreatic Carcinoma,A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,NCT02760797,,Belgium|United States|France,Recruiting
BARD1 Germline Mutation|BARD1 Mutation|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|BRIP1 Germline Mutation|BRIP1 Mutation|MLH1 Germline Mutation|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Mutation|PALB2 Germline Mutation|PALB2 Mutation|PMS2 Germline Mutation|PMS2 Mutation|RAD51C Germline Mutation|RAD51C Mutation|RAD51D Germline Mutation|RAD51D Mutation,Hereditary Breast and Ovarian Cancer Syndrome,The Women Choosing Surgical Prevention (WISP) Trial,NCT02760849,,United States|U.S.A.,Recruiting
"AKT1 Mutation|AKT2 Mutation|AKT3 Mutation|PIK3CA Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency",Malignant Solid Tumor,"Phase 1 Study of ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations or PTEN-null",NCT02761694,,United States,Recruiting
PTCH1 Mutation,Basal Cell Carcinoma,"Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas (BCC) in Gorlin Syndrome Patients",NCT02762084,,England|Scotland|United Kingdom,Completed
,Breast Carcinoma|Malignant Solid Tumor|Ovarian Carcinoma,Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors,NCT02762981,,United States,Recruiting
,Diffuse Large B-Cell Lymphoma|Hodgkin Lymphoma|Post-Transplant Lymphoproliferative Disorder,Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas,NCT02763254,,United States,Recruiting
,"Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL),NCT02763319,,"Singapore|Hungary|England|United Kingdom|Portugal|Spain|Austria|Czech Republic|Finland|Korea, Republic of|Poland|Italy|France|Germany|Croatia",Recruiting
,Breast Carcinoma,Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),NCT02764541,,United States|U.S.A.,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive,Hypopharyngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,NCT02764593,CDKN2A Expression|CDKN2A Overexpression,United States,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|Normal karyotype|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndromes|RAEB-2|Refractory Anemia|Refractory Anemia with Excess Blasts,StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies,NCT02765997,CBFB-MYH11 Fusion|Complex karyotype|DEK-NUP214 Fusion|KMT2A-MLLT3 Fusion|Monosomy 5|Monosomy 7|Normal karyotype|PML-RARA Fusion|RPN1-MECOM Fusion|RUNX1-RUNX1T1 Fusion|Very Complex karyotype|del(5)(q10)|del(7)(q10)|inv(16)(p13q22)|inv(3)(q21q26)|t(16;16)(p13;q22)|t(3;3)(q21;q26)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States,Not yet recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Non-Small Cell Lung Carcinoma,eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients,NCT02767804,,"Hong Kong|United States|Czechia|Wales|England|United Kingdom|Spain|Canada|Netherlands|Turkey|Belgium|Korea, Republic of|Italy|Israel|U.S.A.|Australia|France|Germany",Recruiting
,Breast Carcinoma,Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer,NCT02768701,,United States,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|Normal karyotype|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Trisomy 8|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia,Laboratory-Treated (Central Memory/NaÌøve) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia,NCT02770820,CBFB-MYH11 Fusion|Complex karyotype|DEK-NUP214 Fusion|KMT2A-MLLT3 Fusion|Monosomy 5|Monosomy 7|Normal karyotype|PML-RARA Fusion|RPN1-MECOM Fusion|RUNX1-RUNX1T1 Fusion|Very Complex karyotype|del(5)(q10)|del(7)(q10)|inv(16)(p13q22)|inv(3)(q21q26)|t(16;16)(p13;q22)|t(3;3)(q21;q26)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23)|t(9;22)(q34;q11),United States,Not yet recruiting
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Lymphoma|Malignant Solid Tumor,Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1,NCT02774291,,United States,Not yet recruiting
RB1 Expression|RB1 Overexpression|Retinoblastoma-associated protein Expression Positive,Breast Carcinoma,[18F]Fluorothymidine (FLT) PET/CT Imaging In Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 And Weekly Paclitaxel Therapy,NCT02774473,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis,NCT02774681,,United States|U.S.A.,Recruiting
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Malignant Solid Tumor,"Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",NCT02775292,,United States,Recruiting
,Head and Neck Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,"Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",NCT02775812,CDKN2A Expression|CDKN2A Overexpression,United States,Recruiting
B-lymphocyte antigen CD20 Expression Positive|CCND1 Expression|CCND1 Overexpression|G1/S-specific cyclin-D1 Expression Positive|G1/S-specific cyclin-D1 Overexpression|IGH-CCND1 Fusion|MS4A1 Expression|MS4A1 Overexpression|t(11;14)(q13;32),Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Grade 3b Follicular Lymphoma|Mantle Cell Lymphoma|Mediastinal Large B-Cell Lymphoma,Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma,NCT02776813,,United States,Recruiting
,Breast Carcinoma,"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",NCT02776917,,United States,Not yet recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,"Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib",NCT02778685,,United States,Recruiting
CD274 Expression|CD274 High Expression|CD274 Overexpression|KRAS Mutation|Programmed cell death 1 ligand 1 Expression Positive,Breast Carcinoma|Non-Small Cell Lung Carcinoma,A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,NCT02779751,,Turkey|Belgium|United States|Taiwan|Italy|France|Spain,Recruiting
,Myelodysplastic Syndromes,"Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes",NCT02779777,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer,NCT02779855,,United States,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Lymphoma|Malignant Solid Tumor,Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies,NCT02780011,,United States,Not yet recruiting
ALK Fusion|ALK Mutation|ARAF Mutation|BRAF Mutation|CRKL Mutation|HRAS Mutation|KRAS Mutation|MAP2K1 Mutation|MAP2K2 Mutation|MAP2K4 Mutation|MAP3K1 Mutation|MAPK1 Mutation|NF1 Large Deletion|NF1 Loss|NF1 Mutation|NRAS Mutation|RAF1 Mutation|SRC Mutation,Neuroblastoma,Next Generation Personalized Neuroblastoma Therapy,NCT02780128,TP53 Codon 47 Missense|TP53 Codon 72 Missense|TP53 Frameshift|TP53 Nonsense|TP53 c.1-c.137 Missense|TP53 c.142-c.212 Missense|TP53 c.217-c.1178 Missense,United States,Recruiting
,Breast Carcinoma,"Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission",NCT02780401,,United States,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,Pilot Study of Bisphosphonates for Breast Cancer,NCT02781805,,United States,Recruiting
,Acute Myeloid Leukemia,Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With LDAC in Patients With Previously Untreated AML,NCT02781883,PML-RARA Fusion|t(15;17)(q22;q12),United States,Recruiting
ABL1 T315I|BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,"Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases",NCT02782403,,United States,Recruiting
TP53 Deletion|TP53 Loss|TP53 Mutation,Bladder Transitional Cell Carcinoma|Breast Carcinoma|Glioblastoma|Malignant Solid Tumor|Non-Hodgkin Lymphoma|Renal Pelvis Transitional Cell Carcinoma|Ureter Transitional Cell Carcinoma,Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma,NCT02783300,TP53 Deletion|TP53 Loss|TP53 Mutation,Canada|Netherlands|United States|France,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Oropharyngeal Squamous Cell Carcinoma,Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer,NCT02784288,,United States,Not yet recruiting
APH1A Deletion|APH1A Mutation|DLL4 Amplification|DLL4 Mutation|FBXW7 Mutation|JAG1 Amplification|JAG1 Mutation|MAML1 Deletion|MAML1 Mutation|NCSTN Deletion|NCSTN Mutation|NOTCH1 Amplification|NOTCH1 Deletion|NOTCH1 Fusion|NOTCH1 Mutation|NOTCH2 Amplification|NOTCH2 Deletion|NOTCH2 Fusion|NOTCH2 Mutation|NOTCH3 Amplification|NOTCH3 Deletion|NOTCH3 Fusion|NOTCH3 Mutation|NOTCH4 Amplification|NOTCH4 Deletion|NOTCH4 Fusion|NOTCH4 Mutation,Breast Carcinoma|Cholangiocarcinoma|Lymphoma|Malignant Solid Tumor|Soft Tissue Sarcoma,A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,NCT02784795,,United States|Denmark|France|Spain,Recruiting
,Colorectal Carcinoma,Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer,NCT02785068,BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States,Recruiting
MYCN Amplification,Neuroblastoma,A Study of High Risk Induction Chemotherapy for Neuroblastoma Without Prophylactic Administration of Myeloid Growth Factors,NCT02786719,,United States,Recruiting
CD274 Expression|CD274 High Expression|CD274 Low Expression|CD274 No Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Negative|Programmed cell death 1 ligand 1 Expression Positive,Prostate Carcinoma,Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199),NCT02787005,CD274 Expression|CD274 Overexpression,"Hong Kong|United States|Japan|England|United Kingdom|Switzerland|Spain|Canada|Netherlands|Turkey|Ireland|Finland|Taiwan|Korea, Republic of|Poland|Australia|France|Germany|Estonia",Recruiting
Glucocorticoid receptor Expression Positive|NR3C1 Expression|NR3C1 Overexpression,Breast Carcinoma,"A Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxaneå¨) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer",NCT02788981,,United States,Recruiting
EGFR T790M,Non-Small Cell Lung Carcinoma,A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer,NCT02789345,,"Hong Kong|United States|Taiwan|Korea, Republic of|Italy|France|Spain",Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,NCT02789657,,United States,Recruiting
MSLN Expression|MSLN Overexpression|Mesothelin Expression Positive|Mesothelin Overexpression,Breast Carcinoma,T-Cell Therapy for Advanced Breast Cancer,NCT02792114,,United States,Recruiting
IGH-CCND1 Fusion|IGH-CCND3 Fusion|IGH-FGFR3 Fusion|IGH-MAF Fusion|IGH-MAFB Fusion|del(17)(p10)|t(11;14)(q13;32)|t(14;16)(q32;q23)|t(14;20)(q32;q12)|t(4;14)(p16;q32)|t(6;14)(p21;q32),Multiple Myeloma,CART-19 Post-ASCT for Multiple Myeloma,NCT02794246,,United States|U.S.A.,Recruiting
ABL1 Amplification|ABL1 Fusion|ABL1 Mutation|BRAF Amplification|BRAF Mutation|DDR2 Amplification|DDR2 Mutation|EGFR Amplification|EGFR Mutation|EPHA2 Amplification|EPHA2 Mutation|ERBB2 Amplification|ERBB2 Mutation|ERBB4 Amplification|ERBB4 Mutation|FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FLT1 Amplification|FLT1 Mutation|FLT4 Amplification|FLT4 Mutation|FRK Mutation|KDR Amplification|KDR Mutation|KIT Amplification|KIT Fusion|KIT Mutation|MAPK11 Amplification|MAPK11 Mutation|PDGFRA Amplification|PDGFRA Fusion|PDGFRA Mutation|PDGFRB Amplification|PDGFRB Fusion|PDGFRB Mutation|RAF1 Amplification|RAF1 Mutation|RET Amplification|RET Fusion|RET Mutation|TEK Mutation|TRNAK2 Mutation|VEGFA Amplification|VEGFB Amplification|VEGFC Amplification,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Carcinoma|Gastric Carcinoma|Gastrointestinal Stromal Tumor|Hepatobiliary Neoplasm|Lip and Oral Cavity Cancer|Malignant Laryngeal Neoplasm|Nasopharyngeal Carcinoma|Non-Small Cell Lung Carcinoma|Oropharyngeal carcinoma|Pancreatic Carcinoma|Paranasal Sinus and Nasal Cavity Cancer|Salivary Gland Cancer|Urothelial Carcinoma,Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,NCT02795156,,United States,Recruiting
EGFR Overexpression|Receptor tyrosine-protein kinase erbB-1 Expression Positive,Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Glioblastoma,"Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",NCT02800486,,United States,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,NCT02803203,,United States|U.S.A.,Recruiting
,Breast Carcinoma|Endometrial Carcinoma|Melanoma|Pancreatic Cancer,Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,NCT02807844,,United States|Finland|Spain,Recruiting
BCR-ABL1 Fusion|Histone-lysine N-methyltransferase 2A Expression Positive|KMT2A Expression|KMT2A Overexpression|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia,Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia,NCT02807883,,United States,Recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,B Acute Lymphoblastic Leukemia,Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia,NCT02808442,,Belgium|Scotland|United Kingdom|France,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Anal Carcinoma|Cervical Carcinoma|Oropharyngeal carcinoma|Penile Carcinoma|Vaginal Carcinoma|Vulvar Carcinoma,Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,NCT02812056,,United States,Not yet recruiting
KIT Amplification|KIT Mutation,Melanoma,Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification,NCT02812693,,United States,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),B Acute Lymphoblastic Leukemia,"Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone",NCT02815059,,United States,Recruiting
MYC Amplification|MYC Expression|MYC Fusion|MYC Overexpression|Myc proto-oncogene protein Expression Positive,Diffuse Large B-Cell Lymphoma,DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma,NCT02815397,,United States,Recruiting
BRAF V600E|BRAF V600K,Melanoma,Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,NCT02818023,,United States|U.S.A.,Recruiting
,Breast Carcinoma,Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),NCT02819518,,"Russian Federation|Hong Kong|United States|Czechia|England|Malaysia|Netherlands|Ireland|Korea, Republic of|Poland|Chile|France|Colombia|Hungary|Japan|Ukraine|United Kingdom|Spain|New Zealand|Canada|Turkey|Belgium|Taiwan|Denmark|Italy|Mexico|Australia|Germany",Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia,Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,NCT02819804,,United States,Recruiting
DLL3 Expression|DLL3 Overexpression|Delta-like protein 3 Expression Positive,Small Cell Lung Carcinoma,A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer,NCT02819999,,United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer,NCT02820961,,United States,Recruiting
MSLN Expression|MSLN Overexpression|Mesothelin Expression Positive|Mesothelin Overexpression,Breast Carcinoma|Fallopian Tube Carcinoma|Lung Adenocarcinoma|Ovarian Carcinoma|Pancreatic Adenocarcinoma|Peritoneal Mesothelioma|Pleural Mesothelioma|Primary Peritoneal Cancer,Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,NCT02824042,,United States|Australia,Recruiting
,Breast Carcinoma,Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer,NCT02824575,,United States,Recruiting
CCND1 Overexpression|G1/S-specific cyclin-D1 Overexpression|IGH-CCND1 Fusion|t(11;14)(q13;32),Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma,BTK Inhibitor in B Cell Malignancies,NCT02825836,,Poland|Italy|Scotland|United Kingdom,Recruiting
,Breast Carcinoma,Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer,NCT02826434,,United States,Recruiting
,Oral Cavity Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer,NCT02827838,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Copper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer,NCT02827877,,United States,Recruiting
,Breast Carcinoma|Glioblastoma|Malignant Solid Tumor|Pancreatic Cancer,Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors,NCT02829723,,Singapore|United States|Taiwan|Italy|Spain,Recruiting
FLT3 ITD|FLT3 Mutation,Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,"Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)",NCT02829840,,United States,Not yet recruiting
CD70 Expression|CD70 Overexpression|CD70 antigen Expression Positive|CD70 antigen Overexpression,Malignant Solid Tumor,Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers,NCT02830724,,United States,Recruiting
NF2 Germline Mutation|NF2 Mutation,Meningioma,AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas,NCT02831257,,United States,Recruiting
,Non-Small Cell Lung Carcinoma,Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS),NCT02831959,ALK Fusion|BRAF D594E|BRAF D594G|BRAF D594H|BRAF D594N|BRAF D594V|BRAF G466V|BRAF G469A|BRAF G469E|BRAF G469L|BRAF G469V|BRAF G596R|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF R444W|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|BRAF Y472C|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ROS1 Fusion,Canada|United States,Recruiting
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",NCT02833506,,United States,Not yet recruiting
,Breast Carcinoma,L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,NCT02834403,,United States,Recruiting
,Acute Myeloid Leukemia,A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,NCT02835729,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Recruiting
,Myelodysplastic Syndromes,"A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)",NCT02835794,,United States,Withdrawn
MSLN Expression|MSLN Overexpression|Mesothelin Expression Positive,Non-Small Cell Lung Carcinoma,Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma,NCT02839681,,United States|U.S.A.,Recruiting
NF1 Germline Mutation|NF1 Mutation,Neurofibroma,Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Dermal Neurofibroma,NCT02839720,,United States,Not yet recruiting
SF3B1 Mutation|SRSF2 Mutation|U2AF1 Mutation|ZRSR2 Mutation,Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,"Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia",NCT02841540,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(16;16)(p13;q22)|t(8;21)(q22;q22),United States,Recruiting
,Head and Neck Carcinoma,"A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study",NCT02841748,,United States,Recruiting
,Acute Myeloid Leukemia,Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (‰ä´65 Years) AML Patients,NCT02845297,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Recruiting
TP53 Large Deletion|TP53 Loss|TP53 Mutation|del(11)(q10)|del(17)(p10),Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL),NCT02846623,IGH Mutation,United States,Recruiting
FGF1 Amplification|FGF1 Mutation|FGF10 Amplification|FGF10 Mutation|FGF11 Amplification|FGF11 Mutation|FGF12 Amplification|FGF12 Mutation|FGF13 Amplification|FGF13 Mutation|FGF14 Amplification|FGF14 Mutation|FGF16 Amplification|FGF16 Mutation|FGF17 Amplification|FGF17 Mutation|FGF18 Amplification|FGF18 Mutation|FGF19 Amplification|FGF19 Mutation|FGF2 Amplification|FGF2 Mutation|FGF20 Amplification|FGF20 Mutation|FGF21 Amplification|FGF21 Mutation|FGF22 Amplification|FGF22 Mutation|FGF23 Amplification|FGF23 Mutation|FGF3 Amplification|FGF3 Mutation|FGF4 Amplification|FGF4 Mutation|FGF5 Amplification|FGF5 Mutation|FGF6 Amplification|FGF6 Mutation|FGF7 Amplification|FGF7 Mutation|FGF8 Amplification|FGF8 Mutation|FGF9 Amplification|FGF9 Mutation|FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FGFR4 Amplification|FGFR4 Fusion|FGFR4 Mutation,Cancer,Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling,NCT02846766,FGFR2 D626A|FGFR3 D617G|FGFR3 G637W,United States,Not yet recruiting
PDGFRA D842V|PDGFRA Germline D842V,Gastrointestinal Stromal Tumor,Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST,NCT02847429,,United States|Norway|Poland|Italy|Scotland|United Kingdom|France|Germany|Spain,Recruiting
,Non-Small Cell Lung Carcinoma,A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST],NCT02848651,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States,Recruiting
BRCA1 Deletion|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Deletion|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer,NCT02849496,,United States,Recruiting
,Adenocarcinoma,CAR-T Hepatic Artery Infusions for CEA-Expressing Liver Metastases,NCT02850536,,United States,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer,NCT02855697,,England|United Kingdom,Not yet recruiting
BRCA1 Deletion|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Deletion|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",NCT02855944,,Russian Federation|Hungary|United States|Czechia|Ukraine|England|United Kingdom|Scotland|Spain|Canada|Brazil|Poland|Italy|Israel,Recruiting
ARAF Mutation|BRAF Mutation|CRKL Mutation|HRAS Mutation|KRAS Mutation|MAP2K1 Mutation|MAP2K2 Mutation|MAP2K4 Mutation|MAP3K1 Mutation|MAPK1 Mutation|NF1 Mutation|NRAS Mutation|RAF1 Mutation|SRC Mutation,Acute Leukemia|Cancer|Chronic Leukemia|Colon Cancer|Colorectal Carcinoma|Melanoma|Non-Small Cell Lung Carcinoma|Pancreatic Ductal Adenocarcinoma|Rectal Cancer,A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,NCT02857270,,United States|Australia|France,Recruiting
,Anal Carcinoma|Cervical Carcinoma|Oropharyngeal carcinoma|Penile Carcinoma|Vaginal Carcinoma|Vulvar Carcinoma,E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers,NCT02858310,,United States,Recruiting
VHL Germline Mutation|VHL Mutation,Adrenal Gland Pheochromocytoma|Cerebellar Hemangioblastoma|Pancreatic Neuroendocrine Neoplasm|Pheochromocytoma|Renal Cell Carcinoma|Retinal Hemangioblastoma|Von Hippel-Lindau Syndrome,A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab,NCT02859441,,United States,Recruiting
,Breast Carcinoma,"Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",NCT02860000,,United States,Not yet recruiting
BAP1 Deletion|BAP1 Loss|BAP1 Mutation|Ubiquitin carboxyl-terminal hydrolase BAP1 Deficiency|Ubiquitin carboxyl-terminal hydrolase BAP1 Expression Negative,Malignant Mesothelioma,Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma,NCT02860286,,United States|England|United Kingdom|France,Recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression|CD5 Expression|CD5 Overexpression|T-cell surface glycoprotein CD5 Expression Positive,Chronic Lymphocytic Leukemia,Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961,NCT02860676,,United States,Enrolling by invitation
BRAF Mutation|KRAS Mutation,Cancer|Colon Cancer|Colorectal Carcinoma|Non-Small Cell Lung Carcinoma,A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer,NCT02860780,,United States|Germany,Recruiting
PIK3CA Mutation,Colon Cancer|Malignant Solid Tumor,CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer,NCT02861300,,United States,Recruiting
EGFR Expression|Epidermal growth factor receptor Expression Positive,Glioblastoma,Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma,NCT02861898,,United States,Recruiting
,Cervical Intraepithelial Neoplasia,Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3),NCT02864147,,United States,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,"A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy",NCT02864251,EGFR T790M,"Singapore|Hong Kong|United States|Japan|China|Taiwan|Korea, Republic of",Recruiting
MET Exon 14 Skipping,Non-Small Cell Lung Carcinoma,Tepotinib Phase II Study in Lung Adenocarcinoma Harbouring MET Exon 14 (METex14) Skipping Alterations,NCT02864992,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Belgium|United States|Poland|Italy|France|Germany|Spain,Recruiting
NOTCH1 Mutation|TP53 Deletion|del(17)(p10),Chronic Lymphocytic Leukemia|Follicular Lymphoma|Hodgkin Lymphoma|Mantle Cell Lymphoma,Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant,NCT02869633,,United States,Recruiting
CD274 High Expression|CD274 Low Expression|CD274 No Expression,Non-Small Cell Lung Carcinoma,An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers,NCT02869789,,Russian Federation|Romania|Hungary|United States|England|United Kingdom|Scotland|Switzerland|Spain|Greece|Canada|Czech Republic|Netherlands|Turkey|Belgium|Poland|Italy|Mexico|France|Germany,Recruiting
,Breast Carcinoma,Palbociclib With Everolimus + Exemestane In BC,NCT02871791,,United States,Recruiting
FGF1 Amplification|FGF1 Mutation|FGF10 Amplification|FGF10 Mutation|FGF11 Amplification|FGF11 Mutation|FGF12 Amplification|FGF12 Mutation|FGF13 Amplification|FGF13 Mutation|FGF14 Amplification|FGF14 Mutation|FGF16 Amplification|FGF16 Mutation|FGF17 Amplification|FGF17 Mutation|FGF18 Amplification|FGF18 Mutation|FGF19 Amplification|FGF19 Mutation|FGF2 Amplification|FGF2 Mutation|FGF20 Amplification|FGF20 Mutation|FGF21 Amplification|FGF21 Mutation|FGF22 Amplification|FGF22 Mutation|FGF23 Amplification|FGF23 Mutation|FGF3 Amplification|FGF3 Mutation|FGF4 Amplification|FGF4 Mutation|FGF5 Amplification|FGF5 Mutation|FGF6 Amplification|FGF6 Mutation|FGF7 Amplification|FGF7 Mutation|FGF8 Amplification|FGF8 Mutation|FGF9 Amplification|FGF9 Mutation|FGFR1 Amplification|FGFR1 Fusion|FGFR1 Mutation|FGFR2 Amplification|FGFR2 Fusion|FGFR2 Mutation|FGFR3 Amplification|FGFR3 Fusion|FGFR3 Mutation|FGFR4 Amplification|FGFR4 Fusion|FGFR4 Mutation,Urothelial Carcinoma,A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma,NCT02872714,,Belgium|United States|Denmark|England|Italy|United Kingdom|Scotland|France|Spain,Recruiting
,Oral Cavity Squamous Cell Carcinoma,Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity,NCT02873819,,Puerto Rico|Hungary|United States|Ukraine|Poland|Serbia|Germany|Spain,Recruiting
ATM Deletion|ATM Mutation|ATR Deletion|ATR Mutation|BARD1 Mutation|BCL2 Amplification|BCL2 Fusion|BRCA1 Deletion|BRCA1 Mutation|BRCA2 Deletion|BRCA2 Mutation|BRIP1 Mutation|CCND1 Amplification|CCND2 Amplification|CCNE1 Amplification|CHEK1 Mutation|CHEK2 Mutation|FANCA Mutation|FANCB Mutation|FANCC Mutation|FANCD2 Mutation|FANCE Mutation|FANCF Mutation|FANCG Mutation|FANCI Mutation|FANCL Mutation|FANCM Mutation|FBXW7 Mutation|HRAS Mutation|KRAS Mutation|MCPH1 Mutation|MRE11A Deletion|MRE11A Mutation|MYC Amplification|NBN Deletion|NBN Mutation|NRAS Mutation|PALB2 Deletion|PALB2 Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|RAD50 Deletion|RAD50 Mutation|RAD51 Mutation|RAD51B Mutation|RAD51C Mutation|RAD51D Mutation|RB1 Deletion|RB1 Loss|RB1 Mutation|SLX4 Mutation,Malignant Solid Tumor,A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency,NCT02873975,,United States,Recruiting
,Nasopharyngeal Carcinoma,Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer,NCT02875613,,United States,Recruiting
FOLH1 Expression|FOLH1 Overexpression|Glutamate Carboxypeptidase 2 Expression Positive,Glioblastoma,Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma,NCT02876003,,United States,Withdrawn
,Breast Carcinoma,A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC),NCT02876107,,United States,Recruiting
,Breast Carcinoma,Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer,NCT02876302,,United States,Recruiting
,Malignant Solid Tumor,ACTolog in Patients With Solid Cancers,NCT02876510,,United States,Not yet recruiting
,B Acute Lymphoblastic Leukemia,Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia,NCT02877303,BCR-ABL1 Fusion,United States,Recruiting
,Acute Myeloid Leukemia,Decitabine and Talazoparib in Untreated AML and R/R AML,NCT02878785,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Recruiting
,Non-Small Cell Lung Carcinoma,A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients,NCT02879617,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ROS1 Fusion,United States,Recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia,Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia,NCT02879695,,United States,Recruiting
EGFR Mutation,Non-Small Cell Lung Carcinoma,"Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer",NCT02879994,,United States,Recruiting
CD274 Expression|CD274 High Expression|CD274 Low Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive,Bladder Carcinoma|Breast Carcinoma|Colorectal Carcinoma|Gastric Carcinoma|Head and Neck Squamous Cell Carcinoma|Melanoma|Non-Small Cell Lung Carcinoma|Ovarian Carcinoma|Pancreatic Ductal Adenocarcinoma,A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,NCT02880371,,United States,Recruiting
,Acute Myeloid Leukemia,Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML),NCT02882321,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Recruiting
,Breast Carcinoma,"Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer",NCT02883062,,United States,Not yet recruiting
ERBB2 Amplification|MYC Amplification,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Carcinoma|Gastric Adenocarcinoma|Gastric Squamous Cell Carcinoma,Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma,NCT02884453,,England|United Kingdom,Recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Clear Cell Renal Cell Carcinoma,Enzalutamide Before Surgery in Treating Patients With Kidney Cancer,NCT02885649,,United States,Not yet recruiting
,Smoldering Plasma Cell Myeloma,"A Study of PVX-410, a Cancer Vaccine, and Durvalumab +/- Lenalidomide for Smoldering MM",NCT02886065,,United States,Recruiting
,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer,NCT02889900,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States,Recruiting
,Breast Carcinoma|Colorectal Carcinoma|Non-Small Cell Lung Carcinoma,"A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",NCT02890069,,"Netherlands|United States|Taiwan|Korea, Republic of|England|United Kingdom|Spain",Recruiting
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia,NCT02890329,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Breast Carcinoma|Gastric Carcinoma|Malignant Solid Tumor,Trial of ZW25 in Patients With Advanced HER2-expressing Cancers,NCT02892123,,United States,Recruiting
,Breast Carcinoma,Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer,NCT02892734,,United States,Not yet recruiting
CCND1 Amplification|CCND2 Amplification|CCND3 Amplification|CCNE1 Amplification|CDK4 Amplification|CDK6 Amplification|CDKN2A Large Deletion|CDKN2A Loss|Cyclin-dependent kinase inhibitor 2A Deficiency,Malignant Solid Tumor,Palbociclib In Progressive Brain Metastases,NCT02896335,,United States,Recruiting
ALK Fusion,Non-Small Cell Lung Carcinoma,"A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer",NCT02898116,,United States,Recruiting
,Breast Carcinoma|Fallopian Tube Carcinoma|Ovarian Cancer|Primary Peritoneal Cancer,"Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",NCT02898207,BRCA1 Frameshift|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Nonsense|BRCA2 Frameshift|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Nonsense,United States,Not yet recruiting
MRC1 Mutation|POLE Mutation,Endometrial Adenocarcinoma|Uterine Corpus Carcinosarcoma,Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer,NCT02899793,,United States,Recruiting
,Breast Carcinoma|Colorectal Carcinoma|Non-Small Cell Lung Carcinoma,"A Study of PDR001 in Combination With CJM112, EGF816, Ilariså¨ (Canakinumab) or Mekinistå¨ (Trametinib)",NCT02900664,DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation,Canada|Singapore|Belgium|United States|France|Spain,Recruiting
EGFR Amplification|EGFR Overexpression|EGFRvIII|Epidermal Growth Factor Receptor Overexpression,Glioma,A Microdose Evaluation Study of ABY-029 in Recurrent Glioma,NCT02901925,,United States,Recruiting
IGH-FGFR3 Fusion|StrucGain(1)(q10qter)|del(17)(p10)|dup(1)(q10qter)|t(4;14)(p16;q32),Smoldering Plasma Cell Myeloma,"A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma",NCT02903381,,United States,Recruiting
,Gastric Carcinoma|Head and Neck Squamous Cell Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma|Renal Cell Carcinoma|Urothelial Carcinoma,Arginase Inhibitor CB-1158 in Patients With Solid Tumors,NCT02903914,EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR Exon 20 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,United States,Recruiting
,Colorectal Carcinoma,Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients,NCT02904031,BRAF Mutation|HRAS Mutation|KRAS Mutation|NRAS Mutation,Italy,Recruiting
GPC3 Expression|GPC3 Overexpression|Glypican-3 Expression Positive,Hepatocellular Carcinoma,Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR),NCT02905188,,United States,Not yet recruiting
CBFB-MYH11 Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(16;16)(p13;q22)|t(8;21)(q22;q22),Acute Myeloid Leukemia|Acute Promyelocytic Leukemia,Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia,NCT02905994,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Withdrawn
BRAF Codon 600 Missense|KRAS Codon 117 Missense|KRAS Codon 12 Missense|KRAS Codon 13 Missense|KRAS Codon 146 Missense|KRAS Codon 59 Missense|KRAS Codon 61 Missense|NRAS Codon 117 Missense|NRAS Codon 12 Missense|NRAS Codon 13 Missense|NRAS Codon 146 Missense|NRAS Codon 59 Missense|NRAS Codon 61 Missense,Colorectal Carcinoma,"Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer",NCT02906059,,United States,Recruiting
Hypodiploidy|IGH-FGFR3 Fusion|IGH-WHSC1 Fusion|Nullisomy 13|Nullisomy 17|StrucGain(1)(q10qter)|TP53 Deletion|TP53 Large Deletion|TP53 Loss|del(1)(p10)|del(13)(q10)|del(17p)|t(14;16)(q32;q23)|t(14;20)(q32;q12)|t(4;14)(p16;q32),Multiple Myeloma,Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM),NCT02906332,,United States,Recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,B Acute Lymphoblastic Leukemia,Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome,NCT02906371,,United States,Recruiting
,Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs,NCT02907359,,Canada|United States|Japan,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer,NCT02907918,,United States,Not yet recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive|HPV Positive,Oropharyngeal Squamous Cell Carcinoma,Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer,NCT02908477,,United States,Recruiting
BRAF Codon 600 Missense,Melanoma,A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,NCT02908672,,"Russian Federation|Hungary|United States|Wales|England|United Kingdom|Scotland|Portugal|Spain|Greece|New Zealand|Canada|Austria|Netherlands|Belgium|Brazil|Korea, Republic of|Poland|Italy|Israel|Australia|France|Germany",Recruiting
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,NCT02909972,Monosomy 17|TP53 Mutation|del(17)(p10),United States,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|NRAS Mutation,Melanoma,Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma,NCT02910700,BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,United States,Recruiting
DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation,Colon Adenocarcinoma|Lynch Syndrome,Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability,NCT02912559,,United States,Not yet recruiting
DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation|POLE Mutation,Endometrial Carcinoma,"Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer",NCT02912572,DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation,United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen,NCT02913430,,United States,Recruiting
BTK Mutation,Chronic Lymphocytic Leukemia,Safety and Activity of SNX-5422 Plus Ibrutinib in CLL,NCT02914327,,United States,Recruiting
BRAF Codon 600 Missense,Melanoma,A Clinical Trial of Patients With Melanoma,NCT02915666,,United States,Recruiting
IGH-FGFR3 Fusion|StrucGain(1)(q10qter)|TP53 Large Deletion|TP53 Loss|del(17)(p10)|t(4;14)(p16;q32),Smoldering Plasma Cell Myeloma,Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma,NCT02916771,,United States,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Hodgkin Lymphoma|Non-Hodgkin Lymphoma,"CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)",NCT02917083,,United States,Not yet recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer,NCT02917993,,United States,Recruiting
,Acute Myeloid Leukemia,"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",NCT02920008,BCR-ABL1 Fusion|PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(9;22)(q34;q11),Canada|United States,Recruiting
"PIK3CA Amplification|PIK3CA Mutation|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency",Non-Small Cell Lung Carcinoma,"Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)",NCT02920450,PTEN Expression|PTEN Overexpression,United States,Recruiting
MET Exon 14 Mutation|MET Exon 14 Skipping|NTRK1 Fusion|NTRK2 Fusion|NTRK3 Fusion,Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,Merestinib In Non-Small Cell Lung Cancer And Solid Tumors,NCT02920996,,United States,Recruiting
PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),Acute Myeloid Leukemia|Myelodysplastic Syndromes,"Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",NCT02921061,,United States,Recruiting
,Astrocytoma|Oligoastrocytoma|Oligodendroglioma,A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),NCT02924038,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy,NCT02924883,,"Canada|United States|Taiwan|Korea, Republic of|England|Italy|United Kingdom|Scotland|Australia|Germany|Spain",Recruiting
Hepatocyte growth factor receptor Expression Positive|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Malignant Solid Tumor,"A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.",NCT02925104,,Austria|Netherlands|Sweden|United States|England|United Kingdom|Germany|Spain,Recruiting
EGFR T790M,Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors,NCT02926768,EGFR Exon 20 Insertion,United States,Recruiting
,Breast Carcinoma,"Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy",NCT02927249,,Puerto Rico|United States,Recruiting
FLT3 ITD,Acute Myeloid Leukemia,"A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission",NCT02927262,,"Canada|Hungary|United States|Japan|Korea, Republic of|Poland|Australia|France|Germany|Croatia|Spain",Recruiting
ALK Fusion|ROS1 Fusion,Non-Small Cell Lung Carcinoma,A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions,NCT02927340,,United States,Recruiting
BRAF V600E,Colorectal Carcinoma,Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer,NCT02928224,,"Hungary|United States|Czechia|Ukraine|Spain|Canada|Austria|Netherlands|Turkey|Belgium|Korea, Republic of|Poland|Israel|Australia",Recruiting
,Breast Carcinoma,"Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer",NCT02929576,,United States,Recruiting
GPC3 Expression|GPC3 Overexpression|Glypican-3 Expression Positive,Malignant Solid Tumor,Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP),NCT02932956,,United States,Not yet recruiting
B-lymphocyte antigen CD20 Expression Positive|FCGR2B Expression|FCGR2B Overexpression|MS4A1 Expression|MS4A1 Overexpression|low affinity immunoglobulin gamma Fc region receptor II-b Expression Positive,Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma,BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia,NCT02933320,,England|United Kingdom|Scotland,Recruiting
CDKN2A Deletion|CDKN2A Loss|CDKN2B Deletion|CDKN2B Loss|CDKN2C Deletion|CDKN2C Loss|RB1 Expression|RB1 Overexpression|Retinoblastoma-associated protein Expression Positive|del(9)(p21),Glioma|Meningioma,Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients,NCT02933736,RB1 Mutation,United States,Recruiting
,Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed,NCT02935361,,United States,Recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,B Acute Lymphoblastic Leukemia,CART19 in Patient With ALL,NCT02935543,,United States,Recruiting
,Breast Carcinoma|Malignant Solid Tumor,A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,NCT02936102,,Canada|Singapore|United States|Japan|Israel|Spain,Recruiting
,Breast Carcinoma,Vaccination of Triple Negative Breast Cancer Patients,NCT02938442,,United States,Not yet recruiting
,Breast Carcinoma,Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,NCT02941926,,Canada|Netherlands|Belgium|United States|England|United Kingdom,Recruiting
EGFR Mutation|KRAS Codon 12 Missense|KRAS Codon 13 Missense,Non-Small Cell Lung Carcinoma|Pancreatic Ductal Adenocarcinoma,Study of Ixazomib and Erlotinib in Solid Tumors,NCT02942095,,United States,Recruiting
,Breast Carcinoma,Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer,NCT02942355,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Eliminating Breast Cancer Surgery in Exceptional Responders With Neoadjuvant Systemic Therapy,NCT02945579,,United States,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive,Laryngeal Squamous Cell Carcinoma|Nasal Cavity Squamous Cell Carcinoma|Nasopharyngeal Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Quarterback 2 - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer,NCT02945631,,United States,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Follicular Lymphoma,Study of Ibrutinib and Rituximab in Treatment NaÌøve Follicular Lymphoma,NCT02947347,,United States,Recruiting
,Hypopharyngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,NCT02949700,,United States,Recruiting
ALK Fusion|BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ERBB2 Mutation|MET Mutation|RET Mutation|ROS1 Fusion,Non-Small Cell Lung Carcinoma,Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations,NCT02949843,,United States,Recruiting
ATM Loss|ATM Mutation|ATR Loss|ATR Mutation|ATRX Loss|ATRX Mutation|BARD1 Germline Mutation|BARD1 Mutation|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|BRIP1 Mutation|C11orf30 Loss|C11orf30 Mutation|CDK12 Mutation|CHEK1 Mutation|CHEK2 Mutation|FANCA Amplification|FANCA Mutation|FANCB Amplification|FANCB Mutation|FANCC Amplification|FANCC Mutation|FANCD2 Amplification|FANCD2 Mutation|FANCE Amplification|FANCE Mutation|FANCF Amplification|FANCF Mutation|FANCG Amplification|FANCG Mutation|FANCI Amplification|FANCI Mutation|FANCL Amplification|FANCL Mutation|FANCM Amplification|FANCM Mutation|MDM2 Amplification|MDM2 Mutation|MDM4 Mutation|MLH1 Mutation|MRE11A Loss|MRE11A Mutation|MUTYH Mutation|NBN Loss|NBN Mutation|NPM1 Mutation|NPM1-MLF1 Fusion|PALB2 Loss|PALB2 Mutation|PARP1 Mutation|PARP2 Mutation|PPP2R1A Mutation|PPP2R2A Mutation|RAD50 Loss|RAD50 Mutation|RAD51 Mutation|RAD51B Mutation|RAD51C Mutation|RAD51D Mutation|SLX4 Mutation|STAG2 Mutation|XRCC1 Mutation,Breast Carcinoma|Malignant Solid Tumor|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma,A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations,NCT02950064,,United States,Recruiting
CCND1 Overexpression|G1/S-specific cyclin-D1 Overexpression|t(11;14)(q13;32),Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Lymphoblastic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma,Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,NCT02950220,,United States,Recruiting
ATM Deletion|ATM Mutation|ATR Deletion|ATR Mutation|BARD1 Mutation|BRCA1 Deletion|BRCA1 Mutation|BRCA2 Deletion|BRCA2 Mutation|BRIP1 Mutation|CHEK1 Mutation|CHEK2 Mutation|FANCA Mutation|FANCB Mutation|FANCC Mutation|FANCD2 Mutation|FANCE Mutation|FANCF Mutation|FANCG Mutation|FANCI Mutation|FANCL Mutation|FANCM Mutation|MCPH1 Mutation|MRE11A Deletion|MRE11A Mutation|NBN Deletion|NBN Mutation|PALB2 Deletion|PALB2 Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|RAD50 Deletion|RAD50 Mutation|RAD51 Mutation|RAD51B Mutation|RAD51C Mutation|RAD51D Mutation|SLX4 Mutation,Prostate Adenocarcinoma|Prostate Carcinoma,A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency,NCT02952534,,United States,Recruiting
,Hypopharyngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100),NCT02952586,,"United States|Japan|Taiwan|Korea, Republic of",Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Gastric Carcinoma|Non-Small Cell Lung Carcinoma,Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,NCT02952729,ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression,United States,Recruiting
KRAS Mutation,Colorectal Carcinoma|Malignant Solid Tumor,Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,NCT02953782,KRAS Mutation,United States,Recruiting
,Breast Carcinoma,Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer,NCT02953860,,United States,Not yet recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations,NCT02954523,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Adenocarcinoma|Gastric Adenocarcinoma,Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer,NCT02954536,,United States,Recruiting
FLT3 ITD,Acute Myeloid Leukemia,"A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",NCT02954653,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(16;16)(p13;q22)|t(8;21)(q22;q22),United States,Recruiting
,Breast Carcinoma,Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer,NCT02954874,,United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer,NCT02955394,,United States,Not yet recruiting
,Breast Carcinoma,Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,NCT02957968,,United States,Recruiting
,Colorectal Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206),NCT02959437,DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation,United States,Recruiting
H3F3A K27M|HLA-A*02 Positive,Diffuse Intrinsic Pontine Glioma|Glioma,H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas,NCT02960230,,United States,"Active, not recruiting"
BRAF Codon 600 Missense|PIK3CA Mutation|PTEN Loss|PTEN Mutation,Colorectal Carcinoma|Malignant Solid Tumor|Melanoma|Non-Small Cell Lung Carcinoma,Study of ASN003 in Subjects With Advanced Solid Tumors,NCT02961283,,United States,Recruiting
APC Mutation,Familial Adenomatous Polyposis,Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer,NCT02961374,,Puerto Rico|United States,Not yet recruiting
,Breast Carcinoma,Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer,NCT02964507,,United States,Recruiting
DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation,Prostate Carcinoma,Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,NCT02966587,,United States,Not yet recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",NCT02967692,,Sweden|England|United Kingdom|Australia|Switzerland|Spain,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer,NCT02970682,,Czech Republic|Belgium|England|United Kingdom|France|Spain,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases,NCT02971501,,United States,Not yet recruiting
,Breast Carcinoma,A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy,NCT02971748,,United States,Recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Breast Carcinoma,Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer,NCT02971761,,United States,Recruiting
,Hodgkin Lymphoma|Lymphoma|Lymphoproliferative Disorder|Non-Hodgkin Lymphoma,"Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)",NCT02973113,,United States,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Chronic Myeloid Leukemia,A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML,NCT02973711,,United States,Not yet recruiting
,Breast Carcinoma,Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer,NCT02977468,,United States,Recruiting
IDH1 R132*,Glioma,Trial of IDH305 in IDH1 Mutant Grade II or III Glioma,NCT02977689,,United States,Not yet recruiting
,Glioblastoma|Gliosarcoma,INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),NCT02977780,IDH1 R132H,United States,Recruiting
,Breast Carcinoma,"Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)",NCT02978716,,United States|Slovakia|Slovenia|Serbia|Croatia,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Hodgkin Lymphoma,"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma",NCT02979522,,United States,Not yet recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|EGFR T790M,Non-Small Cell Lung Carcinoma,"A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC",NCT02981108,,United States,Recruiting
,Breast Carcinoma|Melanoma,Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,NCT02981303,,United States,Recruiting
B-cell receptor CD22 Expression Positive|CD22 Expression|CD22 Overexpression,B Acute Lymphoblastic Leukemia,Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia,NCT02981628,,United States,Not yet recruiting
CD276 Expression|CD276 Overexpression|CD276 antigen Expression Positive|CD276 antigen Overexpression,Desmoplastic Small Round Cell Tumor|Ewing Sarcoma|Malignant Solid Tumor|Neuroblastoma|Osteosarcoma|Primitive Neuroectodermal Tumor|Rhabdomyosarcoma|Wilms Tumor,Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors,NCT02982941,,United States,Recruiting
,Melanoma|Non-Small Cell Lung Carcinoma|Renal Cell Carcinoma,A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors,NCT02983045,ALK Fusion|BRAF Mutation|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States,Recruiting
,Breast Carcinoma,"G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer",NCT02983071,,"Romania|Czechia|Moldova, Republic of|England|United Kingdom|Georgia|Bulgaria",Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,"GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer",NCT02983604,,United States,Recruiting
CA6 Expression|CA6 Overexpression|Carbonic anhydrase 6 Expression Positive,Breast Carcinoma,Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer,NCT02984683,,Netherlands|Belgium|United States|Italy|Spain,Recruiting
ATM Deletion|ATM Germline Mutation|ATM Mutation|ATR Deletion|ATR Mutation|BARD1 Mutation|BRCA1 Deletion|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Deletion|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|BRIP1 Mutation|CHEK1 Mutation|CHEK2 Mutation|FANCA Mutation|FANCB Mutation|FANCC Mutation|FANCD2 Mutation|FANCE Mutation|FANCF Mutation|FANCG Mutation|FANCI Mutation|FANCL Mutation|FANCM Mutation|MCPH1 Mutation|MRE11A Deletion|MRE11A Mutation|NBN Deletion|NBN Mutation|PALB2 Deletion|PALB2 Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|RAD50 Deletion|RAD50 Mutation|RAD51 Mutation|RAD51B Mutation|RAD51C Mutation|RAD51D Mutation|SLX4 Mutation,Prostate Adenocarcinoma,Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies,NCT02985021,,United States,Recruiting
ATM Deletion|ATM Mutation|ATR Deletion|ATR Mutation|BARD1 Mutation|BRCA1 Deletion|BRCA1 Mutation|BRCA2 Deletion|BRCA2 Mutation|BRIP1 Mutation|CHEK1 Mutation|CHEK2 Mutation|FANCA Mutation|FANCB Mutation|FANCC Mutation|FANCD2 Mutation|FANCE Mutation|FANCF Mutation|FANCG Mutation|FANCI Mutation|FANCL Mutation|FANCM Mutation|MCPH1 Mutation|MRE11A Deletion|MRE11A Mutation|NBN Deletion|NBN Mutation|PALB2 Deletion|PALB2 Mutation|PTEN Deletion|PTEN Loss|PTEN Mutation|RAD50 Deletion|RAD50 Mutation|RAD51 Mutation|RAD51B Mutation|RAD51C Mutation|RAD51D Mutation|SLX4 Mutation,Prostate Carcinoma,Study of Olaparib (Lynparza‰ã¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),NCT02987543,,"Argentina|United States|Japan|Spain|Canada|Austria|Netherlands|Sweden|Turkey|Norway|Taiwan|Brazil|Denmark|Korea, Republic of|Italy|Israel|Australia|France|Germany",Recruiting
"PIK3CA Mutation|PTEN Deletion|PTEN Frameshift|PTEN Loss|PTEN Mutation|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency",Angiosarcoma|Extraskeletal Osteosarcoma|Leiomyosarcoma|Malignant Peripheral Nerve Sheath Tumor (MPNST)|Myxofibrosarcoma|Pleomorphic Liposarcoma|Pleomorphic Rhabdomyosarcoma|Soft Tissue Sarcoma|Undifferentiated Pleomorphic Sarcoma,Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,NCT02987959,,United States,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Malignant Solid Tumor|Ovarian Carcinoma,HuMax-AXL-ADC Safety Study in Patients With Solid Tumors,NCT02988817,,Belgium|Denmark|England|United Kingdom,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Germ Cell Tumor,Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors,NCT02988843,,United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,"TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer",NCT02988986,,United States,Recruiting
MAGEA10 Expression,Head and Neck Squamous Cell Carcinoma|Melanoma|Urothelial Carcinoma,"MAGE-A10‡¦Ï‰á‰_‰¦T for Urothelial Cancer, Melanoma or Head and Neck Cancers",NCT02989064,,Canada|United States,Recruiting
IDH1 Mutation,Cholangiocarcinoma,Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy),NCT02989857,,United States,Recruiting
,Non-Small Cell Lung Carcinoma,Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC,NCT02991651,EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States,Recruiting
PTEN Germline Loss|PTEN Germline Mutation|PTEN Loss|PTEN Mutation,Bannayan Syndrome|Cowden Syndrome|Proteus Syndrome,RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome (PTEN),NCT02991807,,United States,Recruiting
MYC Amplification|MYC Fusion|MYC Mutation|MYC Overexpression|Myc proto-oncogene protein Overexpression Positive,Diffuse Large B-Cell Lymphoma|Multiple Myeloma,"Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma",NCT02992483,,"United States|Japan|Korea, Republic of|Italy|Australia|France|Germany|Spain",Not yet recruiting
CTAG1B Expression|CTAG1B Overexpression|Cancer/testis antigen 1 Expression Positive|FUS-DDIT3 Fusion|t(12;16)(q13;p11)|t(12;22)(q13;q12),Myxoid Liposarcoma|Round Cell Liposarcoma,A Pilot Study of NY-ESO-1‡¦Ïå_‰µ‰_T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma,NCT02992743,,United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer,NCT02993159,,United States,Not yet recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging,NCT02993198,,United States,Recruiting
FLT3 ITD,Acute Myeloid Leukemia,A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment NaÌøve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy,NCT02993523,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|inv(16)(p13q22)|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(16;16)(p13;q22)|t(8;21)(q22;q22),Puerto Rico|United States|Brazil|Italy|Croatia,Recruiting
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia,NCT02995655,PML-RARA Fusion,United States,Recruiting
FOLR1 Expression|FOLR1 Overexpression|Folate receptor alpha Expression Positive|Folate receptor alpha Overexpression Positive,Breast Carcinoma|Endometrial Carcinoma|Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",NCT02996825,,United States,Recruiting
CD33 Expression|CD33 Overexpression|Myeloid cell surface antigen CD33 Expression Positive,Multiple Myeloma,Lintuzumab-Ac225 for Refractory Multiple Myeloma,NCT02998047,,United States,Recruiting
,Breast Carcinoma,A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer,NCT02999477,,United States,Recruiting
,Non-Small Cell Lung Carcinoma,Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017,NCT03003468,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Diffuse Large B-Cell Lymphoma,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,NCT03003520,,Austria|United States|Denmark|Poland|England|United Kingdom|Slovakia|France|Portugal|Germany|Estonia,Recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,B-Cell Non-Hodgkin Lymphoma,Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma,NCT03003546,,United States,Not yet recruiting
KRAS Mutation,Non-Small Cell Lung Carcinoma,MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC),NCT03004105,,United States,Not yet recruiting
,Breast Carcinoma|Non-Small Cell Lung Carcinoma,SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,NCT03004183,,United States,Not yet recruiting
DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation,Colorectal Carcinoma,Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver,NCT03005002,,United States,Not yet recruiting
BRAF Codon 600 Missense,Melanoma,ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,NCT03005639,,United States,Recruiting
PIK3CA Mutation,Breast Carcinoma|Malignant Solid Tumor,"To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",NCT03006172,,United States,Recruiting
BCR-ABL1 Fusion|t(9;22)(q34;q11),Acute Lymphoblastic Leukemia,Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,NCT03007147,,United States,Not yet recruiting
,Breast Carcinoma,Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,NCT03007979,,United States,Not yet recruiting
Complex karyotype|DEK-NUP214 Fusion|Monosomal karyotype|RPN1-MECOM Fusion|Very Complex karyotype|inv(3)(q21q26)|t(3;3)(q21;q26)|t(6;9)(p21-22;q34)|t(6;9)(p22;q34)|t(6;9)(p23;q34),Acute Myeloid Leukemia,Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia,NCT03009240,,United States,Not yet recruiting
,Myelodysplastic Syndromes,Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,NCT03011034,,Netherlands|Russian Federation|Belgium|United States|Spain,Recruiting
FGFR1 Fusion|ins(12;8)(p11;p11p21)|ins(12;8)(p11;p11p22)|t(2;8)(q37;p11)|t(6;8)(q27;p11)|t(6;8)(q27;p11.2)|t(7;8)(q34;p11)|t(8;11)(p11;p15)|t(8;12)(p11.2;p11.2)|t(8;12)(p11;q15)|t(8;13)(p11.2;p12)|t(8;13)(p11;p12)|t(8;13)(p11;q11)|t(8;13)(p11;q12)|t(8;13)(p11;q12-13)|t(8;13)(p11;q13)|t(8;13)(p11;q21)|t(8;13)(p12;q12)|t(8;17)(p11;q23)|t(8;17)(p11;q25)|t(8;19)(p12;q13.3)|t(8;22)(p11;q11)|t(8;9)(p11;q33)|t(8;9)(p11;q34)|t(8;9)(p12;q33),Hematopoietic and Lymphoid Cell Neoplasm,A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement,NCT03011372,,Austria|United States|England|Italy|Scotland|United Kingdom|France|Switzerland|Germany|Spain,Recruiting
,Breast Carcinoma,"Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer",NCT03012100,,United States,"Active, not recruiting"
,Breast Carcinoma,Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer,NCT03012230,,United States,Not yet recruiting
ATM Germline Mutation|ATM Loss|ATM Mutation|ATR Loss|ATR Mutation|ATRX Loss|ATRX Mutation|BARD1 Germline Mutation|BARD1 Mutation|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|BRIP1 Mutation|C11orf30 Loss|C11orf30 Mutation|CDK12 Mutation|CHEK1 Mutation|CHEK2 Mutation|FANCA Amplification|FANCA Mutation|FANCB Amplification|FANCB Mutation|FANCC Amplification|FANCC Mutation|FANCD2 Amplification|FANCD2 Mutation|FANCE Amplification|FANCE Mutation|FANCF Amplification|FANCF Mutation|FANCG Amplification|FANCG Mutation|FANCI Amplification|FANCI Mutation|FANCL Amplification|FANCL Mutation|FANCM Amplification|FANCM Mutation|MDM2 Amplification|MDM2 Mutation|MDM4 Mutation|MLH1 Mutation|MRE11A Loss|MRE11A Mutation|MUTYH Mutation|NBN Loss|NBN Mutation|NPM1 Mutation|NPM1-MLF1 Fusion|PALB2 Loss|PALB2 Mutation|PARP1 Mutation|PARP2 Mutation|PPP2R1A Mutation|PPP2R2A Mutation|RAD50 Loss|RAD50 Mutation|RAD51 Mutation|RAD51B Mutation|RAD51C Mutation|RAD51D Mutation|SLX4 Mutation|STAG2 Mutation|XRCC1 Mutation,Prostate Adenocarcinoma,"Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects",NCT03012321,,United States,Recruiting
,Breast Carcinoma,CISPLATIN + AZD-1775 In Breast Cancer,NCT03012477,,United States,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Hodgkin Lymphoma,"Brentuximab Vedotin, Cyclosporine, and Verapamil in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma",NCT03013933,,United States,Recruiting
CBFB-MYH11 Inversion|IDH1 Mutation|IDH2 Mutation|RUNX1-RUNX1T1 Fusion|TET2 Mutation|WT1 Mutation|inv(16)(p13q22)|t(16;16)(p13.1;q22)|t(8;21)(q22;q22),Acute Myeloid Leukemia,Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,NCT03013998,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|FLT3 Mutation|Hypodiploidy|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TCF3-PBX1 Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(1;19)(q23;p13)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Burkitt Leukemia|Chronic Myeloid Leukemia|Lymphoma|Malignant Solid Tumor|Multiple Myeloma|Myelodysplastic Syndromes|T Lymphoblastic Leukemia/Lymphoma,Combined Cord Blood Transplant,NCT03016806,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,Hodgkin Lymphoma,"Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma",NCT03016871,,United States,Recruiting
,Breast Carcinoma,Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer,NCT03018080,,United States,Not yet recruiting
,Glioblastoma,Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM),NCT03018288,IDH1 R132C|IDH1 R132G|IDH1 R132H|IDH1 R132L|IDH1 R132P|IDH1 R132S|IDH2 R140G|IDH2 R140L|IDH2 R140Q|IDH2 R140W|IDH2 R172K|IDH2 R172M|IDH2 R172S,United States,Recruiting
,Acute Myeloid Leukemia|Breast Carcinoma|Colorectal Carcinoma|Fallopian Tube Carcinoma|Multiple Myeloma|Myelodysplastic Syndromes|Ovarian Carcinoma|Pancreatic Carcinoma|Urothelial Carcinoma,A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications,NCT03018405,,Belgium|United States,Recruiting
B-lymphocyte antigen CD19 Expression Positive|B-lymphocyte antigen CD20 Expression Positive|CD19 Expression|CD19 Overexpression|MS4A1 Expression|MS4A1 Overexpression,Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Non-Hodgkin Lymphoma,Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies,NCT03019055,,United States,Not yet recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,B-Cell Non-Hodgkin Lymphoma|Multiple Myeloma,Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL,NCT03019666,,United States,Not yet recruiting
MSLN Expression|MSLN Overexpression|Mesothelin Expression Positive|Mesothelin Overexpression,Pancreatic Carcinoma,Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer,NCT03023722,,United States,Recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Breast Carcinoma,Pembrolizumab in Advanced BRCA-mutated Breast Cancer,NCT03025035,,United States,Not yet recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,NCT03026517,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,A Study Of Pembrolizumab In Combination With Trastuzumab-DM1,NCT03032107,,United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma,"CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer",NCT03032406,,United States,Recruiting
MYCN Amplification,Neuroblastoma,A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma,NCT03033303,MYCN Amplification,United States,Recruiting
RET Amplification|RET Fusion|RET Germline Mutation|RET Mutation,Malignant Solid Tumor|Non-Small Cell Lung Carcinoma|Thyroid Gland Medullary Carcinoma,"Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",NCT03037385,ALK Fusion|ALK Mutation|EGFR Mutation|ROS1 Fusion|ROS1 Mutation,United States,Recruiting
ALK Amplification|ALK Expression|ALK Fusion|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive|BCL2 Fusion|BCL6 Fusion|IRF4 Fusion|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|MYC Fusion|Trisomy 11|del(11)(q10)|inv(11)(p15;q23)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(9;11)(p21;q23),"B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma|Lymphomatoid Granulomatosis|Mediastinal Large B-Cell Lymphoma|Primary Central Nervous System Lymphoma (PCNSL)|Primary Effusion Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas,NCT03038672,,United States,Not yet recruiting
B-lymphocyte antigen CD20 Expression Positive|MS4A1 Expression|MS4A1 Overexpression,Follicular Lymphoma,Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102),NCT03039114,,United States,Recruiting
KRAS G12R,Pancreatic Carcinoma,Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations,NCT03040986,,United States,Not yet recruiting
,Hypopharyngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharyngeal carcinoma,Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),NCT03040999,,"Canada|Netherlands|Turkey|United States|Japan|Korea, Republic of|Poland|Israel|Spain",Recruiting
,Non-Small Cell Lung Carcinoma,Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab,NCT03041181,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN|ROS1 Fusion,United States,Recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia,"MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia",NCT03041688,CBFB-MYH11 Fusion|CBFB-MYH11 Inversion|CEBPA Biallelic Mutation|CEBPA Mutation|KMT2A-MLLT3 Fusion|NPM1 Mutation|Normal karyotype|PML-RARA Fusion|RUNX1-RUNX1T1 Fusion|TP53 Frameshift|TP53 Large Deletion|TP53 Nonsense|del(17)(p10)|inv(16)(p13q22)|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(16;16)(p13;q22)|t(8;21)(q22;q22)|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Not yet recruiting
,Breast Carcinoma,Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery,NCT03044730,ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,United States,Not yet recruiting
,Breast Carcinoma,Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC,NCT03045393,,United States,Recruiting
ATM Loss|ATM Mutation|ATR Loss|ATR Mutation|ATRX Loss|ATRX Mutation|BARD1 Germline Mutation|BARD1 Mutation|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|BRIP1 Mutation|C11orf30 Loss|C11orf30 Mutation|CDK12 Mutation|CHEK1 Mutation|CHEK2 Mutation|FANCA Amplification|FANCA Mutation|FANCB Amplification|FANCB Mutation|FANCC Amplification|FANCC Mutation|FANCD2 Amplification|FANCD2 Mutation|FANCE Amplification|FANCE Mutation|FANCF Amplification|FANCF Mutation|FANCG Amplification|FANCG Mutation|FANCI Amplification|FANCI Mutation|FANCL Amplification|FANCL Mutation|FANCM Amplification|FANCM Mutation|MDM2 Amplification|MDM2 Mutation|MDM4 Mutation|MLH1 Mutation|MRE11A Loss|MRE11A Mutation|MUTYH Mutation|NBN Loss|NBN Mutation|NPM1 Mutation|NPM1-MLF1 Fusion|PALB2 Loss|PALB2 Mutation|PARP1 Mutation|PARP2 Mutation|PPP2R1A Mutation|PPP2R2A Mutation|RAD50 Loss|RAD50 Mutation|RAD51 Mutation|RAD51B Mutation|RAD51C Mutation|RAD51D Mutation|SLX4 Mutation|STAG2 Mutation|XRCC1 Mutation,Prostate Adenocarcinoma|Prostate Carcinoma,"Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis",NCT03047135,,United States,Recruiting
TSC1 Mutation|TSC2 Mutation,Transitional Cell Carcinoma|Urothelial Carcinoma,Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations,NCT03047213,,United States,Recruiting
ASXL1 Frameshift|ASXL1 Mutation|ASXL1 Nonsense|EZH2 Frameshift|EZH2 Mutation|EZH2 Nonsense|IDH1 Mutation|IDH2 Mutation|Monosomy 5|RUNX1 Deletion|RUNX1 Frameshift|RUNX1 Fusion|RUNX1 Large Deletion (Exon -1)|RUNX1 Mutation|RUNX1 Nonsense|TP53 Deletion|TP53 Frameshift|TP53 Nonsense|del(5)(q10),Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes,CB-839 + Azacitidine for Treatment of Myelodysplastic Syndrome (MDS),NCT03047993,,United States,Not yet recruiting
,Non-Small Cell Lung Carcinoma,A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer,NCT03048136,ALK Fusion|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR L858R|EGFR L861Q|EGFR T790M,Canada|Argentina|United States|Peru|Germany,Not yet recruiting
,Breast Carcinoma,Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer,NCT03048942,,England|Scotland|United Kingdom,Recruiting
SSTR1 Expression|SSTR1 Overexpression|SSTR2 Expression|SSTR2 Overexpression|SSTR3 Expression|SSTR3 Overexpression|SSTR4 Expression|SSTR4 Overexpression|SSTR5 Expression|SSTR5 Overexpression|Somatostatin receptor type 1 Expression Positive|Somatostatin receptor type 1 Overexpression|Somatostatin receptor type 2 Expression Positive|Somatostatin receptor type 2 Overexpression|Somatostatin receptor type 3 Expression Positive|Somatostatin receptor type 3 Overexpression|Somatostatin receptor type 4 Expression Positive|Somatostatin receptor type 4 Overexpression|Somatostatin receptor type 5 Expression Positive|Somatostatin receptor type 5 Overexpression,Digestive System Neuroendocrine Tumor|Functional Pancreatic Neuroendocrine Tumor|Non-functioning Pancreatic Endocrine Tumor,Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients,NCT03049189,,Austria|Netherlands|Poland|England|Italy|South Africa|United Kingdom|Australia|France|Switzerland|Germany,Recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,"Anaplastic Large Cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Enteropathy-Associated T-Cell Lymphoma|Hodgkin Lymphoma|Mature T-Cell and NK-Cell Lymphoma/Leukemia|Mediastinal Large B-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified",T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas,NCT03049449,,United States,Recruiting
,Colorectal Carcinoma,Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004,NCT03050814,DNA mismatch repair protein Mlh1 Deficiency|DNA mismatch repair protein Mlh1 Expression Negative|DNA mismatch repair protein Msh2 Deficiency|DNA mismatch repair protein Msh2 Expression Negative|DNA mismatch repair protein Msh6 Deficiency|DNA mismatch repair protein Msh6 Expression Negative|MLH1 Germline Mutation|MLH1 Large Deletion (Exon -1)|MLH1 Loss|MLH1 Mutation|MSH2 Germline Mutation|MSH2 Large Deletion|MSH2 Loss|MSH2 Mutation|MSH6 Germline Mutation|MSH6 Large Deletion (Exon -1)|MSH6 Loss|MSH6 Mutation|Mismatch Repair endonuclease PMS2 Deficiency|Mismatch Repair endonuclease PMS2 Expression Negative|PMS2 Germline Mutation|PMS2 Large Deletion (Exon -1)|PMS2 Loss|PMS2 Mutation,United States,Recruiting
BRAF Mutation|HRAS Mutation|KRAS Mutation|NRAS Mutation,Head and Neck Squamous Cell Carcinoma|Malignant Solid Tumor|Non-Small Cell Lung Carcinoma,First-in-Human Study of KO-947 in Non-Hematological Malignancies,NCT03051035,,United States,Recruiting
CDKN2A Expression|CDKN2A Overexpression|Cyclin-dependent kinase inhibitor 2A Expression Positive,Anal Neoplasm|Vulvar Squamous Neoplasm,HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions,NCT03051516,,United States,Not yet recruiting
,Breast Carcinoma,A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer,NCT03051659,,United States,Recruiting
,Breast Carcinoma,Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC,NCT03051672,,United States,Recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Non-Small Cell Lung Carcinoma,A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,NCT03052608,,United States|Japan,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer,NCT03054038,,United States,Not yet recruiting
MSLN Expression|MSLN Overexpression|Mesothelin Expression Positive|Mesothelin Overexpression,Fallopian Tube Carcinoma|Lung Adenocarcinoma|Malignant Pleural Mesothelioma|Ovarian Serous Adenocarcinoma|Peritoneal Mesothelioma|Primary Peritoneal Cancer,CAR T Cells in Mesothelin Expressing Cancers,NCT03054298,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,"Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",NCT03054363,,United States,Not yet recruiting
Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Expression|MET Overexpression,Breast Cancer|Melanoma,Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET),NCT03060356,,United States,Recruiting
ATM Loss|ATM Mutation|ATR Loss|ATR Mutation|ATRX Loss|ATRX Mutation|BAP1 Mutation|BARD1 Germline Mutation|BARD1 Mutation|BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation|BRIP1 Mutation|C11orf30 Loss|C11orf30 Mutation|CDK12 Mutation|CHEK1 Mutation|CHEK2 Mutation|ERCC2 Mutation|FANCA Amplification|FANCA Mutation|FANCB Amplification|FANCB Mutation|FANCC Amplification|FANCC Mutation|FANCD2 Amplification|FANCD2 Mutation|FANCE Amplification|FANCE Mutation|FANCF Amplification|FANCF Mutation|FANCG Amplification|FANCG Mutation|FANCI Amplification|FANCI Mutation|FANCL Amplification|FANCL Mutation|FANCM Amplification|FANCM Mutation|MDM2 Amplification|MDM2 Mutation|MDM4 Mutation|MLH1 Mutation|MRE11A Loss|MRE11A Mutation|MUTYH Mutation|NBN Loss|NBN Mutation|NPM1 Mutation|NPM1-MLF1 Fusion|PALB2 Loss|PALB2 Mutation|PARP1 Mutation|PARP2 Mutation|POLD1 Mutation|POLE Mutation|POLQ Mutation|PPP2R1A Mutation|PPP2R2A Mutation|PRKDC Mutation|RAD50 Loss|RAD50 Mutation|RAD51 Mutation|RAD51B Mutation|RAD51C Mutation|RAD51D Mutation|SLX4 Mutation|STAG2 Mutation|XRCC1 Mutation,Diffuse Large B-Cell Lymphoma|Malignant Solid Tumor|Mantle Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma,Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes,NCT03061188,,United States,Not yet recruiting
TP53 Mutation|del(17)(p10)|del(5)(q10),Acute Myeloid Leukemia,Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia,NCT03063203,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Not yet recruiting
,Acute Myeloid Leukemia,STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy,NCT03063944,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Recruiting
"AKT1 Amplification|EGFR Amplification|EGFR Mutation|ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|KIT Amplification|KIT Mutation|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression|PDGFRA Mutation|PIK3CA Amplification|PIK3CA Mutation|PTEN Deletion|PTEN Loss|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression",Malignant Solid Tumor|Oropharyngeal Squamous Cell Carcinoma,"Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",NCT03065062,,United States,Recruiting
EGFR Amplification|EGFR Mutation|ERBB2 Amplification|ERBB2 Mutation|ERBB3 Mutation|ERBB4 Mutation,Malignant Solid Tumor,"Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation",NCT03065387,,United States,Not yet recruiting
,Melanoma,Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma,NCT03068624,,United States,Not yet recruiting
,Breast Carcinoma,"Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells",NCT03070002,,United States,Recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,Diffuse Large B-Cell Lymphoma,Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL),NCT03072771,,United States,Not yet recruiting
,Myelodysplastic Syndromes,Dose Escalation and Proof-of-Concept Studies of TEW-7197 Monotherapy in Patients With Myelodysplastic Syndrome (MDS),NCT03074006,,United States,Not yet recruiting
,Chronic Neutrophilic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm|Myeloproliferative Neoplasm,A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms,NCT03075826,BCR-ABL1 Fusion|t(9;22)(q34;q11),United States,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Lung Adenocarcinoma,A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib,NCT03076164,,United States,Recruiting
ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive,Breast Carcinoma|Ductal Carcinoma In Situ,Optimizing Preventative Adjuvant Linac-Based Radiation: the OPAL Trial - Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer,NCT03077841,,United States,Recruiting
CD44 Expression|CD44 Overexpression|CD44 antigen Expression Positive,Ovarian Carcinoma,Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer,NCT03078400,,United States,Recruiting
EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,Non-Small Cell Lung Carcinoma,A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations,NCT03082300,,United States,Recruiting
,Head and Neck Squamous Cell Carcinoma|Laryngeal Carcinoma|Lip and Oral Cavity Cancer|Nasopharyngeal Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma|Sinonasal Undifferentiated Carcinoma,Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma,NCT03082534,,United States,Recruiting
EGFR Expression|EGFR Overexpression|Epidermal Growth Factor Receptor Overexpression|Epidermal growth factor receptor Expression Positive,Chordoma,Afatinib in Locally Advanced and Metastatic Chordoma,NCT03083678,,Netherlands|Italy|Scotland|United Kingdom,Not yet recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,Chronic Lymphocytic Leukemia,"A Trial of ""Armored"" CAR T Cells Targeting CD19 For Patients With Relapsed CLL",NCT03085173,,United States,Recruiting
BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|EGFR G465E|EGFR G465R|EGFR I491M|EGFR K467T|EGFR R451C|EGFR S464L|EGFR S492R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS A59E|KRAS A59G|KRAS A59P|KRAS A59S|KRAS A59T|KRAS A59V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS A59D|NRAS A59G|NRAS A59P|NRAS A59S|NRAS A59T|NRAS A59V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,Colorectal Adenocarcinoma,Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer,NCT03087071,BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R|EGFR G465E|EGFR G465R|EGFR I491M|EGFR K467T|EGFR R451C|EGFR S464L|EGFR S492R|KRAS A146P|KRAS A146T|KRAS A146V|KRAS A59E|KRAS A59G|KRAS A59P|KRAS A59S|KRAS A59T|KRAS A59V|KRAS G12A|KRAS G12C|KRAS G12D|KRAS G12R|KRAS G12S|KRAS G12V|KRAS G13A|KRAS G13C|KRAS G13D|KRAS G13R|KRAS G13S|KRAS G13V|KRAS K117N|KRAS Q61H|KRAS Q61K|KRAS Q61L|KRAS Q61P|KRAS Q61R|NRAS A146P|NRAS A146T|NRAS A146V|NRAS A59D|NRAS A59G|NRAS A59P|NRAS A59S|NRAS A59T|NRAS A59V|NRAS G12A|NRAS G12C|NRAS G12D|NRAS G12R|NRAS G12S|NRAS G12V|NRAS G13A|NRAS G13C|NRAS G13D|NRAS G13R|NRAS G13S|NRAS G13V|NRAS K117N|NRAS Q61E|NRAS Q61H|NRAS Q61K|NRAS Q61L|NRAS Q61P|NRAS Q61R,United States,Not yet recruiting
BRAF K601E|BRAF L597Q|BRAF L597R|BRAF L597S|BRAF L597V|BRAF V600D|BRAF V600E|BRAF V600G|BRAF V600K|BRAF V600M|BRAF V600R,Melanoma,Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,NCT03088176,,United States,Not yet recruiting
ALK Fusion|MET Codon 1003 Missense|MET Exon 14 Skipping|MET Fusion|ROS1 Fusion|ROS1 Inversion,Non-Small Cell Lung Carcinoma,Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer,NCT03088930,,United States,Not yet recruiting
AR Expression|AR Overexpression|Androgen Receptor Expression Positive,Breast Carcinoma,Ribociclib and Bicalutamide in AR+ TNBC,NCT03090165,,United States,Recruiting
Hepatocyte growth factor receptor Expression Positive|Hepatocyte growth factor receptor Overexpression|MET Amplification|MET Exon 14 Skipping|MET Fusion|MET Mutation|MET Overexpression,Papillary Renal Cell Carcinoma,Savolitinib vs. Sunitinib in MET-driven PRCC,NCT03091192,FH Mutation|VHL Mutation,United States,Not yet recruiting
BRAF Mutation|KRAS Mutation|NRAS Mutation,Multiple Myeloma,A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma,NCT03091257,,United States,Recruiting
,Acute Myeloid Leukemia|Myelodysplastic Syndromes|Refractory Anemia with Excess Blasts,"Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",NCT03092674,BCR-ABL1 Fusion|PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21)|t(9;22)(q34;q11),United States,Not yet recruiting
ALK Fusion|NTRK1 Fusion|NTRK2 Fusion|NTRK3 Fusion|ROS1 Fusion,Malignant Solid Tumor|Non-Hodgkin Lymphoma,"A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",NCT03093116,,United States,Recruiting
B-cell receptor CD22 Expression Positive|CD22 Expression|CD22 Overexpression,Acute Lymphoblastic Leukemia,Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia,NCT03094611,,United States,Not yet recruiting
,Breast Carcinoma,"A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease",NCT03095352,,United States,Not yet recruiting
KRAS Codon 12 Missense|KRAS Codon 13 Missense|KRAS Codon 61 Missense,Non-Small Cell Lung Carcinoma,Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC),NCT03095612,,United States,Not yet recruiting
,Head and Neck Squamous Cell Carcinoma|Melanoma|Pancreatic Carcinoma|Prostate Carcinoma,Immunotherapy Study of Evofosfamide in Combination With Ipilimumab,NCT03098160,,United States,Recruiting
,Breast Carcinoma|Malignant Solid Tumor,This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,NCT03099174,,United States|Japan|France|Spain,Recruiting
Hypodiploidy|IGH-FGFR3 Fusion|IGH-WHSC1 Fusion|Nullisomy 13|Nullisomy 17|StrucGain(1)(q10qter)|del(1)(p10)|del(13)(q10)|del(17p)|t(14;16)(q32;q23)|t(14;20)(q32;q12)|t(4;14)(p16;q32),Multiple Myeloma|Plasma Cell Leukemia,"Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma",NCT03100877,,United States,Recruiting
BRAF V600E|BRAF V600K,Melanoma,LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,NCT03101254,,United States,Not yet recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|ESR1 Expression|ESR1 Overexpression|Estrogen Receptor Expression Positive|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma|Inflammatory Breast Carcinoma,3HT With Taxol for Metastatic Breast Cancer,NCT03101748,,United States,Not yet recruiting
MSLN Expression|MSLN Overexpression|Mesothelin Expression Positive,Malignant Solid Tumor,Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors,NCT03102320,,Canada|Netherlands|Singapore|Belgium|United States|Italy|Australia|France|Switzerland|Germany|Spain,Not yet recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,"B Acute Lymphoblastic Leukemia|Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Double-Hit Lymphoma|Mediastinal Large B-Cell Lymphoma",huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia,NCT03103971,,United States,Not yet recruiting
IGH-MAF Fusion|IGH-MAFB Fusion|TP53 Frameshift|TP53 Large Deletion|TP53 Nonsense|del(17)(p10)|t(14;16)(q32;q23)|t(14;20)(q32;q12),Multiple Myeloma|Plasma Cell Leukemia,Combination Study for High Risk Multiple Myeloma Patients,NCT03104270,,United States,Recruiting
B-cell receptor CD22 Expression Positive|CD22 Expression|CD22 Overexpression,Acute Lymphoblastic Leukemia,Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia,NCT03104491,,United States,Not yet recruiting
NF1 Germline Mutation|NF1 Mutation,Neurofibroma|Neurofibromatosis Type 1,Selumetinib Pilot Study for Cutaneous Neurofibromas,NCT03105258,,United States,Not yet recruiting
FOLR1 Expression|FOLR1 Overexpression|Folate receptor alpha Expression Positive,Breast Carcinoma,Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC),NCT03106077,,United States,Not yet recruiting
,Breast Carcinoma,Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer,NCT03106415,,United States,Not yet recruiting
,Head and Neck Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma,Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,NCT03107182,,United States,Not yet recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Neuroblastoma,Study of Lorlatinib (PF-06463922),NCT03107988,,Canada|United States|England|United Kingdom|France,Not yet recruiting
VHL Germline Large Deletion|VHL Germline Loss|VHL Germline Mutation|VHL Large Deletion (Exon -1)|VHL Loss|VHL Mutation,Renal Cell Carcinoma|Von Hippel-Lindau Syndrome,PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma,NCT03108066,,United States,Recruiting
TSC1 Mutation|TSC2 Mutation,Bladder Carcinoma|Bladder Transitional Cell Carcinoma,Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations,NCT03108261,,United States,Not yet recruiting
NF1 Germline Mutation|NF1 Mutation,Gastrointestinal Stromal Tumor|Neurofibromatosis Type 1,Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST),NCT03109301,,United States,Recruiting
ERBB2 Amplification|ERBB2 Expression|ERBB2 Overexpression|Receptor tyrosine-protein kinase erbB-2 Expression Positive|Receptor tyrosine-protein kinase erbB-2 Overexpression,Breast Carcinoma,Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer,NCT03112590,,United States,Recruiting
CD274 Expression|CD274 High Expression|CD274 Overexpression|Programmed cell death 1 ligand 1 Expression Positive|TP53 Frameshift|TP53 Large Deletion|TP53 Nonsense|TP53 Overexpression,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,"P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",NCT03113487,,United States,Not yet recruiting
TNFRSF8 Expression|TNFRSF8 Overexpression|Tumor necrosis factor receptor superfamily member 8 Expression Positive,"Adult T-Cell Leukemia/Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified",Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma,NCT03113500,,United States,Recruiting
,Acute Myeloid Leukemia|Myelodysplastic Syndromes,SL-401 in Combination With Azacitidine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS),NCT03113643,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Not yet recruiting
BRCA1 Large Deletion|BRCA1 Loss|BRCA1 Mutation|BRCA2 Large Deletion|BRCA2 Loss|BRCA2 Mutation,Fallopian Tube Carcinoma|Ovarian Carcinoma|Primary Peritoneal Cancer,Olaparib +/- Cediranib or Chemotherapy in Patients With BRCA Mutated Platinum-resistant Ovarian Cancer,NCT03117933,,England|United Kingdom,Recruiting
,Myelofibrosis,"Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis",NCT03118492,,United States,Not yet recruiting
BCR-ABL1 Fusion|Complex karyotype|DEK-NUP214 Fusion|FLT3 ITD|KMT2A Fusion|KMT2A-AFF1 Fusion|KMT2A-ELL Fusion|KMT2A-MLLT1 Fusion|KMT2A-MLLT10 Fusion|KMT2A-MLLT3 Fusion|KMT2A-MLLT4 Fusion|Monosomal karyotype|Monosomy 5|Monosomy 7|RPN1-MECOM Fusion|TP53 Mutation|Trisomy 11|Very Complex karyotype|del(11)(q10)|del(5)(q10)|del(7)(q10)|inv(11)(p15;q23)|inv(3)(q21q26)|t(10;11)(p12;q23)|t(11;19)(q23; p13.1)|t(11;19)(q23; p13.3)|t(3;3)(q21;q26)|t(4;11)(q21;q23)|t(6;11)(q27; q23)|t(6;9)(p21-22;q34)|t(6;9)(p23;q34)|t(9;11)(p21;q23)|t(9;22)(q34;q11),Acute Myeloid Leukemia|Myelodysplastic Syndromes,Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes,NCT03121014,KMT2A-MLLT3 Fusion|t(9;11)(p21;q23)|t(9;11)(p22;q23),United States,Recruiting
B-lymphocyte antigen CD19 Expression Positive|CD19 Expression|CD19 Overexpression,Chronic Lymphocytic Leukemia|Richter Syndrome,Study of Blinatumomab in Richter Transformation,NCT03121534,,United States,Not yet recruiting
EGFR Exon 19 Deletion|EGFR L858R,Non-Small Cell Lung Carcinoma,Osimertinib and Gefitinib in EGFR Inhibitor naÌøve Advanced EGFR Mutant Lung Cancer,NCT03122717,,United States,Not yet recruiting
ALK Alternative Transcription Site|ALK Amplification|ALK Expression|ALK Fusion|ALK Mutation|ALK Overexpression|ALK tyrosine kinase receptor Expression Positive,Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Hodgkin Lymphoma|Lymphoblastic Lymphoma|Mantle Cell Lymphoma|Mature B-Cell Non-Hodgkin Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Mycosis Fungoides|Non-Hodgkin Lymphoma|Sezary Syndrome,Auto Stem Cell Transplant for Lymphoma Patients,NCT03125642,,United States,Recruiting
CD33 Expression|CD33 Overexpression|Myeloid cell surface antigen CD33 Expression Positive,Acute Myeloid Leukemia,Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia,NCT03126864,PML-RARA Fusion|t(15;17)(q22;q12)|t(15;17)(q24;q21),United States,Not yet recruiting
MYCN Amplification|MYCN Overexpression,Ganglioneuroblastoma|Neuroblastoma,Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,NCT03126916,,United States,Not yet recruiting
IDH1 Mutation,Acute Myeloid Leukemia,BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML),NCT03127735,,United States|Germany,Not yet recruiting
BTK Mutation|Complex karyotype|PLCG2 Mutation|TP53 Frameshift|TP53 Large Deletion|TP53 Nonsense|Very Complex karyotype|del(11)(q10)|del(17)(p10),Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL),NCT03128879,,United States,Not yet recruiting
RB1 Expression|RB1 Overexpression|Retinoblastoma-associated protein Expression Positive,Breast Carcinoma,"Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer",NCT03130439,,United States,Not yet recruiting
,Non-Small Cell Lung Carcinoma,Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC,NCT03130764,ALK Fusion|EGFR A750_E758delinsG|EGFR A763_Y764insFQEA|EGFR E746_A750del|EGFR E746_A750delinsIP|EGFR E746_P753delinsG|EGFR E746_P753delinsVS|EGFR E746_R748del|EGFR E746_S752del|EGFR E746_S752delinsA|EGFR E746_S752delinsG|EGFR E746_S752delinsV|EGFR E746_T751del|EGFR E746_T751delinsA|EGFR E746_T751delinsG|EGFR E746_T751delinsI|EGFR E746_T751delinsIP|EGFR E746_T751delinsV|EGFR E746_T751delinsVA|EGFR E754_A758del|EGFR E754_E757del|EGFR E754_T759del|EGFR E754del|EGFR Exon 19 Deletion|EGFR Exon 19 Insertion|EGFR G719A|EGFR G719C|EGFR G719D|EGFR G719S|EGFR K745_A750delinsT|EGFR K745_E749del|EGFR L747_A750delinsP|EGFR L747_P753delinsQ|EGFR L747_P753delinsS|EGFR L747_S752del|EGFR L747_T751delinsP|EGFR L747_T751delinsQ|EGFR L747_T751delinsS|EGFR L755_K762del|EGFR L858R|EGFR L861Q|EGFR L861R|EGFR S752_I759del|EGFR S768I|EGFR T751_I759delinsN,United States,Not yet recruiting
ALK Fusion|RET Fusion|RET Mutation,Brain metastasis|Non-Small Cell Lung Carcinoma|Thyroid Gland Carcinoma,A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,NCT03131206,,United States,Not yet recruiting
"PTEN Deletion|PTEN Frameshift|PTEN Large Deletion|PTEN Loss|PTEN Nonsense|Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Deficiency",Melanoma,Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss,NCT03131908,,United States,Not yet recruiting
,Breast Carcinoma,Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer,NCT03132467,,United States,Not yet recruiting
Apoptosis regulator Bcl-2 Overexpression Positive|BCL2 Amplification|BCL2 Fusion|BCL2 Overexpression|BCL6 Fusion|CAMPATH-1 antigen Expression Positive|CD52 Expression|CD52 Overexpression|MYC Amplification|MYC Fusion|MYC Overexpression|Myc proto-oncogene protein Overexpression Positive,Diffuse Large B-Cell Lymphoma|Mature B-Cell Lymphoma/Leukemia|Mature T-Cell and NK-Cell Lymphoma/Leukemia|Non-Hodgkin Lymphoma|Transformed Lymphoma,Cyclophosphamide and Alemtuzumab In Lymphoma,NCT03132584,,United States,Not yet recruiting